-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, DoNtvU+7NA+OZ5gKr7UMTq1GjauRCqZZ77/1udqKL59PAoPDAvHGzYQYJxEJFdrd HeSN0NclU2LhwoU3Pa07wg== 0000950123-10-045562.txt : 20100506 0000950123-10-045562.hdr.sgml : 20100506 20100506163340 ACCESSION NUMBER: 0000950123-10-045562 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20100331 FILED AS OF DATE: 20100506 DATE AS OF CHANGE: 20100506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NATIONWIDE HEALTH PROPERTIES INC CENTRAL INDEX KEY: 0000780053 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] IRS NUMBER: 953997619 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-09028 FILM NUMBER: 10808580 BUSINESS ADDRESS: STREET 1: 610 NEWPORT CENTER DR STREET 2: STE 1150 CITY: NEWPORT BEACH STATE: CA ZIP: 92660-6429 BUSINESS PHONE: 9497184400 MAIL ADDRESS: STREET 1: 610 NEWPORT CENTER DR STREET 2: STE 1150 CITY: NEWPORT BEACH STATE: CA ZIP: 92660-6429 FORMER COMPANY: FORMER CONFORMED NAME: BEVERLY INVESTMENT PROPERTIES INC DATE OF NAME CHANGE: 19890515 10-Q 1 c99877e10vq.htm FORM 10-Q Form 10-Q
Table of Contents

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 10-Q
 
     
þ   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2010.
OR
     
o   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     .
Commission file number 1-9028
 
NATIONWIDE HEALTH PROPERTIES, INC.
(Exact Name of Registrant as Specified in Its Charter)
 
     
Maryland
(State or Other Jurisdiction of
Incorporation or Organization)
  95-3997619
(I.R.S. Employer
Identification Number)
     
610 Newport Center Drive, Suite 1150
Newport Beach, California
(Address of Principal Executive Offices)
  92660
(Zip Code)
(949) 718-4400
(Registrant’s Telephone Number, Including Area Code)
 
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes o No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
             
Large accelerated filer þ   Accelerated filer o   Non-accelerated filer o   Smaller reporting company o
        (Do not check if a smaller reporting company)    
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No þ
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
Common stock, $0.10 par value, outstanding at May 6, 2010: 119,797,061
 
 

 

 


 

NATIONWIDE HEALTH PROPERTIES, INC.
FORM 10-Q
MARCH 31, 2010
TABLE OF CONTENTS
         
    Page  
PART I. FINANCIAL INFORMATION
 
       
    2  
 
       
    2  
 
       
    3  
 
       
    4  
 
       
    5  
 
       
    6  
 
       
    29  
 
       
    42  
 
       
    43  
 
       
PART II. OTHER INFORMATION
 
       
    44  
 
       
    44  
 
       
    45  
 
       
    46  
 
       
    47  
 
       
 Exhibit 31.1
 Exhibit 31.2
 Exhibit 32
 EX-101 INSTANCE DOCUMENT
 EX-101 SCHEMA DOCUMENT
 EX-101 CALCULATION LINKBASE DOCUMENT
 EX-101 LABELS LINKBASE DOCUMENT
 EX-101 PRESENTATION LINKBASE DOCUMENT
 EX-101 DEFINITION LINKBASE DOCUMENT

 

1


Table of Contents

Part I. Financial Information
Item 1.   Financial Statements
NATIONWIDE HEALTH PROPERTIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
                 
    March 31,     December 31,  
    2010     2009  
    (Unaudited)          
    (Dollars in thousands)  
ASSETS
               
Investments in real estate:
               
Land
  $ 317,531     $ 318,457  
Buildings and improvements
    3,346,489       3,088,183  
 
           
 
    3,664,020       3,406,640  
Less accumulated depreciation
    (606,231 )     (585,294 )
 
           
 
    3,057,789       2,821,346  
Mortgage loans receivable, net
    197,271       110,613  
Mortgage loan receivable from related party
          47,500  
Investments in unconsolidated joint ventures
    47,797       51,924  
 
           
 
    3,302,857       3,031,383  
Cash and cash equivalents
    210,590       382,278  
Receivables, net
    8,750       6,605  
Intangible assets
    150,120       93,657  
Other assets
    141,327       133,152  
 
           
 
  $ 3,813,644     $ 3,647,075  
 
           
 
               
 
               
LIABILITIES AND EQUITY
               
Unsecured senior credit facility
  $     $  
Senior notes
    991,633       991,633  
Notes and bonds payable
    535,950       431,456  
Accounts payable and accrued liabilities
    125,244       132,915  
 
           
Total liabilities
    1,652,827       1,556,004  
Redeemable OP unitholder interests
    77,557       57,335  
Commitments and contingencies
               
Equity:
               
NHP stockholders’ equity:
               
Preferred stock $1.00 par value; 5,000,000 shares authorized; 7.750% Series B Convertible, none and 513,644 shares issued and outstanding at March 31, 2010 and December 31, 2009, stated at liquidation preference of $100 per share
          51,364  
Common stock $0.10 par value; 200,000,000 shares authorized; issued and outstanding: 118,184,009 and 114,320,786 at March 31, 2010 and December 31, 2009, respectively
    11,818       11,432  
Capital in excess of par value
    2,225,737       2,128,843  
Cumulative net income
    1,736,708       1,705,279  
Accumulated other comprehensive loss
    (1,385 )     (823 )
Cumulative dividends
    (1,915,071 )     (1,862,996 )
 
           
Total NHP stockholders’ equity
    2,057,807       2,033,099  
Noncontrolling interests
    25,453       637  
 
           
Total equity
    2,083,260       2,033,736  
 
           
 
  $ 3,813,644     $ 3,647,075  
 
           
See accompanying notes.

 

2


Table of Contents

NATIONWIDE HEALTH PROPERTIES, INC.
CONDENSED CONSOLIDATED INCOME STATEMENTS
(Unaudited)
                 
    Three Months Ended  
    March 31,  
    2010     2009  
    (In thousands, except per  
    share amounts)  
Revenue:
               
Triple-net lease rent
  $ 74,214     $ 74,095  
Medical office building operating rent
    21,251       16,653  
 
           
 
    95,465       90,748  
Interest and other income
    6,963       6,335  
 
           
 
    102,428       97,083  
 
           
Expenses:
               
Interest expense
    23,590       24,071  
Depreciation and amortization
    31,969       30,832  
General and administrative
    6,984       6,931  
Acquisition costs
    1,443        
Medical office building operating expenses
    8,647       6,834  
 
           
 
    72,633       68,668  
 
           
Operating income
    29,795       28,415  
Income from unconsolidated joint ventures
    1,347       1,013  
Gain on debt extinguishment
    75        
 
           
Income from continuing operations
    31,217       29,428  
 
           
Discontinued operations:
               
Gains on sale of facilities, net
    22       21,152  
Income from discontinued operations
          53  
 
           
 
    22       21,205  
 
           
Net income
    31,239       50,633  
Net loss (income) attributable to noncontrolling interests
    190       (27 )
 
           
Net income attributable to NHP
    31,429       50,606  
Preferred stock dividends
          (1,452 )
 
           
Net income attributable to NHP common stockholders
  $ 31,429     $ 49,154  
 
           
Basic earnings per share amounts:
               
Income from continuing operations attributable to NHP common stockholders
  $ 0.27     $ 0.27  
Discontinued operations attributable to NHP common stockholders
          0.21  
 
           
Net income attributable to NHP common stockholders
  $ 0.27     $ 0.48  
 
           
Basic weighted average shares outstanding
    117,048       102,355  
 
           
Diluted earnings per share amounts:
               
Income from continuing operations attributable to NHP common stockholders
  $ 0.26     $ 0.27  
Discontinued operations attributable to NHP common stockholders
          0.20  
 
           
Net income attributable to NHP common stockholders
  $ 0.26     $ 0.47  
 
           
Diluted weighted average shares outstanding
    119,466       104,408  
 
           
Dividends declared per share
  $ 0.44     $ 0.44  
 
           
See accompanying notes.

 

3


Table of Contents

NATIONWIDE HEALTH PROPERTIES, INC.
CONDENSED CONSOLIDATED STATEMENT OF EQUITY
(Unaudited)
(In thousands)
                                                                                 
    NHP Stockholders’ Equity              
                                                    Accumulated                    
                                    Capital in             other                    
    Preferred Stock     Common stock     excess of     Cumulative     comprehensive     Cumulative     Noncontrolling     Total  
    Shares     Amount     Shares     Amount     par value     net income     (loss) income     dividends     interests     equity  
Balances at December 31, 2009
    514     $ 51,364       114,321     $ 11,432     $ 2,128,843     $ 1,705,279     $ (823 )   $ (1,862,996 )   $ 637     $ 2,033,736  
Comprehensive income:
                                                                               
Net income
                                  31,429                   (190 )     31,239  
Amortization of gain on Treasury lock agreements
                                        (126 )                 (126 )
Pro rata share of accumulated other comprehensive loss from unconsolidated joint venture
                                        (436 )                 (436 )
 
                                                                             
Comprehensive income
                                                                            30,677  
Conversion/redemption of preferred stock
    (514 )     (51,364 )     2,315       231       51,041                               (92 )
Issuance of common stock, net
                1,548       155       45,821                               45,976  
Amortization of stock-based compensation
                            1,594                               1,594  
Common dividends
                                              (52,075 )           (52,075 )
Adjust redeemable OP unitholder interests to current redemption value
                            (1,562 )                             (1,562 )
Noncash contributions from noncontrolling interests
                                                    25,289       25,289  
Distributions to noncontrolling interests
                                                    (283 )     (283 )
 
                                                           
Balances at March 31, 2010
        $       118,184     $ 11,818     $ 2,225,737     $ 1,736,708     $ (1,385 )   $ (1,915,071 )   $ 25,453     $ 2,083,260  
 
                                                           
See accompanying notes.

 

4


Table of Contents

NATIONWIDE HEALTH PROPERTIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
                 
    Three Months Ended  
    March 31,  
    2010     2009  
    (In thousands)  
Cash flows from operating activities:
               
Net income
  $ 31,239     $ 50,633  
Adjustments to reconcile net income to cash provided by operating activities:
               
Depreciation and amortization
    31,969       31,123  
Stock-based compensation
    1,594       1,573  
Gain on re-measurement of equity interest upon acquisition, net
    (620 )      
Gains on sale of facilities, net
    (22 )     (21,152 )
Gain on debt extinguishment
    (75 )      
Amortization of deferred financing costs
    719       703  
Mortgage and other loan premium amortization
          19  
Straight-line rent
    (1,733 )     (1,621 )
Equity in earnings from unconsolidated joint ventures
    (286 )     5  
Distributions of income from unconsolidated joint ventures
    258       201  
Changes in operating assets and liabilities:
               
Receivables
    (1,706 )     (525 )
Intangible and other assets
    (210 )     (987 )
Accounts payable and accrued liabilities
    (17,394 )     (16,063 )
 
           
Net cash provided by operating activities
    43,733       43,909  
 
           
Cash flows from investing activities:
               
Acquisition of real estate and related assets and liabilities
    (65,056 )     (8,583 )
Proceeds from sale of real estate facilities
          36,284  
Investment in mortgage and other loans receivable
    (140,437 )     (13,179 )
Principal payments on mortgage and other loans receivable
    1,270       5,445  
Contributions to unconsolidated joint ventures
          (110 )
Distributions from unconsolidated joint ventures
    751       559  
 
           
Net cash (used in) provided by investing activities
    (203,472 )     20,416  
 
           
Cash flows from financing activities:
               
Repayment of senior notes
          (27,000 )
Issuance of notes and bonds payable
          6,862  
Principal payments on notes and bonds payable
    (5,020 )     (1,652 )
Issuance of common stock, net
    45,875       3,309  
Redemption of preferred stock
    (92 )      
Distributions to noncontrolling interests
    (283 )     (364 )
Distributions to redeemable OP unitholders
    (370 )     (682 )
Dividends paid
    (51,979 )     (46,681 )
Payment of deferred financing costs
    (80 )     (82 )
 
           
Net cash used in financing activities
    (11,949 )     (66,290 )
 
           
Decrease in cash and cash equivalents
    (171,688 )     (1,965 )
Cash and cash equivalents, beginning of period
    382,278       82,250  
 
           
Cash and cash equivalents, end of period
  $ 210,590     $ 80,285  
 
           
 
               
Supplemental schedule of cash flow information:
               
Non-cash investing activities:
               
Assumption of debt upon acquisition of real estate
  $ 109,514     $  
 
           
Retirement of mortgage loan receivable upon acquisition of real estate
  $ 47,500     $  
 
           
Capital contributions from noncontrolling interests upon acquisition of real estate
  $ 25,289     $  
 
           
Issuance of redeemable OP units upon acquisition of real estate
  $ 18,986     $  
 
           
Issuance of mortgage loan receivable upon sale of real estate
  $ 6,258     $  
 
           
Non-cash financing activities:
               
Conversion of preferred stock to common stock
  $ 51,272     $  
 
           
Adjust redeemable OP unitholder interest to current redemption value
  $ 1,562     $  
 
           
See accompanying notes.

 

5


Table of Contents

NATIONWIDE HEALTH PROPERTIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2010
(Unaudited)
1. Organization
Nationwide Health Properties, Inc., a Maryland corporation, is a real estate investment trust (“REIT”) that invests in healthcare related real estate, primarily senior housing, long-term care properties and medical office buildings. Whenever we refer herein to “NHP” or to “us” or use the terms “we” or “our,” we are referring to Nationwide Health Properties, Inc. and its subsidiaries, unless the context otherwise requires.
We primarily make our investments by acquiring an ownership interest in senior housing and long-term care facilities and leasing them to unaffiliated tenants under “triple-net” “master” leases that transfer the obligation for all facility operating costs (including maintenance, repairs, taxes, insurance and capital expenditures) to the tenant. We also invest in medical office buildings which are not generally subject to “triple-net” leases and generally have several tenants under separate leases in each building, thus requiring active management and responsibility for many of the associated operating expenses (although many of these are, or can effectively be, passed through to the tenants). Some of the medical office buildings are subject to “triple-net” leases. In addition, but to a much lesser extent because we view the risks of this activity to be greater due to less favorable bankruptcy treatment and other factors, from time to time, we extend mortgage loans and other financing to operators. For the three months ended March 31, 2010, approximately 93% of our revenues were derived from leases, with the remaining 7% from mortgage loans, other financing activities and other miscellaneous income.
We believe we have operated in such a manner as to qualify as a REIT under Sections 856 through 860 of the Internal Revenue Code of 1986, as amended (the “Code”). We intend to continue to qualify as such and therefore distribute at least 90% of our REIT taxable income (computed without regard to the dividends paid deduction and excluding capital gain) to our stockholders. If we qualify for taxation as a REIT, and we distribute 100% of our taxable income to our stockholders, we will generally not be subject to U.S. federal income taxes on our income that is distributed to stockholders. Accordingly, no provision has been made for federal income taxes.
As of March 31, 2010, we had investments in 606 healthcare facilities and one land parcel located in 43 states, consisting of:
Consolidated facilities:
    251 assisted and independent living facilities;
    167 skilled nursing facilities;
    9 continuing care retirement communities;
    7 specialty hospitals;
    19 triple-net medical office buildings, one of which is operated by a consolidated joint venture (see Note 5); and
    67 multi-tenant medical office buildings, 20 of which are operated by consolidated joint ventures (see Note 5).
Unconsolidated facilities:
    19 assisted and independent living facilities;
    14 skilled nursing facilities; and
    1 continuing care retirement community.

 

6


Table of Contents

NATIONWIDE HEALTH PROPERTIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Mortgage loans secured by:
    26 medical office buildings;
    16 skilled nursing facilities;
    9 assisted and independent living facilities;
    1 continuing care retirement community; and
    1 land parcel.
As of March 31, 2010, our directly owned facilities, other than our multi-tenant medical office buildings, were operated by 84 different healthcare providers, including the following publicly traded companies:
         
    Number of  
    Facilities  
    Operated  
Assisted Living Concepts, Inc.
    4  
Brookdale Senior Living, Inc.
    96  
Emeritus Corporation
    6  
Extendicare, Inc.
    1  
HealthSouth Corporation
    2  
Kindred Healthcare, Inc.
    1  
Sun Healthcare Group, Inc.
    4  
Two of our triple-net lease tenants each accounted for more than 10% of our revenues at March 31, 2010 as follows:
         
Brookdale Senior Living, Inc.
    14.3 %
Hearthstone Senior Services, L.P.
    10.1 %
2. Summary of Significant Accounting Policies
Basis of Presentation
We have prepared the condensed consolidated financial statements included herein without audit. These financial statements include all adjustments that are, in the opinion of management, necessary for a fair presentation of the results of operations for the three months ended March 31, 2010 and 2009 pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). All such adjustments are of a normal recurring nature. Certain items in prior period financial statements have been reclassified to conform to current year presentation, including those required by the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 360, Property, Plant and Equipment (“ASC 360”), which require the operating results of any assets with their own identifiable cash flows that are disposed of or held for sale and in which we have no continuing interest to be removed from income from continuing operations and reported as discontinued operations. Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been condensed or omitted pursuant to these rules and regulations. Although we believe that the disclosures in the financial statements included herein are adequate to make the information presented not misleading, these condensed consolidated financial statements should be read in conjunction with our financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2009 filed with the SEC. The results of operations for the three months ended March 31, 2010 and 2009 are not necessarily indicative of the results for a full year.
We have evaluated events subsequent to March 31, 2010 for their impact on our condensed consolidated financial statements.

 

7


Table of Contents

NATIONWIDE HEALTH PROPERTIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Principles of Consolidation
The condensed consolidated financial statements include our accounts, the accounts of our wholly-owned subsidiaries and the accounts of our joint ventures that are controlled through voting rights or other means. We apply the provisions of ASC Topic 810, Consolidation (“ASC 810”), for arrangements with variable interest entities (“VIEs”) and would consolidate those VIEs where we are the primary beneficiary. All material intercompany accounts and transactions have been eliminated.
Our judgment with respect to our level of influence or control of an entity and whether we are the primary beneficiary of a VIE involves the consideration of various factors including, but not limited to, the form of our ownership interest, our representation on the entity’s governing body, the size of our investment, estimates of future cash flows, our ability to participate in policy-making decisions and the rights of the other investors to participate in the decision-making process and to replace us as manager and/or liquidate the venture, if applicable. Our ability to correctly assess our influence or control over an entity or determine the primary beneficiary of a VIE affects the presentation of these entities in our consolidated financial statements.
We apply the provisions of ASC Topic 323, Investments — Equity Method and Joint Ventures (“ASC 323”), to investments in joint ventures. Investments in entities that we do not consolidate but for which we have the ability to exercise significant influence over operating and financial policies are reported under the equity method. Under the equity method of accounting, our share of the entity’s earnings or losses is included in our operating results.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ materially from those estimates.
Revenue Recognition
Rental income from operating leases is recognized in accordance with the provisions of ASC Topic 840, Leases, and ASC Topic 605, Revenue Recognition. Our leases generally contain annual rent escalators. Many of our leases contain non-contingent rent escalators for which we recognize income on a straight-line basis over the lease term. Recognizing income on a straight-line basis requires us to calculate the total non-contingent rent to be paid over the life of a lease and to recognize the revenue evenly over that life. This method results in rental income in the early years of a lease being higher than actual cash received, creating a straight-line rent receivable asset included in the caption “Other assets” on our consolidated balance sheets. At some point during the lease, depending on its terms, the cash rent payments eventually exceed the straight-line rent which results in the straight-line rent receivable asset decreasing to zero over the remainder of the lease term. Certain leases contain rent escalators contingent on revenues or other factors, including increases based on changes in the Consumer Price Index. Such revenue increases are recognized as the related contingencies are met.
We assess the collectability of straight-line rents in accordance with the applicable accounting standards and our reserve policy and defer recognition of straight-line rent if its collectability is not reasonably assured. Our assessment of the collectability of straight-line rents is based on several factors, including the financial strength of the tenant and any guarantors, the historical operations and operating trends of the facility, the historical payment pattern of the tenant and the type of facility, among others. If our evaluation of these factors indicates we may not receive the rent payments due in the future, we defer recognition of the straight-line rental income and, depending on the circumstances, we will provide a reserve against the previously recognized straight-line rent receivable asset for a portion, up to its full value, that we estimate may not be recoverable. If we change our assumptions or estimates regarding the collectability of future rent payments required by a lease, we may adjust our reserve to increase or reduce the rental revenue recognized, and/or to increase or reduce the reserve against the existing straight-line rent receivable balance.
We recorded $1.7 million and $1.6 million of revenues in excess of cash received during the three months ended March 31, 2010 and 2009, respectively. We had straight-line rent receivables, net of reserves, recorded under the caption “Other assets” on our consolidated balance sheets of $29.3 million at March 31, 2010 and $27.5 million at December 31, 2009, net of reserves of $108.2 million and $108.3 million, respectively. We evaluate the collectability of the straight-line rent receivable balances on an ongoing basis and provide reserves against receivables we believe may not be fully recoverable. The ultimate amount of straight-line rent we realize could be less than amounts currently recorded.

 

8


Table of Contents

NATIONWIDE HEALTH PROPERTIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Gains on Sale of Facilities
We recognize sales of facilities upon closing. Payments received from purchasers prior to closing are recorded as deposits. Gains on facilities sold are recognized using the full accrual method upon closing when the requirements of gain recognition on sale of real estate under the provisions of ASC 360 are met, including: the collectability of the sales price is reasonably assured; we have received adequate initial investment from the buyer; we are not obligated to perform significant activities after the sale to earn the gain; and other profit recognition criteria have been satisfied. Gains may be deferred in whole or in part until the sales satisfy these requirements. Gains on facilities sold to unconsolidated joint ventures in which we maintain an ownership interest are included in income from continuing operations, and the portion of the gain representing our retained ownership interest in the joint venture is deferred and included in the caption “Accounts payable and accrued liabilities” on our consolidated balance sheets. We had $15.3 million of such deferred gains at March 31, 2010 and December 31, 2009. All other gains are included in discontinued operations.
Asset Impairment
We review our long-lived assets individually on a quarterly basis to determine if there are indicators of impairment in accordance with the provisions of ASC 360. Indicators may include, among others, a tenant’s inability to make rent payments, operating losses or negative operating trends at the facility level, notification by a tenant that it will not renew its lease, or a decision to dispose of an asset or adverse changes in the fair value of any of our properties. For operating assets, if indicators of impairment exist, we compare the undiscounted cash flows from the expected use of the property to its net book value to determine if impairment exists. The evaluation of the undiscounted cash flows from the expected use of the property is highly subjective and is based in part on various factors and assumptions, including, but not limited to, historical operating results, available market information and known trends and market/economic conditions that may affect the property, as well as estimates of future operating income, occupancy, rental rates, leasing demand and competition. If the sum of the future estimated undiscounted cash flows is higher than the current net book value, we conclude no impairment exists. If the sum of the future estimated undiscounted cash flows is lower than its current net book value, we recognize an impairment loss for the difference between the net book value of the asset and its estimated fair value. To the extent we decide to sell an asset, we recognize an impairment loss if the current net book value of the asset exceeds its fair value less selling costs.
We evaluate our equity method investments for impairment whenever events or changes in circumstances indicate that the carrying value of our investment in an unconsolidated joint venture may exceed the fair value. If it is determined that a decline in the fair value of our investment in an unconsolidated joint venture is other-than-temporary, and if such reduced fair value is below its carrying value, an impairment is recorded. The determination of the fair value of investments in unconsolidated joint ventures involves significant judgment. Our estimates consider all available evidence including, as appropriate, the present value of the expected future cash flows discounted at market rates, general economic conditions and trends and other relevant factors.
The above analyses require us to determine whether there are indicators of impairment for individual assets or investments in unconsolidated joint ventures, to estimate the most likely stream of cash flows from operating assets and to determine the fair value of assets that are impaired or held for sale. If our assumptions, projections or estimates regarding an asset change in the future, we may have to record an impairment charge to reduce or further reduce the net book value of such individual asset or investment in unconsolidated joint venture.
No impairment charges were recorded during the three months ended March 31, 2010 or 2009.

 

9


Table of Contents

NATIONWIDE HEALTH PROPERTIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Collectability of Receivables
We evaluate the collectability of our rent, mortgage and other loans and other receivables on a regular basis based on factors including, among others, payment history, the financial strength of the borrower and any guarantors, the value of the underlying collateral, the operations and operating trends of the underlying collateral, if any, the asset type and current economic conditions. If our evaluation of these factors indicates we may not recover the full value of the receivable, we provide a reserve against the portion of the receivable that we estimate may not be recovered. This analysis requires us to determine whether there are factors indicating a receivable may not be fully collectible and to estimate the amount of the receivable that may not be collected. We had reserves included in the caption “Receivables, net” on our consolidated balance sheets of $14.3 million at March 31, 2010 and $12.7 million at December 31, 2009.
Accounting for Stock-Based Compensation
We account for stock-based compensation in accordance with the provisions of ASC Topic 718, Compensation-Stock Compensation, which require stock-based compensation awards to be valued at the fair value on the date of grant and amortized as an expense over the vesting period and require any dividend equivalents earned to be treated as dividends for financial reporting purposes. Net income reflects stock-based compensation expense of $1.6 million for each of the three months ended March 31, 2010 and 2009.
Land, Buildings and Improvements and Depreciation and Useful Lives of Assets
We record properties at cost and use the straight-line method of depreciation for buildings and improvements over their estimated remaining useful lives of up to 40 years, generally 20 to 40 years depending on factors including building type, age, quality and location. We review and adjust useful lives periodically. Depreciation expense from continuing operations was $27.8 million and $25.5 million for the three months ended March 31, 2010 and 2009, respectively.
We allocate purchase prices of properties in accordance with the provisions of ASC Topic 805, Business Combinations (“ASC 805”), which require that the acquisition method of accounting be used for all business combinations and for an acquirer to be identified for each business combination. ASC 805 also establishes principles and requirements for how the acquirer recognizes and measures in its financial statements the identifiable assets acquired, the liabilities assumed and any noncontrolling interest in the acquiree. Certain transaction costs that have historically been capitalized as acquisition costs are expensed for business combinations completed on or after January 1, 2009, which may have a significant impact on our future results of operations and financial position based on historical acquisition costs and activity levels. During the three months ended March 31, 2010, we incurred $1.4 million of acquisition costs that are included on our consolidated income statements.
The allocation of the cost between land, building and, if applicable, equipment and intangible assets and liabilities, and the determination of the useful life of a property are based on management’s estimates, which are based in part on independent appraisals or other consultants’ reports. For our triple-net leased facilities, the allocation is made as if the property was vacant, and a significant portion of the cost of each property is allocated to buildings. This amount generally approximates 90% of the total property value. Historically, we have generally acquired properties and simultaneously entered into a new market rate lease for the entire property with one tenant. For our multi-tenant medical office buildings, the percentage allocated to buildings may be substantially lower as allocations are made to assets such as lease-up intangible assets, above market tenant and ground lease intangible assets and in-place lease intangible assets (collectively “intangible assets”) included on our consolidated balance sheets and/or below market tenant and ground lease intangible liabilities included in the caption “Accounts payable and accrued liabilities” on our consolidated balance sheets.
We calculate depreciation and amortization on equipment and lease costs using the straight-line method based on estimated useful lives of up to five years or the lease term, whichever is appropriate. We amortize intangible assets and liabilities over the remaining lease terms of the respective leases to real estate amortization expense or medical office building operating rent, as appropriate. We review and adjust useful lives periodically.

 

10


Table of Contents

NATIONWIDE HEALTH PROPERTIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Cash and Cash Equivalents
Cash and cash equivalents include short-term investments with original maturities of three months or less when purchased.
Deferred Financing Costs
Deferred financing costs are amortized as a component of interest expense over the terms of the related borrowings using a method that approximates a level yield. Deferred financing cost amortization is included in the caption “Interest expense” on our consolidated income statements.
Derivatives
In the normal course of business, we are exposed to financial market risks, including interest rate risk on our interest-bearing liabilities. We endeavor to limit these risks by following established risk management policies, procedures and strategies, including, on occasion, the use of derivative instruments. We do not use derivative instruments for trading or speculative purposes.
Derivative instruments are recorded on our consolidated balance sheets as assets or liabilities based on each instrument’s fair value. Changes in the fair value of derivative instruments are recognized currently in earnings, unless the derivative instrument meets the criteria for hedge accounting contained in ASC Topic 815, Derivatives and Hedging (“ASC 815”). If the derivative instruments meet the criteria for a cash flow hedge, the gains and losses recognized upon changes in the fair value of the derivative instrument are recorded in other comprehensive income. Gains and losses on a cash flow hedge are reclassified into earnings when the forecasted transaction affects earnings. A contract that is designated as a hedge of an anticipated transaction which is no longer likely to occur is immediately recognized in earnings.
For investments in entities reported under the equity method of accounting, we record our pro rata share of the entity’s derivative instruments’ fair value, other comprehensive income or loss and gains and losses determined in accordance with ASC 323 and ASC 815 as applicable.
Segment Reporting
We report our consolidated financial statements in accordance with the provisions of ASC Topic 280, Segment Reporting. We operate in two segments based on our investment and leasing activities: triple-net leases and multi-tenant leases (see Note 16).
Redeemable Limited Partnership Unitholders
NHP/PMB L.P. (“NHP/PMB”) is a limited partnership that we formed in February 2008 to acquire properties from entities affiliated with Pacific Medical Buildings LLC (see Note 5). We consolidate NHP/PMB consistent with the provisions of ASC 810, as our wholly owned subsidiary is the general partner and exercises control. As of March 31, 2010 and December 31, 2009, third party investors owned 2,206,465 and 1,629,752 Class A limited partnership units in NHP/PMB (“OP Units”), respectively, which represented 34.7% and 53.9% of the total units outstanding at March 31, 2010 and December 31, 2009, respectively. During the three months ended March 31, 2010, 575,326 and 1,788 OP Units were issued by NHP/PMB in connection with acquisitions and under terms of an agreement with Pacific Medical Buildings and certain of its affiliates, respectively (see Note 5). After a one year holding period, the OP Units are exchangeable for cash or, at our option, shares of our common stock, initially on a one-for-one basis. We have entered into a registration rights agreement with the holders of the OP Units which, subject to the terms and conditions set forth therein, obligates us to register the shares of common stock that we may issue in exchange for such OP Units. Since we are obligated to register the shares, the redeemable OP unitholder interests are classified outside of permanent equity on our consolidated balance sheets. During the three months ended March 31, 2010, 401 OP Units were converted into 401 shares of our common stock. We applied the provisions of ASC Topic 480, Distinguishing Liabilities from Equity, to reflect the redeemable OP unitholder interests at the greater of cost or fair value. At March 31, 2010, the fair value of the OP Units exceeded the cost basis by $1.6 million, and the adjustment was recorded through capital in excess of par value. The value of the OP Units held by redeemable OP unitholder interests was $77.6 million and $57.3 million at March 31, 2010 and December 31, 2009, respectively.

 

11


Table of Contents

NATIONWIDE HEALTH PROPERTIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Noncontrolling Interests
We have three consolidated joint ventures in which we have equity interests, ranging from 71% to 95%, in nine multi-tenant medical office buildings (see Note 5).
NHP/PMB has equity interests, ranging from 50% to 69%, in three joint ventures which each own one multi-tenant medical office building (see Note 5). The joint ventures are consolidated by NHP/PMB, and we consolidate NHP/PMB in our consolidated financial statements.
We also have five partnerships in which we have equity interests, ranging from 51% to 81%, in three assisted and independent living facilities, one skilled nursing facility and one specialty hospital. We consolidate the partnerships in our consolidated financial statements.
Fair Value
We apply the provisions of ASC Topic 820, Fair Value Measurements and Disclosures (“ASC 820”) to our financial assets and liabilities measured at fair value on a recurring basis and to our nonfinancial assets and liabilities that are not required or permitted to be measured at fair value on a recurring basis.
ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. ASC 820 also specifies a three-level hierarchy of valuation techniques based upon whether the inputs reflect assumptions other market participants would use based upon market data obtained from independent sources (observable inputs) or reflect our own assumptions of market participant valuation (unobservable inputs) and requires the use of observable inputs if such data is available without undue cost and effort. The hierarchy is as follows:
    Level 1 — quoted prices for identical instruments in active markets.
    Level 2 — observable inputs other than Level 1 inputs, including quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and other derived valuations with significant inputs or value drivers that are observable or can be corroborated by observable inputs in active markets.
    Level 3 — unobservable inputs or derived valuations with significant inputs or value drivers that are unobservable.
Fair value measurements at March 31, 2010 are as follow:
                                 
    Fair Value     Level 1     Level 2     Level 3  
    (In thousands)  
Financial assets
  $ 4,723     $ 4,723     $     $  
Financial liabilities
    (4,723 )     (4,723 )            
Redeemable OP unitholder interests
    77,557             77,557        
 
                       
 
  $ 77,557     $     $ 77,557     $  
 
                       
OP Units are exchangeable for cash or, at our option, shares of our common stock, initially on a one-for-one basis. As such, the fair value of OP Units outstanding at March 31, 2010 is based on the closing price of our common stock on March 31, 2010, which was $35.15 per share.
The provisions of ASC Topic 825, Financial Instruments, provide companies with an option to report selected financial assets and liabilities at fair value and establish presentation and disclosure requirements designed to facilitate comparisons between companies that choose different measurement attributes for similar types of assets and liabilities. We have not elected to apply the fair value option to any specific financial assets or liabilities.

 

12


Table of Contents

NATIONWIDE HEALTH PROPERTIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The carrying amount of cash and cash equivalents approximates fair value because of the short maturities of these instruments. The fair value of mortgage and other loans receivable are based upon the estimates of management and on rates currently prevailing for comparable loans. The fair value of long-term debt is estimated based on discounting future cash flows utilizing current rates offered to us for debt of a similar type and remaining maturity.
The table below details the book value and fair value for mortgage and other loans receivable and the components of long-term debt at March 31, 2010. These fair value estimates are not necessarily indicative of the amounts that would be realized upon disposition of these financial instruments.
                 
    Book Value     Fair Value  
    (In thousands)  
Mortgage loans receivable
  $ 216,589     $ 216,349  
Other loans receivable
  $ 71,326     $ 67,049  
Unsecured senior credit facility
  $     $  
Senior notes
  $ 991,633     $ 1,067,918  
Notes and bonds payable
  $ 535,950     $ 532,376  
Earnings per Share (EPS)
Basic EPS is computed by dividing income from continuing operations available to common stockholders by the weighted average common shares outstanding. Income from continuing operations available to common stockholders is calculated by deducting amounts attributable to noncontrolling interests, amounts attributable to participating securities and dividends declared on preferred stock from income from continuing operations.
We apply the provisions of ASC Topic 260, Earnings per Share, which require that the two-class method of computing basic earnings per share be applied when there are unvested share-based payment awards that contain rights to nonforfeitable dividends outstanding during a reporting period. These participating securities share in undistributed earnings with common stockholders for purposes of calculating basic earnings per share.
Diluted EPS includes the effect of any potential shares outstanding, which for us is comprised of dilutive stock options, other share-settled compensation plans and, if the effect is dilutive, 7.75% Series B Cumulative Convertible Preferred Stock (“Series B Preferred Stock”), which was redeemed on January 18, 2010 (see Note 10) and/or OP Units. The dilutive effect of stock options and other share-settled compensation plans that do not contain rights to nonforfeitable dividends is calculated using the treasury stock method with an offset from expected proceeds upon exercise of the stock options and unrecognized compensation expense.
Impact of New Accounting Standards Updates
In June 2009, the FASB updated ASC 810 to require ongoing analyses to determine whether an entity’s variable interest gives it a controlling financial interest in a variable interest entity (“VIE”), making it the primary beneficiary, based on whether the entity (i) has the power to direct activities of the VIE that most significantly impact its economic performance, including whether it has an implicit financial responsibility to ensure the VIE operates as designed, and (ii) has the obligation to absorb losses or the right to receive benefits of the VIE that could potentially be significant to the VIE. Enhanced disclosures regarding an entity’s involvement with VIEs are also required under the provisions of ASC 810. These requirements became effective January 1, 2010. The adoption of these requirements did not have a material impact on our results of operations or financial position.
In January 2010, the FASB issued Accounting Standards Update (“ASU”) 2010-06, Improving Disclosures About Fair Value Measurements (“ASU 2010-06”). ASU 2010-06 adds new requirements for disclosures of significant transfers into and out of Levels 1, 2 and 3 of the fair value hierarchy, the reasons for the transfers and the policy for determining when transfers are recognized. ASU 2010-06 also adds new requirements for disclosures about purchases, sales, issuances and settlements on a gross rather than net basis relating to the reconciliation of the beginning and ending balances of Level 3 recurring fair value measurements. It also clarifies the level of disaggregation to require disclosures by “class” rather than by “major category of assets and liabilities” and clarifies that a description of inputs and valuation techniques used to measure fair value is required for both recurring and nonrecurring fair value measurements classified as Level 2 or 3. ASU 2010-06 became effective January 1, 2010 except for the requirements to provide the Level 3 activity of purchases, sales, issuances and settlements on a gross basis which are effective January 1, 2011. The adoption of ASU 2010-06 has not and is not expected to have a material impact on our results of operations or financial position.

 

13


Table of Contents

NATIONWIDE HEALTH PROPERTIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
In February 2010, the FASB issued ASU 2010-09, Amendments to Certain Recognition and Disclosure Requirements (“ASU 2010-09”). ASU 2010-09 amends ASC Topic 855, Subsequent Events, to require SEC registrants and conduit bond obligors to evaluate subsequent events through the date that the financial statements are issued, however, SEC registrants are exempt from disclosing the date through which subsequent events have been evaluated. All other entities are required to evaluate subsequent events through the date that the financial statements are available to be issued and must disclose the date through which subsequent events have been evaluated. ASU 2010-09 was effective upon issuance for all entities except conduit debt obligors. The adoption of ASU 2010-09 did not have an impact on our results of operations or financial position.
3. Real Estate Properties
At March 31, 2010, we had direct ownership of:
    251 assisted and independent living facilities;
    167 skilled nursing facilities;
    9 continuing care retirement communities;
    7 specialty hospitals;
    19 triple-net medical office buildings, one of which is operated by a consolidated joint venture (see Note 5); and
    67 multi-tenant medical office buildings, 20 of which are operated by consolidated joint ventures (see Note 5).
We lease our owned senior housing and long-term care facilities and certain medical office buildings to single tenants under “triple-net,” and in most cases, “master” leases that are accounted for as operating leases. These leases generally have an initial term of up to 21 years and generally have two or more multiple-year renewal options. As of March 31, 2010, approximately 84% of these facilities were leased under master leases. In addition, the majority of these leases contain cross-collateralization and cross-default provisions tied to other leases with the same tenant, as well as grouped lease renewals and grouped purchase options. As of March 31, 2010, leases covering 457 facilities were backed by security deposits consisting of irrevocable letters of credit or cash totaling $72.2 million. Under the terms of the leases, the tenant is responsible for all maintenance, repairs, taxes, insurance and capital expenditures on the leased properties. As of March 31, 2010, leases covering 339 facilities contained provisions for property tax impounds, and leases covering 208 facilities contained provisions for capital expenditure impounds. We generally lease medical office buildings to multiple tenants under separate non-triple-net leases, where we are responsible for many of the associated operating expenses (although many of these are, or can effectively be, passed through to the tenants). However, some of the medical office buildings are subject to triple-net leases, where the lessees are responsible for the associated operating expenses. No individual property owned by us is material to us as a whole.
During the three months ended March 31, 2010, we acquired the remaining 55.05% interest in PMB SB 399-401 East Highland LLC (“PMB SB”), an entity affiliated with Pacific Medical Buildings LLC that owns two multi-tenant medical office buildings. PMB SB was valued at $17.4 million at the date of acquisition, and the acquisition was paid in a combination of cash and the assumption of $11.2 million of mortgage financing (of which $6.2 million was previously attributable to the controlling interest in PMB SB) (see Note 6).

 

14


Table of Contents

NATIONWIDE HEALTH PROPERTIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
During the three months ended March 31, 2010, we funded $3.7 million in expansions, construction and capital improvements at certain facilities in our triple-net leases segment in accordance with existing lease provisions. Such expansions, construction and capital improvements generally result in an increase in the minimum rents earned by us on these facilities either at the time of funding or upon completion of the project. At March 31, 2010, we had committed to fund additional expansions, construction and capital improvements of $108.8 million. During the three months ended March 31, 2010, we also funded $0.2 million in capital and tenant improvements at certain multi-tenant medical office buildings.
During the three months ended March 31, 2010, we sold the assisted living portion of a continuing care retirement community for which we had an existing mortgage loan secured by the skilled nursing portion of such continuing care retirement community (see Note 4) to the tenant of the facility. We provided financing of $6.5 million related to the sale, including the concurrent repayment of a $0.7 million unsecured loan which had previously been included in the caption “Other assets” on our consolidated balance sheets (see Note 4). As we have a continuing interest in the facility, operating results from the facility are included in income from continuing operations on our consolidated income statements.
No impairment charges were recorded on our real estate properties during the three months ended March 31, 2010 or 2009.
4. Mortgage Loans Receivable
At March 31, 2010, we held 15 mortgage loans receivable secured by 26 medical office buildings, 16 skilled nursing facilities, nine assisted and independent living facilities, one continuing care retirement community and one land parcel. At March 31, 2010, the mortgage loans receivable had an aggregate principal balance of $216.6 million and are reflected in our consolidated balance sheets net of aggregate deferred gains totaling $19.3 million, with individual outstanding principal balances ranging from $0.7 million to $80.1 million and maturities ranging from 2010 to 2024.
During the three months ended March 31, 2010, we funded one mortgage loan secured by 26 medical office buildings in the amount of $80.1 million.
During the three months ended March 31, 2010, we also funded $6.8 million and $52.8 million under loans to our consolidated joint ventures with PMB Gilbert LLC and PMB Pasadena LLC, respectively (see Note 5). As we consolidate these joint ventures, these balances have been eliminated for purposes of our consolidated financial statements.
During the three months ended March 31, 2010, we sold the assisted living portion of a continuing care retirement community for which we had an existing mortgage loan secured by the skilled nursing portion of such continuing care retirement community to the tenant of the facility. For facility count purposes, this was previously accounted for in real estate properties as a continuing care retirement community (see Note 3). We provided financing of $6.5 million related to the sale, including the concurrent repayment of a $0.7 million unsecured loan which had previously been included in the caption “Other assets” on our consolidated balance sheets, and funded an additional $0.2 million subsequent to the sale.
As of February 1, 2010, we acquired the multi-tenant medical office building which served as collateral for our $47.5 million mortgage loan from a related party, and as a result, the loan was retired (see Notes 5 and 18).
In 2009, we entered into an agreement with one of our triple-net tenants, Brookdale Senior Living, Inc. (“Brookdale”), under which we became a lender with a commitment of $2.9 million under their $75.0 million revolving loan facility. The revolving loan facility was terminated as of February 23, 2010. There was no balance outstanding at the date of termination.

 

15


Table of Contents

NATIONWIDE HEALTH PROPERTIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
5. Medical Office Building Joint Ventures
NHP/Broe, LLC and NHP/Broe II, LLC
On August 21, 2009, we acquired for $4.3 million the 10% and 5% noncontrolling interests held by The Broe Companies in NHP/Broe, LLC (“Broe I”) and NHP/Broe II, LLC (“Broe II”), respectively. As a result of this acquisition, we now have direct ownership of the 36 multi-tenant medical office buildings located in nine states previously owned by Broe I and Broe II. Activity subsequent to August 21, 2009 related to these facilities is included in our consolidated activity for wholly owned real estate properties (see Note 3). Prior to our acquisition of Broe’s interests, we consolidated both joint ventures in our consolidated financial statements in accordance with ASC 810.
McShane/NHP JV, LLC
In December 2007, we entered into a joint venture with McShane called McShane/NHP JV, LLC (“McShane/NHP”) to invest in multi-tenant medical office buildings. We hold a 95% equity interest in the joint venture and McShane holds a 5% equity interest. McShane is the managing member of McShane/NHP, but we consolidate the joint venture in our consolidated financial statements. The accounting policies of the joint venture are consistent with our accounting policies.
Cash distributions from McShane/NHP are made in accordance with the members’ ownership interests until specified returns are achieved. As the specified returns are achieved, McShane will receive an increasing percentage of the cash distributions from the joint venture. No cash distributions were made during the three months ended March 31, 2010.
At March 31, 2010, McShane/NHP owned seven multi-tenant medical office buildings located in one state.
During the three months ended March 31, 2010, McShane/NHP funded $0.1 million in capital and tenant improvements at certain facilities.
All intercompany balances with McShane/NHP have been eliminated for purposes of our consolidated financial statements.
NHP/PMB L.P.
In February 2008, we entered into an agreement (the “Contribution Agreement”) with Pacific Medical Buildings LLC and certain of its affiliates to acquire up to 18 medical office buildings, including six in development, for $747.6 million, including the assumption of approximately $282.6 million of mortgage financing. Under the Contribution Agreement, in 2008, NHP/PMB acquired interests in nine of the 18 medical office buildings, including one property which is included in our triple-net leases segment and eight properties which are multi-tenant medical office buildings (one of which consisted of a 50% interest through a joint venture which is consolidated by NHP/PMB). During 2008, we also acquired one of the 18 medical office buildings directly (not through NHP/PMB). During 2009, we elected to terminate the Contribution Agreement with respect to six properties after the conditions for us to close on such properties were not satisfied. As a result of the elimination of these six properties, under the Contribution Agreement, NHP/PMB became obligated to pay $3.0 million, of which $2.7 million was payable to Pacific Medical Buildings LLC.
As of February 1, 2010, we entered into an amendment to the Contribution Agreement which reinstated one of the six properties that were previously eliminated from the Contribution Agreement. NHP/PMB acquired such multi-tenant medical office building for $74.0 million, which was paid in a combination of cash and the issuance of 301,599 OP Units with a fair value at the date of issuance of $10.0 million. As a result of such acquisition, we retired our $47.5 million mortgage loan from a related party to which such acquired medical office building had served as collateral (see Note 18). Additionally, as of February 1, 2010, we acquired a majority ownership interest in a joint venture which owns one multi-tenant medical office building (see NHP/PMB Gilbert LLC below), amended and restated our agreement with NHP/PMB, PMB LLC and PMB Real Estate Services LLC (“PMBRES”) as described below and amended our agreement with PMB Pomona LLC to provide for the future acquisition by NHP/PMB of a medical office building currently in development (see Note 18). In connection with these transactions, NHP/PMB entered into a Third Amendment to the Amended and Restated Agreement of Limited Partnership, which, among other things, authorized NHP/PMB to acquire properties affiliated with Pacific Medical Buildings LLC pursuant to agreements other than the Contribution Agreement.

 

16


Table of Contents

NATIONWIDE HEALTH PROPERTIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
As of March 1, 2010, we entered into an amendment to the Contribution Agreement which reinstated another two of the six properties that were previously eliminated from the Contribution Agreement. NHP/PMB acquired a 65% interest in a joint venture which is consolidated by NHP/PMB that owns one of the two multi-tenant medical office buildings valued at $79.9 million. The acquisition was paid in a combination of cash, the assumption of $48.1 million of mortgage financing and the issuance of 152,238 OP Units with a fair value at the date of issuance of $5.0 million. NHP/PMB acquired a 69% interest in a joint venture which is consolidated by NHP/PMB that owns the second multi-tenant medical office building valued at $69.3 million. The acquisition was paid in a combination of cash, the assumption of $50.2 million of mortgage financing and the issuance of 121,489 OP Units with a fair value at the date of issuance of $4.0 million. Additionally, as of March 1, 2010, we acquired the remaining interest in PMB SB (see Note 6).
The amendment to the Contribution Agreement dated as of March 1, 2010 also eliminated one of the two remaining properties from the Contribution Agreement, however, we concurrently entered into a joint venture with PMB Pasadena LLC (an entity affiliated with Pacific Medical Buildings LLC) to acquire this property (see NHP/PMB Pasadena LLC below). As a result of the elimination of this property from the Contribution Agreement, NHP/PMB became obligated to pay $2.1 million (the “Premium Adjustment”), of which $1.9 million was payable to Pacific Medical Buildings LLC in cash. The portion of the Premium Adjustment not payable to Pacific Medical Buildings LLC was paid in the form of $0.1 million in cash and the issuance of 1,788 additional OP Units with an aggregate value of $57,000. As a result of the payment, we received an additional 4,514 Class B limited partnership units in NHP/PMB. Under the Contribution Agreement, if the agreement is terminated with respect to the remaining development property, NHP/PMB will become obligated to pay approximately $2.4 million (the “Future Premium Adjustment”) which has been accrued at March 31, 2010 and of which a portion would be payable to Pacific Medical Buildings LLC.
Under the terms of the Contribution Agreement, a portion of the consideration for the multi-tenant medical office buildings is to be paid in the form of OP Units. After a one-year holding period, the OP Units are exchangeable for cash or, at our option, shares of our common stock, initially on a one-for-one basis. During the three months ended March 31, 2010, 401 OP Units were converted into 401 shares of our common stock. At March 31, 2010, 1,626,800 of the remaining OP Units had been outstanding for one year or longer and were exchangeable for cash of $57.2 million. During the three months ended March 31, 2010, cash distributions from NHP/PMB of $0.4 million were made to OP unitholders.
Additionally, we have entered into an agreement with NHP/PMB, PMB LLC and PMBRES (see Note 6) pursuant to which we or NHP/PMB currently have the right, but not the obligation, to acquire up to approximately $1.3 billion of multi-tenant medical office buildings developed by PMB LLC through April 2019. As of February 1, 2010, this agreement was amended and restated to provide NHP/PMB with the option to acquire medical office buildings developed in the future through a joint venture between NHP and PMB LLC, obligate us to provide or arrange financing for approved developments and provide us with improved terms, including preferred returns, a reduction in PMB LLC’s promote interest and acquisition pricing determined at the time of acquisition rather that at the pre-development stage.
During the three months ended March 31, 2010, NHP/PMB funded $0.1 million in capital and tenant improvements at certain facilities.
All intercompany balances with NHP/PMB have been eliminated for purposes of our consolidated financial statements.
NHP/PMB Gilbert LLC
As of February 1, 2010, we entered into a joint venture with PMB Gilbert LLC (an entity affiliated with Pacific Medical Buildings LLC) called NHP/PMB Gilbert LLC (“Gilbert JV”) to acquire a multi-tenant medical office building. PMB Gilbert LLC contributed the multi-tenant medical office building to Gilbert JV, and we contributed $6.3 million in cash. Additionally, we agreed to loan Gilbert JV up to $8.8 million as project financing at an interest rate of 7.00%, including $6.8 million that was disbursed initially and remains outstanding at March 31, 2010. We hold a 71.17% equity interest in the joint venture and PMB Gilbert LLC holds a 28.83% equity interest. PMB Gilbert LLC is the managing member of Gilbert JV, but we consolidate the joint venture in our consolidated financial statements. The accounting policies of the joint venture are consistent with our accounting policies. Pursuant to a contribution agreement dated as of February 1, 2010, among us, NHP/PMB, Pacific Medical Buildings LLC and PMB Gilbert LLC, NHP/PMB may in the future acquire Gilbert JV if certain conditions are met.

 

17


Table of Contents

NATIONWIDE HEALTH PROPERTIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Net income or loss is allocated between the partners in the joint venture based on the hypothetical liquidation at book value method (the “HLBV method”). Under the HLBV method, net income or loss is allocated between the partners based on the difference between each partner’s claim on the net assets of the partnership at the end and beginning of the period, after taking into account contributions and distributions. Each partner’s share of the net assets of the partnership is calculated as the amount that the partner would receive if the partnership were to liquidate all of its assets at net book value and distribute the resulting cash to creditors and partners in accordance with their respective priorities. Under this method, in any given period, we could be recording more or less income than the joint venture has generated or more or less income than actual cash distributions received and more or less than what we may receive in the event of an actual liquidation. No cash distributions were made during the three months ended March 31, 2010.
All intercompany balances with Gilbert JV have been eliminated for purposes of our consolidated financial statements.
NHP/PMB Pasadena LLC
As of March 1, 2010, we entered into a joint venture with PMB Pasadena LLC (an entity affiliated with Pacific Medical Buildings LLC) called NHP/PMB Pasadena LLC (“Pasadena JV”) to acquire a multi-tenant medical office building. PMB Pasadena LLC contributed the multi-tenant medical office building to Pasadena JV, and we contributed $13.5 million in cash. Additionally, we provided Pasadena JV with a $56.5 million mortgage loan at an initial interest rate equal to the greater of 3.50% or LIBOR plus 165 basis points (increasing to the greater of 5.125% or LIBOR plus 375 basis points as of April 1, 2010), of which $49.8 million has been funded, and a $3.0 million mezzanine loan at an interest rate of 15.00%, both of which remain outstanding at March 31, 2010. We hold a 71% equity interest in the joint venture and PMB Pasadena LLC holds a 29% equity interest. PMB Pasadena LLC is the managing member of Pasadena JV, but we consolidate the joint venture in our consolidated financial statements. The accounting policies of the joint venture are consistent with our accounting policies. Pursuant to a contribution agreement dated as of March 1, 2010, among us, NHP/PMB, Pacific Medical Buildings LLC and PMB Pasadena LLC, NHP/PMB may in the future acquire Pasadena JV if certain conditions are met.
Net income or loss is allocated between the partners in the joint venture based on the HLBV method. No cash distributions were made during the three months ended March 31, 2010.
All intercompany balances with Pasadena JV have been eliminated for purposes of our consolidated financial statements.
6. Investment in Unconsolidated Joint Ventures
State Pension Fund Investor
In January 2007, we entered into a joint venture with a state pension fund investor. The purpose of the joint venture is to acquire and develop assisted living, independent living and skilled nursing facilities. We manage and own 25% of the joint venture, which will fund its investments with approximately 40% equity contributions and 60% debt. The original approved investment target was $475.0 million, but we exceeded that amount in 2007, and the total potential investment amount has been increased to $975.0 million. The financial statements of the joint venture are not consolidated in our financial statements as our joint venture partner has substantive participating rights, and accordingly our investment is accounted for using the equity method.
At March 31, 2010, the joint venture owned 19 assisted and independent living facilities, 14 skilled nursing facilities and one continuing care retirement community located in nine states.

 

18


Table of Contents

NATIONWIDE HEALTH PROPERTIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
During January 2008, the joint venture entered into an interest rate swap contract that is designated as effectively hedging the variability of expected cash flows related to variable rate debt placed on a portion of its portfolio. The cash flow hedge has a fixed rate of 4.235%, a notional amount of $126.1 million and expires on January 1, 2015. The fair value of this contract at March 31, 2010 and December 31, 2009 was $9.9 million and $8.2 million, respectively, which is included in accrued liabilities on the joint venture’s balance sheet.
Cash distributions from the joint venture are made in accordance with the members’ ownership interests until specified returns are achieved. As the specified returns are achieved, we will receive an increasing percentage of the cash distributions from the joint venture. During the three months ended March 31, 2010, we received distributions of $0.7 million from the joint venture. In addition to our share of the income, we receive a monthly management fee calculated as a percentage of the equity investment in the joint venture. This fee is included in our income from unconsolidated joint ventures and in the general and administrative expenses on the joint venture’s income statement. During the three months ended March 31, 2010 and 2009, we earned management fees of $1.1 million and $1.0 million, respectively. During each of the three months ended March 31, 2010 and 2009, our share of the net income was $0.2 million.
PMB Real Estate Services LLC
In February 2008, we entered into an agreement with Pacific Medical Buildings LLC to acquire a 50% interest in PMBRES, a full service property management company. The transaction closed on April 1, 2008. In consideration for the 50% interest, we paid $1.0 million at closing, and we will make additional payments on or before March 31, 2010 and 2011 equal to six times the normalized net operating profit of PMBRES for 2009 and 2010, respectively (in each case, less the amount of all prior payments). During 2009, PMBRES had a normalized net operating loss, and as such, no additional payment was made during the three months ended March 31, 2010. PMBRES provides property management services for 32 multi-tenant medical office buildings that we own or in which we have an ownership interest. During the three months ended March 31, 2010, our share of the net income was $28,000. During the three months ended March 31, 2009, our share of the net loss was $0.2 million.
PMB SB 399-401 East Highland LLC
In August 2008, we acquired from PMB SB (an entity affiliated with Pacific Medical Buildings LLC) a 44.95% interest in an entity that owned two multi-tenant medical office buildings for $3.5 million. As of March 1, 2010, we acquired the remaining 55.05% interest in PMB SB. PMB SB was valued at $17.4 million at the date of acquisition, and the acquisition was paid in a combination of cash and the assumption of $11.2 million of mortgage financing (of which $6.2 million was previously attributable to the controlling interest in PMB SB). Prior to the acquisition, our investment in PMB SB was $3.0 million which was accounted for under the equity method. In connection with the acquisition, we re-measured our previously held equity interest at the acquisition date fair value based on an independent consultant’s report and recognized a net gain on the re-measurement of $0.6 million which is included in the caption “Interest and other income” on our consolidated income statements. Subsequent activity related to these facilities is included in our consolidated activity for wholly owned real estate properties (see Note 3).
During the period from January 1, 2010 to February 28, 2010, we received distributions of $0.1 million from PMB SB. During the period from January 1, 2010 to February 28, 2010, our share of the net income was $12,000. During the three months ended March 31, 2009, our share of the net income was $21,000.
7. Intangible Assets and Liabilities
Intangible assets include items such as lease-up intangible assets, above market tenant and ground lease intangible assets and in-place lease intangible assets. At March 31, 2010 and December 31, 2009, the gross balance of intangible lease assets was $187.8 million and $130.0 million, respectively. At March 31, 2010 and December 31, 2009, the accumulated amortization of intangible lease assets was $37.7 million and $36.3 million, respectively. Intangible liabilities include below market tenant and ground lease intangible liabilities. At March 31, 2010 and December 31, 2009, we had $18.9 million and $18.3 million, respectively, of gross intangible liabilities recorded under the caption “Accounts payable and accrued liabilities” on our consolidated balance sheets. At March 31, 2010 and December 31, 2009, the accumulated amortization of intangible liabilities was $4.0 million and $3.9 million, respectively.

 

19


Table of Contents

NATIONWIDE HEALTH PROPERTIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
For the three months ended March 31, 2010 and 2009, medical office building operating rent included $0.1 million and $0.2 million, respectively, from the amortization of above/below market lease intangibles. For the three months ended March 31, 2010 and 2009, expenses included $4.0 million and $5.1 million, respectively, from the amortization of other intangible lease assets and liabilities.
8. Other Assets
At March 31, 2010 and December 31, 2009, other assets consisted of:
                 
    March 31,     December 31,  
    2010     2009  
    (In thousands)  
Other receivables, net of reserves of $4.2 million at March 31, 2010 and December 31, 2009
  $ 67,152     $ 68,535  
Straight-line rent receivables, net of reserves of $108.2 million and $108.3 million at March 31, 2010 and December 31, 2009, respectively
    29,279       27,450  
Deferred financing costs
    11,436       11,366  
Capitalized lease and loan origination costs
    2,247       2,418  
Investments and restricted funds
    13,911       9,545  
Prepaid ground leases
    12,993       10,051  
Other
    4,309       3,787  
 
           
 
  $ 141,327     $ 133,152  
 
           
Included in other receivables at both March 31, 2010 and December 31, 2009, are two unsecured loans to Emeritus Corporation in the amount of $21.4 million and $30.0 million due in March 2012 and April 2012, respectively.
Investments are recorded at fair value using quoted market prices.
9. Debt
Unsecured Senior Credit Facility
At March 31, 2010, we had no balance outstanding on our $700.0 million revolving unsecured senior credit facility. At our option, borrowings under the credit facility bear interest at the prime rate (3.25% at March 31, 2010) or applicable LIBOR plus 0.70% (0.95% at March 31, 2010). We pay a facility fee of 0.15% per annum on the total commitment under the agreement. The credit facility matures on December 15, 2010. The maturity date may be extended by one additional year at our discretion. As of March 31, 2010, we were in compliance with all covenants under the credit facility.
Senior Notes
The aggregate principal amount of notes outstanding at March 31, 2010 was $991.6 million. At March 31, 2010, the weighted average interest rate on the notes was 6.47% and the weighted average maturity was 4.7 years.
Notes and Bonds Payable
The aggregate principal amount of notes and bonds payable at March 31, 2010 was $536.0 million. Notes and bonds payable are due through the year 2037, at interest rates ranging from 1.08% to 8.63% and are secured by real estate properties with an aggregate net book value as of March 31, 2010 of $799.2 million. At March 31, 2010, the weighted average interest rate on the notes and bonds payable was 5.35% and the weighted average maturity was 6.7 years.
During the three months ended March 31, 2010, we assumed mortgages as part of certain acquisitions totaling $109.5 million.

 

20


Table of Contents

NATIONWIDE HEALTH PROPERTIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
During the three months ended March 31, 2010, we repaid at maturity $2.9 million of fixed rate secured debt that bore interest at 8.02%.
During the three months ended March 31, 2010, we exercised a 12-month extension option on a $32.4 million loan that was scheduled to mature in April 2010.
Debt Maturities
The principal balances of our debt as of March 31, 2010 mature as follows:
                                 
    Credit     Senior     Notes and Bonds        
Year   Facility     Notes     Payable     Total  
    (In thousands)  
2010
  $     $     $ 77,275     $ 77,275  
2011
          339,040       71,483       410,523  
2012
          72,950       51,131       124,081  
2013
          269,850       38,997       308,847  
2014
                22,167       22,167  
Thereafter (1)
          309,793       274,897       584,690  
 
                       
 
  $     $ 991,633     $ 535,950     $ 1,527,583  
 
                       
     
(1)   There are $52.4 million of senior notes due in 2037 which may be put back to us at their face amount at the option of the holder on October 1 of any of the following years: 2012, 2017 or 2027. There are $23.0 million of senior notes due in 2038 which may be put back to us at their face amount at the option of the holder on July 7 of any of the following years: 2013, 2018, 2023 or 2028.
10. Stockholders’ Equity
Preferred Stock
On January 18, 2010, we redeemed all outstanding shares of our Series B Preferred Stock at a redemption price per share of $103.875 plus an amount equal to accumulated and unpaid dividends thereon to the redemption date ($0.3875), for a total redemption price of $104.2625 per share, payable only in cash. As a result of the redemption, each share of Series B Preferred Stock was convertible until January 14, 2010 into 4.5150 shares of common stock. During that time, 512,727 shares were converted into approximately 2,315,000 shares of common stock. On January 18, 2010, we redeemed 917 shares that remained outstanding.
Common Stock
We enter into sales agreements from time to time with agents to sell shares of our common stock through an at-the-market equity offering program. We entered into two new sales agreements, each dated January 15, 2010, to sell up to an aggregate of 5,000,000 shares of our common stock from time to time. During the three months ended March 31, 2010, we issued and sold approximately 1,269,000 shares of common stock at a weighted average price of $35.58 per share, resulting in net proceeds of approximately $44.7 million after sales agent fees. At March 31, 2010, approximately 4,195,000 shares of common stock were available to be sold pursuant to our at-the-market equity offering program. From April 1, 2010 to May 6, 2010, we issued and sold approximately 1,592,000 shares at a weighted average price of $35.08 per share (see Note 19).
We sponsor a dividend reinvestment plan that enables existing stockholders to purchase additional shares of common stock by automatically reinvesting all or part of the cash dividends paid on their shares of common stock at a discount ranging from 0% to 5%, determined by us from time to time in accordance with the plan. The discount at March 31, 2010 was 2%. During the three months ended March 31, 2010, we issued approximately 140,000 shares of common stock, at an average price of $33.09 per share, resulting in net proceeds of approximately $4.6 million.

 

21


Table of Contents

NATIONWIDE HEALTH PROPERTIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
On January 18, 2010, we redeemed all outstanding shares of Series B Preferred Stock, and as a result, 512,727 shares of Series B Preferred Stock were converted into approximately 2,315,000 shares of common stock during the period from January 1, 2010 to January 14, 2010.
During the three months ended March 31, 2010, 401 OP Units issued by NHP/PMB were exchanged for 401 shares of common stock (see Note 5).
11. Earnings Per Share (EPS)
Certain of our share-based payment awards are considered participating securities which requires the use of the two-class method for the computation of basic and diluted EPS.
Diluted EPS also includes the effect of any potential shares outstanding, which for us is comprised of dilutive stock options, other share-settled compensation plans and, if the effect is dilutive, Series B Preferred Stock, which was redeemed on January 18, 2010 (see Note 10) and/or OP Units. There were 270,100 and 243,000 stock options that would not be dilutive for the three months ended March 31, 2010 and 2009, respectively. The calculation below excludes 27,000 restricted stock units, 8,700 restricted stock shares and 6,900 stock appreciation rights that would not be dilutive for the three months ended March 31, 2010 and 1,200 performance shares and 538,000 stock appreciation rights that would not be dilutive for the three months ended March 31, 2009. The Series B Preferred Stock is not dilutive for any period presented. The table below details the components of the basic and diluted EPS calculations:
                 
    Three months ended  
    March 31,  
    2010     2009  
    (In thousands, except per  
    share amounts)  
Numerator:
               
Income from continuing operations
  $ 31,217     $ 29,428  
Net (income) loss attributable to noncontrolling interests
    190       (27 )
Net income attributable to participating securities
    (326 )     (206 )
Undistributed earnings attributable to participating securities
          (13 )
Series B preferred stock dividends
          (1,452 )
 
           
Numerator for Basic and Diluted EPS from continuing operations
  $ 31,081     $ 27,730  
 
           
 
               
Income from discontinued operations
  $ 22     $ 21,205  
 
           
Numerator for Basic and Diluted EPS from discontinued operations
  $ 22     $ 21,205  
 
           
 
               
Denominator:
               
Basic weighted average shares outstanding
    117,048       102,355  
Effect of dilutive securities:
               
Stock options
    70       58  
Other share-settled compensation plans
    426       165  
OP Units
    1,922       1,830  
 
           
Diluted weighted average shares outstanding
    119,466       104,408  
 
           
 
               
Basic earnings per share amounts:
               
Income from continuing operations attributable to NHP common stockholders
  $ 0.27     $ 0.27  
Discontinued operations attributable to NHP common stockholders
          0.21  
 
           
Net income attributable to NHP common stockholders
  $ 0.27     $ 0.48  
 
           
 
               
Diluted earnings per share amounts:
               
Income from continuing operations attributable to NHP common stockholders
  $ 0.26     $ 0.27  
Discontinued operations attributable to NHP common stockholders
          0.20  
 
           
Net income attributable to NHP common stockholders
  $ 0.26     $ 0.47  
 
           

 

22


Table of Contents

NATIONWIDE HEALTH PROPERTIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
12. Discontinued Operations
ASC 360 requires the operating results of any assets with their own identifiable cash flows that are disposed of or held for sale and in which we have no continuing interest be removed from income from continuing operations and reported as discontinued operations. The operating results for any such assets for any prior periods presented must also be reclassified as discontinued operations. If we have a continuing involvement, as in the sales to our unconsolidated joint venture, the operating results remain in continuing operations. The following table details the operating results reclassified to discontinued operations for the periods presented:
                 
    Three months ended  
    March 31,  
    2010     2009  
    (In thousands)  
Rental income
  $     $ 325  
Interest and other income
          19  
 
           
 
          344  
 
           
Expenses:
               
Interest expense and amortization of deferred financing costs
           
Depreciation and amortization
          291  
General and administrative
           
Medical office building operating expenses
           
 
           
 
          291  
 
           
Income from discontinued operations
  $     $ 53  
 
           
13. Derivatives
During January 2008, the unconsolidated joint venture we have with a state pension fund investor entered into an interest rate swap contract (see Notes 6 and 14).
During August and September 2007, we entered into four six-month Treasury lock agreements totaling $250.0 million at a weighted average rate of 4.212%. We entered into these Treasury lock agreements in order to hedge the expected interest payments associated with a portion of our October 2007 issuance of $300.0 million of notes which mature in 2013. These Treasury lock agreements were settled in cash on October 17, 2007 for an amount equal to the present value of the difference between the locked Treasury rates and the unwind rate (equal to the then-prevailing Treasury rate less the forward premium or 4.364%). We reassessed the effectiveness of these agreements at the settlement date and determined that they were highly effective cash flow hedges under ASC 815 for $250.0 million of the $300.0 million of notes as intended. The prevailing Treasury rate exceeded the rates in the Treasury lock agreements and, as a result, the counterparties to those agreements made payments to us of $1.6 million, which was recorded as other comprehensive income. The settlement amounts are being amortized over the life of the debt as a yield reduction. During the three months ended March 31, 2010 and 2009, we recorded $64,000 and $67,000 of amortization, respectively. We expect to record $0.3 million of amortization during the next 12 months.
In June 2006, we entered into two $125.0 million, two-month Treasury lock agreements in order to hedge the expected interest payments associated with a portion of our July 2006 issuance of $350.0 million of notes which mature in 2011. These Treasury lock agreements were settled in cash on July 11, 2006, concurrent with the pricing of the $350 million of notes, for an amount equal to the present value of the difference between the locked Treasury rates and the unwind rate. We reassessed the effectiveness of these agreements at the settlement date and determined that they were highly effective cash flow hedges under ASC 815 for $250.0 million of the $350.0 million of notes as intended. The prevailing Treasury rate exceeded the rates in the Treasury lock agreements and, as a result, the counterparty to those agreements made payments to us of $1.2 million, which was recorded as other comprehensive income. The settlement amounts are being amortized over the life of the debt as a yield reduction. During the three months ended March 31, 2010 and 2009, we recorded $62,000 and $58,000 of amortization, respectively. We expect to record $0.3 million of amortization during the next 12 months.
14. Comprehensive Income
During January 2008, the unconsolidated joint venture we have with a state pension fund investor entered into an interest rate swap contract (see Note 6). As of March 31, 2010, we had recorded our pro rata share of the unconsolidated joint venture’s accumulated other comprehensive loss related to this contract of $2.5 million.

 

23


Table of Contents

NATIONWIDE HEALTH PROPERTIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
We recorded the August and September 2007 Treasury lock agreements on our balance sheets at their estimated fair value of $0.1 million at September 30, 2007. In connection with the settlement of the August and September 2007 Treasury lock agreements on October 17, 2007, we recognized a gain of $1.6 million. The gain was recognized through other comprehensive income and is being amortized over the life of the related $300.0 million of notes which mature in 2013 as a yield reduction. During the three months ended March 31, 2010 and 2009, we recorded $64,000 and $67,000 of amortization, respectively. We expect to record $0.3 million of amortization during the next 12 months.
We recorded the June 2006 Treasury lock agreements on our balance sheets at their estimated fair value of $1.6 million at June 30, 2006. In connection with the settlement of the June 2006 Treasury lock agreements on July 11, 2006, we recognized a gain of $1.2 million. The gain was recognized through other comprehensive income and is being amortized over the life of the related $350.0 million of notes which mature in 2011 as a yield reduction. During the three months ended March 31, 2010 and 2009, we recorded $62,000 and $58,000 of amortization, respectively. We expect to record $0.3 million of amortization during the next 12 months.
The following table sets forth the computation of comprehensive income for the periods presented:
                 
    Three months ended  
    March 31,  
    2010     2009  
    (In thousands)  
Net income
  $ 31,239     $ 50,633  
Other comprehensive income:
               
Pro rata share of accumulated other comprehensive loss from unconsolidated joint venture
    (436 )     (3,547 )
Amortization of gains on Treasury lock agreements
    (126 )     (125 )
 
           
Comprehensive income
    30,677       46,961  
Comprehensive loss (income) attributable to noncontrolling interests
    190       (27 )
 
           
Comprehensive income attributable to NHP
  $ 30,867     $ 46,934  
 
           
15. Income Taxes
The provisions of ASC Topic 740, Income Taxes, which clarify the accounting for uncertainty in income taxes recognized in financial statements and prescribe a recognition threshold and measurement attribute of tax positions taken or expected to be taken on a tax return became effective January 1, 2007. No amounts have been recorded for unrecognized tax benefits or related interest expense and penalties. The taxable periods ending December 31, 2005 through December 31, 2009 remain open to examination by the Internal Revenue Service and the tax authorities of the significant jurisdictions in which we do business.
Hearthstone Acquisition
On June 1, 2006, we acquired the stock of Hearthstone Assisted Living, Inc. (“HAL”), causing HAL to become a qualified REIT subsidiary. As a result of the acquisition, we succeeded to HAL’s tax attributes, including HAL’s tax basis in its net assets. Prior to the acquisition, HAL was a corporation subject to federal and state income taxes. In connection with the acquisition of HAL, NHP acquired approximately $82.5 million of federal net operating losses (“NOLs”) which we can carry forward to future periods and the use of which is subject to annual limitations imposed by IRC Section 382. While we believe that these NOLs are accurate, any adjustments to HAL’s tax returns for periods prior to June 1, 2006 by the Internal Revenue Service could change the amount of the NOLs that we can utilize. We have used a portion of this amount in 2007 and 2008 and anticipate using additional amounts in future years. These NOLs are set to expire between 2017 and 2025. NOLs related to various states were also acquired and are set to expire based on the various laws of the specific states.
In addition, we may be subject to a corporate-level tax on any taxable disposition of HAL’s pre-acquisition assets that occurs within ten years after the June 1, 2006 acquisition. The corporate-level tax would be assessed only to the extent of the built-in gain that existed on the date of acquisition, based on the fair market value of the asset on June 1, 2006. We do not expect to dispose of any asset included in the HAL acquisition if such a disposition would result in the imposition of a material tax liability, and no such sales have taken place through March 31, 2010. Accordingly, we have not recorded a deferred tax liability associated with this corporate-level tax. Gains from asset dispositions occurring more than 10 years after the acquisition will not be subject to this corporate-level tax. However, we may dispose of HAL assets before the 10-year period if we are able to complete a tax-deferred exchange.

 

24


Table of Contents

NATIONWIDE HEALTH PROPERTIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
16. Segment Information
Our operations are organized into two segments — triple-net leases and multi-tenant leases. In the triple-net leases segment, we invest in healthcare related properties and lease the facilities to unaffiliated tenants under “triple-net” and generally “master” leases that transfer the obligation for all facility operating costs (including maintenance, repairs, taxes, insurance and capital expenditures) to the tenant. In the multi-tenant leases segment, we invest in healthcare related properties that have several tenants under separate leases in each building, thus requiring active management and responsibility for many of the associated operating expenses (although many of these are, or can effectively be, passed through to the tenants). During 2009 and the three months ended March 31, 2010, the multi-tenant leases segment was comprised exclusively of medical office buildings.
Non-segment revenues primarily consist of interest income on mortgages and unsecured loans and other income. Interest expense, depreciation and amortization and other expenses not attributable to individual facilities are not allocated to individual segments for purposes of assessing segment performance. Non-segment assets primarily consist of corporate assets including mortgages and unsecured loans, investment in unconsolidated joint ventures, cash, deferred financing costs and other assets not attributable to individual facilities.
Certain items in prior period financial statements have been reclassified to conform to current period presentation, including those required by ASC 360 which require the operating results of any assets with their own identifiable cash flows that are disposed of or held for sale and in which we have no continuing interest to be removed from income from continuing operations and reported as discontinued operations. Summary information related to our reportable segments is as follows:
                 
    Three months ended  
    March 31,  
    2010     2009  
    (In thousands)  
Revenue:
               
Triple-net leases
  $ 74,214     $ 74,095  
Multi-tenant leases
    21,251       16,653  
Non-segment
    6,963       6,335  
 
           
 
  $ 102,428     $ 97,083  
 
           
Net operating income (1):
               
Triple-net leases
  $ 74,214     $ 74,095  
Multi-tenant leases
    12,604       9,819  
 
           
 
  $ 86,818     $ 83,914  
 
           
                 
    March 31,     December 31,  
    2010     2009  
    (In thousands)  
Assets:
               
Triple-net leases
  $ 2,416,724     $ 2,440,158  
Multi-tenant leases
    898,910       572,410  
Non-segment
    498,010       634,507  
 
           
 
  $ 3,813,644     $ 3,647,075  
 
           
 
     
(1)   Net operating income (“NOI”) is a non-GAAP supplemental financial measure used to evaluate the operating performance of our facilities. We define NOI for our triple-net leases segment as rent revenues. For our multi-tenant leases segment, we define NOI as revenues minus medical office building operating expenses. In some cases, revenue for medical office buildings includes expense reimbursements for common area maintenance charges. NOI excludes interest expense and amortization of deferred financing costs, depreciation and amortization expense, general and administrative expense and discontinued operations. We present NOI as it effectively presents our portfolio on a “net” rent basis and provides relevant and useful information as it measures the operating performance at the facility level on an unleveraged basis. We use NOI to make decisions about resource allocations and to assess the property level performance of our properties. Furthermore, we believe that NOI provides investors relevant and useful information because it measures the operating performance of our real estate at the property level on an unleveraged basis. We believe that net income is the GAAP measure that is most directly comparable to NOI. However, NOI should not be considered as an alternative to net income as the primary indicator of operating performance as it excludes the items described above. Additionally, NOI as presented above may not be comparable to other REITs or companies as their definitions of NOI may differ from ours.

 

25


Table of Contents

NATIONWIDE HEALTH PROPERTIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
A reconciliation of net income, a GAAP measure, to NOI, a non-conforming GAAP measure, is as follows:
                 
    Three months ended  
    March 31,  
    2010     2009  
    (In thousands)  
Net income
  $ 31,239     $ 50,633  
Interest and other income
    (6,963 )     (6,335 )
Interest expense and amortization of deferred financing costs
    23,590       24,071  
Depreciation and amortization expense
    31,969       30,832  
General and administrative expense
    6,984       6,931  
Acquisition costs
    1,443        
Income from unconsolidated joint ventures
    (1,347 )     (1,013 )
Gain on debt extinguishment
    (75 )      
Gains on sale of facilities, net
    (22 )     (21,152 )
Income from discontinued operations
          (53 )
 
           
Net operating income from reportable segments
  $ 86,818     $ 83,914  
 
           
17. Commitments and Contingencies
Litigation
From time to time, we are a party to various legal proceedings, lawsuits and other claims (as to some of which we may not be insured) that arise in the normal course of our business. Regardless of their merits, these matters may require us to expend significant financial resources. Except as described herein, we are not aware of any other legal proceedings or claims that we believe may have, individually or taken together, a material adverse effect on our business, results of operations or financial position. However, we are unable to predict the ultimate outcome of pending litigation and claims, and if our assessment of our liability with respect to these actions and claims is incorrect, such actions and claims could have a material adverse effect on our business, results of operations or financial position.
In late 2004 and early 2005, we were served with several lawsuits in connection with a fire at the Greenwood Healthcare Center in Hartford, Connecticut, that occurred on February 26, 2003. At the time of the fire, the Greenwood Healthcare Center was owned by us and leased to and operated by Lexington Healthcare Group. There were a total of 13 lawsuits arising from the fire. Those suits have been filed by representatives of patients who were either killed or injured in the fire. The lawsuits seek unspecified monetary damages. The complaints allege that the fire was set by a resident who had previously been diagnosed with depression. The complaints allege theories of negligent operation and premises liability against Lexington Healthcare, as operator, and us as owner. Lexington Healthcare has filed for bankruptcy. The matters have been consolidated into one action in the Connecticut Superior Court Complex Litigation Docket at the Judicial District at Hartford and are in various stages of discovery and motion practice. We have filed a motion for summary judgment with regard to certain pending claims and will be filing additional summary judgment motions for any remaining claims. Mediation was commenced with respect to most of the claims, and a settlement has been reached in 10 of the 13 pending claims within the limits of our commercial general liability insurance. We obtained a judgment of nonsuit in one case whereby it is now dismissed, and the two remaining claims will be subject to summary judgment motions and ongoing efforts at resolution. Summary judgment rulings are not expected until the middle of 2011, if not later.

 

26


Table of Contents

NATIONWIDE HEALTH PROPERTIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Lexington Insurance, which potentially owes insurance coverage for these claims to us, has filed a lawsuit against us which seeks no monetary damages, but which does seek a court order limiting its insurance coverage obligations to us. We have filed a counterclaim against Lexington Insurance demanding additional insurance coverage from Lexington in amounts up to $10.0 million. The parties to that case, which is pending on the Complex Litigation Docket for the Judicial District of Hartford, filed cross-motions for summary judgment. Those motions have been decided, resulting in an outcome that is largely favorable for us. The court’s ruling indicates $10.0 million in aggregate coverage is available from Lexington Insurance for both the various plaintiffs’ claims and our claims under the Professional Liability part of the Lexington Insurance policy. The court then found that there were 13 separate medical incidents for each of the 13 plaintiffs’ claims. However, the court limited the coverage to $500,000 per claim with a $250,000 self insured retention per claim, which retention will not be paid due to the bankruptcy of Lexington Healthcare. Further, the court has ruled that both the various plaintiffs’ claims and our claims are subject to the same policy limits. The court declined to find coverage for our claims under the comprehensive general liability portions of the Lexington Insurance policy. Lexington Insurance has filed a motion seeking an articulation of the rulings and is pursuing an appeal of the rulings. We anticipate that we will be defending the appeal by Lexington Insurance and pursuing our own issues on appeal. We do not expect the appeal to be resolved before the middle of 2011, if not later.
We are being defended in the matter by our commercial general liability carrier. We believe that we have substantial defenses to the claims and that we have adequate insurance to cover the risks, should liability nonetheless be imposed. However, because the remaining claims are still in the process of discovery and motion practice, it is not possible to predict the ultimate outcome of these claims.
Revolving Loan Facility
In 2009, we entered into an agreement with one of our triple-net tenants, Brookdale under which we became a lender with a commitment of $2.9 million under their $75.0 million revolving loan facility. The revolving loan facility was terminated as of February 23, 2010. There was no balance outstanding at the date of termination.
Lines of Credit
Under the terms of an agreement with PMB LLC, we agreed to extend to PMB LLC a $10.0 million line of credit at an interest rate equal to LIBOR plus 175 basis points to fund certain costs of PMB LLC with respect to the proposed development of multi-tenant medical office buildings. During the three months ended March 31, 2010, we funded $0.1 million under the line of credit. At March 31, 2010, $3.3 million was outstanding and is included in the caption “Other assets” on our consolidated balance sheet.
We have entered into an agreement with PMB LLC, the manager of PMB Pomona LLC, to extend up to $3.0 million of funding at an interest rate of 7.25%, which is secured by 100% of the membership interests in PMB Pomona LLC (see Note 18). During the three months ended March 31, 2010, we funded $0.3 million. At March 31, 2010, $1.9 million was outstanding and is included in the caption “Other assets” on our consolidated balance sheet. On April 1, 2010, the total $1.9 million outstanding was repaid (see Note 19).
As of February 1, 2010, in connection with the formation of Gilbert JV, a consolidated joint venture, we agreed to loan Gilbert JV up to $8.8 million as project financing at an interest rate of 7.00%, including $6.8 million that was disbursed initially and remains outstanding at March 31, 2010 (see Note 5).
As of March 1, 2010, in connection with the formation of Pasadena JV, a consolidated joint venture, we agreed to loan Pasadena JV up to $56.5 million as project financing at an initial interest rate equal to the greater of 3.50% or LIBOR plus 165 basis points (increasing to the greater of 5.125% or LIBOR plus 375 basis points as of April 1, 2010), including $49.8 million that was disbursed initially and remains outstanding at March 31, 2010 (see Note 5).
Indemnities
We have entered into indemnification agreements with those partners who contributed appreciated property into NHP/PMB. Under these indemnification agreements, if any of the appreciated real estate contributed by the partners is sold by NHP/PMB in a taxable transaction within a specified number of years after the property was contributed, we will reimburse the affected partners for the federal and state income taxes associated with the pre-contribution gain that is specially allocated to the affected partner under the Code. We have no current plans to sell any of these properties.

 

27


Table of Contents

NATIONWIDE HEALTH PROPERTIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
18. Related Party Transactions
In August 2008, Dr. Jeffrey Rush became a director of NHP. In August 2008, we acquired for $3.5 million a 44.95% interest in PMB SB, an entity that owns two multi-tenant medical office buildings, and as of March 1, 2010, we acquired the remaining interest in PMB SB (see Note 6). Dr. Rush, through an unaffiliated entity, had an ownership interest in PMB SB.
In September 2008, we funded a mortgage loan secured by a multi-tenant medical office building in the amount of $47.5 million. As of February 1, 2010, we acquired the multi-tenant medical office building, and as a result, the loan was retired (see Notes 4 and 5). Dr. Rush has an ownership interest in another unaffiliated entity that owned the multi-tenant medical office building that was security for this loan.
In February 2008, we entered into an agreement with Pacific Medical Buildings LLC to acquire a 50% interest in PMBRES, a full service property management company (see Note 6). Dr. Rush, through an unaffiliated entity, has an ownership interest in PMB Partners LLC which owns 50% of PMBRES.
We have entered into an agreement with PMB Pomona LLC to acquire a medical office building currently in development for $37.5 million upon completion which was amended as of February 1, 2010 to provide for the future acquisition of the medical office building by NHP/PMB. Dr. Rush, through an unaffiliated entity, has an ownership interest in PMB Pomona LLC. We have also entered into an agreement with PMB LLC, the manager of PMB Pomona LLC, to extend up to $3.0 million of funding at an interest rate of 7.25%, which is secured by 100% of the membership interests in PMB Pomona LLC (see Note 17).
As of March 1, 2010, NHP/PMB became obligated to pay $2.1 million under the Contribution Agreement, of which $1.9 million was paid to Pacific Medical Buildings LLC in cash (see Note 5). Dr. Rush is the Chairman of and owns an interest in Pacific Medical Buildings LLC. In addition, Dr. Rush and certain of his family members own or owned interests, directly and indirectly through partnerships and trusts, in the entities that contributed the five multi-tenant medical office buildings acquired by NHP/PMB, Gilbert JV and Pasadena JV during the three months ended March 31, 2010 (see Note 6) and/or own the remaining development property that may be acquired in the future under the Contribution Agreement.
19. Subsequent Events
On April 1, 2010, the total $1.9 million outstanding under our agreement with PMB LLC, the manager of PMB Pomona LLC, was repaid (see Note 17).
From April 1, 2010 to May 6, 2010, we completed approximately $58 million of investments in eight medical office buildings and one skilled nursing facility.
From April 1, 2010 to May 6, 2010, we issued and sold approximately 1,592,000 shares at a weighted average price of $35.08 per share through our at-the-market equity offering program (see Note 10).

 

28


Table of Contents

Item 2.   Management’s Discussion and Analysis of Financial Condition and Results of Operations
Statement Regarding Forward-Looking Disclosure
Certain information contained in this report includes statements that may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our expectations, beliefs, intentions, plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements which are not statements of historical facts. These statements may be identified, without limitation, by the use of forward-looking terminology such as “may,” “will,” “anticipates,” “expects,” “believes,” “intends,” “should” or comparable terms or the negative thereof. All forward-looking statements included in this report are based on information available to us on the date hereof. These statements speak only as of the date hereof and we assume no obligation to update such forward-looking statements. These statements involve risks and uncertainties that could cause actual results to differ materially from those described in the statements. Risks and uncertainties associated with our business include (without limitation) the following:
    deterioration in the operating results or financial condition, including bankruptcies, of our tenants;
    non-payment or late payment of rent, interest or loan principal amounts by our tenants;
    our reliance on two tenants for a significant percentage of our revenue;
    occupancy levels at certain facilities;
    our level of indebtedness;
    changes in the ratings of our debt securities;
    maintaining compliance with our debt covenants;
    access to the capital markets and the cost and availability of capital;
    the effect of healthcare reform legislation or government regulations, including changes in the reimbursement levels under the Medicare and Medicaid programs;
    the general distress of the healthcare industry;
    increasing competition in our business sector;
    the effect of economic and market conditions and changes in interest rates;
    the amount and yield of any additional investments;
    risks associated with acquisitions, including our ability to identify and complete favorable transactions, delays or failures in obtaining third party consents or approvals, the failure to achieve perceived benefits, unexpected costs or liabilities and potential litigation;
    the ability of our tenants to pay contractual rent and/or interest escalations in future periods;
    the ability of our tenants to obtain and maintain adequate liability and other insurance;
    our ability to attract new tenants for certain facilities;
    our ability to sell certain facilities for their book value;
    our ability to retain key personnel;

 

29


Table of Contents

    potential liability under environmental laws;
    the possibility that we could be required to repurchase some of our senior notes;
    changes in or inadvertent violations of tax laws and regulations and other factors that can affect our status as a real estate investment trust (“REIT”); and
    the risk factors set forth under the caption “Risk Factors” in Item 1A and other factors discussed from time to time in our news releases, public statements and/or filings with the SEC, especially the risk factors set forth in our most recent annual report on Form 10-K and any subsequent quarterly reports on Form 10-Q.
Critical Accounting Policies and Estimates
Our financial statements have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. If our judgment or interpretation of the facts and circumstances relating to various transactions or other matters had been different, it is possible that different accounting would have been applied, resulting in different presentation of our financial statements. For a description of the risks associated with our critical accounting policies and estimates, see “Risk Factors — Risks Relating to Us and Our Operations” included in our Annual Report on Form 10-K for the year ended December 31, 2009. On an ongoing basis, we evaluate our estimates and assumptions, including those that impact our most critical accounting policies. We base our estimates and assumptions on historical experience and on various other factors that we believe are reasonable under the circumstances. Actual results may differ from these estimates. We believe the following are our most critical accounting estimates.
Principles of Consolidation
Our consolidated financial statements include the accounts of NHP, its wholly-owned subsidiaries and its joint ventures that are controlled through voting rights or other means. We apply the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 810, Consolidation (“ASC 810”), for arrangements with variable interest entities (“VIEs”) and would consolidate those VIEs where we are the primary beneficiary. All material intercompany accounts and transactions have been eliminated.
Our judgment with respect to our level of influence or control of an entity and whether we are the primary beneficiary of a VIE involves the consideration of various factors including, but not limited to, the form of our ownership interest, our representation on the entity’s governing body, the size of our investment, estimates of future cash flows, our ability to participate in policy-making decisions and the rights of the other investors to participate in the decision-making process and to replace us as manager and/or liquidate the venture, if applicable. Our ability to correctly assess our influence or control over an entity or determine the primary beneficiary of a VIE affects the presentation of these entities in our consolidated financial statements.
We apply the provisions of ASC Topic 323, Investments — Equity Method and Joint Ventures, to investments in joint ventures. Investments in entities that we do not consolidate but for which we have the ability to exercise significant influence over operating and financial policies are reported under the equity method. Under the equity method of accounting, our share of the entity’s earnings or losses is included in our operating results.

 

30


Table of Contents

Revenue Recognition
Rental income from operating leases is recognized in accordance with the provisions of ASC Topic 840, Leases, and ASC Topic 605, Revenue Recognition. Our leases generally contain annual rent escalators. Many of our leases contain non-contingent rent escalators for which we recognize income on a straight-line basis over the lease term. Recognizing income on a straight-line basis requires us to calculate the total non-contingent rent to be paid over the life of a lease and to recognize the revenue evenly over that life. This method results in rental income in the early years of a lease being higher than actual cash received, creating a straight-line rent receivable asset included in the caption “Other assets” on our consolidated balance sheets. At some point during the lease, depending on its terms, the cash rent payments eventually exceed the straight-line rent which results in the straight-line rent receivable asset decreasing to zero over the remainder of the lease term. We assess the collectability of straight-line rents in accordance with the applicable accounting standards and our reserve policy and defer recognition of straight-line rent if its collectability is not reasonably assured. Certain leases contain rent escalators contingent on revenues or other factors, including increases based on changes in the Consumer Price Index. Such revenue increases are recognized as the related contingencies are met.
Our assessment of the collectability of straight-line rents is based on several factors, including the financial strength of the tenant and any guarantors, the historical operations and operating trends of the facility, the historical payment pattern of the tenant and the type of facility, among others. If our evaluation of these factors indicates we may not receive the rent payments due in the future, we defer recognition of the straight-line rental income and, depending on the circumstances, we will provide a reserve against the previously recognized straight-line rent receivable asset for a portion, up to its full value, that we estimate may not be recoverable. If we change our assumptions or estimates regarding the collectability of future rent payments required by a lease, we may adjust our reserve to increase or reduce the rental revenue recognized, and/or to increase or reduce the reserve against the existing straight-line rent receivable balance.
We evaluate the collectability of the straight-line rent receivable balances on an ongoing basis and provide reserves against receivables we believe may not be fully recoverable. The ultimate amount of straight-line rent we realize could be less than amounts currently recorded.
Land, Buildings and Improvements and Depreciation and Useful Lives of Assets
We record properties at cost and use the straight-line method of depreciation for buildings and improvements over their estimated remaining useful lives of up to 40 years, generally 20 to 40 years depending on factors including building type, age, quality and location. We review and adjust useful lives periodically.
We allocate purchase prices of properties in accordance with the provisions of ASC Topic 805, Business Combinations (“ASC 805”), which require that the acquisition method of accounting be used for all business combinations and for an acquirer to be identified for each business combination. ASC 805 also establishes principles and requirements for how the acquirer recognizes and measures in its financial statements the identifiable assets acquired, the liabilities assumed and any noncontrolling interest in the acquiree. Certain transaction costs that have historically been capitalized as acquisition costs are expensed for business combinations completed on or after January 1, 2009, which may have a significant impact on our future results of operations and financial position based on historical acquisition costs and activity levels.
The allocation of the cost between land, building and, if applicable, equipment and intangible assets and liabilities, and the determination of the useful life of a property are based on management’s estimates, which are based in part on independent appraisals or other consultants’ reports. For our triple-net leased facilities, the allocation is made as if the property was vacant, and a significant portion of the cost of each property is allocated to buildings. This amount generally approximates 90% of the total property value. Historically, we have generally acquired properties and simultaneously entered into a new market rate lease for the entire property with one tenant. For our multi-tenant medical office buildings, the percentage allocated to buildings may be substantially lower as allocations are made to assets such as lease-up intangible assets, above market tenant and ground lease intangible assets and in-place lease intangible assets (collectively “intangible assets”) included on our consolidated balance sheets and/or below market tenant and ground lease intangible liabilities included in the caption “Accounts payable and accrued liabilities” on our consolidated balance sheets.
We calculate depreciation and amortization on equipment and lease costs using the straight-line method based on estimated useful lives of up to five years or the lease term, whichever is appropriate. We amortize intangible assets and liabilities over the remaining lease terms of the respective leases to real estate amortization expense or medical office building operating rent, as appropriate. We review and adjust useful lives periodically. If we do not allocate appropriately between land and building or we incorrectly estimate the useful lives of our assets, our computation of depreciation and amortization will not appropriately reflect the usage of the assets over future periods. If we overestimate the useful life of an asset, the depreciation expense related to the asset will be understated, which could result in a loss if the asset is sold in the future.

 

31


Table of Contents

Asset Impairment
We review our long-lived assets individually on a quarterly basis to determine if there are indicators of impairment in accordance with the provisions of ASC Topic 360, Property, Plant and Equipment (“ASC 360”). Indicators may include, among others, a tenant’s inability to make rent payments, operating losses or negative operating trends at the facility level, notification by a tenant that it will not renew its lease, or a decision to dispose of an asset or adverse changes in the fair value of any of our properties. For operating assets, if indicators of impairment exist, we compare the undiscounted cash flows from the expected use of the property to its net book value to determine if impairment exists. The evaluation of the undiscounted cash flows from the expected use of the property is highly subjective and is based in part on various factors and assumptions, including, but not limited to, historical operating results, available market information and known trends and market/economic conditions that may affect the property, as well as estimates of future operating income, occupancy, rental rates, leasing demand and competition. If the sum of the future estimated undiscounted cash flows is higher than the current net book value, we conclude no impairment exists. If the sum of the future estimated undiscounted cash flows is lower than its current net book value, we recognize an impairment loss for the difference between the net book value of the asset and its estimated fair value. To the extent we decide to sell an asset, we recognize an impairment loss if the current net book value of the asset exceeds its fair value less selling costs.
We evaluate our equity method investments for impairment whenever events or changes in circumstances indicate that the carrying value of our investment in an unconsolidated joint venture may exceed the fair value. If it is determined that a decline in the fair value of our investment in an unconsolidated joint venture is other-than-temporary, and if such reduced fair value is below its carrying value, an impairment is recorded. The determination of the fair value of investments in unconsolidated joint ventures involves significant judgment. Our estimates consider all available evidence including, as appropriate, the present value of the expected future cash flows discounted at market rates, general economic conditions and trends and other relevant factors.
The above analyses require us to determine whether there are indicators of impairment for individual assets or investments in unconsolidated joint ventures, to estimate the most likely stream of cash flows from operating assets and to determine the fair value of assets that are impaired or held for sale. If our assumptions, projections or estimates regarding an asset change in the future, we may have to record an impairment charge to reduce or further reduce the net book value of such individual asset or investment in unconsolidated joint venture.
Collectability of Receivables
We evaluate the collectability of our rent, mortgage and other loans and other receivables on a regular basis based on factors including, among others, payment history, the financial strength of the borrower and any guarantors, the value of the underlying collateral, the operations and operating trends of the underlying collateral, if any, the asset type and current economic conditions. If our evaluation of these factors indicates we may not recover the full value of the receivable, we provide a reserve against the portion of the receivable that we estimate may not be recovered. This analysis requires us to determine whether there are factors indicating a receivable may not be fully collectible and to estimate the amount of the receivable that may not be collected. If our assumptions or estimates regarding the collectability of a receivable change in the future, we may have to record a reserve to reduce or further reduce the carrying value of the receivable.
Income Taxes
As part of the process of preparing our consolidated financial statements, significant management judgment is required to estimate our compliance with REIT requirements. Our determinations are based on interpretation of tax laws, and our conclusions may have an impact on the income tax expense recognized. Adjustments to income tax expense may be required as a result of i) audits conducted by federal and state tax authorities; ii) our ability to qualify as a REIT; iii) the potential for built-in-gain recognized related to prior-tax-free acquisitions of C corporations; and iv) changes in tax laws. Adjustments required in any given period are included in income, other than adjustments to income tax liabilities acquired in business combinations, which would be adjusted through goodwill.

 

32


Table of Contents

Impact of New Accounting Standards Updates
In June 2009, the FASB updated ASC 810 to require ongoing analyses to determine whether an entity’s variable interest gives it a controlling financial interest in a variable interest entity (“VIE”), making it the primary beneficiary, based on whether the entity (i) has the power to direct activities of the VIE that most significantly impact its economic performance, including whether it has an implicit financial responsibility to ensure the VIE operates as designed, and (ii) has the obligation to absorb losses or the right to receive benefits of the VIE that could potentially be significant to the VIE. Enhanced disclosures regarding an entity’s involvement with variable interest entities are also required under the provisions of ASC 810. These requirements became effective January 1, 2010. The adoption of these requirements did not have a material impact on our results of operations or financial position.
In January 2010, the FASB issued Accounting Standards Update (“ASU”) 2010-06, Improving Disclosures About Fair Value Measurements (“ASU 2010-06”). ASU 2010-06 adds new requirements for disclosures of significant transfers into and out of Levels 1, 2 and 3 of the fair value hierarchy, the reasons for the transfers and the policy for determining when transfers are recognized. ASU 2010-06 also adds new requirements for disclosures about purchases, sales, issuances and settlements on a gross rather than net basis relating to the reconciliation of the beginning and ending balances of Level 3 recurring fair value measurements. It also clarifies the level of disaggregation to require disclosures by “class” rather than by “major category of assets and liabilities” and clarifies that a description of inputs and valuation techniques used to measure fair value is required for both recurring and nonrecurring fair value measurements classified as Level 2 or 3. ASU 2010-06 became effective January 1, 2010 except for the requirements to provide the Level 3 activity of purchases, sales, issuances and settlements on a gross basis which are effective January 1, 2011. The adoption of ASU 2010-06 has not and is not expected to have a material impact on our results of operations or financial position.
In February 2010, the FASB issued ASU 2010-09, Amendments to Certain Recognition and Disclosure Requirements (“ASU 2010-09”). ASU 2010-09 amends ASC Topic 855, Subsequent Events, to require Securities and Exchange Commission (“SEC”) registrants and conduit bond obligors to evaluate subsequent events through the date that the financial statements are issued, however, SEC registrants are exempt from disclosing the date through which subsequent events have been evaluated. All other entities are required to evaluate subsequent events through the date that the financial statements are available to be issued and must disclose the date through which subsequent events have been evaluated. ASU 2010-09 was effective upon issuance for all entities except conduit debt obligors. The adoption of ASU 2010-09 did not have an impact on our results of operations or financial position.
Operating Results
Three Months Ended March 31, 2010 vs. Three Months Ended March 31, 2009
                                 
    Three Months Ended  
    March 31,  
    2010     2009     $ Change     % Change  
    (Dollars in thousands)  
Revenue:
                               
Triple-net lease rent
  $ 74,214     $ 74,095     $ 119       0 %
Medical office building operating rent
    21,251       16,653       4,598       28 %
 
                       
 
    95,465       90,748       4,717       5 %
Interest and other income
    6,963       6,335       628       10 %
 
                       
 
    102,428       97,083       5,345       6 %
 
                       
Expenses:
                               
Interest expense
    23,590       24,071       481       2 %
Depreciation and amortization
    31,969       30,832       (1,137 )     (4 %)
General and administrative
    6,984       6,931       (53 )     (1 %)
Acquisition costs
    1,443             (1,443 )     (100 %)
Medical office building operating expenses
    8,647       6,834       (1,813 )     (27 %)
 
                       
 
    72,633       68,668       (3,965 )     (6 %)
 
                       
Operating income
    29,795       28,415       1,380       5 %
Income from unconsolidated joint ventures
    1,347       1,013       334       33 %
Gain on debt extinguishment
    75             75       100 %
 
                       
Income from continuing operations
    31,217       29,428       1,789       6 %
 
                       
Discontinued operations:
                               
Gains on sale of facilities, net
    22       21,152       (21,130 )     (100 %)
Income from discontinued operations
          53       (53 )     (100 %)
 
                       
 
    22       21,205       (21,183 )     (100 %)
 
                       
Net income
    31,239       50,633       (19,394 )     (38 %)
Net loss (income) attributable to noncontrolling interests
    190       (27 )     217       804 %
 
                       
Net income attributable to NHP
    31,429       50,606       (19,177 )     (38 %)
Preferred stock dividends
          (1,452 )     1,452       100 %
 
                       
Net income attributable to NHP common stockholders
  $ 31,429     $ 49,154     $ (17,725 )     (36 %)
 
                       

 

33


Table of Contents

Triple-net lease rental income increased $0.1 million in 2010 as compared to 2009. The increase was primarily due to rent increases at existing facilities, offset in part by reserves and decreased straight-line rental income.
Medical office building operating rent increased $4.6 million, or 28%, in 2010 as compared to 2009. The increase was primarily due to operating rent from seven multi-tenant medical office buildings acquired during 2010, including five multi-tenant medical office buildings acquired through consolidated joint ventures, and operating rent growth at existing facilities.
Interest and other income increased $0.6 million, or 10%, in 2010 as compared to 2009. The increase was primarily due to a net gain recognized upon acquisition of the controlling interest in an unconsolidated joint venture during 2010, additional fundings on one loan during 2010 and four loans funded during 2009, offset in part by loan repayments.
Interest expense decreased $0.5 million, or 2%, in 2010 as compared to 2009. The decrease was primarily due to the repayment of $64.6 million of senior notes during 2009 and the repayment of $2.7 million and $2.9 million of secured debt during 2009 and 2010, respectively, offset in part by the assumption of $109.5 million of secured debt during 2010 and the addition of $6.9 million of secured debt in 2009.
Depreciation and amortization increased $1.1 million, or 4%, in 2010 as compared to 2009. The increase was primarily due to the acquisition of seven multi-tenant medical office buildings during 2010, including five multi-tenant medical office buildings acquired through consolidated joint ventures.
General and administrative expenses increased $0.1 million, or 1%, in 2010 as compared to 2009. The increase was primarily due to increased employee related costs, offset in part by decreased expenses for third party advisors.
Acquisition costs represent costs related to acquisition transactions. Acquisition costs were $1.4 million during 2010. No acquisition costs were incurred during 2009.
Medical office building operating expenses increased $1.8 million, or 27%, in 2010 as compared to 2009. The increase was primarily due to operating expenses from seven multi-tenant medical office buildings acquired during 2010, including five multi-tenant medical office buildings acquired through consolidated joint ventures.
Income from unconsolidated joint ventures increased $0.3 million, or 33%, in 2010 as compared to 2009. The increase was primarily due to increased income from PMB Real Estate Services LLC (“PMBRES”) and our unconsolidated joint venture with a state pension fund investor.
In connection with our acquisition of one multi-tenant medical office building through a consolidated joint venture, we provided funding that was concurrently used to prepay existing debt, and as a result the consolidated joint venture recognized a gain on debt extinguishment.
ASC 360 requires the operating results of any assets with their own identifiable cash flows that are disposed of or held for sale and in which we have no continuing interest be removed from income from continuing operations and reported as discontinued operations. The operating results for any such assets for any prior periods presented must also be reclassified as discontinued operations. If we have a continuing investment, as in the sales to our unconsolidated joint venture with a state pension fund investor, the operating results remain in continuing operations. Discontinued operations income decreased $21.2 million in 2010 as compared to 2009. Discontinued operations income of $22,000 for 2010 represents recognition of deferred gains on sale. Discontinued operations income of $21.2 million for 2009 was comprised of gains on sale of $21.1 million and rental income of $0.3 million and interest and other income of $19,000, offset in part by depreciation and amortization expense of $0.3 million. We expect to have future sales of facilities or reclassifications of facilities to assets held for sale, and the related income or loss would be included in discontinued operations unless the facilities were transferred to an entity in which we maintain an interest.

 

34


Table of Contents

Funds From Operations and Funds Available for Distribution
                 
    Three months ended  
    March 31,  
    2010     2009  
    (In thousands, except per  
    share amounts)  
Funds From Operations (“FFO”):
               
Net income
  $ 31,239     $ 50,633  
Net loss (income) attributable to noncontrolling interests
    190       (27 )
Preferred stock dividends
          (1,452 )
Real estate related depreciation and amortization
    31,545       30,808  
Depreciation in income from unconsolidated joint ventures
    1,239       1,307  
Gains on sale of facilities, net
    (22 )     (21,152 )
 
           
FFO available to NHP common stockholders
    64,191       60,117  
Series B preferred stock dividends add-back
          1,452  
 
           
Diluted FFO
    64,191       61,569  
Acquisition costs
    1,443        
Gain on re-measurement of equity interest upon acquisition, net
    (620 )      
Gain on debt extinguishment
    (75 )      
 
           
Adjusted diluted FFO
  $ 64,939     $ 61,569  
 
           
 
               
Funds Available for Distribution (“FAD”):
               
Net income
  $ 31,239     $ 50,633  
Net loss (income) attributable to noncontrolling interests
    190       (27 )
Preferred stock dividends
          (1,452 )
Real estate related depreciation and amortization
    31,545       30,808  
Gains on sale of facilities, net
    (22 )     (21,152 )
Straight-lined rent
    (1,687 )     (1,590 )
Amortization of intangible assets and liabilities
    (59 )     (222 )
Non-cash stock-based compensation expense
    1,594       1,573  
Deferred financing cost amortization
    845       814  
Lease commissions and tenant and capital improvements
    (637 )     (726 )
NHP’s share of FAD reconciling items from unconsolidated joint ventures:
               
Real estate related depreciation and amortization
    1,239       1,307  
Straight-lined rent
    (1 )     (12 )
Deferred financing cost amortization
    21       21  
 
           
FAD available to NHP common stockholders
    64,267       59,975  
Series B preferred stock dividends add-back
          1,452  
 
           
Diluted FAD
    64,267       61,427  
Acquisition costs
    1,443        
Gain on re-measurement of equity interest upon acquisition, net
    (620 )      
Gain on debt extinguishment
    (75 )      
 
           
Adjusted diluted FAD
  $ 65,015     $ 61,427  
 
           
 
               
Weighted average shares outstanding for FFO:
               
Diluted weighted average shares outstanding (1)
    119,600       104,451  
Series B preferred stock add-back if not already converted
    69       3,358  
 
           
Diluted weighted average shares outstanding
    119,669       107,809  
 
           
 
               
Diluted per share amounts — FFO:
               
FFO
  $ 0.54     $ 0.57  
 
           
Adjusted FFO
  $ 0.54     $ 0.57  
 
           
 
     
(1)   Diluted weighted average shares outstanding includes the effect of all participating and non-participating share-based payment awards which for us consists of stock options and other share-based payment awards if the effect is dilutive. The dilutive effect of all share-based payment awards is calculated using the treasury stock method. Additionally, our redeemable OP units are included as if converted to common stock on a one-for-one basis.

 

35


Table of Contents

While net income and its related per share amounts, as defined by accounting principles generally accepted in the United States (“GAAP”), are the most appropriate earnings measures, we believe that FFO and FAD and the related per share amounts are important non-GAAP supplemental measures of operating performance. GAAP requires the use of straight-line depreciation of historical costs and implies that real estate values diminish predictably and ratably over time. However, real estate values have historically risen and fallen based on various market conditions and other factors. FFO was developed as a supplemental measure of operating performance primarily in order to exclude historical cost-based depreciation and amortization and its effects as it does not generally reflect the actual change in value of real estate over time. We calculate FFO in accordance with the National Association of Real Estate Investment Trusts’ (“NAREIT”) definition. FFO is defined as net income (computed in accordance with GAAP) excluding gains and losses from the sale of real estate plus real estate related depreciation and amortization. The same adjustments are made to reflect our share of these same items from unconsolidated joint ventures. Adjusted FFO is defined as FFO excluding impairments of assets, acquisition costs and gains and losses other than those from the sale of real estate.
FAD was developed as a supplemental measure of operating performance primarily to exclude non-cash revenues and expenses that are included in FFO. FAD is defined as net income (computed in accordance with GAAP) excluding gains and losses from the sale of real estate plus real estate related depreciation and amortization, plus or minus straight-lined rent (plus cash in excess of rent or minus rent in excess of cash), plus or minus amortization of above or below market lease intangibles, plus non-cash stock based compensation, plus deferred financing cost amortization plus any impairments minus lease commissions, tenant improvements and capital improvements paid. The same adjustments are made to reflect our share of these same items from unconsolidated joint ventures. Adjusted FAD is defined as FAD excluding acquisition costs and gains and losses other than those from the sale of real estate.
We believe that the use of FFO, adjusted FFO and the related per share amounts, and FAD and adjusted FAD in conjunction with the required GAAP disclosures provides investors with a more comprehensive understanding of the operating results of a REIT and enables investors to compare the operating results between REITs without having to account for differences caused by different depreciation assumptions and different non-cash revenues and expenses. Additionally, FFO and FAD are used by us and widely used by industry analysts as a measure of operating performance for equity REITs.
Our calculations of FFO, adjusted FFO and the related per share amounts, and FAD and adjusted FAD presented herein may not be comparable to similar measures reported by other REITs that do not define FFO in accordance with the NAREIT definition, interpret that definition differently than we do or that do not use the same definitions as we do for such terms. These supplemental reporting measures should not be considered as alternatives to net income (a GAAP measure) as primary indicators of our financial performance or as alternatives to cash flow from operating activities (a GAAP measure) as primary measures of our liquidity, nor are these measures necessarily indicative of sufficient cash flow to satisfy all of our liquidity requirements. We believe that these supplemental reporting measures should be examined in conjunction with net income as presented in our consolidated financial statements and data included elsewhere in this quarterly report on Form 10-Q in order to facilitate a clear understanding of our consolidated operating results.
Other Factors That Affect Our Business
Leases and Mortgage Loans
Our leases and mortgages generally contain provisions under which rents or interest income increase with increases in facility revenues and/or increases in the Consumer Price Index. If facility revenues and/or the Consumer Price Index do not increase, our revenues may not increase. Rent levels under renewed leases will also impact revenues. Excluding multi-tenant medical office buildings, as of March 31, 2010, we had 18 leases expiring in 2010. Tenant purchase option exercises would decrease rental income. We believe our tenants may exercise purchase options on assets with option prices totaling approximately $40.7 million during the remainder of 2010.

 

36


Table of Contents

Acquisitions
We may make additional acquisitions during 2010, although we cannot predict the quantity or timing of any such acquisitions as we continue to be confronted with uncertainty surrounding the future of the capital markets and general economic conditions. If we make additional investments in facilities, depreciation and/or interest expense would also increase. We expect any such increases to be at least partially offset by associated rental or interest income. While additional investments in healthcare facilities would increase revenues, facility sales or mortgage repayments would serve to offset revenue increases and could reduce revenues.
Liquidity and Capital Resources
Operating Activities
Cash provided by operating activities during the three months ended March 31, 2010 decreased $0.2 million, or 0.4%, as compared to the same period in 2009. This was primarily due to the payment of certain amounts included in the caption “Accounts payable and accrued liabilities” during 2010, offset in part by revenue increases from our owned facilities as a result of acquisitions during 2010. There have been no significant changes in the underlying sources and uses of cash provided by operating activities.
Investing Activities
During the three months ended March 31, 2010, we acquired the remaining 55.05% interest in PMB SB 399-401 East Highland LLC (“PMB SB”), an entity affiliated with Pacific Medical Buildings LLC that owns two multi-tenant medical office buildings. PMB SB was valued at $17.4 million at the date of acquisition, and the acquisition was paid in a combination of cash and the assumption of $11.2 million of mortgage financing (of which $6.2 million was previously attributable to the controlling interest in PMB SB). In connection with the acquisition, we re-measured our previously held equity interest at the acquisition date fair value and recognized a gain on the re-measurement of $0.6 million.
During the three months ended March 31, 2010, we funded $3.7 million in expansions, construction and capital improvements at certain facilities in accordance with existing lease provisions. Such expansions, construction and capital improvements generally result in an increase in the minimum rents earned by us on these facilities either at the time of funding or upon completion of the project. At March 31, 2010, we had committed to fund additional expansions, construction and capital improvements of $108.8 million. Additionally, at March 31, 2010, we had committed to fund additional amounts under existing loan agreements of $22.4 million, including our commitments under agreements related to two of our consolidated joint ventures, the PMB LLC line of credit and PMB Pomona LLC loan described below. During the three months ended March 31, 2010, we also funded $0.2 million in capital and tenant improvements at certain multi-tenant medical office buildings.
During the three months ended March 31, 2010, we funded $0.1 million in capital and tenant improvements at certain facilities through our medical office building joint venture with McShane Medical Office Properties, Inc.
In February 2008, we entered into an agreement (the “Contribution Agreement”) with Pacific Medical Buildings LLC and certain of its affiliates to acquire up to 18 medical office buildings, including six in development, for $747.6 million, including the assumption of approximately $282.6 million of mortgage financing. Under the Contribution Agreement, in 2008, NHP/PMB acquired interests in nine of the 18 medical office buildings, including one property which is included in our triple-net leases segment and eight properties which are multi-tenant medical office buildings (one of which consisted of a 50% interest through a joint venture which is consolidated by NHP/PMB). During 2008, we also acquired one of the 18 medical office buildings directly (not through NHP/PMB). During 2009, we elected to terminate the Contribution Agreement with respect to six properties after the conditions for us to close on such properties were not satisfied. As a result of the elimination of these six properties, under the Contribution Agreement, NHP/PMB became obligated to pay $3.0 million, of which $2.7 million was payable to Pacific Medical Buildings LLC.

 

37


Table of Contents

As of February 1, 2010, we entered into an amendment to the Contribution Agreement which reinstated one of the six properties that were previously eliminated from the Contribution Agreement. NHP/PMB acquired such multi-tenant medical office building for $74.0 million, which was paid in a combination of cash and the issuance of 301,599 Class A limited partnership units in NHP/PMB (“OP Units”) with a fair value at the date of issuance of $10.0 million. As a result of such acquisition, we retired our $47.5 million mortgage loan from a related party to which such acquired medical office building had served as collateral. Additionally, as of February 1, 2010, we acquired a majority ownership interest in a joint venture which owns one multi-tenant medical office building as described below, amended and restated our agreement with NHP/PMB, PMB LLC and PMBRES as described below and amended our agreement with PMB Pomona LLC to provide for the future acquisition by NHP/PMB of a medical office building currently in development. In connection with these transactions, NHP/PMB entered into a Third Amendment to the Amended and Restated Agreement of Limited Partnership, which, among other things, authorized NHP/PMB to acquire properties affiliated with Pacific Medical Buildings LLC pursuant to agreements other than the Contribution Agreement.
As of March 1, 2010, we entered into an amendment to the Contribution Agreement which reinstated another two of the six properties that were previously eliminated from the Contribution Agreement. NHP/PMB acquired a 65% interest in a joint venture which is consolidated by NHP/PMB that owns one of the two multi-tenant medical office buildings valued at $79.9 million. The acquisition was paid in a combination of cash, the assumption of $48.1 million of mortgage financing and the issuance of 152,238 OP Units with a fair value at the date of issuance of $5.0 million. NHP/PMB acquired a 69% interest in a joint venture which is consolidated by NHP/PMB that owns the second multi-tenant medical office building valued at $69.3 million. The acquisition was paid in a combination of cash, the assumption of $50.2 million of mortgage financing and the issuance of 121,489 OP Units with a fair value at the date of issuance of $4.0 million.
The amendment to the Contribution Agreement dated as of March 1, 2010 also eliminated one of the two remaining properties from the Contribution Agreement, however, we concurrently entered into a joint venture with PMB Pasadena LLC (an entity affiliated with Pacific Medical Buildings LLC) to acquire this property as described below. As a result of the elimination of this property from the Contribution Agreement, NHP/PMB became obligated to pay $2.1 million (the “Premium Adjustment”), of which $1.9 million was payable to Pacific Medical Buildings LLC in cash. The portion of the Premium Adjustment not payable to Pacific Medical Buildings LLC was paid in the form of $0.1 million in cash and the issuance of 1,788 additional OP Units with an aggregate value of $57,000. As a result of the payment, we received an additional 4,514 Class B limited partnership units in NHP/PMB. Under the Contribution Agreement, if the agreement is terminated with respect to the remaining development property, NHP/PMB will become obligated to pay approximately $2.4 million (the “Future Premium Adjustment”), of which a portion would be payable to Pacific Medical Buildings LLC.
Additionally, we have entered into an agreement with NHP/PMB, PMB LLC and PMBRES pursuant to which we or NHP/PMB currently have the right, but not the obligation, to acquire up to approximately $1.3 billion of multi-tenant medical office buildings developed by PMB LLC through April 2019. As of February 1, 2010, this agreement was amended and restated to provide NHP/PMB with the option to acquire medical office buildings developed in the future through a joint venture between NHP and PMB LLC, obligate us to provide or arrange financing for approved developments and provide us with improved terms, including preferred returns, a reduction in PMB LLC’s promote interest and acquisition pricing determined at the time of acquisition rather that at the pre-development stage.
During the three months ended March 31, 2010, NHP/PMB funded $0.1 million in capital and tenant improvements at certain facilities.
As of February 1, 2010, we entered into a joint venture with PMB Gilbert LLC (an entity affiliated with Pacific Medical Buildings LLC) called NHP/PMB Gilbert LLC (“Gilbert JV”) to acquire a multi-tenant medical office building. PMB Gilbert LLC contributed the multi-tenant medical office building to Gilbert JV, and we contributed $6.3 million in cash. Additionally, we agreed to loan Gilbert JV up to $8.8 million as project financing at an interest rate of 7.00%, including $6.8 million that was disbursed initially and remains outstanding at March 31, 2010. We hold a 71.17% equity interest in the joint venture and PMB Gilbert LLC holds a 28.83% equity interest. PMB Gilbert LLC is the managing member of Gilbert JV, but we consolidate the joint venture in our consolidated financial statements. The accounting policies of the joint venture are consistent with our accounting policies. Pursuant to a contribution agreement dated as of February 1, 2010, among us, NHP/PMB, Pacific Medical Buildings LLC and PMB Gilbert LLC, NHP/PMB may in the future acquire Gilbert JV if certain conditions are met.

 

38


Table of Contents

As of March 1, 2010, we entered into a joint venture with PMB Pasadena LLC (an entity affiliated with Pacific Medical Buildings LLC) called NHP/PMB Pasadena LLC (“Pasadena JV”) to acquire a multi-tenant medical office building. PMB Pasadena LLC contributed the multi-tenant medical office building to Pasadena JV, and we contributed $13.5 million in cash. Additionally, we provided Pasadena JV with a $56.5 million mortgage loan at an initial interest rate equal to the greater of 3.50% or LIBOR plus 165 basis points (increasing to the greater of 5.125% or LIBOR plus 375 basis points as of April 1, 2010), of which $49.8 million has been funded, and a $3.0 million mezzanine loan at an interest rate of 15.00%, both of which remain outstanding at March 31, 2010. We hold a 71% equity interest in the joint venture and PMB Pasadena LLC holds a 29% equity interest. PMB Pasadena LLC is the managing member of Pasadena JV, but we consolidate the joint venture in our consolidated financial statements. The accounting policies of the joint venture are consistent with our accounting policies. Pursuant to a contribution agreement dated as of March 1, 2010, among us, NHP/PMB, Pacific Medical Buildings LLC and PMB Pasadena LLC, NHP/PMB may in the future acquire Pasadena JV if certain conditions are met.
Under the terms of an agreement with PMB LLC, we agreed to extend to PMB LLC a $10.0 million line of credit at an interest rate equal to LIBOR plus 175 basis points to fund certain costs of PMB LLC with respect to the proposed development of multi-tenant medical office buildings. During the three months ended March 31, 2010, we funded $0.1 million under the line of credit.
We have entered into an agreement with PMB Pomona LLC to acquire a medical office building currently in development for $37.5 million upon completion which was amended as of February 1, 2010 to provide for the future acquisition of the medical office building by NHP/PMB. We have also entered into an agreement with PMB LLC, the manager of PMB Pomona LLC, to extend up to $3.0 million of funding at an interest rate of 7.25%, which is secured by 100% of the membership interests in PMB Pomona LLC. During the three months ended March 31, 2010, we funded $0.3 million. At March 31, 2010, $1.9 million was outstanding and was repaid on April 1, 2010.
During the three months ended March 31, 2010, we funded one mortgage loan secured by 26 medical office buildings in the amount of $80.1 million.
During the three months ended March 31, 2010, we sold the assisted living portion of a continuing care retirement community for which we had an existing mortgage loan secured by the skilled nursing portion of such continuing care retirement community, to the tenant of the facility. For facility count purposes, this was previously accounted for in real estate properties as a continuing care retirement community. We provided financing of $6.5 million related to the sale, including the concurrent repayment of a $0.7 million unsecured loan which had previously been included in the caption “Other assets” on our consolidated balance sheets, and funded an additional $0.2 million subsequent to the sale.
During the three months ended March 31, 2010, we received payments of $1.3 million on other mortgage and other loans.
During the three months ended March 31, 2010, we received distributions of $0.7 million and $0.1 million from our unconsolidated joint venture with a state pension fund investor and PMB SB, respectively.
Financing Activities
At March 31, 2010 and December 31, 2009, we had $700.0 million available under our $700.0 million revolving unsecured senior credit facility. At our option, borrowings under the credit facility bear interest at the prime rate (3.25% at March 31, 2010) or applicable LIBOR plus 0.70% (0.95% at March 31, 2010). We pay a facility fee of 0.15% per annum on the total commitment under the agreement. The credit facility expires on December 15, 2010. The maturity date may be extended by one additional year at our discretion.

 

39


Table of Contents

We anticipate repaying senior notes at or prior to maturity with a combination of proceeds from borrowings on our credit facility and cash on hand. Borrowings on our credit facility could be repaid by potential asset sales or the repayment of mortgage loans receivable, the potential issuance of debt or equity securities under the shelf registration statement discussed below or cash from operations. Our senior notes have been investment grade rated since 1994. Our credit ratings at March 31, 2010 were BBB from Fitch Ratings, Baa2 from Moody’s Investors Service and BBB from Standard & Poor’s Ratings Services (upgraded to BBB from BBB- on March 8, 2010).
During the three months ended March 31, 2010, we repaid at maturity $2.9 million of fixed rate secured debt that bore interest at 8.02%, and we made payments of $2.2 million on other notes and bonds payable.
During the three months ended March 31, 2010, we exercised a 12-month extension option on a $32.4 million loan that was scheduled to mature in April 2010.
During the three months ended March 31, 2010, cash distributions of $0.4 million were made to OP unitholders.
On January 18, 2010, we redeemed all outstanding shares of our 7.75% Series B Cumulative Convertible Preferred Stock (“Series B Preferred Stock”) at a redemption price per share of $103.875 plus an amount equal to accumulated and unpaid dividends thereon to the redemption date ($0.3875), for a total redemption price of $104.2625 per share, payable only in cash. As a result of the redemption, each share of Series B Preferred Stock was convertible until January 14, 2010 into 4.5150 shares of common stock. During that time, 512,727 shares were converted into approximately 2,315,000 shares of common stock. On January 18, 2010, we redeemed 917 shares that remained outstanding.
We enter into sales agreements from time to time with agents to sell shares of our common stock through an at-the-market equity offering program. We entered into two new sales agreements, each dated January 15, 2010, to sell up to an aggregate of 5,000,000 shares of our common stock from time to time. During the three months ended March 31, 2010, we issued and sold approximately 1,269,000 shares of common stock at a weighted average price of $35.58 per share, resulting in net proceeds of approximately $44.7 million after sales agent fees. At March 31, 2010, approximately 4,195,000 shares of common stock were available to be sold pursuant to our at-the-market equity offering program. From April 1, 2010 to May 6, 2010, we issued and sold approximately 1,592,000 shares at a weighted average price of $35.08 per share through our at-the-market equity offering program.
We sponsor a dividend reinvestment plan that enables existing stockholders to purchase additional shares of common stock by automatically reinvesting all or part of the cash dividends paid on their shares of common stock at a discount ranging from 0% to 5%, determined by us from time to time in accordance with the plan. The discount at March 31, 2010 was 2%. During the three months ended March 31, 2010, we issued approximately 140,000 shares of common stock, at an average price of $33.09 per share, resulting in net proceeds of approximately $4.6 million.
We paid $52.0 million, or $0.44 per common share, in dividends to our common stockholders during the three months ended March 31, 2010. We expect that this common stock dividend policy will continue, but it is subject to regular review by our board of directors. Common stock dividends are paid at the discretion of our board of directors and are dependent upon various factors, including our future earnings, our financial condition and liquidity, our capital requirements and applicable legal and contractual restrictions. On May 4, 2010, our board of directors declared a quarterly cash dividend of $0.45 per share of common stock. This dividend will be paid on June 4, 2010 to stockholders of record on May 21, 2010.
On January 15, 2010, we filed a new shelf registration statement with the Securities and Exchange Commission under which we may issue securities including debt, convertible debt, common and preferred stock and warrants to purchase any of these securities.
Assuming certain conditions are met under our Contribution Agreement with Pacific Medical Buildings LLC and certain of its affiliates, we would expect to finance the acquisitions of the buildings subject to the Contribution Agreement with a combination of assumed debt, the issuance of OP Units, cash on hand and borrowings under our credit facility.

 

40


Table of Contents

Financing for other future investments and for the repayment of the obligations and commitments noted above may be provided by cash on hand, borrowings under our credit facility discussed above, the sale of debt or equity securities in private placements or public offerings, which may be made under the shelf registration statement discussed above or under new registration statements, proceeds from asset sales or mortgage loan receivable payoffs, the assumption of secured indebtedness, or mortgage financing on a portion of our owned portfolio or through joint ventures.
We invest in various short-term investments that are intended to preserve principal value and maintain a high degree of liquidity while providing current income. These investments may include (either directly or indirectly) obligations of the U.S. government or its agencies, obligations (including certificates of deposit) of banks, commercial paper, money market funds and other highly rated short-term securities. We monitor our investments on a daily basis and do not believe our cash and cash equivalents are exposed to any material risk of loss. However, given the recent market volatility, there can be no assurances that future losses of principal will not occur.
Recent market and economic conditions have been unprecedented and challenging with tighter credit conditions and slow growth. While there are current signs of a strengthening and stabilizing economy and more liquid and attractive capital markets, there is continued uncertainty over whether our economy will again be adversely impacted by inflation, deflation or stagflation, and the systemic impact of rising unemployment, energy costs, geopolitical issues, the availability and cost of capital, the U.S. mortgage market and a declining real estate market in the U.S., resulting in a return to illiquid credit markets and widening credit spreads. We had $700.0 million available under our credit facility at March 31, 2010, and we currently have no reason to believe that we will be unable to access the facility in the future. However, continued concern about the stability of the markets generally and the strength of borrowers specifically has led many lenders and institutional investors to reduce and, in some cases, cease to provide, funding to borrowers. If we were unable to access our credit facility, it could result in an adverse effect on our liquidity and financial condition. In addition, continued turbulence in market conditions may adversely affect the liquidity and financial condition of our tenants.
At March 31, 2010, we had approximately $77.3 million of indebtedness that matures in 2010. Additionally, some of our senior notes can be put to us prior to the stated maturity date; however, there are no such senior notes that we may be required to repay in 2010 or 2011. If these recent market conditions continue or do not fully abate, they may limit our ability, and the ability of our tenants, to timely refinance maturing liabilities and access the capital markets to meet liquidity needs, resulting in a material adverse effect on our financial condition and results of operations. Additionally, certain of our debt obligations are floating-rate obligations with interest rate and related payments that vary with the movement of LIBOR or other indexes. If the recent market turbulence continues, there could be a rise in interest rates which could reduce our profitability or adversely affect our ability to meet our obligations.
Our plans for growth require regular access to the capital and credit markets. If capital is not available at an acceptable cost, it will significantly impair our ability to make future investments and make acquisitions and development projects difficult or impractical to pursue.
We anticipate the possible sale of certain facilities, primarily due to purchase option exercises. In addition, mortgage loans receivable might be prepaid. In the event that there are facility sales or mortgage loan receivable repayments in excess of new investments, revenues may decrease. We anticipate using the proceeds from any facility sales or mortgage loans receivable repayments to provide capital for future investments, to reduce any outstanding balance on our credit facility or to repay other borrowings as they mature. Any such reduction in debt levels would result in reduced interest expense that we believe would partially offset any decrease in revenues. We believe the combination of cash on hand, the ability to draw on our $700.0 million credit facility and the ability to sell securities under the shelf registration statement, as well as our unconsolidated joint venture with a state pension fund investor, provide sufficient liquidity and financing capability to finance anticipated future investments, maintain our current dividend level and repay borrowings at or prior to their maturity, for at least the next 12 months.

 

41


Table of Contents

Off-Balance Sheet Arrangements
The only off-balance sheet financing arrangements that we currently utilize are the unconsolidated joint ventures discussed in Note 6 to our condensed consolidated financial statements. Except in limited circumstances, our risk of loss is limited to our investment carrying amount.
Contractual Obligations and Cash Requirements
As of March 31, 2010, our contractual obligations and commitments were as follows:
                                         
    2010 (1)     2011 – 2012     2013 – 2014     Thereafter     Total  
    (In thousands)  
Contractual Obligations:
                                       
Long-term debt
  $ 77,275     $ 534,604     $ 331,014     $ 584,690     $ 1,527,583  
 
                             
Interest expense
  $ 90,840     $ 129,191     $ 72,814     $ 201,631     $ 494,476  
 
                             
Ground leases
  $ 1,326     $ 3,326     $ 3,394     $ 87,671     $ 95,717  
 
                             
Operating leases
  $ 417     $ 643     $     $     $ 1,060  
 
                             
Commitments:
                                       
Capital expenditures
  $ 28,893     $ 78,004     $ 325     $ 1,590     $ 108,812  
 
                             
 
     
(1)   Amounts reflect obligations and commitments for the remaining nine months of 2010.
The long-term debt amount shown above includes our senior notes and our notes and bonds payable.
Interest expense shown above is estimated assuming the interest rates in effect at March 31, 2010 remain constant for the $119.3 million of floating rate notes and bonds payable. Maturities of our senior notes range from 2011 to 2038 (although certain notes may be put back to us at their face amount at the option of the holders at earlier dates) and maturities of our notes and bonds payable range from 2010 to 2037.
Item 3.   Quantitative and Qualitative Disclosures About Market Risk
We are exposed to market risks related to fluctuations in interest rates on our mortgage loans receivable and debt. We may hold derivative instruments to manage our exposure to these risks, and all derivative instruments are matched against specific debt obligations. Readers are cautioned that many of the statements contained in these paragraphs are forward-looking and should be read in conjunction with our disclosures under the heading “Statement Regarding Forward-Looking Disclosure” set forth above.
We provide mortgage loans to tenants of healthcare facilities as part of our normal operations, which generally have fixed rates.
We utilize debt financing primarily for the purpose of making additional investments in healthcare facilities. Historically, we have made short-term borrowings on our variable rate unsecured revolving credit facility to fund our acquisitions until market conditions were appropriate, based on management’s judgment, to issue stock or fixed rate debt to provide long-term financing.
At our option, borrowings under our credit facility bear interest at the prime rate (3.25% at March 31, 2010) or applicable LIBOR plus 0.70% (0.95% at March 31, 2010). At March 31, 2010 and December 31, 2009, we did not have any borrowings under our unsecured revolving credit facility. Additionally, a portion of our secured debt has variable rates.

 

42


Table of Contents

For fixed rate debt, changes in interest rates generally affect the fair market value, but do not impact earnings or cash flows. Conversely, for variable rate debt, changes in interest rates generally do not impact fair market value, but do affect the future earnings and cash flows. We generally cannot prepay fixed rate debt prior to maturity. Therefore, interest rate risk and changes in fair market value should not have a significant impact on the fixed rate debt until we would be required to refinance such debt. Any future interest rate increases will increase the cost of borrowings on our credit facility and any borrowings to refinance long-term debt as it matures or to finance future acquisitions. Holding the variable rate debt balance at March 31, 2010 constant, each one percentage point increase in interest rates would result in an increase in interest expense for the remaining nine months of 2010 of $0.9 million.
The table below sets forth certain information regarding our debt as of March 31, 2010 and December 31, 2009:
                                                 
    March 31, 2010     December 31, 2009  
                    % of                     % of  
    Principal     Rate     Total     Principal     Rate     Total  
Fixed rate debt:
                                               
Senior notes
  $ 991,633       6.5 %     64.9 %   $ 991,633       6.5 %     69.7 %
Notes and bonds payable
    416,612       6.0 %     27.3 %     323,025       6.1 %     22.7 %
 
                                   
Total fixed rate debt
    1,408,245       6.3 %     92.2 %     1,314,658       6.4 %     92.4 %
 
                                   
Variable rate debt:
                                               
Unsecured senior credit facility
                                   
Notes and bonds payable
    119,338       3.2 %     7.8 %     108,431       3.2 %     7.6 %
 
                                   
Total variable rate debt
    119,338       3.2 %     7.8 %     108,431       3.2 %     7.6 %
 
                                   
Total debt
  $ 1,527,583       6.1 %     100.0 %   $ 1,423,089       6.1 %     100.0 %
 
                                   
Item 4.   Controls and Procedures
As of the end of the period covered by this report, we carried out an evaluation, with the participation of our Chief Executive Officer and Chief Financial and Portfolio Officer, of the effectiveness of our disclosure controls and procedures. Disclosure controls and procedures are designed to ensure that information required to be disclosed in our periodic reports filed or submitted under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms. Based upon that evaluation, our Chief Executive Officer and Chief Financial and Portfolio Officer concluded that our disclosure controls and procedures were effective as of the end of the quarterly period covered by this report. No change in our internal control over financial reporting occurred during our last fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

43


Table of Contents

PART II. OTHER INFORMATION
Item 1.   Legal Proceedings
The information set forth under the heading “Litigation” of Note 17 to the Condensed Consolidated Financial Statement, included in Part I, Item 1 of this Report, is incorporated herein by reference.
Item 1A.   Risk Factors
Except as provided below, as of the date of this report, there have been no material changes to the risk factors in our Annual Report on Form 10-K for the year ended December 31, 2009.
Risks Relating to Our Tenants
Our financial position could be weakened and our ability to make distributions could be limited if any of our major tenants were unable to meet their obligations to us or failed to renew or extend their relationship with us as their lease terms expire or their mortgages mature, or if we were unable to lease or re-lease our facilities or make mortgage loans on economically favorable terms. We have no operational control over our tenants. There may end up being more serious tenant financial problems that lead to more extensive restructurings or tenant disruptions than we currently expect. This could be unique to a particular tenant or it could be more industry wide, such as further federal or state governmental reimbursement reductions in the case of our skilled nursing facilities as governments work through their budget deficits, continuing reduced occupancies or slow lease-ups for our assisted and independent living facilities or medical office buildings due to general economic and other factors and increases in insurance premiums, labor and other expenses. These adverse developments could arise due to a number of factors, including those listed below.
Our tenants may be affected by legislative developments impacting the healthcare system.
During March 2010, the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act were signed into federal law. The provisions included in the combination of these two bills provide increased access to health benefits for uninsured or underinsured populations through reform of both the private insurance industry and existing government programs. The combined bills also call for reductions in federal health program expenditures over 10 years through reductions in the annual market basket updates for Medicare fee-for-service providers (beginning October 1, 2011), reduced subsidies to Medicare Advantage health plans, reductions in Medicare and Medicaid disproportionate share funding and cuts in payments to hospitals with high readmission rates. Additionally, many states have enacted or are considering enacting measures to reduce Medicaid expenditures, reduce coverage and program eligibility and/or impose additional taxes. The fiscal condition of certain states may be impacted as budget shortfalls could potentially widen due to provisions within the healthcare reform legislation that expand certain Medicaid programs and other related healthcare expenditures. In addition, the full impact associated with increased costs for our tenants to provide healthcare insurance to their employees may cause additional pressure on our tenant’s operating performance. While the expansion of coverage may result in some additional demand for services provided by our tenants, reimbursement may be lower than the cost required to provide such services which could adversely affect our tenants’ ability to meet their obligations to us.
Most of the provisions of these healthcare bills do not go into effect immediately and may be delayed for several years. During this time, the bills could be subject to further adjustments through future legislation or even constitutional challenges, and additional legislative proposals may be introduced in Congress or in some state legislatures that could affect further changes in the healthcare system, nationally or at the state level. We cannot predict whether any such adjustments or proposals will be adopted or, if adopted, what effect, if any, these adjustments or proposals would have on our tenants and, thus, our business.

 

44


Table of Contents

Item 2.   Unregistered Sales of Equity Securities and Use of Proceeds
                                 
                    Total Number     Maximum Number  
                    of Shares Purchased     of Shares that May  
    Total Number     Average     as Part of Publicly     Yet Be Purchased  
    of Shares     Price Paid     Announced Plans     Under the Plans  
Period   Purchased(1)     per Share     or Programs     or Programs  
January 1, 2010 – January 31, 2010
    811     $ 32.96              
February 1, 2010 – February 28, 2010
    1,209       32.70              
March 1, 2010 – March 31, 2010
                       
 
                       
Total
    2,020     $ 32.80              
 
                       
 
     
(1)   Represents shares withheld by us to satisfy tax withholding due in connection with the vesting of restricted stock awards.

 

45


Table of Contents

Item 6.   Exhibits
         
Exhibit No.   Description
       
 
  2.1    
Twelfth Amendment to Formation and Contribution Agreement and Joint Escrow Instructions, dated as of February 1, 2010, by and among Company, NHP/PMB L.P., and Pacific Medical Buildings LLC and certain of its affiliates (Exhibit 2.1 to the Company’s Current Report on Form 8-K, dated February 5, 2010, is incorporated herein by reference).
       
 
  2.2    
Thirteenth Amendment to Formation and Contribution Agreement and Joint Escrow Instructions, dated as of March 1, 2010, by and among the Company, NHP/PMB L.P., and Pacific Medical Buildings LLC and certain of its affiliates (Exhibit 2.1 to the Company’s Current Report on Form 8-K, dated March 4, 2010, is incorporated herein by reference).
       
 
  3.1    
Charter of the Company (Exhibit 3.2 to the Company’s Current Report on Form 8-K, dated August 1, 2008, is incorporated herein by reference).
       
 
  3.2    
Bylaws of the Company, as amended and restated on February 10, 2009 (Exhibit 3.1 to the Company’s Current Report on Form 8-K, dated February 17, 2009, is incorporated herein by reference).
       
 
  10.1    
Incentive Compensation Repayment Policy (Exhibit 10.1 to the Company’s Current Report on Form 8-K, dated February 12, 2010, is incorporated herein by reference).
       
 
  10.2    
Form of Stock Option Agreement (Exhibit 10.2 to the Company’s Current Report on Form 8-K, dated February 12, 2010, is incorporated herein by reference).
       
 
  31.1    
Certification of CEO pursuant to Securities Exchange Act Rules 13a-14(a)/15d-14(a).
       
 
  31.2    
Certification of CFO pursuant to Securities Exchange Act Rules 13a-14(a)/15d-14(a).
       
 
  32    
Section 1350 Certifications of CEO and CFO.
       
 
  101.INS    
XBRL Instance Document*
       
 
  101.SCH    
XBRL Taxonomy Extension Schema Document*
       
 
  101.CAL    
XBRL Taxonomy Extension Calculation Linkbase Document*
       
 
  101.LAB    
XBRL Taxonomy Extension Label Linkbase Document*
       
 
  101.PRE    
XBRL Taxonomy Extension Presentation Linkbase Document*
       
 
  101.DEF    
XBRL Taxonomy Extension Definition Linkbase Document*

                         

*   Attached as Exhibit 101 to this Quarterly Report on Form 10-Q are the following materials, formatted in XBRL (Extensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets at March 31, 2010 and December 31, 2009, (ii) the Condensed Consolidated Income Statements for the three months ended March 31, 2010 and 2009, (iii) the Condensed Consolidated Statement of Equity for the three months ended March 31, 2010, (iv) the Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2010 and 2009 and (v) the Notes to Condensed Consolidated Financial Statements tagged as blocks of text.

      Users of this data are advised pursuant to Rule 401 of Regulation S-T that the information contained in the XBRL Related Documents (as defined in Regulation S-T) is unaudited and unreviewed, and that these documents are not the official financial statements of Nationwide Health Properties, Inc. filed with the Securities and Exchange Commission. The purpose of submitting these XBRL formatted documents is to test the related format and technology and, as a result, investors should not rely on the information contained in the XBRL documents when making investment decisions.

In accordance with Rule 402 of Regulation S-T, the XBRL related information in this Quarterly Report on Form 10-Q, Exhibit 101, shall not be deemed “filed” for purposes of Section 11 of the Securities Act of 1933, as amended (the “Securities Act”), or Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of those sections, and is not part of any registration statement to which it may relate, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing or document.

 

46


Table of Contents

SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
         
Date: May 6, 2010 Nationwide Health Properties, Inc.
 
 
  By:   /s/ Abdo H. Khoury  
    Abdo H. Khoury   
    Executive Vice President and Chief Financial & Portfolio Officer
(Principal Financial Officer and Duly Authorized Officer) 
 
 

 

47


Table of Contents

EXHIBIT INDEX
         
Exhibit No.   Description
       
 
  31.1    
Certification of CEO pursuant to Securities Exchange Act Rules 13a-14(a)/15d-14(a).
       
 
  31.2    
Certification of CFO pursuant to Securities Exchange Act Rules 13a-14(a)/15d-14(a).
       
 
  32    
Section 1350 Certifications of CEO and CFO.
       
 
  101.INS    
XBRL Instance Document*
       
 
  101.SCH    
XBRL Taxonomy Extension Schema Document*
       
 
  101.CAL    
XBRL Taxonomy Extension Calculation Linkbase Document*
       
 
  101.LAB    
XBRL Taxonomy Extension Label Linkbase Document*
       
 
  101.PRE    
XBRL Taxonomy Extension Presentation Linkbase Document*
       
 
  101.DEF    
XBRL Taxonomy Extension Definition Linkbase Document*

                         

*   Attached as Exhibit 101 to this Quarterly Report on Form 10-Q are the following materials, formatted in XBRL (Extensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets at March 31, 2010 and December 31, 2009, (ii) the Condensed Consolidated Income Statements for the three months ended March 31, 2010 and 2009, (iii) the Condensed Consolidated Statement of Equity for the three months ended March 31, 2010, (iv) the Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2010 and 2009 and (v) the Notes to Condensed Consolidated Financial Statements tagged as blocks of text.

      Users of this data are advised pursuant to Rule 401 of Regulation S-T that the information contained in the XBRL Related Documents (as defined in Regulation S-T) is unaudited and unreviewed, and that these documents are not the official financial statements of Nationwide Health Properties, Inc. filed with the Securities and Exchange Commission. The purpose of submitting these XBRL formatted documents is to test the related format and technology and, as a result, investors should not rely on the information contained in the XBRL documents when making investment decisions.

In accordance with Rule 402 of Regulation S-T, the XBRL related information in this Quarterly Report on Form 10-Q, Exhibit 101, shall not be deemed “filed” for purposes of Section 11 of the Securities Act of 1933, as amended (the “Securities Act”), or Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of those sections, and is not part of any registration statement to which it may relate, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing or document.

 

48

EX-31.1 2 c99877exv31w1.htm EXHIBIT 31.1 Exhibit 31.1
Exhibit 31.1
CEO CERTIFICATION
I, Douglas M. Pasquale, certify that:
1.   I have reviewed this quarterly report on Form 10-Q of Nationwide Health Properties, Inc.;
2.   Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.   Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.   The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  a)   Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  b)   Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  c)   Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  d)   Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.   The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
  a)   All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
  b)   Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
         
Date: May 6, 2010
  /s/ Douglas M. Pasquale    
 
 
 
Douglas M. Pasquale
   
 
  Chairman of the Board of Directors and    
 
  President and Chief Executive Officer    

 

 

EX-31.2 3 c99877exv31w2.htm EXHIBIT 31.2 Exhibit 31.2
Exhibit 31.2
CFO CERTIFICATION
I, Abdo H. Khoury, certify that:
1.   I have reviewed this quarterly report on Form 10-Q of Nationwide Health Properties, Inc.;
2.   Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.   Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.   The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  a)   Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  b)   Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  c)   Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  d)   Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.   The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
  a)   All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
  b)   Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
         
Date: May 6, 2010 
  /s/ Abdo H. Khoury    
 
 
 
Abdo H. Khoury
   
 
  Executive Vice President and Chief Financial & Portfolio Officer    
 
  (Principal Financial Officer)    

 

 

EX-32 4 c99877exv32.htm EXHIBIT 32 Exhibit 32
Exhibit 32
WRITTEN STATEMENT
PURSUANT TO
18 U.S.C. SECTION 1350
The undersigned, Douglas M. Pasquale, the Chief Executive Officer, and Abdo H. Khoury, the Chief Financial and Portfolio Officer, of Nationwide Health Properties, Inc. (the “Company”), pursuant to 18 U.S.C. §1350, hereby certify that, to the best of my knowledge:
(i) the Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2010 of the Company (the “Report”) fully complies with the requirements of section 13(a) and 15(d) of the Securities Exchange Act of 1934; and
(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
         
Dated: May 6, 2010
  /s/ Douglas M. Pasquale    
 
 
 
Douglas M. Pasquale
   
 
  Chairman of the Board of Directors and    
 
  President and Chief Executive Officer    
 
  /s/ Abdo H. Khoury    
 
 
 
Abdo H. Khoury
   
 
  Executive Vice President and Chief Financial & Portfolio Officer    
 
  (Principal Financial Officer)    
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. The foregoing certification is being furnished pursuant to 18 U.S.C. Section 1350. It is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and it is not to be incorporated by reference into any filing of the Company, regardless of any general incorporation language in such filing.

 

 

EX-101.INS 5 nhp-20100331.xml EX-101 INSTANCE DOCUMENT 0000780053 us-gaap:RetainedEarningsUnappropriatedMember 2010-03-31 0000780053 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2010-03-31 0000780053 us-gaap:AdditionalPaidInCapitalMember 2010-03-31 0000780053 us-gaap:NoncontrollingInterestMember 2010-03-31 0000780053 us-gaap:RetainedEarningsAppropriatedMember 2010-03-31 0000780053 us-gaap:NoncontrollingInterestMember 2009-12-31 0000780053 us-gaap:RetainedEarningsAppropriatedMember 2009-12-31 0000780053 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2009-12-31 0000780053 us-gaap:AdditionalPaidInCapitalMember 2009-12-31 0000780053 us-gaap:RetainedEarningsUnappropriatedMember 2009-12-31 0000780053 us-gaap:PreferredStockMember 2010-03-31 0000780053 us-gaap:CommonStockMember 2010-03-31 0000780053 us-gaap:CommonStockMember 2009-12-31 0000780053 us-gaap:PreferredStockMember 2009-12-31 0000780053 us-gaap:RetainedEarningsAppropriatedMember 2010-01-01 2010-03-31 0000780053 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2010-01-01 2010-03-31 0000780053 us-gaap:RetainedEarningsUnappropriatedMember 2010-01-01 2010-03-31 0000780053 2009-01-01 2009-12-31 0000780053 2009-03-31 0000780053 2008-12-31 0000780053 us-gaap:CommonStockMember 2010-01-01 2010-03-31 0000780053 us-gaap:PreferredStockMember 2010-01-01 2010-03-31 0000780053 us-gaap:NoncontrollingInterestMember 2010-01-01 2010-03-31 0000780053 2009-01-01 2009-03-31 0000780053 us-gaap:AdditionalPaidInCapitalMember 2010-01-01 2010-03-31 0000780053 2010-03-31 0000780053 2009-12-31 0000780053 2009-06-30 0000780053 2010-05-06 0000780053 2010-01-01 2010-03-31 iso4217:USD xbrli:shares xbrli:shares iso4217:USD <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 1 - us-gaap:NatureOfOperations--> <!-- xbrl,ns --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"><b></b> </div> <div align="left"> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"><b></b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"><b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>1. Organization</b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Nationwide Health Properties, Inc., a Maryland corporation, is a real estate investment trust (&#8220;REIT&#8221;) that invests in healthcare related real estate, primarily senior housing, long-term care properties and medical office buildings. Whenever we refer herein to &#8220;NHP&#8221; or to &#8220;us&#8221; or use the terms &#8220;we&#8221; or &#8220;our,&#8221; we are referring to Nationwide Health Properties, Inc. and its subsidiaries, unless the context otherwise requires. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We primarily make our investments by acquiring an ownership interest in senior housing and long-term care facilities and leasing them to unaffiliated tenants under &#8220;triple-net&#8221; &#8220;master&#8221; leases that transfer the obligation for all facility operating costs (including maintenance, repairs, taxes, insurance and capital expenditures) to the tenant. We also invest in medical office buildings which are not generally subject to &#8220;triple-net&#8221; leases and generally have several tenants under separate leases in each building, thus requiring active management and responsibility for many of the associated operating expenses (although many of these are, or can effectively be, passed through to the tenants). Some of the medical office buildings are subject to &#8220;triple-net&#8221; leases. In addition, but to a much lesser extent because we view the risks of this activity to be greater due to less favorable bankruptcy treatment and other factors, from time to time, we extend mortgage loans and other financing to operators. For the three months ended March&#160;31, 2010, approximately 93% of our revenues were derived from leases, with the remaining 7% from mortgage loans, other financing activities and other miscellaneous income. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We believe we have operated in such a manner as to qualify as a REIT under Sections&#160;856 through 860 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;). We intend to continue to qualify as such and therefore distribute at least 90% of our REIT taxable income (computed without regard to the dividends paid deduction and excluding capital gain) to our stockholders. If we qualify for taxation as a REIT, and we distribute 100% of our taxable income to our stockholders, we will generally not be subject to U.S. federal income taxes on our income that is distributed to stockholders. Accordingly, no provision has been made for federal income taxes. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As of March&#160;31, 2010, we had investments in 606 healthcare facilities and one land parcel located in 43 states, consisting of: </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Consolidated facilities: </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>251 assisted and independent living facilities;</td> </tr> </table> </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>167 skilled nursing facilities;</td> </tr> </table> </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>9 continuing care retirement communities;</td> </tr> </table> </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>7 specialty hospitals;</td> </tr> </table> </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>19 triple-net medical office buildings, one of which is operated by a consolidated joint venture (see Note 5); and</td> </tr> </table> </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>67 multi-tenant medical office buildings, 20 of which are operated by consolidated joint ventures (see Note 5).</td> </tr> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Unconsolidated facilities: </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>19 assisted and independent living facilities;</td> </tr> </table> </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>14 skilled nursing facilities; and</td> </tr> </table> </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>1 continuing care retirement community.</td> </tr> </table> </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Mortgage loans secured by: </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>26 medical office buildings;</td> </tr> </table> </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>16 skilled nursing facilities;</td> </tr> </table> </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>9 assisted and independent living facilities;</td> </tr> </table> </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>1 continuing care retirement community; and</td> </tr> </table> </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>1 land parcel.</td> </tr> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As of March&#160;31, 2010, our directly owned facilities, other than our multi-tenant medical office buildings, were operated by 84 different healthcare providers, including the following publicly traded companies: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="86%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2"><b>Number of</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2"><b>Facilities</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Operated</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b><b>&#8226;</b> </b>Assisted Living Concepts, Inc. </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">4</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px"><b><b>&#8226;</b> </b>Brookdale Senior Living, Inc. </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">96</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b><b>&#8226;</b> </b>Emeritus Corporation </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">6</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px"><b><b>&#8226;</b> </b>Extendicare, Inc. </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b><b>&#8226;</b> </b>HealthSouth Corporation </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">2</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px"><b><b>&#8226;</b> </b>Kindred Healthcare, Inc. </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b><b>&#8226;</b> </b>Sun Healthcare Group, Inc. </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">4</td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Two of our triple-net lease tenants each accounted for more than 10% of our revenues at March 31, 2010 as follows: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="86%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b><b>&#8226;</b> </b>Brookdale Senior Living, Inc. </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">14.3</td> <td nowrap="nowrap">%</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px"><b><b>&#8226;</b> </b>Hearthstone Senior Services, L.P. </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">10.1</td> <td nowrap="nowrap">%</td> </tr> <!-- End Table Body --> </table> </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 2 - us-gaap:SignificantAccountingPoliciesTextBlock--> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>2. Summary of Significant Accounting Policies</b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Basis of Presentation</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We have prepared the condensed consolidated financial statements included herein without audit. These financial statements include all adjustments that are, in the opinion of management, necessary for a fair presentation of the results of operations for the three months ended March&#160;31, 2010 and 2009 pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). All such adjustments are of a normal recurring nature. Certain items in prior period financial statements have been reclassified to conform to current year presentation, including those required by the provisions of Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 360, <i>Property, Plant and Equipment </i>(&#8220;ASC 360&#8221;), which require the operating results of any assets with their own identifiable cash flows that are disposed of or held for sale and in which we have no continuing interest to be removed from income from continuing operations and reported as discontinued operations. Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) have been condensed or omitted pursuant to these rules and regulations. Although we believe that the disclosures in the financial statements included herein are adequate to make the information presented not misleading, these condensed consolidated financial statements should be read in conjunction with our financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2009 filed with the SEC. The results of operations for the three months ended March&#160;31, 2010 and 2009 are not necessarily indicative of the results for a full year. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We have evaluated events subsequent to March&#160;31, 2010 for their impact on our condensed consolidated financial statements. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Principles of Consolidation</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The condensed consolidated financial statements include our accounts, the accounts of our wholly-owned subsidiaries and the accounts of our joint ventures that are controlled through voting rights or other means. We apply the provisions of ASC Topic 810, <i>Consolidation </i>(&#8220;ASC 810&#8221;), for arrangements with variable interest entities (&#8220;VIEs&#8221;) and would consolidate those VIEs where we are the primary beneficiary. All material intercompany accounts and transactions have been eliminated. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our judgment with respect to our level of influence or control of an entity and whether we are the primary beneficiary of a VIE involves the consideration of various factors including, but not limited to, the form of our ownership interest, our representation on the entity&#8217;s governing body, the size of our investment, estimates of future cash flows, our ability to participate in policy-making decisions and the rights of the other investors to participate in the decision-making process and to replace us as manager and/or liquidate the venture, if applicable. Our ability to correctly assess our influence or control over an entity or determine the primary beneficiary of a VIE affects the presentation of these entities in our consolidated financial statements. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We apply the provisions of ASC Topic 323, <i>Investments &#8212; Equity Method and Joint Ventures </i>(&#8220;ASC 323&#8221;), to investments in joint ventures. Investments in entities that we do not consolidate but for which we have the ability to exercise significant influence over operating and financial policies are reported under the equity method. Under the equity method of accounting, our share of the entity&#8217;s earnings or losses is included in our operating results. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Use of Estimates</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ materially from those estimates. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Revenue Recognition</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Rental income from operating leases is recognized in accordance with the provisions of ASC Topic 840, <i>Leases, </i>and ASC Topic 605, <i>Revenue Recognition</i>. Our leases generally contain annual rent escalators. Many of our leases contain non-contingent rent escalators for which we recognize income on a straight-line basis over the lease term. Recognizing income on a straight-line basis requires us to calculate the total non-contingent rent to be paid over the life of a lease and to recognize the revenue evenly over that life. This method results in rental income in the early years of a lease being higher than actual cash received, creating a straight-line rent receivable asset included in the caption &#8220;Other assets&#8221; on our consolidated balance sheets. At some point during the lease, depending on its terms, the cash rent payments eventually exceed the straight-line rent which results in the straight-line rent receivable asset decreasing to zero over the remainder of the lease term. Certain leases contain rent escalators contingent on revenues or other factors, including increases based on changes in the Consumer Price Index. Such revenue increases are recognized as the related contingencies are met. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We assess the collectability of straight-line rents in accordance with the applicable accounting standards and our reserve policy and defer recognition of straight-line rent if its collectability is not reasonably assured. Our assessment of the collectability of straight-line rents is based on several factors, including the financial strength of the tenant and any guarantors, the historical operations and operating trends of the facility, the historical payment pattern of the tenant and the type of facility, among others. If our evaluation of these factors indicates we may not receive the rent payments due in the future, we defer recognition of the straight-line rental income and, depending on the circumstances, we will provide a reserve against the previously recognized straight-line rent receivable asset for a portion, up to its full value, that we estimate may not be recoverable. If we change our assumptions or estimates regarding the collectability of future rent payments required by a lease, we may adjust our reserve to increase or reduce the rental revenue recognized, and/or to increase or reduce the reserve against the existing straight-line rent receivable balance. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We recorded $1.7&#160;million and $1.6&#160;million of revenues in excess of cash received during the three months ended March&#160;31, 2010 and 2009, respectively. We had straight-line rent receivables, net of reserves, recorded under the caption &#8220;Other assets&#8221; on our consolidated balance sheets of $29.3&#160;million at March&#160;31, 2010 and $27.5&#160;million at December&#160;31, 2009, net of reserves of $108.2 million and $108.3&#160;million, respectively. We evaluate the collectability of the straight-line rent receivable balances on an ongoing basis and provide reserves against receivables we believe may not be fully recoverable. The ultimate amount of straight-line rent we realize could be less than amounts currently recorded. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Gains on Sale of Facilities</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We recognize sales of facilities upon closing. Payments received from purchasers prior to closing are recorded as deposits. Gains on facilities sold are recognized using the full accrual method upon closing when the requirements of gain recognition on sale of real estate under the provisions of ASC 360 are met, including: the collectability of the sales price is reasonably assured; we have received adequate initial investment from the buyer; we are not obligated to perform significant activities after the sale to earn the gain; and other profit recognition criteria have been satisfied. Gains may be deferred in whole or in part until the sales satisfy these requirements. Gains on facilities sold to unconsolidated joint ventures in which we maintain an ownership interest are included in income from continuing operations, and the portion of the gain representing our retained ownership interest in the joint venture is deferred and included in the caption &#8220;Accounts payable and accrued liabilities&#8221; on our consolidated balance sheets. We had $15.3&#160;million of such deferred gains at March&#160;31, 2010 and December&#160;31, 2009. All other gains are included in discontinued operations. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Asset Impairment</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We review our long-lived assets individually on a quarterly basis to determine if there are indicators of impairment in accordance with the provisions of ASC 360. Indicators may include, among others, a tenant&#8217;s inability to make rent payments, operating losses or negative operating trends at the facility level, notification by a tenant that it will not renew its lease, or a decision to dispose of an asset or adverse changes in the fair value of any of our properties. For operating assets, if indicators of impairment exist, we compare the undiscounted cash flows from the expected use of the property to its net book value to determine if impairment exists. The evaluation of the undiscounted cash flows from the expected use of the property is highly subjective and is based in part on various factors and assumptions, including, but not limited to, historical operating results, available market information and known trends and market/economic conditions that may affect the property, as well as estimates of future operating income, occupancy, rental rates, leasing demand and competition. If the sum of the future estimated undiscounted cash flows is higher than the current net book value, we conclude no impairment exists. If the sum of the future estimated undiscounted cash flows is lower than its current net book value, we recognize an impairment loss for the difference between the net book value of the asset and its estimated fair value. To the extent we decide to sell an asset, we recognize an impairment loss if the current net book value of the asset exceeds its fair value less selling costs. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We evaluate our equity method investments for impairment whenever events or changes in circumstances indicate that the carrying value of our investment in an unconsolidated joint venture may exceed the fair value. If it is determined that a decline in the fair value of our investment in an unconsolidated joint venture is other-than-temporary, and if such reduced fair value is below its carrying value, an impairment is recorded. The determination of the fair value of investments in unconsolidated joint ventures involves significant judgment. Our estimates consider all available evidence including, as appropriate, the present value of the expected future cash flows discounted at market rates, general economic conditions and trends and other relevant factors. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The above analyses require us to determine whether there are indicators of impairment for individual assets or investments in unconsolidated joint ventures, to estimate the most likely stream of cash flows from operating assets and to determine the fair value of assets that are impaired or held for sale. If our assumptions, projections or estimates regarding an asset change in the future, we may have to record an impairment charge to reduce or further reduce the net book value of such individual asset or investment in unconsolidated joint venture. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">No impairment charges were recorded during the three months ended March&#160;31, 2010 or 2009. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Collectability of Receivables</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We evaluate the collectability of our rent, mortgage and other loans and other receivables on a regular basis based on factors including, among others, payment history, the financial strength of the borrower and any guarantors, the value of the underlying collateral, the operations and operating trends of the underlying collateral, if any, the asset type and current economic conditions. If our evaluation of these factors indicates we may not recover the full value of the receivable, we provide a reserve against the portion of the receivable that we estimate may not be recovered. This analysis requires us to determine whether there are factors indicating a receivable may not be fully collectible and to estimate the amount of the receivable that may not be collected. We had reserves included in the caption &#8220;Receivables, net&#8221; on our consolidated balance sheets of $14.3&#160;million at March&#160;31, 2010 and $12.7&#160;million at December&#160;31, 2009. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Accounting for Stock-Based Compensation</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We account for stock-based compensation in accordance with the provisions of ASC Topic 718, <i>Compensation-Stock Compensation, </i>which require stock-based compensation awards to be valued at the fair value on the date of grant and amortized as an expense over the vesting period and require any dividend equivalents earned to be treated as dividends for financial reporting purposes. Net income reflects stock-based compensation expense of $1.6&#160;million for each of the three months ended March 31, 2010 and 2009. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Land, Buildings and Improvements and Depreciation and Useful Lives of Assets</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We record properties at cost and use the straight-line method of depreciation for buildings and improvements over their estimated remaining useful lives of up to 40&#160;years, generally 20 to 40 years depending on factors including building type, age, quality and location. We review and adjust useful lives periodically. Depreciation expense from continuing operations was $27.8&#160;million and $25.5&#160;million for the three months ended March&#160;31, 2010 and 2009, respectively. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We allocate purchase prices of properties in accordance with the provisions of ASC Topic 805, <i>Business Combinations </i>(&#8220;ASC 805&#8221;), which require that the acquisition method of accounting be used for all business combinations and for an acquirer to be identified for each business combination. ASC 805 also establishes principles and requirements for how the acquirer recognizes and measures in its financial statements the identifiable assets acquired, the liabilities assumed and any noncontrolling interest in the acquiree. Certain transaction costs that have historically been capitalized as acquisition costs are expensed for business combinations completed on or after January&#160;1, 2009, which may have a significant impact on our future results of operations and financial position based on historical acquisition costs and activity levels. During the three months ended March&#160;31, 2010, we incurred $1.4&#160;million of acquisition costs that are included on our consolidated income statements. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The allocation of the cost between land, building and, if applicable, equipment and intangible assets and liabilities, and the determination of the useful life of a property are based on management&#8217;s estimates, which are based in part on independent appraisals or other consultants&#8217; reports. For our triple-net leased facilities, the allocation is made as if the property was vacant, and a significant portion of the cost of each property is allocated to buildings. This amount generally approximates 90% of the total property value. Historically, we have generally acquired properties and simultaneously entered into a new market rate lease for the entire property with one tenant. For our multi-tenant medical office buildings, the percentage allocated to buildings may be substantially lower as allocations are made to assets such as lease-up intangible assets, above market tenant and ground lease intangible assets and in-place lease intangible assets (collectively &#8220;intangible assets&#8221;) included on our consolidated balance sheets and/or below market tenant and ground lease intangible liabilities included in the caption &#8220;Accounts payable and accrued liabilities&#8221; on our consolidated balance sheets. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We calculate depreciation and amortization on equipment and lease costs using the straight-line method based on estimated useful lives of up to five years or the lease term, whichever is appropriate. We amortize intangible assets and liabilities over the remaining lease terms of the respective leases to real estate amortization expense or medical office building operating rent, as appropriate. We review and adjust useful lives periodically. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Cash and Cash Equivalents</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Cash and cash equivalents include short-term investments with original maturities of three months or less when purchased. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Deferred Financing Costs</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Deferred financing costs are amortized as a component of interest expense over the terms of the related borrowings using a method that approximates a level yield. Deferred financing cost amortization is included in the caption &#8220;Interest expense&#8221; on our consolidated income statements. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Derivatives</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In the normal course of business, we are exposed to financial market risks, including interest rate risk on our interest-bearing liabilities. We endeavor to limit these risks by following established risk management policies, procedures and strategies, including, on occasion, the use of derivative instruments. We do not use derivative instruments for trading or speculative purposes. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Derivative instruments are recorded on our consolidated balance sheets as assets or liabilities based on each instrument&#8217;s fair value. Changes in the fair value of derivative instruments are recognized currently in earnings, unless the derivative instrument meets the criteria for hedge accounting contained in ASC Topic 815, <i>Derivatives and Hedging </i>(&#8220;ASC 815&#8221;). If the derivative instruments meet the criteria for a cash flow hedge, the gains and losses recognized upon changes in the fair value of the derivative instrument are recorded in other comprehensive income. Gains and losses on a cash flow hedge are reclassified into earnings when the forecasted transaction affects earnings. A contract that is designated as a hedge of an anticipated transaction which is no longer likely to occur is immediately recognized in earnings. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">For investments in entities reported under the equity method of accounting, we record our pro rata share of the entity&#8217;s derivative instruments&#8217; fair value, other comprehensive income or loss and gains and losses determined in accordance with ASC 323 and ASC 815 as applicable. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Segment Reporting</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We report our consolidated financial statements in accordance with the provisions of ASC Topic 280, <i>Segment Reporting</i>. We operate in two segments based on our investment and leasing activities: triple-net leases and multi-tenant leases (see Note 16). </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Redeemable Limited Partnership Unitholders</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">NHP/PMB L.P. (&#8220;NHP/PMB&#8221;) is a limited partnership that we formed in February&#160;2008 to acquire properties from entities affiliated with Pacific Medical Buildings LLC (see Note 5). We consolidate NHP/PMB consistent with the provisions of ASC 810, as our wholly owned subsidiary is the general partner and exercises control. As of March&#160;31, 2010 and December&#160;31, 2009, third party investors owned 2,206,465 and 1,629,752 Class&#160;A limited partnership units in NHP/PMB (&#8220;OP Units&#8221;), respectively, which represented 34.7% and 53.9% of the total units outstanding at March&#160;31, 2010 and December&#160;31, 2009, respectively. During the three months ended March&#160;31, 2010, 575,326 and 1,788 OP Units were issued by NHP/PMB in connection with acquisitions and under terms of an agreement with Pacific Medical Buildings and certain of its affiliates, respectively (see Note 5). After a one year holding period, the OP Units are exchangeable for cash or, at our option, shares of our common stock, initially on a one-for-one basis. We have entered into a registration rights agreement with the holders of the OP Units which, subject to the terms and conditions set forth therein, obligates us to register the shares of common stock that we may issue in exchange for such OP Units. Since we are obligated to register the shares, the redeemable OP unitholder interests are classified outside of permanent equity on our consolidated balance sheets. During the three months ended March&#160;31, 2010, 401 OP Units were converted into 401 shares of our common stock. We applied the provisions of ASC Topic 480, <i>Distinguishing Liabilities from Equity</i>, to reflect the redeemable OP unitholder interests at the greater of cost or fair value. At March&#160;31, 2010, the fair value of the OP Units exceeded the cost basis by $1.6&#160;million, and the adjustment was recorded through capital in excess of par value. The value of the OP Units held by redeemable OP unitholder interests was $77.6&#160;million and $57.3&#160;million at March&#160;31, 2010 and December&#160;31, 2009, respectively. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Noncontrolling Interests</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We have three consolidated joint ventures in which we have equity interests, ranging from 71% to 95%, in nine multi-tenant medical office buildings (see Note 5). </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">NHP/PMB has equity interests, ranging from 50% to 69%, in three joint ventures which each own one multi-tenant medical office building (see Note 5). The joint ventures are consolidated by NHP/PMB, and we consolidate NHP/PMB in our consolidated financial statements. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We also have five partnerships in which we have equity interests, ranging from 51% to 81%, in three assisted and independent living facilities, one skilled nursing facility and one specialty hospital. We consolidate the partnerships in our consolidated financial statements. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Fair Value</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We apply the provisions of ASC Topic 820, <i>Fair Value Measurements and Disclosures </i>(&#8220;ASC 820&#8221;) to our financial assets and liabilities measured at fair value on a recurring basis and to our nonfinancial assets and liabilities that are not required or permitted to be measured at fair value on a recurring basis. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. ASC 820 also specifies a three-level hierarchy of valuation techniques based upon whether the inputs reflect assumptions other market participants would use based upon market data obtained from independent sources (observable inputs) or reflect our own assumptions of market participant valuation (unobservable inputs) and requires the use of observable inputs if such data is available without undue cost and effort. The hierarchy is as follows: </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>Level 1 &#8212; quoted prices for identical instruments in active markets.</td> </tr> </table> </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>Level 2 &#8212; observable inputs other than Level 1 inputs, including quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and other derived valuations with significant inputs or value drivers that are observable or can be corroborated by observable inputs in active markets.</td> </tr> </table> </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>Level 3 &#8212; unobservable inputs or derived valuations with significant inputs or value drivers that are unobservable.</td> </tr> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Fair value measurements at March&#160;31, 2010 are as follow: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="44%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Fair Value</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Level 1</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Level 2</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Level 3</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="14"><b>(In thousands)</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Financial assets </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">4,723</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">4,723</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Financial liabilities </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(4,723</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(4,723</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Redeemable OP unitholder interests </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">77,557</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">77,557</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">77,557</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">77,557</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">OP Units are exchangeable for cash or, at our option, shares of our common stock, initially on a one-for-one basis. As such, the fair value of OP Units outstanding at March&#160;31, 2010 is based on the closing price of our common stock on March&#160;31, 2010, which was $35.15 per share. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The provisions of ASC Topic 825, <i>Financial Instruments</i>, provide companies with an option to report selected financial assets and liabilities at fair value and establish presentation and disclosure requirements designed to facilitate comparisons between companies that choose different measurement attributes for similar types of assets and liabilities. We have not elected to apply the fair value option to any specific financial assets or liabilities. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The carrying amount of cash and cash equivalents approximates fair value because of the short maturities of these instruments. The fair value of mortgage and other loans receivable are based upon the estimates of management and on rates currently prevailing for comparable loans. The fair value of long-term debt is estimated based on discounting future cash flows utilizing current rates offered to us for debt of a similar type and remaining maturity. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The table below details the book value and fair value for mortgage and other loans receivable and the components of long-term debt at March&#160;31, 2010. These fair value estimates are not necessarily indicative of the amounts that would be realized upon disposition of these financial instruments. </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="72%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Book Value</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Fair Value</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6"><b>(In thousands)</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Mortgage loans receivable </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">216,589</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">216,349</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Other loans receivable </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">71,326</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">67,049</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Unsecured senior credit facility </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Senior notes </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">991,633</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">1,067,918</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Notes and bonds payable </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">535,950</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">532,376</td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Earnings per Share (EPS)</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Basic EPS is computed by dividing income from continuing operations available to common stockholders by the weighted average common shares outstanding. Income from continuing operations available to common stockholders is calculated by deducting amounts attributable to noncontrolling interests, amounts attributable to participating securities and dividends declared on preferred stock from income from continuing operations. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We apply the provisions of ASC Topic 260, <i>Earnings per Share</i>, which require that the two-class method of computing basic earnings per share be applied when there are unvested share-based payment awards that contain rights to nonforfeitable dividends outstanding during a reporting period. These participating securities share in undistributed earnings with common stockholders for purposes of calculating basic earnings per share. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Diluted EPS includes the effect of any potential shares outstanding, which for us is comprised of dilutive stock options, other share-settled compensation plans and, if the effect is dilutive, 7.75% Series&#160;B Cumulative Convertible Preferred Stock (&#8220;Series&#160;B Preferred Stock&#8221;), which was redeemed on January&#160;18, 2010 (see Note 10) and/or OP Units. The dilutive effect of stock options and other share-settled compensation plans that do not contain rights to nonforfeitable dividends is calculated using the treasury stock method with an offset from expected proceeds upon exercise of the stock options and unrecognized compensation expense. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Impact of New Accounting Standards Updates</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In June&#160;2009, the FASB updated ASC 810 to require ongoing analyses to determine whether an entity&#8217;s variable interest gives it a controlling financial interest in a variable interest entity (&#8220;VIE&#8221;), making it the primary beneficiary, based on whether the entity (i)&#160;has the power to direct activities of the VIE that most significantly impact its economic performance, including whether it has an implicit financial responsibility to ensure the VIE operates as designed, and (ii)&#160;has the obligation to absorb losses or the right to receive benefits of the VIE that could potentially be significant to the VIE. Enhanced disclosures regarding an entity&#8217;s involvement with VIEs are also required under the provisions of ASC 810. These requirements became effective January&#160;1, 2010. The adoption of these requirements did not have a material impact on our results of operations or financial position. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In January&#160;2010, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2010-06, <i>Improving Disclosures About Fair Value Measurements </i>(&#8220;ASU 2010-06&#8221;). ASU 2010-06 adds new requirements for disclosures of significant transfers into and out of Levels 1, 2 and 3 of the fair value hierarchy, the reasons for the transfers and the policy for determining when transfers are recognized. ASU 2010-06 also adds new requirements for disclosures about purchases, sales, issuances and settlements on a gross rather than net basis relating to the reconciliation of the beginning and ending balances of Level 3 recurring fair value measurements. It also clarifies the level of disaggregation to require disclosures by &#8220;class&#8221; rather than by &#8220;major category of assets and liabilities&#8221; and clarifies that a description of inputs and valuation techniques used to measure fair value is required for both recurring and nonrecurring fair value measurements classified as Level 2 or 3. ASU 2010-06 became effective January&#160;1, 2010 except for the requirements to provide the Level 3 activity of purchases, sales, issuances and settlements on a gross basis which are effective January&#160;1, 2011. The adoption of ASU 2010-06 has not and is not expected to have a material impact on our results of operations or financial position. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In February&#160;2010, the FASB issued ASU 2010-09, <i>Amendments to Certain Recognition and Disclosure Requirements </i>(&#8220;ASU 2010-09&#8221;). ASU 2010-09 amends ASC Topic 855, <i>Subsequent Events</i>, to require SEC registrants and conduit bond obligors to evaluate subsequent events through the date that the financial statements are issued, however, SEC registrants are exempt from disclosing the date through which subsequent events have been evaluated. All other entities are required to evaluate subsequent events through the date that the financial statements are available to be issued and must disclose the date through which subsequent events have been evaluated. ASU 2010-09 was effective upon issuance for all entities except conduit debt obligors. The adoption of ASU 2010-09 did not have an impact on our results of operations or financial position. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 3 - us-gaap:RealEstateDisclosureTextBlock--> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>3. Real Estate Properties</b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">At March&#160;31, 2010, we had direct ownership of: </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>251 assisted and independent living facilities;</td> </tr> </table> </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>167 skilled nursing facilities;</td> </tr> </table> </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>9 continuing care retirement communities;</td> </tr> </table> </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>7 specialty hospitals;</td> </tr> </table> </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>19 triple-net medical office buildings, one of which is operated by a consolidated joint venture (see Note 5); and</td> </tr> </table> </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>67 multi-tenant medical office buildings, 20 of which are operated by consolidated joint ventures (see Note 5).</td> </tr> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We lease our owned senior housing and long-term care facilities and certain medical office buildings to single tenants under &#8220;triple-net,&#8221; and in most cases, &#8220;master&#8221; leases that are accounted for as operating leases. These leases generally have an initial term of up to 21&#160;years and generally have two or more multiple-year renewal options. As of March&#160;31, 2010, approximately 84% of these facilities were leased under master leases. In addition, the majority of these leases contain cross-collateralization and cross-default provisions tied to other leases with the same tenant, as well as grouped lease renewals and grouped purchase options. As of March&#160;31, 2010, leases covering 457 facilities were backed by security deposits consisting of irrevocable letters of credit or cash totaling $72.2&#160;million. Under the terms of the leases, the tenant is responsible for all maintenance, repairs, taxes, insurance and capital expenditures on the leased properties. As of March&#160;31, 2010, leases covering 339 facilities contained provisions for property tax impounds, and leases covering 208 facilities contained provisions for capital expenditure impounds. We generally lease medical office buildings to multiple tenants under separate non-triple-net leases, where we are responsible for many of the associated operating expenses (although many of these are, or can effectively be, passed through to the tenants). However, some of the medical office buildings are subject to triple-net leases, where the lessees are responsible for the associated operating expenses. No individual property owned by us is material to us as a whole. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During the three months ended March&#160;31, 2010, we acquired the remaining 55.05% interest in PMB SB 399-401 East Highland LLC (&#8220;PMB SB&#8221;), an entity affiliated with Pacific Medical Buildings LLC that owns two multi-tenant medical office buildings. PMB SB was valued at $17.4&#160;million at the date of acquisition, and the acquisition was paid in a combination of cash and the assumption of $11.2 million of mortgage financing (of which $6.2&#160;million was previously attributable to the controlling interest in PMB SB) (see Note 6). </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During the three months ended March&#160;31, 2010, we funded $3.7&#160;million in expansions, construction and capital improvements at certain facilities in our triple-net leases segment in accordance with existing lease provisions. Such expansions, construction and capital improvements generally result in an increase in the minimum rents earned by us on these facilities either at the time of funding or upon completion of the project. At March&#160;31, 2010, we had committed to fund additional expansions, construction and capital improvements of $108.8&#160;million. During the three months ended March&#160;31, 2010, we also funded $0.2&#160;million in capital and tenant improvements at certain multi-tenant medical office buildings. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During the three months ended March&#160;31, 2010, we sold the assisted living portion of a continuing care retirement community for which we had an existing mortgage loan secured by the skilled nursing portion of such continuing care retirement community (see Note 4) to the tenant of the facility. We provided financing of $6.5&#160;million related to the sale, including the concurrent repayment of a $0.7&#160;million unsecured loan which had previously been included in the caption &#8220;Other assets&#8221; on our consolidated balance sheets (see Note 4). As we have a continuing interest in the facility, operating results from the facility are included in income from continuing operations on our consolidated income statements. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">No impairment charges were recorded on our real estate properties during the three months ended March&#160;31, 2010 or 2009. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 4 - us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock--> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>4. Mortgage Loans Receivable</b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">At March&#160;31, 2010, we held 15 mortgage loans receivable secured by 26 medical office buildings, 16 skilled nursing facilities, nine assisted and independent living facilities, one continuing care retirement community and one land parcel. At March&#160;31, 2010, the mortgage loans receivable had an aggregate principal balance of $216.6&#160;million and are reflected in our consolidated balance sheets net of aggregate deferred gains totaling $19.3&#160;million, with individual outstanding principal balances ranging from $0.7&#160;million to $80.1&#160;million and maturities ranging from 2010 to 2024. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During the three months ended March&#160;31, 2010, we funded one mortgage loan secured by 26 medical office buildings in the amount of $80.1&#160;million. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During the three months ended March&#160;31, 2010, we also funded $6.8&#160;million and $52.8&#160;million under loans to our consolidated joint ventures with PMB Gilbert LLC and PMB Pasadena LLC, respectively (see Note 5). As we consolidate these joint ventures, these balances have been eliminated for purposes of our consolidated financial statements. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During the three months ended March&#160;31, 2010, we sold the assisted living portion of a continuing care retirement community for which we had an existing mortgage loan secured by the skilled nursing portion of such continuing care retirement community to the tenant of the facility. For facility count purposes, this was previously accounted for in real estate properties as a continuing care retirement community (see Note 3). We provided financing of $6.5&#160;million related to the sale, including the concurrent repayment of a $0.7&#160;million unsecured loan which had previously been included in the caption &#8220;Other assets&#8221; on our consolidated balance sheets, and funded an additional $0.2&#160;million subsequent to the sale. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As of February&#160;1, 2010, we acquired the multi-tenant medical office building which served as collateral for our $47.5&#160;million mortgage loan from a related party, and as a result, the loan was retired (see Notes 5 and 18). </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In 2009, we entered into an agreement with one of our triple-net tenants, Brookdale Senior Living, Inc. (&#8220;Brookdale&#8221;), under which we became a lender with a commitment of $2.9&#160;million under their $75.0&#160;million revolving loan facility. The revolving loan facility was terminated as of February&#160;23, 2010. There was no balance outstanding at the date of termination. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 5 - nhp:MedicalOfficeBuildingJointVenturesDisclosureTextBlock--> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>5. Medical Office Building Joint Ventures</b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>NHP/Broe, LLC and NHP/Broe II, LLC</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On August&#160;21, 2009, we acquired for $4.3&#160;million the 10% and 5% noncontrolling interests held by The Broe Companies in NHP/Broe, LLC (&#8220;Broe I&#8221;) and NHP/Broe II, LLC (&#8220;Broe II&#8221;), respectively. As a result of this acquisition, we now have direct ownership of the 36 multi-tenant medical office buildings located in nine states previously owned by Broe I and Broe II. Activity subsequent to August&#160;21, 2009 related to these facilities is included in our consolidated activity for wholly owned real estate properties (see Note 3). Prior to our acquisition of Broe&#8217;s interests, we consolidated both joint ventures in our consolidated financial statements in accordance with ASC 810. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>McShane/NHP JV, LLC</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In December&#160;2007, we entered into a joint venture with McShane called McShane/NHP JV, LLC (&#8220;McShane/NHP&#8221;) to invest in multi-tenant medical office buildings. We hold a 95% equity interest in the joint venture and McShane holds a 5% equity interest. McShane is the managing member of McShane/NHP, but we consolidate the joint venture in our consolidated financial statements. The accounting policies of the joint venture are consistent with our accounting policies. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Cash distributions from McShane/NHP are made in accordance with the members&#8217; ownership interests until specified returns are achieved. As the specified returns are achieved, McShane will receive an increasing percentage of the cash distributions from the joint venture. No cash distributions were made during the three months ended March&#160;31, 2010. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">At March&#160;31, 2010, McShane/NHP owned seven multi-tenant medical office buildings located in one state. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During the three months ended March&#160;31, 2010, McShane/NHP funded $0.1&#160;million in capital and tenant improvements at certain facilities. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">All intercompany balances with McShane/NHP have been eliminated for purposes of our consolidated financial statements. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>NHP/PMB L.P.</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In February&#160;2008, we entered into an agreement (the &#8220;Contribution Agreement&#8221;) with Pacific Medical Buildings LLC and certain of its affiliates to acquire up to 18 medical office buildings, including six in development, for $747.6&#160;million, including the assumption of approximately $282.6 million of mortgage financing. Under the Contribution Agreement, in 2008, NHP/PMB acquired interests in nine of the 18 medical office buildings, including one property which is included in our triple-net leases segment and eight properties which are multi-tenant medical office buildings (one of which consisted of a 50% interest through a joint venture which is consolidated by NHP/PMB). During 2008, we also acquired one of the 18 medical office buildings directly (not through NHP/PMB). During 2009, we elected to terminate the Contribution Agreement with respect to six properties after the conditions for us to close on such properties were not satisfied. As a result of the elimination of these six properties, under the Contribution Agreement, NHP/PMB became obligated to pay $3.0&#160;million, of which $2.7&#160;million was payable to Pacific Medical Buildings LLC. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As of February&#160;1, 2010, we entered into an amendment to the Contribution Agreement which reinstated one of the six properties that were previously eliminated from the Contribution Agreement. NHP/PMB acquired such multi-tenant medical office building for $74.0&#160;million, which was paid in a combination of cash and the issuance of 301,599 OP Units with a fair value at the date of issuance of $10.0&#160;million. As a result of such acquisition, we retired our $47.5&#160;million mortgage loan from a related party to which such acquired medical office building had served as collateral (see Note 18). Additionally, as of February&#160;1, 2010, we acquired a majority ownership interest in a joint venture which owns one multi-tenant medical office building (see <i>NHP/PMB Gilbert LLC </i>below), amended and restated our agreement with NHP/PMB, PMB LLC and PMB Real Estate Services LLC (&#8220;PMBRES&#8221;) as described below and amended our agreement with PMB Pomona LLC to provide for the future acquisition by NHP/PMB of a medical office building currently in development (see Note 18). In connection with these transactions, NHP/PMB entered into a Third Amendment to the Amended and Restated Agreement of Limited Partnership, which, among other things, authorized NHP/PMB to acquire properties affiliated with Pacific Medical Buildings LLC pursuant to agreements other than the Contribution Agreement. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As of March&#160;1, 2010, we entered into an amendment to the Contribution Agreement which reinstated another two of the six properties that were previously eliminated from the Contribution Agreement. NHP/PMB acquired a 65% interest in a joint venture which is consolidated by NHP/PMB that owns one of the two multi-tenant medical office buildings valued at $79.9&#160;million. The acquisition was paid in a combination of cash, the assumption of $48.1&#160;million of mortgage financing and the issuance of 152,238 OP Units with a fair value at the date of issuance of $5.0&#160;million. NHP/PMB acquired a 69% interest in a joint venture which is consolidated by NHP/PMB that owns the second multi-tenant medical office building valued at $69.3&#160;million. The acquisition was paid in a combination of cash, the assumption of $50.2&#160;million of mortgage financing and the issuance of 121,489 OP Units with a fair value at the date of issuance of $4.0&#160;million. Additionally, as of March&#160;1, 2010, we acquired the remaining interest in PMB SB (see Note 6). </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The amendment to the Contribution Agreement dated as of March&#160;1, 2010 also eliminated one of the two remaining properties from the Contribution Agreement, however, we concurrently entered into a joint venture with PMB Pasadena LLC (an entity affiliated with Pacific Medical Buildings LLC) to acquire this property (see <i>NHP/PMB Pasadena LLC </i>below). As a result of the elimination of this property from the Contribution Agreement, NHP/PMB became obligated to pay $2.1&#160;million (the &#8220;Premium Adjustment&#8221;), of which $1.9&#160;million was payable to Pacific Medical Buildings LLC in cash. The portion of the Premium Adjustment not payable to Pacific Medical Buildings LLC was paid in the form of $0.1&#160;million in cash and the issuance of 1,788 additional OP Units with an aggregate value of $57,000. As a result of the payment, we received an additional 4,514 Class&#160;B limited partnership units in NHP/PMB. Under the Contribution Agreement, if the agreement is terminated with respect to the remaining development property, NHP/PMB will become obligated to pay approximately $2.4&#160;million (the &#8220;Future Premium Adjustment&#8221;) which has been accrued at March&#160;31, 2010 and of which a portion would be payable to Pacific Medical Buildings LLC. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Under the terms of the Contribution Agreement, a portion of the consideration for the multi-tenant medical office buildings is to be paid in the form of OP Units. After a one-year holding period, the OP Units are exchangeable for cash or, at our option, shares of our common stock, initially on a one-for-one basis. During the three months ended March&#160;31, 2010, 401 OP Units were converted into 401 shares of our common stock. At March&#160;31, 2010, 1,626,800 of the remaining OP Units had been outstanding for one year or longer and were exchangeable for cash of $57.2 million. During the three months ended March&#160;31, 2010, cash distributions from NHP/PMB of $0.4 million were made to OP unitholders. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Additionally, we have entered into an agreement with NHP/PMB, PMB LLC and PMBRES (see Note 6) pursuant to which we or NHP/PMB currently have the right, but not the obligation, to acquire up to approximately $1.3&#160;billion of multi-tenant medical office buildings developed by PMB LLC through April&#160;2019. As of February&#160;1, 2010, this agreement was amended and restated to provide NHP/PMB with the option to acquire medical office buildings developed in the future through a joint venture between NHP and PMB LLC, obligate us to provide or arrange financing for approved developments and provide us with improved terms, including preferred returns, a reduction in PMB LLC&#8217;s promote interest and acquisition pricing determined at the time of acquisition rather that at the pre-development stage. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During the three months ended March&#160;31, 2010, NHP/PMB funded $0.1&#160;million in capital and tenant improvements at certain facilities. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">All intercompany balances with NHP/PMB have been eliminated for purposes of our consolidated financial statements. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>NHP/PMB Gilbert LLC</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As of February&#160;1, 2010, we entered into a joint venture with PMB Gilbert LLC (an entity affiliated with Pacific Medical Buildings LLC) called NHP/PMB Gilbert LLC (&#8220;Gilbert JV&#8221;) to acquire a multi-tenant medical office building. PMB Gilbert LLC contributed the multi-tenant medical office building to Gilbert JV, and we contributed $6.3&#160;million in cash. Additionally, we agreed to loan Gilbert JV up to $8.8&#160;million as project financing at an interest rate of 7.00%, including $6.8 million that was disbursed initially and remains outstanding at March&#160;31, 2010. We hold a 71.17% equity interest in the joint venture and PMB Gilbert LLC holds a 28.83% equity interest. PMB Gilbert LLC is the managing member of Gilbert JV, but we consolidate the joint venture in our consolidated financial statements. The accounting policies of the joint venture are consistent with our accounting policies. Pursuant to a contribution agreement dated as of February 1, 2010, among us, NHP/PMB, Pacific Medical Buildings LLC and PMB Gilbert LLC, NHP/PMB may in the future acquire Gilbert JV if certain conditions are met. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Net income or loss is allocated between the partners in the joint venture based on the hypothetical liquidation at book value method (the &#8220;HLBV method&#8221;). Under the HLBV method, net income or loss is allocated between the partners based on the difference between each partner&#8217;s claim on the net assets of the partnership at the end and beginning of the period, after taking into account contributions and distributions. Each partner&#8217;s share of the net assets of the partnership is calculated as the amount that the partner would receive if the partnership were to liquidate all of its assets at net book value and distribute the resulting cash to creditors and partners in accordance with their respective priorities. Under this method, in any given period, we could be recording more or less income than the joint venture has generated or more or less income than actual cash distributions received and more or less than what we may receive in the event of an actual liquidation. No cash distributions were made during the three months ended March&#160;31, 2010. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">All intercompany balances with Gilbert JV have been eliminated for purposes of our consolidated financial statements. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>NHP/PMB Pasadena LLC</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As of March&#160;1, 2010, we entered into a joint venture with PMB Pasadena LLC (an entity affiliated with Pacific Medical Buildings LLC) called NHP/PMB Pasadena LLC (&#8220;Pasadena JV&#8221;) to acquire a multi-tenant medical office building. PMB Pasadena LLC contributed the multi-tenant medical office building to Pasadena JV, and we contributed $13.5&#160;million in cash. Additionally, we provided Pasadena JV with a $56.5&#160;million mortgage loan at an initial interest rate equal to the greater of 3.50% or LIBOR plus 165 basis points (increasing to the greater of 5.125% or LIBOR plus 375 basis points as of April&#160;1, 2010), of which $49.8&#160;million has been funded, and a $3.0&#160;million mezzanine loan at an interest rate of 15.00%, both of which remain outstanding at March&#160;31, 2010. We hold a 71% equity interest in the joint venture and PMB Pasadena LLC holds a 29% equity interest. PMB Pasadena LLC is the managing member of Pasadena JV, but we consolidate the joint venture in our consolidated financial statements. The accounting policies of the joint venture are consistent with our accounting policies. Pursuant to a contribution agreement dated as of March&#160;1, 2010, among us, NHP/PMB, Pacific Medical Buildings LLC and PMB Pasadena LLC, NHP/PMB may in the future acquire Pasadena JV if certain conditions are met. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Net income or loss is allocated between the partners in the joint venture based on the HLBV method. No cash distributions were made during the three months ended March&#160;31, 2010. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">All intercompany balances with Pasadena JV have been eliminated for purposes of our consolidated financial statements. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 6 - us-gaap:EquityMethodInvestmentsDisclosureTextBlock--> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>6. Investment in Unconsolidated Joint Ventures</b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>State Pension Fund Investor</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In January&#160;2007, we entered into a joint venture with a state pension fund investor. The purpose of the joint venture is to acquire and develop assisted living, independent living and skilled nursing facilities. We manage and own 25% of the joint venture, which will fund its investments with approximately 40% equity contributions and 60% debt. The original approved investment target was $475.0&#160;million, but we exceeded that amount in 2007, and the total potential investment amount has been increased to $975.0&#160;million. The financial statements of the joint venture are not consolidated in our financial statements as our joint venture partner has substantive participating rights, and accordingly our investment is accounted for using the equity method. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">At March&#160;31, 2010, the joint venture owned 19 assisted and independent living facilities, 14 skilled nursing facilities and one continuing care retirement community located in nine states. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During January&#160;2008, the joint venture entered into an interest rate swap contract that is designated as effectively hedging the variability of expected cash flows related to variable rate debt placed on a portion of its portfolio. The cash flow hedge has a fixed rate of 4.235%, a notional amount of $126.1&#160;million and expires on January&#160;1, 2015. The fair value of this contract at March&#160;31, 2010 and December&#160;31, 2009 was $9.9&#160;million and $8.2&#160;million, respectively, which is included in accrued liabilities on the joint venture&#8217;s balance sheet. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Cash distributions from the joint venture are made in accordance with the members&#8217; ownership interests until specified returns are achieved. As the specified returns are achieved, we will receive an increasing percentage of the cash distributions from the joint venture. During the three months ended March&#160;31, 2010, we received distributions of $0.7&#160;million from the joint venture. In addition to our share of the income, we receive a monthly management fee calculated as a percentage of the equity investment in the joint venture. This fee is included in our income from unconsolidated joint ventures and in the general and administrative expenses on the joint venture&#8217;s income statement. During the three months ended March&#160;31, 2010 and 2009, we earned management fees of $1.1&#160;million and $1.0&#160;million, respectively. During each of the three months ended March&#160;31, 2010 and 2009, our share of the net income was $0.2&#160;million. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>PMB Real Estate Services LLC</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In February&#160;2008, we entered into an agreement with Pacific Medical Buildings LLC to acquire a 50% interest in PMBRES, a full service property management company. The transaction closed on April 1, 2008. In consideration for the 50% interest, we paid $1.0&#160;million at closing, and we will make additional payments on or before March&#160;31, 2010 and 2011 equal to six times the normalized net operating profit of PMBRES for 2009 and 2010, respectively (in each case, less the amount of all prior payments). During 2009, PMBRES had a normalized net operating loss, and as such, no additional payment was made during the three months ended March&#160;31, 2010. PMBRES provides property management services for 32 multi-tenant medical office buildings that we own or in which we have an ownership interest. During the three months ended March&#160;31, 2010, our share of the net income was $28,000. During the three months ended March&#160;31, 2009, our share of the net loss was $0.2&#160;million. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>PMB SB 399-401 East Highland LLC</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In August&#160;2008, we acquired from PMB SB (an entity affiliated with Pacific Medical Buildings LLC) a 44.95% interest in an entity that owned two multi-tenant medical office buildings for $3.5 million. As of March&#160;1, 2010, we acquired the remaining 55.05% interest in PMB SB. PMB SB was valued at $17.4&#160;million at the date of acquisition, and the acquisition was paid in a combination of cash and the assumption of $11.2&#160;million of mortgage financing (of which $6.2&#160;million was previously attributable to the controlling interest in PMB SB). Prior to the acquisition, our investment in PMB SB was $3.0&#160;million which was accounted for under the equity method. In connection with the acquisition, we re-measured our previously held equity interest at the acquisition date fair value based on an independent consultant&#8217;s report and recognized a net gain on the re-measurement of $0.6&#160;million which is included in the caption &#8220;Interest and other income&#8221; on our consolidated income statements. Subsequent activity related to these facilities is included in our consolidated activity for wholly owned real estate properties (see Note 3). </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During the period from January&#160;1, 2010 to February&#160;28, 2010, we received distributions of $0.1 million from PMB SB. During the period from January&#160;1, 2010 to February&#160;28, 2010, our share of the net income was $12,000. During the three months ended March&#160;31, 2009, our share of the net income was $21,000. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 7 - nhp:IntangibleAssetsAndLiabilitiesDisclosureTextBlock--> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>7. Intangible Assets and Liabilities</b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Intangible assets include items such as lease-up intangible assets, above market tenant and ground lease intangible assets and in-place lease intangible assets. At March&#160;31, 2010 and December 31, 2009, the gross balance of intangible lease assets was $187.8&#160;million and $130.0&#160;million, respectively. At March&#160;31, 2010 and December&#160;31, 2009, the accumulated amortization of intangible lease assets was $37.7&#160;million and $36.3&#160;million, respectively. Intangible liabilities include below market tenant and ground lease intangible liabilities. At March&#160;31, 2010 and December&#160;31, 2009, we had $18.9&#160;million and $18.3&#160;million, respectively, of gross intangible liabilities recorded under the caption &#8220;Accounts payable and accrued liabilities&#8221; on our consolidated balance sheets. At March&#160;31, 2010 and December&#160;31, 2009, the accumulated amortization of intangible liabilities was $4.0&#160;million and $3.9&#160;million, respectively. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">For the three months ended March&#160;31, 2010 and 2009, medical office building operating rent included $0.1&#160;million and $0.2&#160;million, respectively, from the amortization of above/below market lease intangibles. For the three months ended March&#160;31, 2010 and 2009, expenses included $4.0 million and $5.1&#160;million, respectively, from the amortization of other intangible lease assets and liabilities. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 8 - us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock--> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>8. Other Assets</b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">At March&#160;31, 2010 and December&#160;31, 2009, other assets consisted of: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="72%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2"><b>March 31,</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2"><b>December 31,</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2009</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6"><b>(In thousands)</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Other receivables, net of reserves of $4.2 million at March&#160;31, 2010 and December&#160;31, 2009 </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">67,152</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">68,535</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Straight-line rent receivables, net of reserves of $108.2&#160;million and $108.3&#160;million at March&#160;31, 2010 and December&#160;31, 2009, respectively </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">29,279</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">27,450</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Deferred financing costs </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">11,436</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">11,366</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Capitalized lease and loan origination costs </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,247</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,418</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Investments and restricted funds </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">13,911</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">9,545</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Prepaid ground leases </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">12,993</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">10,051</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Other </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">4,309</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,787</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">141,327</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">133,152</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Included in other receivables at both March&#160;31, 2010 and December&#160;31, 2009, are two unsecured loans to Emeritus Corporation in the amount of $21.4&#160;million and $30.0&#160;million due in March&#160;2012 and April&#160;2012, respectively. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Investments are recorded at fair value using quoted market prices. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 9 - us-gaap:DebtDisclosureTextBlock--> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>9. Debt</b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Unsecured Senior Credit Facility</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">At March&#160;31, 2010, we had no balance outstanding on our $700.0&#160;million revolving unsecured senior credit facility. At our option, borrowings under the credit facility bear interest at the prime rate (3.25% at March&#160;31, 2010) or applicable LIBOR plus 0.70% (0.95% at March&#160;31, 2010). We pay a facility fee of 0.15% per annum on the total commitment under the agreement. The credit facility matures on December&#160;15, 2010. The maturity date may be extended by one additional year at our discretion. As of March&#160;31, 2010, we were in compliance with all covenants under the credit facility. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Senior Notes</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The aggregate principal amount of notes outstanding at March&#160;31, 2010 was $991.6&#160;million. At March&#160;31, 2010, the weighted average interest rate on the notes was 6.47% and the weighted average maturity was 4.7&#160;years. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Notes and Bonds Payable</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The aggregate principal amount of notes and bonds payable at March&#160;31, 2010 was $536.0 million. Notes and bonds payable are due through the year 2037, at interest rates ranging from 1.08% to 8.63% and are secured by real estate properties with an aggregate net book value as of March&#160;31, 2010 of $799.2&#160;million. At March&#160;31, 2010, the weighted average interest rate on the notes and bonds payable was 5.35% and the weighted average maturity was 6.7&#160;years. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During the three months ended March&#160;31, 2010, we assumed mortgages as part of certain acquisitions totaling $109.5&#160;million. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During the three months ended March&#160;31, 2010, we repaid at maturity $2.9&#160;million of fixed rate secured debt that bore interest at 8.02%. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During the three months ended March&#160;31, 2010, we exercised a 12-month extension option on a $32.4&#160;million loan that was scheduled to mature in April&#160;2010. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Debt Maturities</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The principal balances of our debt as of March&#160;31, 2010 mature as follows: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="44%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2"><b>Credit</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2"><b>Senior</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2"><b>Notes and Bonds</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2">&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000"><b>Year</b></td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Facility</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Notes</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Payable</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Total</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="14"><b>(In thousands)</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">2010 </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">77,275</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">77,275</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">2011 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">339,040</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">71,483</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">410,523</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">2012 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">72,950</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">51,131</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">124,081</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">2013 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">269,850</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">38,997</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">308,847</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">2014 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">22,167</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">22,167</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Thereafter (1) </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">309,793</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">274,897</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">584,690</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">991,633</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">535,950</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">1,527,583</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> </div> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr style="font-size: 6pt"> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="96">&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left">(1)</td> <td>&#160;</td> <td>There are $52.4&#160;million of senior notes due in 2037 which may be put back to us at their face amount at the option of the holder on October 1 of any of the following years: 2012, 2017 or 2027. There are $23.0&#160;million of senior notes due in 2038 which may be put back to us at their face amount at the option of the holder on July 7 of any of the following years: 2013, 2018, 2023 or 2028.</td> </tr> </table> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 10 - us-gaap:StockholdersEquityNoteDisclosureTextBlock--> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>10. Stockholders&#8217; Equity</b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Preferred Stock</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On January&#160;18, 2010, we redeemed all outstanding shares of our Series&#160;B Preferred Stock at a redemption price per share of $103.875 plus an amount equal to accumulated and unpaid dividends thereon to the redemption date ($0.3875), for a total redemption price of $104.2625 per share, payable only in cash. As a result of the redemption, each share of Series&#160;B Preferred Stock was convertible until January&#160;14, 2010 into 4.5150 shares of common stock. During that time, 512,727 shares were converted into approximately 2,315,000 shares of common stock. On January&#160;18, 2010, we redeemed 917 shares that remained outstanding. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Common Stock</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We enter into sales agreements from time to time with agents to sell shares of our common stock through an at-the-market equity offering program. We entered into two new sales agreements, each dated January&#160;15, 2010, to sell up to an aggregate of 5,000,000 shares of our common stock from time to time. During the three months ended March&#160;31, 2010, we issued and sold approximately 1,269,000 shares of common stock at a weighted average price of $35.58 per share, resulting in net proceeds of approximately $44.7&#160;million after sales agent fees. At March&#160;31, 2010, approximately 4,195,000 shares of common stock were available to be sold pursuant to our at-the-market equity offering program. From April&#160;1, 2010 to May 6, 2010, we issued and sold approximately 1,592,000 shares at a weighted average price of $35.08 per share (see Note 19). </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We sponsor a dividend reinvestment plan that enables existing stockholders to purchase additional shares of common stock by automatically reinvesting all or part of the cash dividends paid on their shares of common stock at a discount ranging from 0% to 5%, determined by us from time to time in accordance with the plan. The discount at March&#160;31, 2010 was 2%. During the three months ended March&#160;31, 2010, we issued approximately 140,000 shares of common stock, at an average price of $33.09 per share, resulting in net proceeds of approximately $4.6&#160;million. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On January&#160;18, 2010, we redeemed all outstanding shares of Series&#160;B Preferred Stock, and as a result, 512,727 shares of Series&#160;B Preferred Stock were converted into approximately 2,315,000 shares of common stock during the period from January&#160;1, 2010 to January&#160;14, 2010. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During the three months ended March&#160;31, 2010, 401 OP Units issued by NHP/PMB were exchanged for 401 shares of common stock (see Note 5). </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 11 - us-gaap:EarningsPerShareTextBlock--> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>11. Earnings Per Share (EPS)</b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Certain of our share-based payment awards are considered participating securities which requires the use of the two-class method for the computation of basic and diluted EPS. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Diluted EPS also includes the effect of any potential shares outstanding, which for us is comprised of dilutive stock options, other share-settled compensation plans and, if the effect is dilutive, Series&#160;B Preferred Stock, which was redeemed on January&#160;18, 2010 (see Note 10) and/or OP Units. There were 270,100 and 243,000 stock options that would not be dilutive for the three months ended March&#160;31, 2010 and 2009, respectively. The calculation below excludes 27,000 restricted stock units, 8,700 restricted stock shares and 6,900 stock appreciation rights that would not be dilutive for the three months ended March&#160;31, 2010 and 1,200 performance shares and 538,000 stock appreciation rights that would not be dilutive for the three months ended March&#160;31, 2009. The Series&#160;B Preferred Stock is not dilutive for any period presented. The table below details the components of the basic and diluted EPS calculations: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="72%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6"><b>Three months ended</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>March 31,</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2009</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6"><b>(In thousands, except per</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6"><b>share amounts)</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Numerator:</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Income from continuing operations </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">31,217</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">29,428</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Net (income)&#160;loss attributable to noncontrolling interests </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">190</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(27</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Net income attributable to participating securities </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(326</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(206</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Undistributed earnings attributable to participating securities </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(13</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Series&#160;B preferred stock dividends </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1,452</td> <td nowrap="nowrap">)</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Numerator for Basic and Diluted EPS from continuing operations </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">31,081</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">27,730</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"><!-- Blank Space --> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Income from discontinued operations </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">22</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">21,205</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Numerator for Basic and Diluted EPS from discontinued operations </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">22</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">21,205</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"><!-- Blank Space --> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Denominator:</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Basic weighted average shares outstanding </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">117,048</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">102,355</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Effect of dilutive securities: </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:45px; text-indent:-15px">Stock options </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">70</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">58</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:45px; text-indent:-15px">Other share-settled compensation plans </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">426</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">165</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:45px; text-indent:-15px">OP Units </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,922</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,830</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Diluted weighted average shares outstanding </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">119,466</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">104,408</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"><!-- Blank Space --> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Basic earnings per share amounts:</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Income from continuing operations attributable to NHP common stockholders </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">0.27</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">0.27</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Discontinued operations attributable to NHP common stockholders </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">0.21</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Net income attributable to NHP common stockholders </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">0.27</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">0.48</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"><!-- Blank Space --> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Diluted earnings per share amounts:</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Income from continuing operations attributable to NHP common stockholders </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">0.26</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">0.27</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Discontinued operations attributable to NHP common stockholders </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">0.20</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Net income attributable to NHP common stockholders </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">0.26</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">0.47</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 12 - us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock--> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>12. Discontinued Operations</b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">ASC 360 requires the operating results of any assets with their own identifiable cash flows that are disposed of or held for sale and in which we have no continuing interest be removed from income from continuing operations and reported as discontinued operations. The operating results for any such assets for any prior periods presented must also be reclassified as discontinued operations. If we have a continuing involvement, as in the sales to our unconsolidated joint venture, the operating results remain in continuing operations. The following table details the operating results reclassified to discontinued operations for the periods presented: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="72%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6"><b>Three months ended</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>March 31,</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2009</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6"><b>(In thousands)</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Rental income </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">325</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Interest and other income </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">19</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">344</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Expenses: </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Interest expense and amortization of deferred financing costs </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Depreciation and amortization </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">291</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">General and administrative </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Medical office building operating expenses </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">291</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Income from discontinued operations </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">53</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 13 - us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock--> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>13. Derivatives</b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During January&#160;2008, the unconsolidated joint venture we have with a state pension fund investor entered into an interest rate swap contract (see Notes 6 and 14). </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During August and September&#160;2007, we entered into four six-month Treasury lock agreements totaling $250.0&#160;million at a weighted average rate of 4.212%. We entered into these Treasury lock agreements in order to hedge the expected interest payments associated with a portion of our October&#160;2007 issuance of $300.0&#160;million of notes which mature in 2013. These Treasury lock agreements were settled in cash on October&#160;17, 2007 for an amount equal to the present value of the difference between the locked Treasury rates and the unwind rate (equal to the then-prevailing Treasury rate less the forward premium or 4.364%). We reassessed the effectiveness of these agreements at the settlement date and determined that they were highly effective cash flow hedges under ASC 815 for $250.0&#160;million of the $300.0&#160;million of notes as intended. The prevailing Treasury rate exceeded the rates in the Treasury lock agreements and, as a result, the counterparties to those agreements made payments to us of $1.6&#160;million, which was recorded as other comprehensive income. The settlement amounts are being amortized over the life of the debt as a yield reduction. During the three months ended March&#160;31, 2010 and 2009, we recorded $64,000 and $67,000 of amortization, respectively. We expect to record $0.3&#160;million of amortization during the next 12&#160;months. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In June&#160;2006, we entered into two $125.0&#160;million, two-month Treasury lock agreements in order to hedge the expected interest payments associated with a portion of our July&#160;2006 issuance of $350.0&#160;million of notes which mature in 2011. These Treasury lock agreements were settled in cash on July&#160;11, 2006, concurrent with the pricing of the $350&#160;million of notes, for an amount equal to the present value of the difference between the locked Treasury rates and the unwind rate. We reassessed the effectiveness of these agreements at the settlement date and determined that they were highly effective cash flow hedges under ASC 815 for $250.0&#160;million of the $350.0&#160;million of notes as intended. The prevailing Treasury rate exceeded the rates in the Treasury lock agreements and, as a result, the counterparty to those agreements made payments to us of $1.2&#160;million, which was recorded as other comprehensive income. The settlement amounts are being amortized over the life of the debt as a yield reduction. During the three months ended March&#160;31, 2010 and 2009, we recorded $62,000 and $58,000 of amortization, respectively. We expect to record $0.3&#160;million of amortization during the next 12&#160;months. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 14 - us-gaap:ComprehensiveIncomeNoteTextBlock--> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>14. Comprehensive Income</b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During January&#160;2008, the unconsolidated joint venture we have with a state pension fund investor entered into an interest rate swap contract (see Note 6). As of March&#160;31, 2010, we had recorded our pro rata share of the unconsolidated joint venture&#8217;s accumulated other comprehensive loss related to this contract of $2.5&#160;million. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We recorded the August and September&#160;2007 Treasury lock agreements on our balance sheets at their estimated fair value of $0.1&#160;million at September&#160;30, 2007. In connection with the settlement of the August and September&#160;2007 Treasury lock agreements on October&#160;17, 2007, we recognized a gain of $1.6&#160;million. The gain was recognized through other comprehensive income and is being amortized over the life of the related $300.0&#160;million of notes which mature in 2013 as a yield reduction. During the three months ended March&#160;31, 2010 and 2009, we recorded $64,000 and $67,000 of amortization, respectively. We expect to record $0.3&#160;million of amortization during the next 12 months. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We recorded the June&#160;2006 Treasury lock agreements on our balance sheets at their estimated fair value of $1.6&#160;million at June&#160;30, 2006. In connection with the settlement of the June&#160;2006 Treasury lock agreements on July&#160;11, 2006, we recognized a gain of $1.2&#160;million. The gain was recognized through other comprehensive income and is being amortized over the life of the related $350.0&#160;million of notes which mature in 2011 as a yield reduction. During the three months ended March&#160;31, 2010 and 2009, we recorded $62,000 and $58,000 of amortization, respectively. We expect to record $0.3&#160;million of amortization during the next 12&#160;months. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The following table sets forth the computation of comprehensive income for the periods presented: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="72%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6"><b>Three months ended</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>March 31,</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2009</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 0px solid #000000"><b>(In thousands)</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Net income </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">31,239</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">50,633</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Other comprehensive income: </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Pro rata share of accumulated other comprehensive loss from unconsolidated joint venture </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(436</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(3,547</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Amortization of gains on Treasury lock agreements </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(126</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(125</td> <td nowrap="nowrap">)</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Comprehensive income </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">30,677</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">46,961</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Comprehensive loss (income)&#160;attributable to noncontrolling interests </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">190</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(27</td> <td nowrap="nowrap">)</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Comprehensive income attributable to NHP </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">30,867</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">46,934</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 15 - us-gaap:IncomeTaxDisclosureTextBlock--> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>15. Income Taxes</b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The provisions of ASC Topic 740, <i>Income Taxes</i>, which clarify the accounting for uncertainty in income taxes recognized in financial statements and prescribe a recognition threshold and measurement attribute of tax positions taken or expected to be taken on a tax return became effective January&#160;1, 2007. No amounts have been recorded for unrecognized tax benefits or related interest expense and penalties. The taxable periods ending December&#160;31, 2005 through December&#160;31, 2009 remain open to examination by the Internal Revenue Service and the tax authorities of the significant jurisdictions in which we do business. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Hearthstone Acquisition</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On June&#160;1, 2006, we acquired the stock of Hearthstone Assisted Living, Inc. (&#8220;HAL&#8221;), causing HAL to become a qualified REIT subsidiary. As a result of the acquisition, we succeeded to HAL&#8217;s tax attributes, including HAL&#8217;s tax basis in its net assets. Prior to the acquisition, HAL was a corporation subject to federal and state income taxes. In connection with the acquisition of HAL, NHP acquired approximately $82.5&#160;million of federal net operating losses (&#8220;NOLs&#8221;) which we can carry forward to future periods and the use of which is subject to annual limitations imposed by IRC Section&#160;382. While we believe that these NOLs are accurate, any adjustments to HAL&#8217;s tax returns for periods prior to June&#160;1, 2006 by the Internal Revenue Service could change the amount of the NOLs that we can utilize. We have used a portion of this amount in 2007 and 2008 and anticipate using additional amounts in future years. These NOLs are set to expire between 2017 and 2025. NOLs related to various states were also acquired and are set to expire based on the various laws of the specific states. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In addition, we may be subject to a corporate-level tax on any taxable disposition of HAL&#8217;s pre-acquisition assets that occurs within ten years after the June&#160;1, 2006 acquisition. The corporate-level tax would be assessed only to the extent of the built-in gain that existed on the date of acquisition, based on the fair market value of the asset on June&#160;1, 2006. We do not expect to dispose of any asset included in the HAL acquisition if such a disposition would result in the imposition of a material tax liability, and no such sales have taken place through March&#160;31, 2010. Accordingly, we have not recorded a deferred tax liability associated with this corporate-level tax. Gains from asset dispositions occurring more than 10&#160;years after the acquisition will not be subject to this corporate-level tax. However, we may dispose of HAL assets before the 10-year period if we are able to complete a tax-deferred exchange. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 16 - us-gaap:SegmentReportingDisclosureTextBlock--> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>16. Segment Information</b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our operations are organized into two segments &#8212; triple-net leases and multi-tenant leases. In the triple-net leases segment, we invest in healthcare related properties and lease the facilities to unaffiliated tenants under &#8220;triple-net&#8221; and generally &#8220;master&#8221; leases that transfer the obligation for all facility operating costs (including maintenance, repairs, taxes, insurance and capital expenditures) to the tenant. In the multi-tenant leases segment, we invest in healthcare related properties that have several tenants under separate leases in each building, thus requiring active management and responsibility for many of the associated operating expenses (although many of these are, or can effectively be, passed through to the tenants). During 2009 and the three months ended March&#160;31, 2010, the multi-tenant leases segment was comprised exclusively of medical office buildings. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Non-segment revenues primarily consist of interest income on mortgages and unsecured loans and other income. Interest expense, depreciation and amortization and other expenses not attributable to individual facilities are not allocated to individual segments for purposes of assessing segment performance. Non-segment assets primarily consist of corporate assets including mortgages and unsecured loans, investment in unconsolidated joint ventures, cash, deferred financing costs and other assets not attributable to individual facilities. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Certain items in prior period financial statements have been reclassified to conform to current period presentation, including those required by ASC 360 which require the operating results of any assets with their own identifiable cash flows that are disposed of or held for sale and in which we have no continuing interest to be removed from income from continuing operations and reported as discontinued operations. Summary information related to our reportable segments is as follows: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="72%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6"><b>Three months ended</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>March 31,</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2009</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6"><b>(In thousands)</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Revenue: </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Triple-net leases </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">74,214</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">74,095</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Multi-tenant leases </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">21,251</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">16,653</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Non-segment </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">6,963</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6,335</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">102,428</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">97,083</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Net operating income (1): </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Triple-net leases </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">74,214</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">74,095</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Multi-tenant leases </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">12,604</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">9,819</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">86,818</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">83,914</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="72%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2"><b>March 31,</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2"><b>December 31,</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2009</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6"><b>(In thousands)</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Assets: </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Triple-net leases </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">2,416,724</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">2,440,158</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Multi-tenant leases </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">898,910</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">572,410</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Non-segment </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">498,010</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">634,507</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">3,813,644</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">3,647,075</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left"> <div style="font-size: 3pt; margin-top: 13pt; width: 18%; border-bottom: 1px solid #000000">&#160; </div> </div> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr style="font-size: 6pt"> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="96">&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left">(1)</td> <td>&#160;</td> <td>Net operating income (&#8220;NOI&#8221;) is a non-GAAP supplemental financial measure used to evaluate the operating performance of our facilities. We define NOI for our triple-net leases segment as rent revenues. For our multi-tenant leases segment, we define NOI as revenues minus medical office building operating expenses. In some cases, revenue for medical office buildings includes expense reimbursements for common area maintenance charges. NOI excludes interest expense and amortization of deferred financing costs, depreciation and amortization expense, general and administrative expense and discontinued operations. We present NOI as it effectively presents our portfolio on a &#8220;net&#8221; rent basis and provides relevant and useful information as it measures the operating performance at the facility level on an unleveraged basis. We use NOI to make decisions about resource allocations and to assess the property level performance of our properties. Furthermore, we believe that NOI provides investors relevant and useful information because it measures the operating performance of our real estate at the property level on an unleveraged basis. We believe that net income is the GAAP measure that is most directly comparable to NOI. However, NOI should not be considered as an alternative to net income as the primary indicator of operating performance as it excludes the items described above. Additionally, NOI as presented above may not be comparable to other REITs or companies as their definitions of NOI may differ from ours.</td> </tr> </table> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">A reconciliation of net income, a GAAP measure, to NOI, a non-conforming GAAP measure, is as follows: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="72%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6"><b>Three months ended</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>March 31,</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2009</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6"><b>(In thousands)</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Net income </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">31,239</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">50,633</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Interest and other income </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(6,963</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(6,335</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Interest expense and amortization of deferred financing costs </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">23,590</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">24,071</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Depreciation and amortization expense </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">31,969</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">30,832</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">General and administrative expense </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">6,984</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6,931</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Acquisition costs </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,443</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Income from unconsolidated joint ventures </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1,347</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1,013</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Gain on debt extinguishment </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(75</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Gains on sale of facilities, net </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(22</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(21,152</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Income from discontinued operations </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(53</td> <td nowrap="nowrap">)</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Net operating income from reportable segments </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">86,818</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">83,914</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 17 - us-gaap:CommitmentsAndContingenciesDisclosureTextBlock--> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>17. Commitments and Contingencies</b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Litigation</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">From time to time, we are a party to various legal proceedings, lawsuits and other claims (as to some of which we may not be insured) that arise in the normal course of our business. Regardless of their merits, these matters may require us to expend significant financial resources. Except as described herein, we are not aware of any other legal proceedings or claims that we believe may have, individually or taken together, a material adverse effect on our business, results of operations or financial position. However, we are unable to predict the ultimate outcome of pending litigation and claims, and if our assessment of our liability with respect to these actions and claims is incorrect, such actions and claims could have a material adverse effect on our business, results of operations or financial position. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In late 2004 and early 2005, we were served with several lawsuits in connection with a fire at the Greenwood Healthcare Center in Hartford, Connecticut, that occurred on February&#160;26, 2003. At the time of the fire, the Greenwood Healthcare Center was owned by us and leased to and operated by Lexington Healthcare Group. There were a total of 13 lawsuits arising from the fire. Those suits have been filed by representatives of patients who were either killed or injured in the fire. The lawsuits seek unspecified monetary damages. The complaints allege that the fire was set by a resident who had previously been diagnosed with depression. The complaints allege theories of negligent operation and premises liability against Lexington Healthcare, as operator, and us as owner. Lexington Healthcare has filed for bankruptcy. The matters have been consolidated into one action in the Connecticut Superior Court Complex Litigation Docket at the Judicial District at Hartford and are in various stages of discovery and motion practice. We have filed a motion for summary judgment with regard to certain pending claims and will be filing additional summary judgment motions for any remaining claims. Mediation was commenced with respect to most of the claims, and a settlement has been reached in 10 of the 13 pending claims within the limits of our commercial general liability insurance. We obtained a judgment of nonsuit in one case whereby it is now dismissed, and the two remaining claims will be subject to summary judgment motions and ongoing efforts at resolution. Summary judgment rulings are not expected until the middle of 2011, if not later. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Lexington Insurance, which potentially owes insurance coverage for these claims to us, has filed a lawsuit against us which seeks no monetary damages, but which does seek a court order limiting its insurance coverage obligations to us. We have filed a counterclaim against Lexington Insurance demanding additional insurance coverage from Lexington in amounts up to $10.0&#160;million. The parties to that case, which is pending on the Complex Litigation Docket for the Judicial District of Hartford, filed cross-motions for summary judgment. Those motions have been decided, resulting in an outcome that is largely favorable for us. The court&#8217;s ruling indicates $10.0 million in aggregate coverage is available from Lexington Insurance for both the various plaintiffs&#8217; claims and our claims under the Professional Liability part of the Lexington Insurance policy. The court then found that there were 13 separate medical incidents for each of the 13 plaintiffs&#8217; claims. However, the court limited the coverage to $500,000 per claim with a $250,000 self insured retention per claim, which retention will not be paid due to the bankruptcy of Lexington Healthcare. Further, the court has ruled that both the various plaintiffs&#8217; claims and our claims are subject to the same policy limits. The court declined to find coverage for our claims under the comprehensive general liability portions of the Lexington Insurance policy. Lexington Insurance has filed a motion seeking an articulation of the rulings and is pursuing an appeal of the rulings. We anticipate that we will be defending the appeal by Lexington Insurance and pursuing our own issues on appeal. We do not expect the appeal to be resolved before the middle of 2011, if not later. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We are being defended in the matter by our commercial general liability carrier. We believe that we have substantial defenses to the claims and that we have adequate insurance to cover the risks, should liability nonetheless be imposed. However, because the remaining claims are still in the process of discovery and motion practice, it is not possible to predict the ultimate outcome of these claims. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Revolving Loan Facility</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In 2009, we entered into an agreement with one of our triple-net tenants, Brookdale under which we became a lender with a commitment of $2.9&#160;million under their $75.0&#160;million revolving loan facility. The revolving loan facility was terminated as of February&#160;23, 2010. There was no balance outstanding at the date of termination. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Lines of Credit</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Under the terms of an agreement with PMB LLC, we agreed to extend to PMB LLC a $10.0&#160;million line of credit at an interest rate equal to LIBOR plus 175 basis points to fund certain costs of PMB LLC with respect to the proposed development of multi-tenant medical office buildings. During the three months ended March&#160;31, 2010, we funded $0.1&#160;million under the line of credit. At March 31, 2010, $3.3&#160;million was outstanding and is included in the caption &#8220;Other assets&#8221; on our consolidated balance sheet. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We have entered into an agreement with PMB LLC, the manager of PMB Pomona LLC, to extend up to $3.0&#160;million of funding at an interest rate of 7.25%, which is secured by 100% of the membership interests in PMB Pomona LLC (see Note 18). During the three months ended March&#160;31, 2010, we funded $0.3&#160;million. At March&#160;31, 2010, $1.9&#160;million was outstanding and is included in the caption &#8220;Other assets&#8221; on our consolidated balance sheet. On April&#160;1, 2010, the total $1.9&#160;million outstanding was repaid (see Note 19). </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As of February&#160;1, 2010, in connection with the formation of Gilbert JV, a consolidated joint venture, we agreed to loan Gilbert JV up to $8.8&#160;million as project financing at an interest rate of 7.00%, including $6.8&#160;million that was disbursed initially and remains outstanding at March&#160;31, 2010 (see Note 5). </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As of March&#160;1, 2010, in connection with the formation of Pasadena JV, a consolidated joint venture, we agreed to loan Pasadena JV up to $56.5&#160;million as project financing at an initial interest rate equal to the greater of 3.50% or LIBOR plus 165 basis points (increasing to the greater of 5.125% or LIBOR plus 375 basis points as of April&#160;1, 2010), including $49.8&#160;million that was disbursed initially and remains outstanding at March&#160;31, 2010 (see Note 5). </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Indemnities</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We have entered into indemnification agreements with those partners who contributed appreciated property into NHP/PMB. Under these indemnification agreements, if any of the appreciated real estate contributed by the partners is sold by NHP/PMB in a taxable transaction within a specified number of years after the property was contributed, we will reimburse the affected partners for the federal and state income taxes associated with the pre-contribution gain that is specially allocated to the affected partner under the Code. We have no current plans to sell any of these properties. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 18 - us-gaap:RelatedPartyTransactionsDisclosureTextBlock--> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>18. Related Party Transactions</b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In August&#160;2008, Dr.&#160;Jeffrey Rush became a director of NHP. In August&#160;2008, we acquired for $3.5&#160;million a 44.95% interest in PMB SB, an entity that owns two multi-tenant medical office buildings, and as of March&#160;1, 2010, we acquired the remaining interest in PMB SB (see Note 6). Dr. Rush, through an unaffiliated entity, had an ownership interest in PMB SB. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In September&#160;2008, we funded a mortgage loan secured by a multi-tenant medical office building in the amount of $47.5&#160;million. As of February&#160;1, 2010, we acquired the multi-tenant medical office building, and as a result, the loan was retired (see Notes 4 and 5). Dr.&#160;Rush has an ownership interest in another unaffiliated entity that owned the multi-tenant medical office building that was security for this loan. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In February&#160;2008, we entered into an agreement with Pacific Medical Buildings LLC to acquire a 50% interest in PMBRES, a full service property management company (see Note 6). Dr.&#160;Rush, through an unaffiliated entity, has an ownership interest in PMB Partners LLC which owns 50% of PMBRES. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We have entered into an agreement with PMB Pomona LLC to acquire a medical office building currently in development for $37.5&#160;million upon completion which was amended as of February&#160;1, 2010 to provide for the future acquisition of the medical office building by NHP/PMB. Dr.&#160;Rush, through an unaffiliated entity, has an ownership interest in PMB Pomona LLC. We have also entered into an agreement with PMB LLC, the manager of PMB Pomona LLC, to extend up to $3.0&#160;million of funding at an interest rate of 7.25%, which is secured by 100% of the membership interests in PMB Pomona LLC (see Note 17). </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As of March&#160;1, 2010, NHP/PMB became obligated to pay $2.1&#160;million under the Contribution Agreement, of which $1.9&#160;million was paid to Pacific Medical Buildings LLC in cash (see Note 5). Dr.&#160;Rush is the Chairman of and owns an interest in Pacific Medical Buildings LLC. In addition, Dr. Rush and certain of his family members own or owned interests, directly and indirectly through partnerships and trusts, in the entities that contributed the five multi-tenant medical office buildings acquired by NHP/PMB, Gilbert JV and Pasadena JV during the three months ended March&#160;31, 2010 (see Note 6) and/or own the remaining development property that may be acquired in the future under the Contribution Agreement. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 19 - us-gaap:ScheduleOfSubsequentEventsTextBlock--> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>19. Subsequent Events</b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On April&#160;1, 2010, the total $1.9&#160;million outstanding under our agreement with PMB LLC, the manager of PMB Pomona LLC, was repaid (see Note 17). </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">From April&#160;1, 2010 to May&#160;6, 2010, we completed approximately $58&#160;million of investments in eight medical office buildings and one skilled nursing facility. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">From April&#160;1, 2010 to May 6, 2010, we issued and sold approximately 1,592,000 shares at a weighted average price of $35.08 per share through our at-the-market equity offering program (see Note 10). </div> </div> false --12-31 Q1 2010 2010-03-31 10-Q 0000780053 119797061 Yes Large Accelerated Filer 2662290000 NATIONWIDE HEALTH PROPERTIES INC No Yes -1862996000 -1915071000 1705279000 1736708000 -1562000 -1562000 31123000 31969000 559000 751000 1013000 1347000 -987000 -210000 6335000 6963000 16653000 21251000 47500000 0 110613000 197271000 25289000 25289000 -514000 2315000 -92000 51041000 -51364000 231000 18986000 74095000 74214000 132915000 125244000 6605000 8750000 -823000 -1385000 2128843000 2225737000 1594000 1594000 703000 719000 3647075000 3813644000 1443000 -620000 82250000 80285000 382278000 210590000 -1965000 -171688000 0.44 0.44 0.1 0.1 200000000 200000000 114320786 118184009 114320786 118184009 11432000 11818000 30677000 51272000 6834000 8647000 30832000 31969000 21152000 22000 53000 -52075000 -52075000 0.48 0.27 0.47 0.26 201000 258000 51924000 47797000 -21152000 -22000 75000 6931000 6984000 28415000 29795000 29428000 31217000 0.27 0.27 0.27 0.26 21205000 22000 0.21 0.2 5000 -286000 -16063000 -17394000 -1621000 -1733000 -525000 -1706000 93657000 150120000 24071000 23590000 3088183000 3346489000 318457000 317531000 1556004000 1652827000 3647075000 3813644000 0 0 637000 25453000 -283000 -283000 6258000 19000 -66290000 -11949000 20416000 -203472000 43909000 43733000 50606000 31429000 27000 -190000 49154000 31429000 109514000 47500000 68668000 72633000 90748000 95465000 133152000 141327000 126000 126000 -436000 -436000 92000 682000 370000 46681000 51979000 82000 80000 8583000 65056000 110000 13179000 140437000 364000 283000 1452000 100 100 1 1 5000000 5000000 513644 0 513644 0 51364000 0 6862000 3309000 45875000 5445000 1270000 36284000 50633000 31239000 31429000 -190000 585294000 606231000 3406640000 3664020000 2821346000 3057789000 3031383000 3302857000 1652000 5020000 27000000 97083000 102428000 431456000 535950000 1573000 1594000 514000 114321000 118184000 0 2033099000 2057807000 2033736000 -1862996000 51364000 11432000 2128843000 -823000 1705279000 637000 2083260000 1736708000 25453000 0 2225737000 -1385000 -1915071000 11818000 1548000 45976000 45821000 155000 57335000 77557000 991633000 991633000 104408000 119466000 102355000 117048000 EX-101.SCH 6 nhp-20100331.xsd EX-101 SCHEMA DOCUMENT 0210 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 0211 - Disclosure - Earnings Per Share (EPS) link:presentationLink link:calculationLink link:definitionLink 0219 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 0218 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 0217 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0216 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 0215 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0214 - Disclosure - Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 0213 - Disclosure - Derivatives link:presentationLink link:calculationLink link:definitionLink 0212 - Disclosure - Discontinued Operations link:presentationLink link:calculationLink link:definitionLink 0209 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 0208 - Disclosure - Other Assets link:presentationLink link:calculationLink link:definitionLink 0207 - Disclosure - Intangible Assets and Liabilities link:presentationLink link:calculationLink link:definitionLink 0206 - Disclosure - Investment in Unconsolidated Joint Ventures link:presentationLink link:calculationLink link:definitionLink 0205 - Disclosure - Medical Office Building Joint Ventures link:presentationLink link:calculationLink link:definitionLink 0204 - Disclosure - Mortgage Loans Receivable link:presentationLink link:calculationLink link:definitionLink 0203 - Disclosure - Real Estate Properties link:presentationLink link:calculationLink link:definitionLink 0202 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0111 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0201 - Disclosure - Organization link:presentationLink link:calculationLink link:definitionLink 0140 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0130 - Statement - Condensed Consolidated Statement of Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0120 - Statement - Condensed Consolidated Income Statements (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0110 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 nhp-20100331_cal.xml EX-101 CALCULATION LINKBASE DOCUMENT EX-101.LAB 8 nhp-20100331_lab.xml EX-101 LABELS LINKBASE DOCUMENT EX-101.PRE 9 nhp-20100331_pre.xml EX-101 PRESENTATION LINKBASE DOCUMENT EX-101.DEF 10 nhp-20100331_def.xml EX-101 DEFINITION LINKBASE DOCUMENT XML 11 R19.xml IDEA: Derivatives 2.0.0.10 false Derivatives 0213 - Disclosure - Derivatives true false false false 1 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 nhp_DerivativesAbstract nhp false na duration string Derivatives Abstract. false false false false false true false false false false false false 1 false false false false 0 0 false false false Derivatives Abstract. false 3 1 us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock us-gaap true na duration string No definition available. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 13 - us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock--> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>13. Derivatives</b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During January&#160;2008, the unconsolidated joint venture we have with a state pension fund investor entered into an interest rate swap contract (see Notes 6 and 14). </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During August and September&#160;2007, we entered into four six-month Treasury lock agreements totaling $250.0&#160;million at a weighted average rate of 4.212%. We entered into these Treasury lock agreements in order to hedge the expected interest payments associated with a portion of our October&#160;2007 issuance of $300.0&#160;million of notes which mature in 2013. These Treasury lock agreements were settled in cash on October&#160;17, 2007 for an amount equal to the present value of the difference between the locked Treasury rates and the unwind rate (equal to the then-prevailing Treasury rate less the forward premium or 4.364%). We reassessed the effectiveness of these agreements at the settlement date and determined that they were highly effective cash flow hedges under ASC 815 for $250.0&#160;million of the $300.0&#160;million of notes as intended. The prevailing Treasury rate exceeded the rates in the Treasury lock agreements and, as a result, the counterparties to those agreements made payments to us of $1.6&#160;million, which was recorded as other comprehensive income. The settlement amounts are being amortized over the life of the debt as a yield reduction. During the three months ended March&#160;31, 2010 and 2009, we recorded $64,000 and $67,000 of amortization, respectively. We expect to record $0.3&#160;million of amortization during the next 12&#160;months. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In June&#160;2006, we entered into two $125.0&#160;million, two-month Treasury lock agreements in order to hedge the expected interest payments associated with a portion of our July&#160;2006 issuance of $350.0&#160;million of notes which mature in 2011. These Treasury lock agreements were settled in cash on July&#160;11, 2006, concurrent with the pricing of the $350&#160;million of notes, for an amount equal to the present value of the difference between the locked Treasury rates and the unwind rate. We reassessed the effectiveness of these agreements at the settlement date and determined that they were highly effective cash flow hedges under ASC 815 for $250.0&#160;million of the $350.0&#160;million of notes as intended. The prevailing Treasury rate exceeded the rates in the Treasury lock agreements and, as a result, the counterparty to those agreements made payments to us of $1.2&#160;million, which was recorded as other comprehensive income. The settlement amounts are being amortized over the life of the debt as a yield reduction. During the three months ended March&#160;31, 2010 and 2009, we recorded $62,000 and $58,000 of amortization, respectively. We expect to record $0.3&#160;million of amortization during the next 12&#160;months. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false false This element can be used to disclose the entity's entire derivative instruments and hedging activities disclosure as a single block of text. Describes an entity's risk management strategies, derivatives in hedging activities and non-hedging derivative instruments, the assets, obligations, liabilities, revenues and expenses arising there from, and the amounts of and methodologies and assumptions used in determining the amounts of such items. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 133 -Paragraph 45 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 133 -Paragraph 44 false false 1 2 false UnKnown UnKnown UnKnown false true ZIP 12 0000950123-10-045562-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950123-10-045562-xbrl.zip M4$L#!!0````(`$&$ICQ%MV5J/9P``&72!``0`!P`;FAP+3(P,3`P,S,Q+GAM M;%54"0`#N2?C2[DGXTMU>`L``00E#@``!#D!``#L/6ESW#:RWU_5^P_8R29K M5\TIV;)U.%NR+"=.?*@D>9/WR84A,3.(.007(#4:__K7W0!(<"X=D63)GM36 M6D."0-\7P.;>O\_'"3L3VDB5OFCTVMT&$VFD8ID.7S0*T^(FDK+Q[Y__]W_V M_M%JL3]?'K]EL8J*L4AS%FG!L_Z4O5235+`W:=1F MK99_^"4W,%BE=I:-=L_=.^_KA`$'WX^-WZR2:-[V]O;';KKAZ:CK!P(?[>TD'D[ M4F.8N-=M=3=;FST_5!KU9*/W;!78=H1_`"@ZY+R:GP87IN.NXS/;K6XO6`)' MR"O0!>_&LKZ`&[S5L3?]T%C(.4#@VB(@C%Q$.QC8Z_SY[NU)-!)CWBI!`:8R MMH=`I;DXS]F)B'*05"LX<"]RUV7\HO&2)[CZOODP^+39`VG$V3X=BYS+5,2? M#KE.0:K-IX\ISS*M,BU1>#^]$^.^T!9FF!'D6N93]PM^RQBO#*30C'`1-4(8 M$;6'ZJQS\.;WQL]=^._9\V[WZ>9>IWJLFLJ((:I->0$N68;LB/,LD9',+2PL MEC#.:J03C)V3'(#%IP__6P!\!VJ6X]L'5<[_5YGX:H5 MG)TZH'N=&DWV,J&EB@,*$=OSGROUV.OX:WZ&X)F]CF/:93FX'X&Y*1)BUH=\ M)/0GQ%Z+$=+H3'P"*Z/&XMOB8X`SH5S#V"+\0)D9QQ(UF">?CKB,@7F?#G@F M<_C];3&PQ!/1?),Z)!\FT]ZK%`=IE8"]'@+/.K[\*O'E+3%S'5\^ M/*:M<_2':D-]P'FDQ4!H#:PZR57T^=MB6(D]]89>15R MV!WQ"\E1>;GKD6-!\'X/"%'SXC<>`3^_3_@]O[4H91WF/RB[M)R1ZZ3@FV+G M>K?MVV7O/?"=UPLB;BU]6F^/?!,"O[#(^]5E_98KI?<(OQLM-W9_*]+[AU]W MJ[79O0G\NEOO^/0>RN=30/&Z^/W&TX+K*>HZV570P&@$\M"Z%WC>D4'Z1ZOU M,97EH6Q_)KO`:TBDCR>O#H].2FK$\@PPJ1;'<>^+L=`\5Y7QA1MCP4VAQ<_N M[/P.S+/7\19KVE4C56*;+)J8S]3MFQ"$(6C;S_!1[G0`#.V@&X1.: ML43XXN46S@+HSDVQE!3A#'A0_C`A[SAW4)[>OQ!#F;*7"03V[)0/AR)F[U4N MRC%EL,ASF/[#X$.&M(59#'-\/\:#^A?(_D])O@NKO?IP= M0!D:@WX6";3'?:O4PA?#'LO)NQ8C7GZKR9=:!I0J,$N&W,-<+42,2I M_$+2=:LK[S)4U99,T6WLL"<_$BCO:6$0,,%^%3S)1^Q(*Y#V7()(TIM:3<89 MZ/(4/'<,"J\S956AR:2!6QJ>8I`T@F]@,CV#O\C0Y+HP.0']Z"<^SG9_>+ZQ MT=T]/GQS6O[L[3YF^8CG[C$#_[(1P1"!282):6LC7*#),BT!+]`C9D0JE68C M51A(79LL4>FP!9P?,WR:5LY*3!C"/A:QC&`N-1C(2+!^(1-\G\VTV1\CD8HS M<+\37'8`?XP@$09PA0`SV#U^OW"S-PNC``,+3`(F@E'3\3,Z."> M*G0SO`MP69)@$09@QH4OYAQA+8&PIN@;&4L@'-PB:(HT$<8@<-Z&,X5[2!-I M],"O\0`6?'_+-@0(%`G`R^/,@C!`NQYRG#%PFU&(]((@L45U`'&)D8Y^B-=ZZI#ZY3JPR8C&8U(/E.5LR&HD@;HIRAU?T&X M,:,DB^GFR((@5A.,^)D`EI[A3\\()[W(#`.8:C0[[F&`4W"`Q$,&)!@5QDDS MB0/$/C`C^%P^M.$0K@<4R,"QR[ZE-1"?UH!10/@!$88;HR(K#Q4KB(2X[B-4 M/E4,1^$SAC2VB7H=@;B*P4#0ZH!6WW$J@VE1PD::'JXQP3QNLQ,U%AZ"9;:+ MR'X%0@@M8L[@0>)7LS8"?@??H)X`!3S_K(LLC>`0'ENP@ M,X2B#Q$VB.]`*U!*")"(/O!O$Z$@N*QNCY7.A\!/4'+0IG`*B5KAC*5E&\S8 M9J^55;@PU&0:OEEVTSWH.1BI')FYO_HC( MHYG2(*%I`8(P`3O$0#*!S;$%W%*Z:=^$)JH)5%@$ZMF/=HB'WQDJP*$YAX"C MKC=8]O98FD@DX)4%6#L0?MSOOU.+W1>)!-21'Z2IEL:`.AIB%"*."@'*#/J# M//AO`>L/IOB+,XP$G!Z[G,14A'_^=,OZ3*<:S[>Z7A&H1@UA/3NV5&<'*B8M MZ6T_WVK2W&/+S$N.:!G=F1BH!DJ)N#X`O-430JR!(=C[/ M@R9-/:EAU.M6F,P@L6`MJQTPPT2"SZJL-SJ#?LTX?6R?M-E`Q&3/_83HI?#E M?^OP[34*"DT`4NRY4D=R/X)X%"F23)NP'@9\9Q(+PR"0$#((`9Z+@W@@ZHO6 MO3MUV2=3NRM):E:_F_ M;585@I:6D9J434"&8FMYD'N5R3P67BF#\*$\+?*7@LR900:.%43VR`AA-\^> M/M[%4&XMJVM9O;JL0J@V+I)K4N>UGU_+U37EZC+I\_3&?#.>T7H-OE0M M.@7667AGX1Q'^[\Y]D&GK[/J3813[^I[Q$9$$`EBL+@. MI]8FR>Y%;"W--M;!TUJBKK7QL-YW6,O43>\[K'.^M8C=@]A\G?RM!>S:`A8< M6KJO]=<+CFOA6;48E"+*DRF=1`]+M/[X9C[B]E3;PIIV29GYXC8=(PTKVL^? MP&J#@4`1"`^$T7$W.H+'J@/A>(QPH))$3?!7N4Q6]!,9)7C:EN/I2#R,R-.+ M*\KUW&^!.EY:K>84@D/&Y<@XU4T_U*8++%6OO8`9A9$""YLU&W7 M^X(Z`ZC!92S7=TJCUZ6)6A,I)%+I=,D>M2R,`'EVSF@+SCOU.C4_.`-].[2D M=W;!32ZW[[!.>M36@.5!J)+'=OM,WYJK\O*)<6*$=(+8:8`S?@?BUSV;6RW#ME.2G2 M@$'L%X`QNX=LNM$HK!YV+PJIOT(QZG2BRK??5>:Y+6]5%2)?WL)W0VT!:5T;^MYK0]]M&GK7><_%5?KK M^;`G[:6'`@%5]W.2=!HE_N"8L&?9_TM16B%I[Q=BC*&;UUTEL8QF> MV`X1OM\$[B#"7=?Z+&Q2PHM8YFUV2FV-5CU-;:MX_%?ANUA0*P_*[[";&K:Y MRF2*#3J`8E4?)MM")!5@J`VRG!I@L0&7&O$IR>I[P,"E(LF)ZJKJ13FX2E\? M6M!&NV"XC= M:,9C:8PO*H2][TX.#^KM9_:!5K:U3$`P>IMI`-BG2H^!QAH7HNY5*5G8-CL0 M&C\!PR30GMJ$9!H]G>W'2JLNY!!)![5$@2D3/$LS7`LWF:?@ M26ND#W:8:0F0C:I1'&U2(U7*_BM$I]HX6K9X]4#'9`Y**<(K]DQJ1V2G(6\0VM[I-5JJL:Y,W;;*CA+NN4]@V M/*,S+I7NSLR+LX1S-]W[9XX(CBPBZ!`6R"DV!L-V7_#+]X("X5838*/KXDL> M.>)FQ`:8>I6:@UUP,H4ZC.)N>Y.-1&)S/(,1JCT*YJ#QS9A2%1[D*7OD47LN M[$*ERAY5KB$._5T]0NL$VF7U(%.:#I]1;Q[?,2D.Q@7B24+%R^Y%*3HQ?"I1 MV*76-G*S0IY,*^L#3RX4W]*NP0!.;7^HIQT1DU?B!;H`CT*.;.>ONA'!&)&Y MUCC()>Q0#+^H;[RIB=`O^_M'-1FJ-*>RIT![-98Y3C%C-XR5A(76`W7>M8J; M5/VS;"_`48TZ'LQ%M*#Y9\TU2@J/012Q(1Y`0DT4<8:0#TZC!7$#&X@ED-&Y M3GEHVDO\:(F+?88!7$`22:*H?1$^\U>1VIY5Q!LL.BQ\UO=F1!A1-HSMKI6K MFBS@X_LI1'#8\`NE#UM%O49KU>NV?B]M/MDK:^M?@1?!LP"SYW:ZV\XV)JX# ME[7CAP?DUV["I]3]B76QG*CDI@T.0XXU'NVWE=49Q6X+M^A:_G0]V&\ MPK,RX#XJ+3RJ3]5C[.N$W:?7B[))/9S;,DW;8]3]\I7:,N6?C!0XL)8]9AAV M\O4M"><>G7GAO8PD_*=^@J:C9RJO'1.D"H0A]V:;3`J.;@L[PF99LBC*P\C( M1EG/>V&45>/,BJ@*GJI'56A-2GBXUAA76^*1U3X#W%U'0A?3T$NW2=EDL`+,*2,M$^1!,0=0+UIS9ZQUZ@6E)3 M0?C#'JF<5NP@_F#.SVV#RR"2`-=/7Q$0\=U9^0\H&D5,G["QM,36MZXW(\I- M`E8?WW_"F"$!HP_QE=)>:FP4:XD]M=0<"9*12Y+,IC5`:FQSJ)(S4;:?-GB( MM[A@TA1J:/;+*^BB%;J"&(Y/V>'AS7Q=+&M`51'*X?B\@IG%=YKZGIC$9@B4M^19)VQFMZ>4-[L0".WC+5*P6L'(ME#1.;9>- M>V*NDF!$93QD&;-<.TJY^:CL8J.[N;$9&-TW00/14I8W=IG]*A9[!PJK[+M# MOY&/^(_W$ MH)[6DKNK!$N<@]G%EO4FJ!`&\H1"5.7CB'?%TLQ5#T-G(ZH<%521MMAI1,&5? M3*G6\"$1F"W;NIT"K)*:7T%B?:/P8Q&I82J_4J)PC*ZG[#Y-I*G4V7_``#]6 M0$!^65SH6NP(2MJ[,/Q)&(:_=1WH*Y21XY7_V.H^#4:OI)5UZP[6JK*&DHL% M/V[+-%0_#M0HXHEKO/_.?1U!5;/X9U.(2@(-H#FJ1\DAE'Z@))$G9J5&``2P M27,,CEH)A@I]NSUSYBRV/S2CQVV/XQ=;'Z69EDY0FHQRK8*B+(`PPN*>=4RY M0A8OPL667:FG>P6+'+A2OX6JC+X\>K5XTRDL%6;PI3,["_:>AVFPA`50.D?D M%52FM'@E=2X.!&<#,V"%R.,XRM3(H%6KA&Z-,@">V1RQ"CP^4$!K#6$0=`2%I2I(Z]MO"H*S M%3`:S%3.#&*;43`2F+0ZFDUF7YZFKN@I?2:'/M'3=#`1JC!!QJ?6KE))K""1 M%^>1<%ML"S"?"5T"=BQY8(Y4$*EK_U$:Q;X(K2JQL5^0B.EEI[J(A,+MJ_`S M>C:K6(&TG1UT!$OBX&YI$ZQ$%4L`^"$^=J3Q%<[J-D_):Y&:-SBI=S0!A/TL2I=6>O%,&!ZA@(> MY&$UP,%V8!R.G%`I0$3I&;;(<9D<84QQD@L\+D(\8"11()`1_SV?4K1F7ET- M0AIX>(A;"(/@PS@V'`-'4BXQ+"`03.U<.`XL(?RPK5SJ^U>5P\6IXS)]]M]9 MFGO>Z7Z0*?,;=&!OBFQ4#QJIG!>5BIW`6C-&$EBO=11,4;I MI&-5_KL?[EUD^B"<%5..7R=U&0=Q^AM4=$+%`QR]C$^WF"`6EN!U=9)1_ MXJX)[I<@246M1&,S3!]XEB3LVP`"99`J%?2=%&>X;'$F"/5AR2H/L%]JF7,F M\ZK@JCYU!H5;Y=Q[(,=:N_]?TW&[#4:F,8AO\'Y<1)4`4+QE+6E%SJ:OU823 MS#Y;YU$]/SUW'PM9S1;G=^_4]B*2&D.'?_;:SZJ=J#%(H-]GACM;\W?"E`=4\,*\*XQI%D8+U]C[:_K**GWPB\KG^'F7E?0,G2R>[R:(B4NF6>%=525N M-&J"U6CQ?VYLM_^_O3=M;MO*%D7_"EZ.4F5700S!F>G3ITH>TE%?Q]:UG.YW M/J4@$I+0(0$V`$I6__J[ACUB(,&9M'FK[NE8!+#77GOM-0_M$KQF"[=\T>HW MNJ5O50=CW?PF\;\OO.:@T2)([".%/Q?!*L&R#&`NNZ++%3&!'QI-A'T8 M/,%D#E`#"\'P#%$G-B(OE7&V9KC?X$3(NEYL?H3.#>P704R+#79+T2N!FFPB MN&?_"81-?AI/6(])*9SO/4<;UWN/OD;$C/>@EO,-<*T+KN- MP-[3'+6!C-E/J:%PH44PGZ$=,HG1>&HX-UK\"@Y/GI?9')@92,4D%8,%W,>,IF,$/:&$JE!CK`F<=JU>$6C-/E5:+.@HH]\G<;/TB['439`RJ M14)$D\+`X,,>']A^,U2YB-._B(?J&;Q:0ICQG9S+J-UK2MO)4,!_KM#MB5L2 MKF=DR)%#1)D*VGAAF^$OREFOD*X2DT*$G31,-2A8>`G1\_\2)&K4+7)(,1*5 MLQ3U;H*$PGRFR]\,4D3A7XP)BH"7^S"SD*JI(`G)D6G$ M;%/0V5-,FI04@)S\3FC9(C4-@_6D;&%>II]D#EIS$P.#_)$72RM.[=->0&`T MG=:2X[E8OYD'2*-A?3.J6#XW%]%M^F3*$P(-8\I5%H]0QPMFA2!6$7*CMTFY M17#0#"P=WHM?L.=*X`Q`B5S. M8EV.M26O6Z8MH36,/@X%.ND#RY2H:E6)N7V!2"=`CSN@E/0^NFXXZ MA_>#%40,(R,R M2M$LRP1US8`#QQB!3T7!@\A%5#_JF\5>$A%X4M.H*4T$YVUF.@>;K%KA#N'Q MG1G[!=AM$<$AH*TN[%XRY=4R,B^!T,W)SB+9A"U_?'H,"G(:Y!V,5"%`IK_, ML1;A!3WYG>?]:A-:!X.)""ASH?(,R1(F,YUR>Q*V*T#"XC7C2ELC8YL8IL66 M,+`VHF!RJF)V`K07Z;Y`,^@NCO\4^\B37!Z:E$T$;:SGG4F+P5L*%5`]>OY- MN2XFN"*1$!.6SCPIXF#I?,Y.+F9JZ!@ZBS24+#:-O<2CT7P&M__%5;X:GL M2EY,`F#$=*M.6YRCC."0D!3%'3;%"?(6>8E1;%*<[1)*:T&V`"#X7PE/J"U2 M@D>ME`-,*_OXDH8,&9C*SI;-$;&-8I`]!T*#SMVLO(["S(4H.DN-#6BF`E[$P\DK_10FW93%JP8GHF!5QCY(054<&5QR(#!&F!G#"EPB@'C:$O M+`4+`]8HYR_QIEQFP13[U"0OK'6'0KED9ZY)K<28`[ACQF)XRRQ$N;E[)%(. MR!U$@D5NTQ(I]M;,PS7WMM5(NL_#RM M14N].DZ<7%[@0LJ@1$(5I\$#F@(K`_7@S\#20@"M_E2Y[`V=)J_3R4P*.V$T MIRORDRHU/L>NN<++*K-3X3M+KP%Z(]UH0;1(Z;$BR&1>F5R\#OD0ISG&XEKF MKBM\(GD0/U,P!P?;SQ-!92J\HX2*6DMMG)A'_LSL(UMV8OLCWX]Q@C M+8YX")(IGG2$)7"45*98;LG9-X$6W,BKZ(DL\-,@"47<)PD M9"/()(]\;HTH2)UFV%?FC?$ M2-ZBRR-*#]@P163;L8I'D#&+&QF0U??C$A4&AT*!YEDB;567`>@"1-AE@)0'\"(MROJR?1!RZ`RA1>5>=(_AA]@QHJ6!4',P3=`(# M__Q(/CX[RSL)[B=4U%6)'[6/^XIL(%R8.B;*/+X*Q;&L.:)(\3G`7?I`"7EO MY*`0`N5ZBH1H5'Z\PZ`;X%.Y1']/`V"AV+^._997G!YTL-!],C:\\TBVZ+@B M2-$=74S,T=558W-K>(1J9HH9X1RCR:!Q(FDY3`P7'^=0(ZG-&3L3B1U.*^PT M-XB)BV-2A-HA.Y8-VRK*X-6F+D M$K;VRNHGA.1`I7YP*@.=N4&.*S+[0;.;8_9O,.<#_;/`XN^$%VU1=25\84%/ M(>WN]$?P!^X=5UIOB#QVGIJ!`6**SE/\C7I@&/C?" M,=TEY`@OJWG#+UF-E*0GB+\^9A7>JJ9#+XY(*[!D611'LD^"U3E)Z(+BBT8? M+J/"GYWP?&KDQ]'A+(PI8V!"ZY_^+,PH:X_%KW'`_!54F,5-'@MV5W:2*/DF M0<:6&9XHY;^H943[0WTK5?XE4YIR.?EV#:W5R$5E-)?UR+$,++.\5NQ&F8U& M;*]DMY2=05D\(L(,XO]=WK>C#80:?(=L(J#".25A@";0*40)>+DWYU(^:&K,]),1<(FI#4H$43_LJKU7=+:N/D9)]ED?O00 MVG4II26I.@^H-&J@Q)6L4=(: M;EB\78PW^\+EK',Z0OAO8K]F<%X*,E:LI0(D;'(S6P0-&Z/]&49&O@K?])#[ M@6>J9%$M(()>OQILRU7I?/IK>AW!7RV5#O:6AE-"=L"E'N0"I/,"H'T'LT&, MD(HH7).*!7+QQ$"@6HS[B46R[$8?5>F`O>)-:FQ&S4ADD:53C-'!?BR!3.#ZWP*[>,$OZ%"MHUSSQ7WJJ*XDTB2J:I M=O!).T)6N%)(3&=!6YA3_H"DBCN4>8C9?^X7MU6TT*H-LW-\Z1Q?6AY?PH`V MDA/]QWOM0SN`ET;!0E%VTY\G6]>ECW"U+O$Z6F%^ELY)"&OXU!E-]D>F*UNF MO&.O&S1GJ.1!VN4[ZH>V$/_O9**VZ%A,8P?3@Z!?@7*O0-'6H.VO)^AN>'DGKF*<5FJJK*?GD!LI/"Q#?"DJV`HR]49?=(A["8/)&'U.I;!:6JAF MPF$MP7Z=V\8RN;TGVVL)^21P25`8'8)BKD6R([<+![4H8<^W]!:XLJ(&,$IM MI$FX2RM=JN%A^J=5BJ_(21M(*%;Q.7D.\I'+.]`22&!K><[%F`"H_\35593L M*VM=<#',&"\94ZU=2&->S.C1)!MVN=RP;DSN(;(V,@3N@7XR8M((YPC8&`59 MA$%JW8.Q.C@'HZ3)7)3?_%-U)L,WRI]BN;.*B/4)OGIT#'+_;(-DIA MM$K8ZFCQJ9'#I=!DZFE:?_0ICTBN95GL9O[DVT49^P9J#3=?$7Y13Z=+6+&$ M6[1,0)*GN=-$_BPKV@RHJ-XFMP'Y:3V=@!P&JCF> MJHV$[0?PKI4(;[IA9=M'^6;#N>+&DOY(EJ=@T`;]+S(JZ0L01.%)))MG5JS` MGBCJFT*519A6PPF+V$MU-)J3011.T=Z`K]CM+@SJW1^+^*68EAG(?HS+FA[F M>QL^JU">*+:QQ(1O]ST,BNT.R^G<],MI8G1+"4PV[.)VB7;\KW`#C-3MD@`/ MU6"UVH[LBP:W5%A]LIWI_E6*VX"[]'Z6,?%#Q6NYY7Z=OJBKQL[4D;4&9K^Z M!3LGP.DI(M555PCS8,._B%9$GTYLH_OXJ!?N% MQC!YO=<'Z6$X#H(I>;H^B+*I&S_)9!4M#K-XC"=PK0ZA@7[\]>:GF]_>T(0U MJP>W^,%V*I(9(?8P,_8@D]"PH(LOZB_!76+'KEK-YH"^"-TMCN_"1>03J3X\.&M<<+=UT1H!L'3.G*75)J0RYG5Z7ON2YO=;0[7=;SEN4Q_J#5Z7'-X]"Y@$23R8A?+HA M$K7;KLQS(4M>,UXGE&O-+KAE4ESM-HR#-G] M9`K1QWI!QVZ_Z[9;/95'X;G]P<"1*.#L]3!-Y]P+2J*+F]5&@3$ZQ0A,,F<2 MTEG:\S[/F/(?`#;=T[V:S,FK(X+6,3>$4W.]%-$_U30UKD!L-ZR8H94"XZT(II6 M<04)Y2O.1[R.A+3AW(8D>%F-MGIGE"SI"B^0DBOPG;D2(\JXIY.D=0RM'&\< MYAEC[@P@PBKFK!"L]!4DF#QT?T$C-TY*:9!$& M>OI0E8;2L123=]P4#6[D(P+_P3"*2>YPBW4M?EU&/.4JYG`MSZT:/N+7>\$DQ3DG\Y:U(UC5R>SO@82QD6;^@_O`/E-$'*LU9/FVL M96IG&EXP?"ASV"B),,9J+G#.MZPY9)*7V?,K*[)71+(R5>'8A3=4WB8&^.K> MH>*[BF2B.%JZADI*Y?I`D7?'@W_%)%).X*X`QN!&1:CV=]T%JK$Y&H8G30A] M.:5'02S#=>(03@6`4SAX\<]?=DK4H,OHC&&ZBH8G\OTY!3=]GM[9A!SEDN.C#^&08*J)17AZJ+/+!@]1N&_YRJ`1O$7 MHSX2H)O-J4TEVPMF$VI]@C0:^X;S4")H6IVA^S[$H",G;^:1\9'C;`0?]TH#4C-$&T! M$-7WA+:#UTCU`A&#RM$[,@]T-9$.*=^C4<[B5)]/2-%.CD`+=W`E^0N*+YU8 MKQ[,!#"@2?_U!Z_9_/$'S*T`:OOK#\T?G!$0[S0]?/7I.N#MU-@*KZ*Z-X$B<_.__5I/_W%Z"2T9^#-O;]H M57[Y&E*NU0"+2NSH%GO6[+1_SV-R=G*]$'4SHDJ3$5FX.DI+\0^*:?&-2!OY MM?C?2>[?2#?+Q>N9!K\O&FQ9-%CDAW&F>KM)HN5?S"R>`NG23GTR-&['JJ^L0.SRE>%>5CGOY;R7[:Y2 MQA>SI()/_%#CJJXB)6KMI$*RR3`(B&1@4_"'EI:KQ*HN&4:`?/;5(7^BE-NV M0,QY]I;(PY/;GE"&O^&]M;[AO;4WW]NW<\.]CHVB5U3J$<]3L*'2U[O!%*HP M[\%$JU9@\DK.FWC\LES)*;,!_FLT"H+[^RJ<+S"E*&;A=6=?;:WS$O_$>F?. MFUY0([=PC'F3XV+YLY2"1`]WW'ZKO+>GB55=KJ*K5Y%LF..U%&+4D&>F`7/ MF=`E$.,;U4V/N5P"2^/:W8;7Q01QWOU^^Q)7)^Z;772T__#:Z`2"((HJ2CG4 MAB;P1IA[S<71D3A9*_-;-*Q(@XF8\+R>]F!2@X/U.TXU3)C55%@ M-S;GEC*BQQ:7BF#A!P\/#E-$A4PVU]NAA)[18XQCC^4D4Z/OEI$W`]!F27@W MST0^GDS!P[$"J3'5+K=)71Z->7@2-5@@3446%NF9%*W0B_W11>K[J(A2[,%B M+%9-8^>*2.L[WWA%9!5;4/-(]'?EF#1CE)3N.ZY6HD(+:G)DCH8V>M9QG1A/#C7ZEP%KP?H%.1:) M&00M0JL:$*JE%*@TR)[:;XZ#.^IDI7OY*GDBYY?2"H4QI_,,UOX/=3H38\P8 M0+583&R(F,2<>0VM15W<3:XC"CADRUZ!^#V.]D`\<:H?MYX>!QG@-173Y-18 M91IWH0\<-U3GQ+4J$,E2>=%R,RTYB6I13^>96C2G"48F2*O%H@!KYD%@4*,[ MGI3VI$=#3[GS=;Y`2HR2((J$TU?C%_3`.<6XU4KFI5B%]=@FX+>0:=EO?4]9 M<-_27NI[)8X]WV?=U*DWR.>^W8R^;28L?CO$TCOGAJWI1OQ-"OZ\N#\Z%W[+ MZ[G=P7"/=WEC<-N=M<&MN)N[#^)\*E7^CHX:^AZVE3L58NCUW>:N:6'/C./W M*,6N"=C$,8A"--O@O\-,-04Y.HHYP:#:*:="WC)5@"VWFPS(C1`[''INKWTR M6;R>VP0.,O0&WQ0'P=9.[)Z]BW$`LIA>=73$TFUWW6&W>2K$TFVWW'9_;=&X M7-<]0.!K87>F][(C/H9V;JG9^JOW-[>L]^^W5],;/PU'#BR.CDATC\U%P3V- M^>91(M2J?<$P8MW+)8MEG$N=(`6\9'?6.^X)]1S@V6.+HR?XR$.@@F,BQJ?C M;PWG>NGRVLM7`H>U/&Y13FOC30;C^2C3WNQ4A6CD9W+C9`W7F^I?5O6JZJA# M"Y#N$:H)BWJ*^A@')B3L]ITEZ5 M:`34YTH#)53;!&NE!$RIBBJY5T2Y639](`E%^CQVT41G$!\48 M>F#H4RMZYS_[R5C&^'BJB&A$+(CC/D[N@Y#/7)^I&4$><[=<7P0W=T(6)# M/&2*0P`!#0+A9MDOSBS&MNW46Z_`*"0%X8[GJ61F26B%>W!D#2Z%[G@1B.<^ M6')(!=-"&F09=@W$+P11R@'DV<3G-MZN'!$K@,-1).*CQF#%?J/?_=&YA8,. MC-[K;YRW\ZD<,_26.Q_36,4;=?%O"2ZSNUWQ([FGU;/&!')K;"VWXF464QPH M/1#Y#,:0A.9K.1%4MZ?&4(W"GCX8"X]VF+TF3NERB8%-*]PQ;`UQD'U6DP50`?IS",[.!?&+Y6W/,\,N<CW2+=X;XVN\S[%IYH+%G?Y]'@29#.>,@<'ZYNGT# M!\#]-,4P!F[&S<(ACAYB'H7M3U[$[%`U(D9UY?,-':1DA,V3GX2BLXN8E/9` MDZ#"C";S:8FOPV[F*'F_Y`.\"BUJ7M]_7+^W+^C4_Y/TJDRV2YSB-(F[(`KN M@?O#?[LZ#FSV&.3O.Z_"UQIKC[+I(LTU1D0`AD:F`%,S4V0`$N#A*S?%5GM& MVQH,5S+)4(MQ0$(\!<$`\@!G>F`'>+,WE80L-!9#:`#O\!6<])89N,.FVSAX M0S1SQ*E0$>7?2(C$7!CJZB?3<+@3[JNP;,.:R7"C?)GJ/)D3#&`3XDQD=BJTN#=HE6HGNU4.JY$:A-60A/F64PEM\:=%[F_ M$>$VJ&8LLH=4]-G.DPK'Q*TI*=$)KY?-GJ$"`T?&HS/M"+.Y[=4= M]L&L:H6KF71N4;F0N3@V/E4_P'$"Q#BUW3K%>_,H3-)%J6Z2NFC'FHJQ'!%- MD,"GJ.E#ZB`-T9_;\D(9B1*J9:=KRU`4SD@/1O<+L73"> MR'S:FC'(^U8+*03@E:K&@KEYGPY!CK,%S3#U)S28$H@!;WE.QV&]AC]%G7D? M$AQH!M2N^OOA?"KN'4Q#6TD]B04.@,F.:(*+OFQP:8%\(^8<9A]4-B?$,(Y4 MX1^PKKL!WYP7$EVP0"1]L M6_>4UJK-LFDVQRQ3%\BB:G0_B,1;_$T2BM`&7JPC7T;K%23.),W6!F5R+X/8 M8^:.@L:4+R:C0NE.S2:QO3O_I]+-L[B^O-':@25X5I(WYW17ZSO?8;KK=?D, MNU(=01'QT)#W5W!IQNI"OA6SNSZSM"JFI6M=`)XQ+O,RR3^LDOQ#QY^2K6QD M[W?-[/W;^5T**Z$.^OXIG[F?%;50Y_;]6S652_;GQQ%:<]#V,2;"ZGBIB`KN;_2I86+YY MR\=M&B>"$'D")AAV8M.!^?%U=JJ)B99"OY+F].0FD=*"IQH#9A1.A(22!,(Y MR()`&J6"(*>Y#7.F1E37Q%B)T^L__/=/\_3RP?=G/]]J!5CK_S=B@OD78!9O M)O'HS__!;_RW##;1GYPOH#_!09`C[?)2/\&)5=7/R)4_!_[D/9VZY@=J07)- MP#\^!_=__4'(V?WG[YWYOWSF,VG3@WO[_Y M'RIY_^V7[[TT_OOKQS_O]?O_SVP?$:3><+:M6$+7_RTT_O/_[@_/"8 M9;.??_KI^?FY\=QNQ,G#3U\^__05O^7AR^(_+S/CS<8X&_]0G5I6Q$#;N71J M[?[0`G0UH6)G^(&JAWMS>'/.C1I[>@#!MFCZ',WI&4L_$DX6Y0&A\?UYRL*Y M6S;]J=7U5IC$5"M>?V[)?B8RF\B\7K]J?->9J,Y$M1Y1#)AB[K8!(O[9-!(%YZ3#J+56O:G"C^QC44.#JF!RSA( M$_X#_8"$\U3D!Q@.8LT^W'P4#;^.V1\C#OM8`3JPZA+S>=J/GEM$CSDUP']\>/RVP$\?)#$,'OF$^A_'CXI9:G2>XE\!.NPT"( M$:L<786=?R![U?Z.XP6%1-.WAET?C2J[O79 M/&/J*&U()F,PLM26KR.,,8?/(G&1"LBT-:2L`PBI\"BH5VNOT"\I`%\ET7R:V8@4T.VI1N?Y@2 M"6'T-DF"IWC$+36"#!##2,.L7Z[:DJVBLAB4+'SKHM]JM#1T4S`=T>WK_*[R M9I#65,X/P^N*'XAM4=Q7Y"F)J@[ITL8.&?04)D$EP

=2VVT,3M8*0^+N20"CSEY=Y03AI MG7`Z0_F3-PB!).&9=N--(U!,T>6I7F5R,T$T0(J^R,% M1\0[?'OHRL*773F84$4^*#/,=6:8O3#6<9S8(*?T=*.&?1$WII%/P4OO.88E8,0+K(F^V/9%". MDB1DKYMNM]'L_F@E==[\]H;`OWWCM(?#RT[3<]X#AW=^#1\>)WAC/GQX:V5\ MP0OPL)W=J;+]'!_.=L*H)\Y\XW,'KM_$57BC#AV^*PC.)Y=[2O*MEDK55`@MF7IE_)$^3".Z*>UU%$_OPDCE M*ZG63^*.B<'2^-.%YS5:M(IS3)`)T6UHC[W7YZR/<];'#CC-_9P>N6@W^D4R#JD4`*.D5&^B MK"C4>[)D/M(ZGQ"O(26+ZH&;TBPP1'3(4?""D`#1^4`NS=!LAPDZ>S(F-878 M4?!5J%LLH+60;SBW.*G=A+8>D&HI+?PY0$^L`U$P2FBMD+4A3.BHA&+" MN9]HHXU<$2,L3EH#$HTU0+EJ27K"SO,\91TV"QCIVAQ","( M;PO5-T=LFCRE,5I+&)W`)4WCB9)6',$4$4LJSF-B\96!MB14P-G)HN**"0?E MO[Q94[-5C2.[3W`1+"V1#W`9,&"7VGH@:,G6>6VKH(8BJ[I<4#=1D1LZ-L0P M$F:OT2T2#"4M\SU@VW)BU8$(^2L:$=)R:!]Q'24U'`0Z+.&'<]6-@Y##.$0$ M&K*>DI%$0>!8<@V@7L*1H8=1!QBI[@:9E30L,H5,YY+,H7;2QP!SCTT$DJW[ M',A44^,`3*5"GI]$JFLHUS(GB5+/3,QS\IJQF^65U7'$:EI^`^)-G1NVOYN' M%L,4[5^FPD=X29KWF,Z>C+EPB;.SD$5ROHLV>65!;.'N*IZS\!(C?\=:L17S MN1;F%>TBC>L#]B.BAA%?$G\<7$5CHM+/JD%1^KVD=W6,]*ZUL')H#7J3M*]. MPU$-RVCSCM[K`93;99I/`,+1Z]J"RVJI:@BQ5F^AB]IUO-Z"#`[7B;! M$86ZZ@MF[MP+.\#_F,&>@\EBQ8\T4FO?0IBIO0OQ+NMCJ'8SPGK]B9(H*$5; M7J_1*[&]`0Z&]EZT\&;U76ZI4CRA7H^"5"T[EM7?#Z"9I88'U!LVVH6%75;W MM9M'B!3=H:"P#:Q?BAX(_2B;R@4XZ`,7@V;#*]^IT<-9?(L%)GZ/V#AZ^YNM MSBFHC$*?1FJJU.A:7+U3Z>84RHMNFEV.NU-`AV5C]$HL&2*`BVZKY"?:#;MW MF;5@#".OW>3B?NP\^^V-\[=P<@H["3LC3^4SCB;\](RMM% MMDU$Z_R"=0-25Z?XICI<)`DL=LNY(JTH*':M*%=XT5]>'UF:9-NO-S#6E.&W MV&#;FK'&PG\5@VTM8XU]U(+[^'PC#8=,N<_#J'4QK-C]742.[Q5KR2K#%'6\ M+;*.)TB>J*Y44)@,(Q--(C(O.OTR2K&O'8)&7??N%>MP^Y)FZ9-#H`U&K#FI3$AA=%D2Z5,YM*B)V MKO,FB>,_QT`<#G>#)(@_$.]SL159PXK_J*?M$!#+-\7P1$6O[TP"_H$ZT`@/ MH[QY%ZW&L.S>C85C`S`?PEGVNXUFV:W'7A+DRZ7#5*Z>+Q3R*OV1F!E7U=.1 M8Q('>XM*:A[;1I<(C+=2F:Y6>NUY2:K@#+FL6.!<:ON-!5W*?"QK&??;]+U$ MC[.?173U$S%+&6+].RIX_Q#ZW??B=^DZE\[:&#GT!=K$Y])MJ!@[;UJ%VAW: MMB/WO6,'S,+N7!]_O?D)Y`>H9M**B4^)M(.[O-7^D'75_S/?/5&TSR=7$.N,+B2G:^5LU50THVL90 M3NX"EJQF.V4(+'GGVI;4IJVH4K&DNL-6`JC]5HK$,^8C/;--6%(D2?MO]Q9I M<+E,3KAMPJ?/'C$R'RP[0V7C\!YHKV([8-/*EAZ6DLM[J3C*7$C'CK*&J:7` M%]1QU4*$C3HX5U;]&<@*"\BV:6X23(@5EK^9:@+HPWWE^F2I1JO/ROUG6`?8 MDB7G,"@#N[2@'L/2N:CXU2VGXF!'K?TSA=]&MX]^%/P$E.S\_1^'X@*@3K\# MF3V]DXG`HC]?OT3!SA44$`[%+K`K(]KM)9LBR,W;:3QC7>L,\].>1-2M9D(4 M3DM$_X7O#($!84N&[$61D<@/HFMJ@XZW2D*.[R,C*+[?4,^$J,IMWY=JB4EG.U>W9AL)CH32`Z4VUH2R/Q:;0C1W2M\8']& MVUM,'5/M;#F[%*U0DUP0\"FHDF4WE5,I$>>IP3`T,[8RP3"G-`LG<@PF<2I` M322::HP>P^")VEWPH2Y^S%4T\`Q"SX@2!$:6B^CSBRHY6MGB7$85FRZ<&:5F MXM/T>?L-"K826JI"J0L]?'OT>RP(MYC'+`LE8._U+KDA-%GX2+EY],Y5<]LZ M3Z4M M6Q5+6+B!-"D3GRF\(VP&4>'C#:JKPP3'EH[J-/R*MV",O>OB&<+GLMW1[_1+ M`JQY'[>=C6R5^3@7K4&K(2)VBY*3S>J1V$L\FA$#@:Y4)J0B;^W=*XS.NA45AG6$0,(HSX41EJ,H6$MYC M/5U;^487G#Y?$F%%2K,+Z=:,_MQG@H*P#U:8J3J:.5T/;M)%08K1HW5`@1@L MBXW$4U1&2#WQ99!36:B!8JA6QUX;#-?H'UQ%R9*`V6'-A,7=E1DC,_\%DYN+ M#FA7$\5%JRQ^Q#4$+S)G?V$EQ'&%90HL5;;TDY&D*L)`;(BCPC&]7(&C"3=' M)#P-&$_KUF@TXT1"5Y)(&\"6I\V%Q5?="FM MPTSQ,-NFW0)"0U0ORYP(\/#G][>V6S`5?8'O4,S0B'$*:@J82L"@I)(8E'E* M*3$;Z9IE=6(FN^F\NGM1%Y#D814>]11Y6[G)T00MZT@="BWR6AZ*Y%_:6!MZ#?[P!VA=D)5@!33Q" MU40T>6:5Q9]GCT"&./]"@J.5/^8?R6(H\[40)R]OK6-`"S@ZY2`_Q(D"XV,=B>.J#76J03^$XO5_9:5T?7]_K1 MK!!24D1LI7;IJEFNVA^6I#^(%K$&CU6++BU*=5FJU&34DJ9" MXG5;;JL]J*_2V.I,61*'/BJUHGEFPVV<&9<6/U(6=VR6M-52`(SCZI4E&A>/ MRSXEM5K=X^J6)G,M/BX3SVI!K^6YG<$*&JA]7&5J<;G.IE9K5G#_]KJ^RW]7A1"5BZ<6^BZ2'PRC+=5O$0L&\\?=3S M)(R48-QM$19RI-3^OLFW+!F`@["()52[["N,8,_M#P9FIFJ.%YEE)WI`<&6XTY M=_@O;,XMIF&5]IQR&,,?C1(A$*MJ%:D(2?4[4V2JU1B:-W87'*%SK*)M4M71 M^_D[2-[AL:AD54-J5M(X*!F%QQR8MU%>0CV:\HI`8)`KJ2]C$;<:N)#ER5%9YE$PY=F57,\S9B00\ M\,U+E'DT+J>DQK]>V!![T2BX-?D$'-C',:)2UN&3I;`2B(M+X#RWU^JY@V93 M'J*^E&I-!07ZM^@>F.F_E'0.NZ53B!/J=$?#&,<,;`6ZBW1'6PJEK$%?DL]>Y37[_/[6TA_9`V,X4E1Z M.AR"1(U6G[C)WJ.8G<@9+"A"\4]ZXJ);C.]I]<=FQ9YI,-P9JGPM/B!$`ILT M4K>L6.%,YQ4]C%0L>RER6AB=0RZ+LT99B8IJ)@98: M>Y)\C8505>A,K7,79,]X[RA!1OA(L?I-B4,169+08@N[!(LP37N)&MO-*)%@ M;$K]8IJ``DETCV4%Q2+:F7$7+WHJREE$/UJM3TRG2599RF*!AM(EQ> M_4:S^:/)T;&VV]*2V"N-(;4PO0-5@LA$*KPL*Z?4D2!7$%:5AXB9NI:F#L?6 M]QI>OY!U6YVQFS]`F;G;`GRTU7<*XJ5X\I7IO-:1+LSD5:NLE=*[6CJOX4RM ME]?KW)A1-$V41":E#CW)*`P_JFJ:3`'`N0X]NDL\*B5'I47:U'\I>EJ,`"O\ MKT'OX;V26T9"#24R!>=0WSG4MZ!U59#)SEEDFJ;D8`#N)9*)I6+-7C7VB95S MGCMJXQSG:/;Q98:!O8SH?Q("Y8Y%*V\&(!C0,V?C.83R1:-'BYJ5J=X03CS9"5`6$0#>1E,&UG22$`]QF7V MK!B(G?'@<$TWUF:%=4Z>8.XG0;W017?T.,G;<08YEQ12A(E1"H>F5LR]>S3Q M81=H07C4S//%>0@Q75\>W;,EDH17DQO"B28?3)U!FDIBE9D;N;N%_E5N($KA MHJ3T7'\,A/K8_1"\^:SF_&W@YFE-7./UDU@+DED\S^O!GVDS\4 MC;)")'05H\Q:<*%5ID,*%7D+%%-14):;95Z[+#&TVB[+.\C&YA(RO>"B6]JC MQ^Z\(JTQ'H=B6V5@O7#3?4M`@;*.F:246MO`K'NX>1^NWWSZ[,PF\]3Q>ET. M-H#N'Z*CYY51D2:^97RBV_!:W?PWU%KM?NYC;!KD/*V"7*TH;V=89I"JX!F[ ML42+F?*LJW:$K7(^'LR18OLT1*2&QBD5O^X52Q2\[ZO:Y*>AGU#5H=Q%U$+ MW(':3.Y[DE! MX:_'SY%#6F0),*J`#!.W>#,9EY*%^NJ(K5LY`YVF4IN*7I\>_#@.[C+65^(D MA(/!J*<(:>>^[V38IIZ#%Q>=TB9Z2J$*OHZ"8$R6!BJ:[.SA(M^^GI!$39=! MI4%M)Q1%7<9ZXC6E[LK1)Q3*N1B60L!;*6U48^*5EC+U+\S+R$T'('%4^B74 MI^`WFURD!^M1U/AA*R%0EMD9!+^%V!V:AQM@.HAHPLE^)/@KICO-$W/[U#3) M;([*LR_)KT(GRG$E5B7V)_.7=/^VD<)-*;SA2BW*O&^H< MY#@'.9:EEY1)H$$9F>?SRVRS.GWV9\Q]_9%P>9N)YN,@!<"EH69.1WP,Q@_R MRC_Y2>C?<==1X&0X?9"*[,E^N)_$SZG9D8R?G@0,@+'47>;,)OZ(#1,KWQ3= MYOC/>Z1O9J/JVP0)>Y5]8(E?,4%).`PZC5:[^Z-KEJ8`+^64::-1N]?J576Y MAZV$8KQG`>',6KJ"J^M*$YFMK["J_62+$XF+/;G:LJ$;R;6R$BINQ3XHJ:.Q MF]^YNH+(C"FI-G`RUWDB#C+4,TTMI1,P/J`OU$VDM&;+.LR/``X:A%G0Y.J-%4 MC7)^TS+5QV:U#^)LX<_O;U$XW\^!"Z:,#EW:9M"@<.&QI#4Z(W!O'5(7*&"1 M2V1J#AJBP4))H8H)#FV9*E!*29@R:6$E,J=%<(DX]]3_,R@R-30;N62+KC.L M=Q?<8V1Z\0WT/!T.PFKQC/1M(N@XF>+8>+0WS)P0/9(.D'8?DC(C*@/NQ1`U M^>VF?0TQ9,17$&1)X,J`N3F^QCRP MXF*+^078H]N[@:M9PB4B>$:-IA:"FL92>1T1=>U6S;H%4<=/_A$>$6*,06%1 MKH^KT+UE[1*8)3R/EKQH#;BD<(TU*ODJQ1R.C:LN&N=]&,Y::,RL^IRI_MJH M0L@R\'7*D159433?=SJ=QC#?]T%]5C8'0`.L=O<&:AG5;G39E6.T9%J9:"!QA3F MX_+Y,A_S=(D,#!M/=0%@/A]7?A+2G42H'=!I+B/XH>(Y)=/+`]G M\!DT$@FZEK"K^2[-LIF`90T=A0U7F)ET;59&<0,99NE&WHT%2(VIL%#7'O9,9FDR>4L,;P.2 M@GC6+JZ<_>.UMJ\'Y+,T::&61PO5"WVO'FK=]B`9N&\XN!(X[15EY%Y%XP_: M^_6]A+W[8HC,RM@X=-Q@D\AW'Z65W*]S)1*R46/46SZ`:]^`222)"U[LA,#0 M4]&7,N7VOY=S,B3L%T#WN8N?T.F9_*G&GJEX[T,28WB67B^^*UQ5E^2#KWIH M47\!RXE-"VHNPDF):#T8DW2-K_-R`A!F6X-^Y>A1KUW6+[0X'K0VM&6,CW66 MT7PJ'8RHYX7_42UY-/2T;G$'[7Z9?Y0VT"XK$\R[R@QR,-WR@B9H4>YX63CM MRI,VOK,>;FA5Y2Y$DQ\.JC(N`3\MVR:EE#)EE,,I#E5,GM?:9XD&=<6*JFXT M)*+8^G0.)9]#R27RYA?A M"UTK6E"5C:\]?C1^MAAM+.]L0/19X1PH3?: MO(K7Z%W!+;64?YZ17;+5VAN2-F"YD+3*OTR^7C_U=&6=;Q=II^]$6Y&W<9JE M;[FY!9K?-SBX.!S+(9,,X?>BE0^,9-1-$71HKKR)HCYH.#Q*FG=WB/;!Z\M] MOK_BNIK#-'Y>1:Y8/[-CL&I'!#^]_;/#>Q\%DTDZ\]$G^=1QO%>!W@#RV;S]`51W-5"80C<>>C9Y7UQB3B>Z MQ#_Q_&A2:1(]\)W;E("Q`C8-SL))14-UJ]7G>HFORM54T):V0"JFAHB_7RQ_ MEDHCZ.%>W_6ZK3TRB,V@';C==G?+M[[>[=Z$U&[!@,(]7$ZP,()\"65T)WV^ MFOB\9EDZM'!(-LL\DOR1M;.S706$LNIW0+*K$HLF@-;0;?6'^X-@`TC[;J?; MW"VI[IEC2NO=2`X9H2%_5!3B>6ZGW3L%"@%(V[VU(3T8,S/<-M*+A^$9;'8A M2ALYG_7H**/EMCK]4R",EMOQ!M\4YS"R(52CZB2DPBJLLCTN.O':[M#S3H%0 MAFZW9)Z)QM MMS]86\)5$$.)3T0.F_C9!:+4E!1BF%T@FAYI:5&E&I7EG'JC.?46R`'-4#,_F]\LSBT MJ%4[16_K1V!8E$F@LRH!^T;Q#/?R^?<\SJ@4G#*I<#I/[=RB;66N[";=Z"[[ M7K*(AE864>F^3SDY:-AP<%=$?0=J3/>[9#?.;1!A%=Y;:L_N_,(552\$S)[[ M32]H@B52MJ-89^$;;7-%*O1%OUG*ZY+@*9Y00RR;R::\G*\( MTC")GZFRU$CBME]R[G"L8*[BCQ8!_C,5'8->M1O8BJXZ7//:X=EGDW!$`M#H M>]QL])L_.J^:5"N[X`O8_X[7Q:&C&C[L"P*"HMGPX/T9#3Z,YFI(`O>,P^Y> M(==9ZHWZ>F+[%[5O6D%]>^ISQQ#X6%'2>5U9U?Z%6@?#H_@.U3UB,]L[["&2 M0NBRKB;]`OA'VV#/[3D4(6LI*L3G.V:M M"]+;05K^$_@(])LX&J?.#=>!'/'QT[@4@E75K"PA@FZ[9V>:-YR/59]*`M)0 MY<1)/$EB!:UFNT\#<"TB2!T<(DGM#)-X2DN`\C+X$17H0:/79G+`CTJA=_=2 M5>U;''J='W:";&<1V9)"WA\.R_I,+!QR6YO::?6J8T!<=QOM;O4=L.F_MR?Z MW^+$R6?1XB`8JQ8&U#\4.X)2,P1N>*=K3T`"-T[N'!-#HMR-4X`3$;@(BJ=)B%$F@"I3ZVUIE@5]3O MO`ZDT_F>:B?.>SGO9==[J1]1.O84_5RI"[O5M+:RC]#/9A"S^^&4(,X9SZ<` M^JZ"\.M?F*H=6`K(:M4[_PO&Y#8/8^?E1I;S^W@I:+W-:7_BM[8STUGVK>WM M"WHL-M_9MR-?OWW1ZZS<[:573[!+7ON9W!2=0, M=+RFVVVM#6J]R[1_0=8Z7[0-J+?E#M>O5MTGI%W/]=HG49WEM3IN<[#CXIS= MW*7V^2ZM#VZK-W0'IW&9V@-W.#R)FMAV<^`.UB_?/5:AU3E?M.\&W%;+]7HG M<=DV@_1@@NO+8Y`$_GT6),XK[_7Y9FW";8=N_S0JH%O]CCLX#1G6'733.GO)FRZ[V=5@*'N"_!_^T[,_;):S5:?BFKE MCEJETU"K=S2HM2-:"W=5G'Z-[;1I.P,YF*O5=FCT=VO0J$-5"R^O MVW]5AU]BDI&Q-KS:,?866!,Y?AF-3D-;57U M2;=PR'+R'7[CC9/;&W(D+A;#+XJYU]3VA1H=J!&P%UZSW1CTN]Q0`4M\F:$% M_Y[[$^1ZUJB["$?V4=D>X"6$G8F^I=CW)<`RW%C,4U9+4DN#5Q?-1AL6>>W2 M?&%?M%8H0,;P=!JM7JNKP61F*"MYXVCR0NT+_/21VAWXV'YG/LDD6]5?=9W` M!U:N]KH<:<\^[P>8T1.6/N."@(UP4G)J'5$'%D:PZTZCZW6;QB%AVPC85XJ? M-8;UHIR`6^HZ79!<_5:?5A-O46,&L3(U5D+LSV9)_#6<`A9AVRVW[75Q*F_E M0LOH2U$$T=@0!*?X$H'&\]UI@+KXQ_H5WP#%-[<=>5#XL,F0I,U_'CALDL@VTO1F4F,28_O M@2Z19.#X'Q)_BAU,&"I)&=@>*P+>GX>/;PL1/H^_+-)#5]76"V#G,[KI9GT_ M`$Z4EJ,VO1G>""M">8RL-9U:,,`P3>>"U:0@0^P;0,MY+J875-\"8GW%^G[- M8MK=1G=@\!?!0!!@8"Q1P/TW8-E1$(SI\_8UO.AT2D?!4MA-G@0X("ZPY:Y!=&K9MFA-(U#,0;,>\,]3IB':Y;.<'HLBBDI MY(!`0M5L#22E++,.(FYW%WP-4R*?U%!]$&]P(J-'/Q7&C^[@4W&T=R^./\]` MFFIL^YB0Q"6=NB!$F"R\(=@TB46^V"7&:U!^D M^Z/KC`,@YRF)`X!KGNHV(A;S@QL#*@*8_[J3$(*&2.+N1FJ=):U06C\6V08M MMS+KL(FQD^=A)BJH;0HR/J,1CD&38#P.%S&*A4RBK+E/-1V?6VE8W\E9"/4- MAM-MI;$-VV"IBNMRUQ]4FY4KB*E:Z:2K?&X5I=74=?,<::PO/ERW,!XS-RKB M0\ND2HW\Z!M^=)J>\^G&^3T*06$43`M8[,=?;WZZ^>T-HS3X"H(C0D^".B8T MG?#5"A1J@=E=)"_+'$*U71.[!,DM[NP;=PEYADNH.S/_A10Z_]E/QMQ# ME^;ZCLG*0D4KQ.XPK-EAMZ&0FZ&A@U@8TG!9V'K&/KN!U,O`-KL<3?PT=:9! M]HC,3$PGQYZ+\TR-!`&S:2S'G_-^`C`21IGT M6<^`>*,L-'17+7]#*&4LH1Y);0Q<)[PWX1*KR`^[=40?@XG*IA*E\0*A:]H@S=<(Q$^P MPT\WM#!Q;QEJ();=ZC==KRGFRG?:K'6:VQ6]F>+Y!*,[&=IM"B_W)?/KV9*O M.ZD'-74G]R0@==XC&NV`2/Z-0X?-M]0DZ8P:1MN;GN#'7&;C]DB>410?K M]MRAVB&*_&`4\F(4[%RT6_8:E.RXQF[!^H=504F`]Z=D8E)`]][?ZKSG/)3W4O]1*5C[].0&U7\IMU! MMCC]_=M!YGF*^GF*^MI3U%W4'(-9AHK*&6>5../`!0?0SUUW%N?^2IQ]G$^# MQ,_BY.<%OH']L9WOX[F*&[B=\L1V<]$07#!<`O;MHG5G0\SY3C6837K1RA,_GL@GS;+O_^%F>G%7;;UNU/3.B,R,Z$49T5FS/BNWYN0,IMK6R)=X%43P-HW.^ MQ#$>_)XU$-8Y"A75Q?*,`Y)'2?C;Z[O-SMHI"GL%M=ERV]WCG+BTB##>J\(= M776CXH?%(H#C.XK3?NY@S**S0(+;\="8<_,0=:B'Q4M>.YPGRZ)30`=G,-L.S#BSV[1(]4OI8OS M]$R/H=OIG8:$:7;<3G/;.L>9JYQ]G&>EDJ9UMT!1='=V MBAX;I>Q`_UA:1%9(IO_XZXW5*TNTNMJ%<-HHLMEL+"JLV97:L7]8#\9D%JNU MI8'Z`Q+3^OHCOW4RLQ:!EK8](_JLZYXMZ*.58`N*$,^B:A>PKA]P/+.7LRE] M-J6/T@`Y]N<.IN762R427MRS,7T,SQU,%?FFC>D]^OK/QO39F#X:8_HE_GXW+^Y52.=`X`"BR(OQ$`LP0'Q_/,CE0/[7"FX4$GM=LX>$IGCS17%<7/Q+27$)Y24EM/ M.OW)'M_27NH;-R?6UOX\I>0\I61/R#Q/*3E/*5E[2LEYXL8BW]=G^*<_$=KS MT7E`#Q)CV;`;:.LX6P,L(H)K:5BAB<2S-W=&$*N>PLD&W+SA[OGR2?G#*WCZ M482IOI5]U&,A^TXN.H;DLI/G)^U.Y\Q03N8B?BO[.)A.\OXKMB0Y=R8ZEB3# M/6>**94T8#H@U=2?QDD6_H?[U&`C*SG.Y#Z,_`@]MG!ICFVRUXF)F2V`NU.> ML3"],#"FNN<)YDP4ZX/;&FZ[$.^PW.5O010D_H1I9#P-(YR]Y6-/O#.5?)^L MX[=@'(Z`(N+[^W`4.'?S<#(V0I_P7T(0G87+45+(V98YVS)'*XK.SI'34U#. M#.7,4(Y66SG%D48G&,OK+IC]^ETRE6U=R'-)P[I$M)V2AK+\^$T3LG>21A\D MX1/9Y=<16.AS3'E-KZ+QK\$8/O!P-8*?J'_]=Y-"WS93Z#?`SDFGS[<;CM[[ M(5+FW\T3=`D(JM(WN-5L#CB[>E'^M/=!Y\@N^ES_Z,:#WQ1YGS*@T"(I74Z9%[R^N\;NP;+U?S MA[G()KD-9EDPO0L2"TE]%W%@[>L>L];3\.LE993"_0I\(-@7AZZ`_Y`$E.\N M*@KB#("&A2Y:W6:CJ3\-1#LAWR\L7FQ$3.B*[YU.`Y20'QO./W,@P+FE@;TR M+:=7Q[QXXOR89O\(URR@PT;7T"CCS_#)S/P7?L%/TQ@]TM@8F4\;"Q!$_`*V M3`M\&F5Q`45.F*9S/QH1R!?M9NE&X:>(#IOK)J8^T1=`"7RM3&).:+_P&KW"GEQ9'>1340E> M1"JBH8PUL>`4=O>(G/0I$#ELO&GCK$0?&RI)N@N0C8@P$=I/3P$7H$S">TG` M<*9W&6V0UG@)L6X)F,9\A/<81!$S/:;+?$Z\0YJ&WDK;PUOD-8E8,(V7.*': MS46OXX("B;_28A>]/OT;BZ^,6):+J)XQ'4U>F),1#T(,\L>Q/@EQ'SM_G46"QPEY16F3/,=!(JUM"^2[^N$2**#XN MQ,EV>#E`/K&5@9[)Q/E`VY6WN9*1>Z6,?!D3I^7B*`>41_2'*`65831/$KP1 MLI@/:]@HBJYX2W36N4\NU=\&Q!@XIOMR3?=BZZ M@VWS;#ZM.*]9U3Z+BRY4OY M3\,F0GI=[E&J5HY1@L)%N/,GI(BGCT'`VJ!RQG,?"[B%X91H^-X/$ZVU@E#V M2EU,)9"TF^PD:0`_PRL0!:1P:`W;T&G4\N).;KC'2H>-LC`?(M*7?.:VZR$T;-2W:3)?J'BVX;^L\?RV+IOH:US!_^Q0J<]>PC$;Q?1L(<0-[=6Z@(+OB M+FS'6,E.JHSJTIM691OE+IC:]U9NVJ(+MKXG8BUS2FULU9NV@4VE>?O&-^UP MSK"R7CNR[Y"@9B2)>:8J(DHI)-]41^'FW%WGW%WGM/=2/\_FQ%I8G+OKG+OK M[`F9Y^XZY^XZZ]VVYF(\GMOPU,[7U-W*"YK8%@YZLX8VGMMJK]W+9-_0=IMN MK[WMM-W=5[M_JK3OSO7ONWZNWJ'ON4+UIN"V7^*)9R^\:H>[R,&_"Q93(4O4 M)5ZOK.=5I[U@`D)^47SD]?'NI>UV%\U(J+6;G3*H1?1XE6N]@%XK\H0M3#`X M#2+S%HW9.#$B\Q:UG]N$Q$Z]=*4"[4=11_:M[.-@DG01/;TM4:H.J%.5*-B@ MLO;W.#5W?4@[/7?8VW$GD)U3`.E)KY@.7FMH\T.BHCBB%(9X,C%G#QQ7^P=O MN/9,MRWPG"V)K$4S#L\2ZS@Y_;>RCY.16&5#[([/5=1T![V3F?^.TJQ][JEI M/[>M"WNN\%Z7B'97X;TLH7@7:=R\S!?_ZW=3H=TU4K@7[?[0*:D;I6]W&R)A M&_;^]2`EV%P/$S^%*0V.BN^I_.9+/`M'3K_3=&G-$)\L`$I_E<6$HXD/B'RA M!!E_1+4OJ.]CSLP\&@5)YH/J_P)2F#8BA'&&WS+SM(`41`]2?\(YX*HVDK)L M1B"[`ZJSH5?(BX:94BG.GE75?E-RI8F*%R'O.7?+_^K,8J;)%/[U9X#U:[I6 M+:/A8N+O$:R#+R1!-D\B^&'D"XM75S`5LMT]F;?Z,5;%-I37?H<56BHGB]%B M)JC!0G=!%-R'F!B76!EF85D/5_@O?X)U))S]!N\3GY.Y24%$;??>!:-\9BU# MV%4I<:6/T+H8OY6#S.(9%IC%``+<+F M?[+J#/?FS[/'.*'"%[.>.04Z#N_#D0\G]:]Y$J;C<,2'8\ZP&\.QS-,0*])V MDS1FW7Z9+"/I_M?`3[+'-(NCP+D:_7L>,OWH*["WN_HI7]1IYDOZ(QH[R"BG M>9??KWZH/[E_>6UZXQ\Q#L7.,./ M?$%8CW:P3)&'T7U^?_W%2>=W:3@.X390C86LA9,ID[[&'(&;SD>RUBYVC'6Q M6H*6(ZJ1ES=UD65P)Y7\TWQW?-@;$@W>GRC(Q&3!AG-#XP1%O;L%!.[G694C MP\6G(M!674'OBUAP&WI/IKH?X'+9![?QT\?4O/\]`V""\:[])/D1=7RX_[F ME)8JV88J%$V)7_+[@%@#(WX487WJ))R&F9@V&$YY'N4=%WM>?WX+/(`P8C`5 MV)[SS\=P0J4^=\$D!&ZAJD1A.02>ZA(Q0(=5/"[/R1S_:YYFJD2RY.QI36;2 M//A0#ST41U]Z:9:R+Y!A(%-&CWXD2IJ9G]-R@J@)9MH#X]B99^$$KC5ET!+; MGZ>4OVP4.%-5CRCUI6S@9E\F[@Z4!`-^&(["&=(;74`'\SE9DU)B!64EG]X+ M7/)4%C>A8DN$@8UL*^6:35;H('0&T;=T1-(\GB>,KV+HF@:O*DI M%_O]%I?P:2@I%\R*C]`R$_]9>PK5A;#@=#A.?Y] M)O+,RXG5^!X=M,6S3'"?B6I129)5W7$T>9$,$/!B).QC=U[$$^?.$WS!5Q81 M?(JTREBT>[&8IW765&``I_!GD"M2IYUSGG_)INB6C-%%G`D5C!E_+"?<6K-R MA0!@)1$_COS;1'-X+V;*6F?$^!"R*-2[(IZECM''_'Q@&SXC<1+Z=W"1LQ>7 M2#V*^N(LXD_"I0F59&6SR1^-4+5#Z[RY,4UYO)F1B6W[L-OP5#H MER#J`JVSER*SX?R-(LK4TI#Q9F`C9?JCS/QIG!#_C>#.:*#SU&@B^!E$$H%L M7QL$IXH<&\ZO\3/\(U%7SCA:.D"^&W?!/8,#AE_S$H$07!Q/%94;9$%P_22! M8,K&),"N`[C*I4)<\)7Y];DH\ELJBBQSPBQR">S"`7,;/*`2\ID&7XM^?M^% M'Z9G^&%J(.'0EV$C=PR()+%%4`N!(TU]9>GMUROS:9Y8(]EVH!2,48&$@N\TY\\B_OX>_L:9) MP,BF+X89HV$QC!GZ]@//FP!]QGA\ZH/&DIB/BAVP<8'$?V]T-HGOX)C8SJ.^ M.R#3!*`OAG5%\V\HO"V,3O2"$,2C`*OE9J#R@%%*5B#:IG`'J!Q3:M8C?Q;B M0%!RV8#6"5X49(:\)W#)LJ)6'OH@\,#2KE:IN@MNXZ,U]T*F*5RT)H^EI5 M4)+K2OF?L`:('8,UZI7=96="3@/*&0U35CDF\Y0AA"U,>0"&V)$U!&./QL[' M.+J4X"9LUY(]#&\#^T5!A:X@A%#YBC$$NF-"4@= M:;D:CRK>2!Z!>8)*)QFA;!T0@Z/KKC6M`CSZ!K;'/D8P`DM&R59KLPB8^)HIR17VS/AENP\4,CGQ6%/!H M]YK"VR5^(2Z@&)=@MVA$II95FBJ?'YC`\3/L#/<+(!+"58,SP9B1:(4!-*9F M=PFP]`F'`]"X%+Z?L>7]%I:B(]I'FUE4(F"1!-/X":D"C;[0Z&EOO)+K:,\, M'-4X[B%6T?T>]*'Y%(X6`S=*'S)]1=B*@+\CJJK%K1,FH9^*PNN2^8,+C`H[ M&^!<&GUJY<3?TE[J)Z@V<2Z//I=%'7T%\+HW^+@@DQYK.%<^U\Q=% MU/)V>1Q@>JZ,Z>"QT6QN;^P6TW=XV M3SCU&H8*'>XH"HZ^E7T<3)PL^5V6H-3T36&?;R$YUD64]N'3$5X0C7GFOSR;JKI\[2MOD;+Z>GOFZ`S(X=A/5:[F]YAZ) M8'U(A^[`6[N/X%FE.)LJIR9=3M14&?3@HIZ,I3)HN\/UA>`WRE:V=26/PEHY M^LV4$=%VNCB<,XS*WSG=K)QO:2_UF>>QA_%;.\N%V1_0LA_".8?GG,-SSN$Y MY_#LP8BYHDSRLW]TU\]5W+5S"@\P,[?C]=Q^ZV3;:#53KJV0G MY.PK?\K>SC8$+E1'WD;7?@M=U>YV34#@2V[S;[YUQ!^[EM7X,>_./4<*]646?T'=MV;7O9%WOB\X[ZV MRW_Y=>V9+8X,`MJO=[JWGJM9RBKJQLGG<]F/),>^QNH;@*B'S`W8\1^A=BDSL]$APFSSM_L M`T$%^O/$[)-`#>L"^#"V6;RFLGU\HK)Y#BW@8SL5HP]'P_E%O+>L\8NQ%'U$ M]/&8AM$\7=1HI*3A"C6;21&;(US&E5_CMBW\J4*_$OJV:+N7JN[#21!.[^9) M&NC^&G!,4VSJD02^V2@'FV)+2`Z!G$3XT!=V&:(7*>`FOMR@8(_PQD*PEY$*&`W&A-(YY(Z5BQ&\(] M]9&C'M(&]>9:&A%9<.=:;G`=/X5C:H@]`1(5;7:`:._G$W$4N@<#P2$I.UU` MQ=Q@5?C-2A!D0@ M=_8`T/P)M;@EFL>13$$F;S9UQ<_!0WG2K6NQ=:7X@Z)"X,@XE/4&E*!;VZ6.]I@AVGJBTX_1M0`*)7L M.TR84\H6E_>T"#>;O,?67]0+!A4A/?(?@PY?^HH1>C<*^>ZGOW#BQ8/:Y5\ZY5\[1IZ.<\VR^"P(YY]FLZ_O^J!2VXPN$>&ZKO795S[ZA M[3;=7OLXNV0L.G_5I%9WG]T=.>QHRN^2CAJU!OT>TVX6MMW89&SQ85E-OA_R M2O[-'9#C^F?4:KO=?8['W@#2CMOLG]Y8]7=U?-E'11(@K(:]/0JK#2!MNH-V M:[E\8RCHA605X.3**O&*=:GQSR,@91'*#L\M],YB?9?,BKGM;ZM MU*]KHQG\P@D#)Z0!>VZ[LR"W\\0T8,]M>IOJ\P?C/G^CT<`1*+)WJ.EBH!"X MT>..ZFVSD8>S*E7T5^SU&I2UNXV\=#.HNZZ&Y"-J>>*5V!]:,H7_A6]G&4$JXT MMY5X4\D`I5V0W+F;T6;D<^J<9UNW]ERCL2X1;:=&HVP<`+_ M3>OP1-X0"T22$,LN>#[OU,^R($EI23DM$[:"A34T[=A)`9?A?3C"E'Q=A2-+ M!F"=]U]'P2R3*=PJ:]R!O09AI/!%`TR?:?@UC]QD;!1P1HGAC"+:LE$V`##2 M&CA$TS6FG^*PWL3)_#\#0$S\$."',5L7]@9[Q?#*^"E`''&5!SHF3%2YQC!0 M1I4>U@W?U9N>QP8*!24]P7&KA$TY9EO=VA`#,5$4$*KX&1^VA->?G5A4]Y$$0?0< MQV-,II(#U=]2IA=^X%C9B1&,N-D+A+8<`1U_%SQ/-QY\9@=R[PB:0+A1Z@=3X$7X%& M,P#*^-K?P*J:-9PO>*\9=3Z\GU&IF>.U#58'3`JM(C*'))CX(L[JI4?4+>99 MP/?AA(%+`CWH]XDG/,_@/TDF/3_&O&H0$N/X,YS@6S'B^%\TBEFP1;D:ATX5 M5&D0_(ESF^&Z\-#A:1P%&1;)C/VI3X5M\`[5I$RPZBW%:JC@053RR`\3,E,P M_@!:7U(^C0DF`!]]FE7\A.*`AIS#[L:A_Q#1D&"B'ZIV2U-B(U4+!G$2!HH= M1<$#W`GB`?)JB1*S8!IBF:'F"?X#>EZST@-TL3J!OQ`GKBA'DVP;Z2-IE!_\ M(P[^I2/"\L`[/_HSF<^RT0O#+P6(/DXK,@4;P](Y,0V9[Y$X*.,Z.+=SFO2< MP!_G28;*R&P2?'6T['?>@8X59+("[N]SX++(5=YAQ!P9KKB0\K9Q2#TA82GE M+[DK+O4,5(MB';Z,O_BJG$I^E!90'^:%N2X392:<.'Q8 M?[/A_`;BAA$D)MG#>R-):X9TH!HT9AN&7&`R\)&B,ZZUI=,6$[K]T2-?*Z\I M.0[<\]RN<"%QH)-P&@H9,&=,$3P)'90LW=3$2JH-#VD'A,=WB#-"M]H^UN7` M]N'^.A2;XH)7N&G`!^`"AJK"#JQ%/%.X#G#/>%/$*Y_C`LK4$:3SNW\)Y!0. M5.*=F&/T$$N)#2(03+(4J1`UH,F(E>8#S.P8X'(6"M^ MIM):\81#+`]8(+$35A>EIAV#+'#I[BN_B&1^0H(JV3)/Q4HH45,<9I^7I"XH MAYEX:!P'0O;Z9*G`I49_C5Z&F`8Y4;-26..[B1`!`LPB>X;OXD'27DI$H%I* MX0J$,%#O.,>!RQ"%*HS^$C`A?XJ+I,U&4RML<$LF2L-%X8@F(DIR M4L^!:2#[D@<%*KEDI;$4B%523QR8%GMJ3TK^`2/1FB9C9I3$:7IIRI`\HY-: MF7Q&"W&L$1\C+U4KL8K/[FXL1)9&C:AT!CI)'K!\_MY_BKGB%U><*[T*SE[% MQ/I_206/E"7*@"1")BTG\$@+/3R@8,V,0\$ZRR<_G/`:]@GI(R9=!6Q,PIO4 M`-1F6.4*[^]3`R934*.)(_XYCY!@\3,W27S/NAL`5U"OF)+!8MY':-8C:-,#B:=B[;.H`-APIFWR:**"U8*95%NW+,%LS M!0!=OV`L_B(PC)3=;3;=9K.)M>+\OC1_+EI=^H55H6!R+WT40"'$>E"5DB]) M8M<_D?@5SHV9'XZ=\3P0YJNA6^*V%-K*M%+57,#<#/(O(*M`(+-P_+5.72TK M_YY8N@)^+_6![ODPA=)CGBE9#^)+XEN@WI7M#1?7UTF"@#@% M"P;`2K&G2BPAXAXOL:&"F4O`\=P%K,>A!^`N@.,)!&J$8\!>BS)\SF=H=5L M<"W9]H-H*Z_6TS7-D*3"R"9#)''\YQBSR)A'*EPK7SD2!38^<28!/2&DU$B%,_#S%ZW&L*"F:;8; M)LY%OUNBR6%G)8'3">)4*\<"N=/;/4!:`YO)>NM3(]CHL5[MXE7)#D!QORL) MBIA(.<:0I[6;W]XX'SZ\9:\]_L0-Q+YF`?ORM:1,UB\OBAAH"ZG_084=:_Q5,D3"7> M?FI=1([%,;8NBF>2VJU69%7]P!K.NWF"E&3QRJS0&\&A6*[&1=MC8B4L(O#P MR$6SX2VX7CETH3N;OZK7UE^]:#?:Q6^1#]LD?U9"1#\S)0Q'_HQ8NM&FZQ-Y MBWWJRF_VZQ)A#*WMF5Y+>?72QR#(]BKH290NX9F*CEG^1Z!:4H,G_/M-#(?G MBY\5<9.U2E`#>DL(&U-TYXJQ%&@9?NXW6MT?#=,U#4:D\X/>@5UDI)(XI7$K MZ6,XH]7D9RB28H/GO`)]4T3=!Z\5-:Y-A+R[9@GQ:'HK^\"%5R8:-J0W]G97 MT=P"4G,^1<[5+`DG&B0%*:&&`B[E,)OP/@N_?A*0C67@>OAZ?_1\52'PU)9* MXFL4:5&=WN#UOX43(*G,^?L_7)+KA;(7=85%_4N.OY-(UA^1GIM!8U!$(34S MB\G4TV6\93="RV2\&G`!7$$;^,)%K^S;K"S#"J"$4LM%I*)0>.J0OEBE3?-B MOH1R3:ND:1QN=^]GFP-NI8.]\5.P&8`;;'2RQE?DT79[C>Z*9TOGH->K$.6X M!5@=K3_<0+O117V!-`'5(_DQ4E`=CW:N25OCXZ\U/(%,;CE)^*3>H M:EGR7E#BS;U-A>8*9I-,$QP0\]FC`:Z^*2DF?=,#`A[RVCJ9_Y538C`=S]=L M@'[40?AH3N/9`*27P(?O^O=9WEV@-LT!3@63JWQ(JHDM>W*X&0PS*-\W;8CO#K=09095!DZ9 MU^]M/#:BSF#Z458(,,`9Z`9D):3!9&(<7AJ8?5;/D<)O*%)8EA"\6B;J+G*# M/P?H\QS?8,KC%WVEOY_$X(&1&+P",@Y]73;*"AY@$BEMU:&].N9F#Q#UO@;; M:/XP3S/#==9L#ESG7=+0?_I[<'^?!"_.YWGZJ+V#W'Z9&R&#H*(6ZN4?0Q5S M1(FP8Y7Q`U9SF4;I=#J-(6AM2ET45N[M&\Q!07T`O8",C/PY7N2/[PR+VO0611:USX*&_!I<0V MC/EBFAA:]R7?WVM>YVTPR\C54')ZPBF%<:TD>\"X&QD*AL?"K^4B$QX,EN(4 M]B=7GFF40$;?5,>;.ISMVN53UJ#0 MC7CD-N+J)"T_#8?V.3.[A`X4*2_?@IY?@._0(IPZ"8>`7V*=#-,&8!][)9T2 M_[NDG&5^-Q^UUA'EW.%.W\BK2OXL?(7/5V2&HG&8NR:?W]^BJ7L_!VT.$X\1 M44J_94\>+<>=T5^*5]8^3'5OV=]4>7?3Q7?W1BK*Y&@F#Q^QJR[[]1CNH_2" M&NY$$_T+;[30K2=H15F>)/TCA_)+S*5IS3=1S3 MOY\D#-%CU!1%HG!&6\?_1"G47#4;LS,QSQG/*-%BY(V M)S/Y7$NUX?(6$5Z#[Z/(8:U;D@-ECL2)$&N*,%P]L8.<_Y'ZIWG%I(\!:$JD M1"1S>EGH#73E*`.0TO\,CPI7%#S5UP-2K3YH'N":GFU M[S5^]B?&3T['-)FGDF*T4:PFNS/T'5F:0=R.EBFG2DV1"^YQ`LX=94.Q(XJ:A4B^8)E\7)U*$CPI%C MHH:R*+F`BES[-H(\MSML469P^NCCX"T,H<%KB!`Y*TJDN\**/'[KHMUM-`>4 M%4PO*7<#D5]V"91V"5O!3'97V4UC.F.H* MA7$0_GR%*C]2PB\3_V$5MGX/.G3PWS\5OJ$__99MDU]`:OF3_PW\!*!Y)V,Q M-5>YO/1:\"]>I^J#>LEW\6@^58_<8!7>^!?X6[K*FO]7+%?YL:KU$*255\/_ M6[:>^EAQ-09E#6SB_[ULMA5"2S]87._+RVRE96"1_VLO@%_0WWU/IAL6]";^ M!*.=7_]/\++*`M@,I3]H-KMM7J;T@X7U:!3D;0:WX98N^R=#@)B+O^$DEJOT MT_T?S1XP%%H49$S(O_/;/U!5R11NP5]_N/[X"^S:&_:'_6;/LV!:L&@!0"9O MU2GE-O.SU6CI?X/46KST@_EE?PDG0?(6#OXA3E8ZA0]8(^-^F8/--_IE$@MCH@S_[>;?YQ&FWQKX__WV70'YK5ZOU1HB79C+&ROD M%_\,2B"VIXZRCVA^KK#MCU=?KC]]_.?UN_?.K^^O/GSYU;GY_.GF_>N/;TT`[%7R,/PCGLPCK#4C-*UTTA]C"G(,7' MUR@4DPTHJ^*+O'#T./L9J&(^G9,9\PX;6X"`2*L/V7L7C!8?\F4;9($WZ+6& MPQX=LWNZW^L`P"M<;:$-1" M@M=O]_K-05T(QO^:I_"M,:CEF$3QZ>9W^/8CZ&)!(F=1I%]BQ:O&P932$/_A M3^:KW,LEY];MM33`FX"TBYW1$+??R)_Q'MT9^B3^T#-*_[@!R^2/Z^B/M_XL M!+/HC]_(Y7.`C9MS(:ZB\94Q%8)7$&[_Y1M<1NQMSVNU%?BUUMT$S`THK.T- M>\.U(:6Z5_8:I=<1-B%*X4*^]Q-T3:5H\OQN]4C_.V;0_8/S"-.M8+K;-:#? M")R=;&N#D^EWO:WOC)G)LM*O*"%]*_B]'`XL<&NNO3&\FPBTEM?<$&1F]_+W$M5@ M773VVNVN`5O9.BO!L0&:>L->NS8H(AKSB?Q?,B3S2?;%_;PMF>;U>ET-U/)% MUP9P`[RUO);!-5>"4:2I8-4F77@SF+&I[MOI=YN:[!LV>(B45+;0Q0/3-AV&\9EE(]@#[&$09>PJ2)\3)L,G^[YKQD*H5M.E`IKZD.PY9M$3"#\@U8N;K7HA".QV/4Z:K/; M@OEP6&#OX6HH:+6][OY10!;BNAC81`\:MI9M=E70=KO7W9GZ(+`[WC>#C*4, MH(P8NEZ[M_3^GPP*%M_^,E[?WN'Y?X$'XP2NZ7L*:O*GMV8P#H8#[=GE_4YSJ#EG<9':`&SBJ^BT#`%6!8,,!5^-J%E<>N._^&SJ MP5\2P)7LY@4'*'QY\!O*>%&)M:FJV6X-A9#9%)2=;ZB>J@I:4J>SPPU]#D9! M^(0?VH*FW^LURY%OK;(9(+70-F!S;%5`9+"`C/"W9H\P[2J"]S[=?_&_;APS M&@C_\9KK[PKXFM&F]J!PTAM`K_0+5"^N(Z%<;(KBEM<:##HY+)\09KS';8;1]0#WLFG_SG@C'<0G%0&P;(6;D'\$(5; M#V9YW6&.5^T8\`.B:7?J\J&Q:(2$/MW_(GLXO(WK^@66JC/-W)5KQ9+:`S1,.DM7>R/&4`!QW8D&:,88 M;>%3W.HY>)T_$.-X,T-WC*3Q^QKAW^![_SY$^HTCU[ZR?)"Y!TD<>5D>]@B>8% M,L[>5:UEMPMI+38T:+9R.LP!(*W'$@"I_<&A0:VGXGC-[G!'Y\_"*Q]2W$Z< MU1OVZM!".0A;`GZC+**^UQO4(9%:.ZCN@X&H=+ZFX<]1./GK#QF8G3_8!_`< M3)YR)Z!H_*>M+;,$524+B517E0H'>""5"8";^$G.7U27C-[?W)HGT?KA?YJ- M3L=N*+)LX0U!78%H=@KMC9]\2C"--V!/GGQQ$]Y'$'JE`%8MMTWXEC*\;<+' M@8^K>?88)^%_\#&\5>=^MIOA_I2#F5]P&:$64[0.T$H_OFACSO$Z[U>P/ M>@O`,IV^ZX-4&U.>-_`&H*`/-P6I3E'!EE%5*"G8$+BM(JT.<%M1WQA3%:1> MIOW47[^>#QF1L=KZ>=>==-M=R\Z'-SP@X2KC:#TZ5+_$Y;'ZK>6Q-GO]?GX; MVP0TCP49BOIT3YBZHMXT(A:UXMTN#8JV^GFJ6+QB'KX4MJJ353X'3T%4TT>U MU(\_:'=RH)4NMCI$&YS_H-?)'W\-H!;D.V\G#[PYR%WN!2NN!]I6-Z%DWE>C=@(/0O`$6NM#M"F*.JM"A/YMW\+P/`;7ZM6$(KR M/B56F]@XZ!6UQNV.C6`W!B:6JIWIX_E\"M# MH\7MK8]=+FY4:^CM^*"+:D[UBFM!ME%5S_J0I?@@V-O1^Z_HX9V'Z2-B%W25 MX&Y[^6G=`GP+U\V!R4/<4"$>3\.(*N-Q-OK[KQA*WY)1-6S;G&;)HNM#N%%9 MTJ"S/I"V4L8>_;FNR`%N\X:F__%S7[`+_&]A%"=&3!,6LK]2AP>LS?L'G5RV MX!YWQIZKM6ELV&D-5L32YMZK/2!D([=$R^L?(4Y`-R7- MO1@9VD0S-PV%%6'8W@:V:.SL?@_"-CCP,9A0;',36S2JMKJ/4B=*>>OMH_;=7OJ9W=SRM7=5]YKL4B%==#?64(1V MK`!>MD1IU&8`YSI$U*EOV5+25Z_9:^1U)J0;QW)W5:!W50ON2YTF^&R6>`O]2%4 M?68HG1T8_?NOPH+X6QR/::+=AE[-8;O7S9LQRU?=*ISU$D"Z32^7:KX6H&13 M;=,EUNK(CH45J]0'81.EKIU/65X"A11ELN$,\$_YG]=3'#T2;,5IWFX.!MX@ MSTUJ+KY]F.O5D[0[ONO582:_;&K3Z*Z\+)TX!8^[HF+)JN(M2J65K;@W" MM`[QQ$7JNPC;__;57KU<` MT^WDTE=66U^J-L)DU7':*A_GKTP[6[3I%H._+H![V/:.&E7M"R5&&S)1S?@E M%G'5%XRR;NV,>_F,@>5+5X-J=4RSBV5ODF`:SJ?;Z4TXK(1X.00V]*#K8E'4 M#<^(&[]Y^3T-QM>1*NV]&F7ATQ;=#+U>*Z=?UH=@*Y!O9(-YP\YPE\"S=KA] MM+>:':]7!_`2`+8"^$9,N-GNY++#MPR]:I*Y9;1WVL-F+7HI`6`K@&^`]DX[ M[[S9`';M"]V29[C7+)"S7J/N\AL%;3NMPLG6@F!_L?9^-7RKQXLWV\-&3+O+O*:0]EP=/7%\T!G0?HY&,]'VZQ,T0V3R]>Q85`,5WCD MML-3>X->SU:$"^NL`L8FV8NM7D[RU(6$&O"E3))4;XR>--&5;WL%8<-FOU.! MJ:4`;`7P#7`[['9RO1W6AKVB6_Y:C0K;^63?0C/\U9:MQQ8Z7CLG)!M[$C0^+O40+&/%;]&^5M^OM728CC/?Z5/J" ML@&"NCC1%O5+K`71)@T#JHBH#E!?8M%;[RH:OP-E%-I-P@;=9K>W=8AU,T-SY-9V8@9>.04L67L)P!1R^#68C('/ MZ]2&[0#<]BJN]9+5-P=YHTZ=S4XNYKHAV#+`1KFXCRM$^FID#%3`6;;DVN!M MDHQ4R11J0&@I%=N5?UXG9ZY6++8(H@\AT,*8K`?^(0#S=1-+FGL]54-5NN`V M(5QJ=&\=PEWTV6,@JT"LU\IN8RAKHG*;4.ZBYUXWW]9N\9);`J]V8[2M@[>] MWGLT(J>S&+*R1G=K054;84M051>@+3??JX.KROYVZ\.W+:S5!&TKW??TY*4% MBVP"Q:J9<#66CT=!,*8:&J0O7.O3/4T^"L:%G@D;!#_R`GW)LC6@3+@;1$GR MY-H:6SN73K!\W8W@W"2DU1WDDE$W@?4F"<%&G?F3S\%,6JX1J=%@9''@8C=& M2+?3J=[%.E#M<(\;!0_R3J:=;9,/7%O$^.H]"-CMGEN[UQKD&=T*,!3`OP^S M;6:OY.*;>H%:"V_6;*!=8"&KK+U2K[6K53NM%5,,M@?>1EFO^224*K`T3>F[ M('-'C?B"V7AR8YD^Z+9R18YK0+'+;=12"GK-7BM7-++;;63H\-RXZJ+3[)%& M51=L6G6+4-:KO$`86[N#<@O3\EJ#EM?N]&J#6)A8MSY\]5#8[/;[N5JNC>'; M0E5LO4:K;>[P]Q(JNIE1?-6>XK>=BYFMV\?=/E:*\.SS7&-M4&J M[?9;/BV[?%9\/GFUVMNV(CQOUQA<3P,#AZ1:[@&?-\ZH'RM8K M@%M-]`_9*LJRBMKM5_FV0%$:-/L;0K%Q0[XU\=?/Y6UM![+#['9+S<^]0:\U M''Y#:%EZJVLYSD\:!8L9;6GV2'YLSTGO?\.AQ&6SM$\;'UM,?C.$E$U-2#!FVJ)OA&=KN=J]#N@8W_[>!DDZM0 M;(YRTJA81ZOZ5O:^J3K1:G7[WQ!CW*HZX;5S@\E/&C-;,LF&7C??+/"DT;*& M/9(?X[FS_;/SQBS!8J?.Q^"9?JH=@%[+N]7ME&QS*4BUMD'95N6[V"CQ9]@O M<18L6WY3B!?5]6W&G3O=0=[?>>`-K7Y;NB4L=+4-?`FFLS@!FN"[A75\TQEB M=3MYB?UVVP9Q\7I;@JV6(M_O=W-1S55@JX[5K=-C=^CE4X<6Q.;J+ET+"ZLM M_<\@?'@$<7;U%"3^0_!QCC2*U7BZJWQEEFVMF%(%MVQV.CGS8D5(MK>-NBRT M*JHQ[/1Z.]])X:TU>]Y4'4>KG>,\*\&QK2UL>A3]9J<642W:Q?]W>?E+'&=1 MG`7.;4!=72XOX:?__NGK78+=I?\?4$L#!!0````(`$&$ICQ#I..,WQ```(_. M```4`!P`;FAP+3(P,3`P,S,Q7V-A;"YX;6Q55`D``[DGXTNY)^-+=7@+``$$ M)0X```0Y`0``[5U;;^LV$GY?8/\#-WW8]L%VG)Q+$YRS16ZG39%3&W%2]&VA M2+3-K4RYE.3$_?4[I.X2)5&6'%-IT0,TMCFC&7[#X0PU)#_]\+*RT08SESCT M\]%X>'R$,#4=B]#%YR/?'1BN2<@1*48/QF*!&1+M;JCQ9,.'IVWXX\R9>\\& MP]'ST?AXR/_[>#P8A`^X-%Q@"#\)#B?#&4, M".5=:"94G(V,;GQV=C82OT)3EYR[@O[.,0U/0%0K%RIMP3\-HF8#_M5@?#(X M'0]?7.L(^@"A3\RQ\3V>(R'`N;==`]XN6:UM+KCX;LGP'&Q@N1[P;CP^#8>$/368WXCZ,HP;V$L\)UC4/<> MFYAL^!RC(E`I:6N9L,6-8S('$/"E3VP^E_[L$.K]"J;C,[7^4N'2WF=NL.OQ MT7Y+'\$74A?,Q.*S:F-QE5FUEQFFT04!I"Y<%P;D!;7NB/%$;*)JB74<6OLZ M<`\L8*WDZM+-VS[[&C]Y*@\-VK5^&G$!:?`O/K8F,*:%NU92NHRRO?X,AK%' M-FJFD&G>]ME7SFK-\!)3%_@%H86*#%*R;J*A!^-%=4BDFK>>T_`B\`-SAZV4 M9WP950>(K(AP2GR07PF#6T!VH^@H*LG;SZ,V]XX03WC;!P93D&$JCYYRVO;Q MR).+__!!Y9N-:A1=I&DKQ8W!*'2U.\5LMH2`2T6*(DUK7Q*FM8#]#4#O;1M: M=#5]^PC?,7]?.K8%J7.35*-(%4H"P8;IVT*Z.WAN1B+\XF%J82N2B?-23^U" M3L3C1,=CR+T'*,XSX&\861:X/TC0KU)Q`PJYH)"-D!+DM!TS(YO-,V.'9;LK M%,TS7ASJK&#`!IFP[XY\=[`PC+58+!AAVXN_X?GPV>!X'.;#WX1?_S<5&P"2 ML@X,'FP;3]@6XBB0C`ZE35$8\/VV;XD<@7'P+SR/D2??X\'P@_.+PX,Y#V`% M>180.F&(XCR)SETQCGLF98\7+-M)!C,C">#/C#$6%SW"%B.7)TBZD]6F:6WJDBZ1Z%A1FKM M9QS^BL"=&EL^M8)Z\`WS<7I)],IG+,AC^;P;?)!//3NRT@%8R>2SHS8AX-_K M"?@C)-H@*K:")>`"BKG?=80F)V+8W^_U[.]H9;\X7#)+_@>0+//BH2">Y+7$ M`:P@*UYD`!G9HJ"OVL&N&1$YW(&##<-=\J5D^!^?.3:&+1:7O2N#L2UD,J41 MB!J=9C`I2JT4G^B!WQ088G#S5F6\*&VE<<@HE5?OL.4!K]8.,]@VT.@>6_`% M%[`,DSH"'>8YI=BR3I$X!^X.M\*[!_@BG9Q#`AZ]M\ST>WDS30=#N%EIEDF>6CGCTMF\+"0N.M?$ZHI3@8(I7!1=6A0C^OKF/>K^@NQ*)062WO\TRE7U=U[J7]Q"'3*+JOU/ M%*O]`T9)2Q=]^T@-'Y)\;'UWL.+_I,J0#PGYKK6H_G"*V:7A$C/6F21^4H-5(APNB MM<>FS+2MVAY&%[9,]QV057\&)C$#O8]).J;`_+"\J\=6,.FA24 ME55Y%(NT="CTV!$G>=59L1"D%ZO6F3ZHL\3^8I53H[?.9+>MS3OPT`/H2A@; M[4[NQ6"<,F=.O)*1F/Y13W32$O9HA#6)S5KFR=IH*0NY.CI'85\/.IC-%T>E M>AC;ZD2%/@R>'PU"7=X#V)W0FQ=^P)!/W&5P&&1)V9`"S<'`WN\PB0Q'H0=Z M]`:UOL\N\=QA.'5(5_Y$B@MJ9;FHOQQ\U:>_<;M\U;Z,ZO&JR^6U=_MU,[[> MN]?O\0:#Y/+2_^@GC:V^<\^25#-%VO?($X?]0A=WV("Y)?=N4WP9ZB7!NPGQ M`=]%9^TUWE';0/@]U+?+W_[+3L"-!;TO'D*@2G2PWF]N7W%Y@():^QYH4I`> M&%G;F.)(>BDHLD8]!$&FQKX+QJ2=GG+.8BM\Z>[+LH9:^9\J07M4CQ?;UW2`]5*+;Y*P8'DFZH!UJ?=<9(_5!Z:5*5:W%X;Y>WRM2>MJRH$1+##]]_ MU',+6WJ3`S^79\4SMNBNB`(6E:WUQ:52[.C(&_V]XH\P7S+#YAI8*T*)ZW&U M-[A\[-12Z(M9K>@]6IGD-?*3>5*'6I[XE+;4%ZA2D?5>;9"NE?#%4#[_3BC\ MO'9F[A&+7O7)63X0&.)F0%+CB:-AP2PGWOK+LJ`FQ MOG-+$RTBES$\?7=:'6QWOX20ML/*&YLDJPK*M)H,W'V\\&G8$[N>(+7_+3R2 MZP=#;M$>GE/%/3Q)$V>.`EZ[[^*1'XEE_<]W/7[H&5YQH";31TJ\H'0M`LE] M<,*#6:N/A>N`GS;7,EQC?O>JB\-));!D;N5EEOQ34.TG\<+=L3[DF=[Y@^*C M";2C*IW.G_!WT5RI*]\3FA5E=WUX5REJ=F]=%R+',&`4@:)P3+_@9_&+#%)% MNL.>2BR!_!Z;MN&ZXF93`;7PW&+:HJEK_`*+P-8MC6LM*[*5?3[LK8Z7??99 M_5'>@X.^XBE1_9'"#&F3/[&56C9(5+Y@$/S317JX[6"3;1[R5[/%-GVE]_'] MR:B"^*ODRA6QY8M?\6[QKH%^,8+,,TA"\0RS#3%QH#>,6F=!25F,S#MY_X\\ MX*)8N.LHM0]&NJ@E:]9!%LZMW'"7/#V-PVH>9\NM7Y:+-^;0@=15(00(LH'@ M7X`?)4N3>?"MQT_.%&<*RJY[Z93SJ^?.+H@".'RQG>?B&1COFN;/+D^@.3\D M&&IQ%(;\-/\`(/"Z(D>,Y5*@CXFQ)1PG]S[\VMG)O/KP5@6:0VXS M:VC$J62X3JN&=>>O7Y&]-K:A1ZY&L+1E#W$KU:5^V?F@&=4TE/K!B98=122Y M+%V=K"/H(79U*O5L"V[1?[`9S#'YEPMUKC1'U$=<%=2*AZ>>V>8T=BIAGI=^ M`5`Q.DO:]Q'$:HTB_,XT7;%*Q*\\6T36JM=@R8X3T1ZB6,.R`HGRIKT&*Z], MA%C-C*=;CA@4O.^8(TJ)WU*.*%6P1]L[DBA-5/.PX*36G[!M?7%8LM>A,F2M MH=1M$%<8=#%VK=$MNJ=E6%'FI&<8.V4$G-/:L%,Y%A5JP@@)]I`I64%KEGTT MC]9*Q[M1]EL1;>O-B8A<2BN@8U>:ES6T9]@S6+E2.T&Y\.8$^F5M>VZ#%.DZJM()8(KVZ2 MC\NJQCV#M$X=_6]DSON86WH='O-\+S901#<;EQQ%ITK;0UP;:!?#?%:3]6IV M^5B\ZCYAF:A"@G53!CT$O*F*42`U[,W0;CJ'Y2 M]O[R[-Y-9>*>(=14O5UW9/Z]2:O30=77_5?A74/9BG<)/&4->PA5F2K[3@;_ M/G![3WF&VB':XYK2"3V03>>^"K44UU0A&4?7"MI7>A9E6<,KPB_DJ" M;5,&/42[J8H*:_+:X%\,XBY,T_'Y.J:Q-8)(#KYA/K;NB/%$[+(5VUT9]=`> M=E4UBKCZ,'=+3M:9>7B=.ETG2+F3]U+ABRI\CU?0*3X3FZOXQ#=A)<'T'I[1 M0VO:0R_HO:VVF]LS]+OWHI5#:7`+Q7A8HZV69\V78RGY$%%4>Z4"\, M*,6)'38QT[86(W"21R!DQ/>SIUBAA!=*F'6O1I(6%=\@)T*?YH7F9"B@0RG" M5S*@3&J7O&`HROTN+W=$B00I2M&^ENBR:TJD-5>)%N\+6@1,4,`%16R0X(-B M1J^D4A+MW%*%6K)$KP]YO1).B%"4Y74PY>*7(^*E"*_$+F;4B4X?BSI%#%#` M`1G40FD>KS4Q%-]Z)6)_7Y@7>.M0XM>2,!UF)J*=Y45+1YB=/EYZ=G%!H''! M@Z<)49IR#S(F1S05!2MXZ4SK[H61'"M5%*K@@C-4*'O?3K\%Q18)TE1=&"E->8"J-7\8%!Y>B M%JXM2_]*KB,\-!K"/F_[P&!J-\R2T5OP="$I$K0H2[R/L/')Q7_XT%LWF\S% M/[&`!7^7D*"(IGNYHF+F*6;B'691KD+J$)$@H$&""'U[,YWM)=J^=DR?FQC8 MYPV8%U]7*QU(_"BIJ'WZ3VZ<`?&^!Y1(#L/3*>0'1I^,CPLPIXC^C=*G.GP: M<5I^=AQ\^#]02P,$%`````@`082F/-%>=7\^!@```L``00E#@``!#D!``#E6]US MVC@0?[^9^Q]\].7NP1B2T"1,N-F@7<%93QT64M4#91 M+F,U2VG"*?$$A\L:%[5W?_[ZR\5OMOWI??_&HL(-?.#:PD@K5(LCU3+"4]/4YDF\ZGVYL'=PP^L1DW M`7076L9,EE[S_/S<"9^BJ&)M%>K?")?HD*"-N*Q<"?/+3L1LTV0WC^SC9GVF MZ!P7RE`][V;90,N)'M8P7)9U0:0KA0=]&%HAW+;^-L'<4,R?>,;-L&TL89B+ M.3%HH+0,B#=C-"'=8``V99A0)B5J5MS14[^W"HMQ[:"H$\LXF0:[&I M\`G;$>VJ]H^!"D,2>'IOK(EZD6##>-@^^`.0.P)-JQ8(DGC>;M!"A1C0MFCX M>&*;":MQ'`W4-P\:9STSV]X-K[\&3'^K62\!&!T)3-==X3MASQE*,0YDDW%F MYI8;[#0%!V8:.`6:`#*6=NLCML:T46PTCQN6;MYB*#ZW&\UX;GP3-W^>XWHTZUC2C4<&X(5+9::04SK:*()=X4]P M]>9:=69,;0*?K3/W99$U'9GV"G,]L1VG_9ZS=F1C*(6?']NX8[&U`T)2D%CE M-$KDY06RJWCJS^0C1[8@'E;7H[4DK,NK94YRG(BY.'K57'Q&!GX$'\F:6QPA MD2=5(.4>=P1"87:9&BPI^N)+)"OS9_ED.>!ER)**-!D!+H@Q;NE_71 MSA0M+^I9"9(*=B;>*LS]F"F^X)LCGB%7W7!G@*U"@GYE3<'(?"F5&RPEQ\)#^"I*.9QTO(+<[P*:^J]%$.F;X3*6TN7!MO(6##=$. M*ZKAEU/\'^(%T!4\?J>Q#Q3\B<%X-XQ:-4.0#^"BCL;YA^A>3NX>6"W;-FJ67*NGS]"-/P2?XAXE:Z565T M1S>J<"FR-@'WI&M%^97RM>)'%:Y)%AL8]2ARKK-#X.;M=6I*`ZP+PJU/'[X& M6&AJG#;D,W,A7+%G1H%3M?2Z M2DY.9(M6G<=LU$GL6X>I>:-D,,"QG>Y$6XKL#\XTZ!07[%U,*5O"WPW]%]8,Z\=SCS5:7^\)[. MKT?G>7'AI/]38_Y=./]W'O[X'U!+`P04````"`!!A*8\^V,P`VXY``!=[`(` M%``<`&YH<"TR,#$P,#,S,5]L86(N>&UL550)``.Y)^-+N2?C2W5X"P`!!"4. M```$.0$``.U]>Y/E,3X#U_%R5?_ M_F__\W_\_G]=7+S]G.,XP`'ZK]=W-^C&V^$(W83QWW9>AI&?8B\GSSZ%^1&] M3C[%&#UXAP-.6>NWL;>+R!^[)_[P/MGGG[P4"W;0JY?/X?]^^_+B@K_O->DW M0.01[>&;YZ_*)V_XRY+X1_3JU8MOOGWQS]-_^(3]Y%&,.(^A45=".C M>_7##S^\H$])TRS\,:/T-XGOY?2+#?*%E"W@KPO1[`)^NGCUS<6WKYY_SH*O MR!@@]/LTB?`=WB/*P(_YTYE\_BP\G2-@G/YV3/%>SD64IB^`_D6,#_!IX`W? M7Y"7L#?\;_[S0Y)[T5<(6GZ\NRZ[HMT4V0LB@@?/.[.>(A"P%TW"%]8XG<)D MR1_]%52CP2'F^B-XA`YZOBGK'V2!=@K=)GZCPP@$(TFEF'/O_@)#\,/%RU=B"/C/?[G,,IQGE[LL3ST_%Z^AX*BYD#9Z47(+[2[3 M)LM>ZHM^R#\'1H"W>.$G1'G.^07M49#OT^2DYH*_,R&#Y.T&>&PPF.(L*5(? MC_E(Q(3MD@S?U-GCHR1[.S$"Y#&87!Q??+S_ZM\N[^_?/MS_G@G3LJQ%DWFB M#="?19/_VV;/LBS>D"E)(8'LD1NYJ[,EI$W&CVD9XWRTOR+\;%6N1O!A68"N MXT><3P-%-(V0AZ-Z(X&J"0U\G(9DM1#K.Z M2J3'X&G+FVB6(2)X**PUMJH-H MOZJG%=J#?M!:!D(/K4.+H<38$5NQ_;'V,S<-=DFR%D?U!="MC:G8CH2QTK^ MQLN.9$T!_WG[]R)\]")8#A"7PDO3)R(VOWA1@16JKDGK1N%'`1-J/PF1:>77 M1=*6/B"@)L"'?^"*U+X16!S"!F'R:[)'1)'"Q,P6%>OZ/O?2W"*N'3Z$<0SK MWASJQQ:O+4E@#Z%'GTL561U6'K4LJ6DU.^WM,]MZ=Z\M,\NT*F_)#4CW4A M7TJ.5B%4-Z&W"Z,P)YT0NWV?)_[?CDD4X#0#(TR6W_V'ROKDCH[]1L(KCP8G MXC)^?*B/I[-2O;Y\?7US_7#]]AY=?KA";__/Q^N'/]D]=)S!?45*_80Z\:\0 M(U_/(?C'.,-^D<*6U4ZE.JTV;O1#RJA0@EX.C0E)FZ6V))3/$30PL\8B0J54 MP2'^[G$<)BF*DQP[6`&.&SV3VSL#EDR?T8P-J$_^'>9H[_E@!YY<.V.^GQ1D M?7+K/4'`)#%GY)>TP$'-4+TITI2L8D4TF,4<-7?)'$>Q@<<^Z13H%"= M5`Q1.3JCT`-3GDZ,0V'\7&*0^\YN:D7!=HCK-';W@V?S_J:/=\M*T5VQ7L=^ M5,"Q[VV20BC!99ZGX:[(8>I[2&"F).R3$8H@CC`FZPJ`ALRQ!SBNAJHE]EJ4;N1_!"BA"!/0F-8( M/11M.2NIF+1MR$JM)$3GDM*JHLQ%-XAT#=$O MK[W(,Z6<.D%8,U&\+B.N3`+ICX^;"<'9:8D^X]2NHW]Y^?S52W3V4O0(S7^' MR)LV+]G_4`;FD*RNB_R8I.$_O7=YMMO7FY^^_UO(##K/;$H1_3MJPVBZ1J@Q17V\6E'C"[[]>4/&T1> M=L9^'C[BR+5#UZ9% M5LUM-_B//D%AC/!G'VZE0/"BD%W[5D*?\ZHE@J:`@#O@_C M)*7GMNPL5F%-N\W7-WKAZ-XX M7MM-8Z6![+FI*X34Z9V0<6BB%AIKVQTJ:S(!B<[=Z?5$1UV%CV&`XR"[Q2D- MW+K"?D3^H\HJKD?J/(IJ$)8DLDH;CUGET431%KNR+0IX(\A(Q*)/K%]"FZOPJ@@OU)>LVT5UZ/0 MI-&]N%&JB6"%?LU$:5;5QF/K:AUMBC[QGI#'NA)17[7P+JM*.!^9Z`'Q+A#K M`T[;&#FJT8/"TIZ=5S,0AVWOB!!?A1F[BU?@8$N,(8U6+H_AB%VI#X="2V?U MZ*KBP>Q!J&H@+(;>K";/P]S5ZHH>)64'R&LO[7Z^A8/:,A"4>WF6BRDLB;QQ MO(Y`KE!C,*H^FV?O,$D+6[B&^/_FJ+!;K04Q5!7_4]1?JY\U*/T(P')5GX#4 M]!)Y"D*%>%.Y]LL>OBP5GX6\KMA51PVU7ILJO_52V"FMUA",MX&+H(-4;M14 M$XQ0RI$H3*O@,/`2"HK$.Y:A6DP%/X>YW_/S7 M7A;Z"HT9V<>J5J/]0`?6HGH(G:Q$E;@Z!TKP^Y>R"M5&-7(-2KM9E>,YZ(Y3 MEA=!_*=H4"T=9CA M3(]?VK2*.EK3]*,SN:QBZNB=&&R[5&W.QIEU^XLN'7Y;5MKZ55JM.6@&[VO2 MNAE7FR;TLP+MG7)A:3922V[1M`L?PV*K>;5C'-*V_%8X7\3X`"DBJ(8;!`W9 M)M`S9AV_[IC'V.9%VA'.O6N\UMW?9!_F/0Y"O8$K)[?-8N77JG@S[1%([ M!?:%>9"Q5N:;R1?/7'@(UL"MZ@BH_U!L@0/?=1S^Z,&</OYC.-,%20W2.7(4.F!*F=;J?Z\X"H-::*76MO7V5GLX\I`HY1[C$42?=@`=_3I.@ M\-F?]G7<"C#'2L\76/&!VZ!L8%^AI[T;A1\$(-1=FW/3RM['<2<(DS>QN[@? MPV'95LQBV7J6V'?X$<<%5AV]58_=B&Z;/2&I*K[,FO$:-^UOS!^9W/I5B>(P M5ZXW;04;`X:SV\RMT*G,Y!"?IJVCA#_%A[=K$_7YZC.`-D;073I5B M5H92H77-)HZR4$O8+'-)]_!G7$Z:?`U^[0V_I^XLS?/Z^.U+VMS/;3/ULE%6 M519M@$/V6%4CV$62>\;)59&")6/R0GG\@#_11RH_3Y?889)Z;6B-)/2C,5F9 M>G2P=,X!R0-0!#@TJ=_5V:`8YVZT8RH4=D>!42)&BACM!@F=(O2LQ23G-3Z" MGKPB$+B6D!_^RSR?[_!"!*_ M@--2V:&%V=&@)_X$KE?5*C[S6L4^K^1-GA+S'6&?-#QB\G.:/L'DP&Z#P\R7 MD]FAY23`0^99,C&?DD17LOY*7`GZ^L0MH5]@F[&>9Q06RE M"1$\JI7FSVRIJG#>ENM^'179Y@Z/JI+;4N-B=I-QP=&0A,55Y-9OP*C<2(.` ME1<'Q#O*>+KFN*@BXWZ6WXMW5_1"-T5_/XGS(A>#R??'\&]Z!3?`MZ(`Q7T8C2VN:://BW&(Q64SV>(Z2IBM]ZNH#/?2G\*UEY:D^<$[ MX)O$B^]PQ-9/MRF$C^=/]UZDW#S3(73D66E#*GVFT5C,^04ZS+>%3!`AH$*< MC%[,YX2(4MHWNI/0U/?\3@)9!,A2[./PD:XLBS-,+Z0':$6\F@@15X7T[WH_ MNCB?(TR7FM$;+SN^BY)/U_$^24\L6JC_+%B;VM&.]#APY9;T-%3&]Z2UT71V M/HA5`!*0):5"->3P`/L'<9!_`?.,E^ M)'8@SC.VFWX=LU6.6.VH%@>CNG"T6)@`LUP\S,!GSGD:!ZCC3(%40MPD_4>M MAPT_24&B$_1,=/.U@Z6&`Y0FXV"'EH;SX):[$G1+E$.G_\!5;^YS"P$\XKE` MAK'@]=/'#!-L[\*8."K$B;_T\_"1U@Q56)LQ'3C+)C028BV-T$1L9M5P%")9 M5@LJA`4A`M'<"S+DE72VTW3-@T/-B2!'NR?T["/#]C4J.T&72G"V$^1X3^"+ M9-M]R=R;),N5Z7*4S1TESQE@OTREH\FW,;'J8;23;Y$W!5>WDAC:VE7.K/'< M`_.!R!M9*;4_'\6DM$%&^7>FLH/I7&4M72NJ.HWK,+>F?2PYE^HBTG#&[%*: M>].VULQ(K5"T@[16T]EU?K?@7/+^,]J]L&`P"J:P>:G!N3 MDCY6NY'^YYJTE*U=Y7N8Q#IPGN$X3%(4)[DA)W?PLH[9AS8%9[2T=K7 MD*J]XOE838OF)(S2+1[8*,Y8+(9L<6EWWW@16!-6F>O94U:,P'7\B+-\QAZ/ MM(-5Z6=(5+:6H\-HNO$P M<3/JL("@PRR)PH`&+?P5R-$CH[=<>&0RJ'*)2/!PVBI\,HP1)4>HC(M4[U0>FJD@X&>QJDX/W+"&,>#:.N*HJ`8^?S4)KX&`>'D2._<%ET]QP=](%8)PAZN2#=7%3].*H[8!_H%[,,G;9MU-O1 MVI>E([>-1F!UM&W4CW%HVTBVB%O%MM$X6!,6XZO?-BK3GTW=-I)VL"K][($X MH)<:V)SLK,@1*7=6ZOLI29GN;EWA0?J0>C2PRN6WFO"@=F#A=7SI^[1Z-EEA MP`T!2,SI^VF!@YO0VW%?3:&"4SMS5A9C!O1:88P%,)N>-B=C[=S&YV3HS.A8 M?EQ&B:**U$EIGG\"B"JSM!@Z25B\"[6(^'SG)=OL?Y$>XCB&5^&X$]@U)'M4W:3:-, M`L@U[\B%DBX'%5R`)#_BE-UM/S.*WIH=EM6R"4GK&DX_B1N5TX$A%&P,_Z9% M;8#OSO*OI216+[FH+,-,#`.WC%SD%7]-/-[@37*"FA9]-9!4C1WF&E>RWL@Z M/LBS:;E7\BK-J'NQ@Y:0'+AL:G\/1Y]E:,A9KC=U<;HZFVG7TU.98#-[2.XP M:$$8X0\XKVK0/B2:>^(#NR]F7N5H.C0X;.4T:F&\C$^_9L9)G28V8YE@^8L@ MP;E8P$&Z7)T#)[O;2&X&J'P1K?O? M+Z\L[F.<"K3C/MSK_B*P)IPZKT=?%74@:$;PB85'VK2KJCLB!S90=J0?D?&% MA":2445'UE!L9!!!7ZT12CRWU,BBX=9\HX(R?>NEV_0>-M082L(U77XH-$F7 MV%6`]1AH563U%$RFE4D;2S<(5VQ$<24Z>ZG!4@\J55J`?Y[$E]!"I05&S=0) ME(LE]UV5,K%TPY=%?DS2\!_*8GA#1&M0'A44N=(,8;"K+!+>!Y6$ITSW2B*' MRC**_T:F:W2IY-]=^8"14XP6I?-B`KJ3RP0TII5%#T5_A0$W<\HLSK^`V:23 MZWYP*NFE<*XD0Y/(".XM*H6&^966VW`T=TSB?/VSAD91867KE0B^O-2P)M?6 M!5Y9@%8J[*&T&JWYD[_1;+(C#?>A[<U3K`U6= M(-&+W7VYR7CZ0:`_`S&BU*XWN)MKP/?XM,.I0I'D3=>P;=!D6[Y9(.?7TMJZ M9'!@1;T>1ZA7$B3MG#L_^N%P77,[W?TBL$` MC:O`%PT@503+"`3&1&6(Y>Y!,;M[$\8(?_9Q1F\!*/=&;`N2[Q>G@A8!VT+< M,X22I?B(XRQ\Q"R0HU^H].D="=A8@*6P345F3O!&0)'<0Q6T/,#=KU.C9Q$- MUF&Q3:ZC;J2U=7O%L)_$422-!HPR9F8$_\;D:X#A@9+&(M>9ZXN%7@H55#.Q MUSNTWNQI[^BZX!"`\F:@+N?&!*:/U$H_SI#A_@\K$7YQ^\4_LD7=W,KJP-L5O.=AJ\FIOHY`QV M*Z%#,U2U0]#0N1R\(:*:>M%U'.#/_X&?E(+0:>=*$A0,-T5A@%O#LM!E42$, MO"&B+1%IZE`Q)[YY'V_&/G6+H4YJ!_X8P?,5 M?%863/PV#J[(,K_G^[;:N?O04H;;7[R76^.?OLVB4@9X%6#2$EV9+7D_)`Z7 MA)\`>'H7>0>)&+2>V__\4@:KR_X]W)G;6FNQU+T#SY\C:.#PX[XITA38)%ZF M%_T)>ZE:W=5-[7_R(;;+-8,FS^96!VI&.^L`UA2QM@@:KT']F=_QGSB*_B-. M/L7WV,N2&`#B;T"!!`F+X$F= MR\\O253$N9<^O0NC;@F2GG:NY$7!<%-.!K@U+!]=%A5R439$K*5S:>"F[@Z? M(15,?(#`Z$(M%*KFSM:3O>RWEI5:O)M>7:H85BTR^514$B!&X5QPJ/R^(1/B M(4G5&P^M5J[$1,IL4SIZ.34L%&WV%+)`FR'1SKD$W!:[*/3?18G7SHV@:./J MZTL8;7[['BX-?_DF:XKOSAHAVLKY5^_$,6^+/,N].""V23UM]!(YFSPTH+2F MD!$X3$\D_OX#/JPJ MQ<-X/,9$3A.`I/ID@&.6QZR6#/>U%]%\#_='#,FY5Y1CA*-\@-3V0W+&&SF6 MJ`:K'=F1\FA>2@13W3P9O`'Z,VVRF@]^$\;XFOQ3G4&FV]#QA^^PW/GX2E[- M"T"=N1XA@&:(MG,M"2P*I61MN#J$O+7+$"$E\\WHH$&NC4F'FDW->8.'"I4] MK''JV.ZI;\4KLK(<\_J>2Q^M<]=E&)C$=]%'9,-YZ86@*865_4KVB-=-!8%[.%"PK)\*-$*.*A$@4(7(M32T@ M5\G)"U4)N!5M719F43#>K+\RP+&Y5;R"144UE;(A^C-KZEHV;CW8E^Z_I]IH MXJIH?9?-JD2]FC]CW[W%4+=@.SQ>RRRRW4/"T'>0"E7?B9&0./==E#`D+LL@ M_S8\%1G#8QT4>AV19GRE/:W'2VG?+AF0+77S==SC4-8C M-%7M'_W+&`,T;L1'"XB0H5$(9@O20%Z1(<[;0E6K*@5)I\\XM5X0=0TLMT6^ M8OA%C`]@LVDZHE[NJPIUG*NGVKW?*WQ.L1^J"HKC M++LG9Z:+DJ$YO>3HQ`Z)VN7!V4JKX".KSBF#ARD-^^,M]LU)RE[N_J5UUT&$;Y+ZOW5^B763%W1YF0I)L331'K'V/K[T(WP&_ MT2*KH[<(_X+@N>O]"_^(@R+"VWT;TF".0AU*1[L9^J#*38WQ:$S/`GHH!D7- M;OK!:3QS*II,L:OJ1HP\/H!^7\?[)#UY/4%30XT=&/I!UDM3KVQIU]@/L-&5 M!T:`:A3.#?X2&%9C]!EO9:"\_I)`B]*1T=<'51K]\6B,&WTM%!K"9M?LS^*Z MNK"QH&N_;+*;=HJY#TD^M!4_2.4LG8T.F%K^FC$HC$G8,-N2##6UU'X\(&HU M6_0*/!HIDP;(5B55?6F11N$P;78U^->1+]MI\I?@&0'1FLSM%4[#1S*'`2BB MK(7(4O4S#@Z-`I[Z;LN\+MVHU!+#4*8161"_:56A!*HPRU-@9S"_4AIJ7UFCG!KU88PR^#,V([2Y]^34*FL[4U%9EET=/< M*9))(5VW:)HY*UMW"P-<[*RC"HBZCC]"K$H9`/O')(SS7\B#`JHAJ@]`1O=@ M_U1D(DAQ5#*2W.KYR23>)-G#12]0A*79#Z(=(=&3Z\,6^X!GGX]#D+? MB[;[?>CCUT48@;NFJV]CB.VKVGAH0LOT*:TJV%BV.J+&.T"L!R2Z6)E:V8*Y MEF/.9MPL+6"M\`.E+==0);#!M+Q(H)1;8UZQ MRCU;@O,-Y#8%B>=Y60PBN<^]-#>+Y34^A'%L&DYOD>)E@)@K43S@\H]EGT7E M_\NKYR]?5L7O?H=^O7GY\B7\KUL@_7?HM\]_^^N7_XKNB520)Z_A`MLC7+78 M160$XB3&=!/XUZ^^W?SFN^^:1:?IDZ1*686\'+TGMNB(OGVU0>"RT!97V*=W M+/FO+W_8('J1(H#V44@6(P&+7SE3(!@2$B5[`@-0$#+Z3J>A^Y<^83+%HEK7 M=5R?U:3G8'$SAK]H>H=_I1/:(Y_0%HPLIC6#M_O>*KV]\<;C.G`1A3P%8A6; M/(;:-9F%(UV[2M:AKO@NBM)\X-WP#>)%V=WQ+*%CY`_JV^Q-43A8(6E M!Z)<5O4WM[N6TN&EN[+@5(B2H8K.M1XL#&^IX-4CZUI4]N5]!!@A\QHD M5N5>FY^1I=0NS)-F0%L2(45,AJM&[5G:SZ-:U'<@2.K,=!*U= MP2;!&C8'91#D>X1]O-O=(VGQW!:BWLV.QMZ&Z[VJ`2"=+2N>0-S\EI7>SNTL M]E>HR.K4^MI4ZU'IGN3Z(U&X4.[^[/HZ&IZHL^R[V6'7`:92F1J5K2WWD6;[$8G6 MKK`?D?_()J$J-U#`&RUUW#!]_6@8AN69]`&?SDGJI4],.NYP0'Z`Q4'?8?D0 MD9MY5`^*F$;'83`M6(.\=[/C!!B?Z/[H]A85<9@S-5/$N=3>X#'BIZH$WM.JNB%KAN?L51J$PKCSX:=8!@!A&"*>0SQ+2G M'QTE7AR+H)Z"L1;N*(@WB)"O)UJ_G6/UM9>%OD*%%&W7D<6VP;@JA:V48[,[ M%"H^VV(#4A&RR[]>S@(AZ%R2)^C#S[?(9Y7/LIKG:54?=&%T$_&2!1:T79F< M7X51T8U@&6R]#EEO,:^2=@77=N6]XO4+EW@U$)G,\]:KJ`MUDV39.R)0[&BL M(*Q6EQ++6XNWD.XEB2]K7^(A^=!(HRI"N11*8^IE+JM2F1JZ9E$KTV-F5N.- MC537-Z3&`KX3\LO7H,3-G6+;L)_!J[YFZ*NW->X75U>0^1O19=NP-O,BB[>N MRDRQY>=[3-;/06TYH&5UE+1K,"(#P.0V01.1)3%70]"06GY'E%'7UD9F]':$ MS3*#RF$,_%1X'`M9>&/ATU",BX=B+V@\N`&,#V\_GZ&00PS4FM$]2E).F[*R06?I3$>7A18YCN!10C4&$/:KC8>EAGL(X M/!4G]D3TON%^^0%V/,O?2"\^P#R4[>A1:%;L&L36XT^_5+E16F\'@"8;SX.:E:%,>RVL&K\5*_O&@;1$-&6Z,Z4B`YHW4B&+X!C M82L<&6-]EJ<;W[Q"Z]CTVM\`2(&?*\S^>QU7UW-Z%OY]-,X6_,-`:@M]?006 MEHR]G'>/.D'*RSBX/,%N^C_8G\%?"[9_)O$1-.GL>["C``FG M5HO(JI\[@B-)LN:*%A%B5*=&%;D+=W@Q7.#;>35J)Y[R'#3@//M%"EZ^\(SY M!B/RCUYZ@/PG![!@>;5#37!'27RXB,)'N,5S/CYE="'KL1MO<9*C`JJ,AY`L M)0D*6K)P0\?JTS'TCPBJ14,K"-2,`^Z;DY'QX/I#GB`OHJ:#6)NT\N"I\^XG M&?7OLP*Z8>]+R,>&AV$*K]T7$0+&LM\!->D,.D@#2IUBS@RPMDN2O['<,]"A M![^5=_=HSV7':$>6(?NP'*#&^ZO7["/LY[`HR`H>Q!D4*2P?:JL.]B;6?7[T MR!"HQNLY/UR$,':ZK,G(*U@Y2/*VH)[QN#J/=;VLN,,YD14I"JD)$QV(Q-MUK,=^YX,WJ/D.6_;B,&%J98'V,O:FB M)2==AW#UP5*)EPX>:P*F`-`C8LKJW"NH183S[?[!^SPEK&1"7:Q%WK:>RD<+ M#EY?P20#HV9Z^6ANM/I+'3%+;C>LWQ56]BH6^T^<+O*Z&=%:Z[D]L/!PVK%. M_R16R;`U^L*MD*;UL;]U;1OGHI;'Q2[Y%SU@KF^]R"/_](NQC.G`T=V8T1#+ MZS*3L1F3]5%@9M16,&/V<#H4D4J421<+C;,E[6O59);;W^<[F)=Q\#;.R8CK ME9S7(W.PNS\"3KFYKT%C9&]_?=M,?)GRK&(!')X4 MQTSW?SA#[S:N;C^365`69-;;W'%N7@7[TL2\K;;NLO)*&5'GL(UH#MND<4'> MW/'M4`SE;"!I&<)@#L2HK,)Z*."T:L<2*Q$(Q(?,:-X".&"I8K\80GJZ`@=- M&?8+2#>S>ZI_.W3B;V>'\$!7Q'#"1<]AF$,*QU"?Z+O@?`JZ)?\ORWABH2+F M!W^0RH:,S=&#,QS"TRDL3AF<"M%#FH)>3`GAW.?)4()ON')RQ\Z&;KV4YD;J M'>MN>\<&1`5`:D':C=V9$#DG0ZI'`P_%4=X9Z)R;D"E`:B;$%J11!D43DPF+ M@H)",B:+)OB_]'UVA((#8BV9\RX9$7DS^]K>QZY0UH`>CV!:ZUS7BJ*.8/JA4D0O`UW,:PJ;'3$!$M!(D3WR9?B,J%R9S*X? M6ZV94Y7KL"M1N;*-*Y5K,="KJ,V.SN\DC.=8YY+:M;D,\3U.W$AYLS-*4 MCCQ_S'+:5QX`QL&6\)0JISQ50R?Y_GM8KN7WE[2RG<]?R8(LPST[$Z5EU:"Y MRYED&NM\G4?C`&$+E_S;][)C_!^]-$R*C.,^D?4=CL@K,/PFKON$ M.3X9*NW1:YG,?,49"MN^:U$KK,!99"42I%CTB5TH]EAHE;+K4EHV`./84E^4 M$3T0CQC5:V$0*:.]\*H8+CSE!4!6\<&EUGCF\`S;OIF`8+('3]D_DE]Q/5J9 MK(1A:XO\Q>.6PV9X=`L^#6&F/WP*R;[%Y)68!527;R6J=@NUBW M:+M'9:Y!Z-G%(6_?G&]A,,:G([)S:FD".;T,0QQ!8KGV4?))`SO8.':G!2P= M9D>'08*923QZ9'&4%9#?(83CQ8_WZ*?+R]OJ)LTSK[:J35)A,9L7Z)7CXA+!34='O$C!,F8UBLA66HPG)6>)L>O%C< M,U(?XLN;V;>8?>P*.RAKX^107LU(-]]2K:G=$_>)3)HX3J\.#ZO;J3TRV=_< MOFSJL"]DM*^M$UD=9J@W97M%9%=Z%V/;2'B(+*E08PH;#BFI+(383Y<`PSA"-\ M8CF&RN-IGU@>2,X0E#UE32\//,D^MY7YK,FG&)WD6M"L"K,5GF(+?*`J^PTO%(*[6#!O3$$+[8R7M" M.\S2&O!T!:0O#"%UL,Z%E:LX70QK@;:U#`?M;`QLR**9E93E"]EJI[1O'2MK MY6`9JV:V7,5VF[A9Q*KXZ"X/:V<#EM>PDW@TX?)?X9WJUGCWL8N,1EWVJL1% MU3,W=Q@Z#$C2]NQR)-I8OIF@R9T)H:KEB:D*5_2)V0"!DY,.#0BUDXR>UFZ$ M4X,EV29\E>!GJT[P8_JL93'.S9C,-'RD(4B](BUKY<*`*IFM[&BGB2-SJN!# M8K?*ELZ,ZQ1>#0AC>>&R5QBEK9R$L*B8K<6JM)LX$48E'SUW6)U)XT1FC9R( M5'C6C%HM'4M'A+&Y0+2P[4E$6FR.B0DK+5Q,9F1 M^J4%>+#UJI*ZM(7%=6W$T87UUE#Z<$RQP_(I'."MN0A@%3TQ+.N*MJY2KO8P M7N58U>#8F)2K6.P+1W$JX3,9=EBW4Y?S!K?2NHN6]>_29ZDEJEHDW<0Q`VW= MZ%\OXT+_M#@VIG\J%B574EEB]KO:-;$/AK*I]"K@7(X=:J`NZXW209*4-=8+ M:#7/S@G3;S_SRX,_)4GP*8S::,>1NBJGI0^KJJHU'H\QW=4$,!B@P=)1/BMI MD2#^VD7Q+=.8G%;.G@M.?@7/LCVX"6.\W;])<1"JIN%F$S?Z+6-3Z'$??\;T MM<50^S/?0)V9'*;GR&4'F[+2-.W#OJ+;Q>?06,P"6K)_2)/, MM?,JLL&\997_U.O69BMG2U09L[75:!^7)A>>+;:4.7=X$R<+R9$\NET8ZC*+ MY0-JO39/EF_WU8YR_ZRK;.VJ5DXO\U7-&RVNC6F9FLUNC1%6*;1^YN!L3M1G M^[W\.IZH\4G^Q87=_9P!TQT4AX9<&V]8Q"_AKXKX?8WW28IK$7'OPSA):6+^ M,E-9LY=Q1^A6.7`UUUD?Y&H>=3:Z!N=HF\.IB/CD!=5I;IF*A7JD_(XR@90A M#*533#G0?W*!:]M&W^SWVQ/`5_6^#BTNL8&"OJ@98\(-3W5XJ=#X3JB,*1PFI.'M,D5375Z"R5[ MMD7.@HBGF-O9KUJ1\5UHV'I-\<+C9=+)@=+G@]%7LJY_4)4O9'Z M5;6;V.*EL,JM2BDM9\#:REL-X(L8'^!BA>N!O&1E!-E`$<@'<$+)/Q\@JWN1 M/B&:6_S;N;2_J:NUOYJ MMJNU^S"_!M?>4@:[:V?>;(-80T1;NECMSN'7Z::A%N.<6V4)0]L7'TL/,WM( M+H,@!"_1BVZ]D'B7;[QS2$;S'@S-#NIQ@VTC1H6ZDG?X[P6Q6SF^Q^ECZ&-F MN(@'FQQBVLLO7J0,US'_6D?7,2T-9WFST_(X&C-3%@:NLRZJ7@D9S>(OOF"OAK5WPU+<_YVQ%\ONQZG`I77IGP4[C`-9"E:8A,QEHI`U%64OQF:#^ M&E1;=("@A]K];2?;07/PW>>I%QZ.1!3@HAS4N7*L6+?>D[`W/C$A*11/O,*/ M.$K.5<2F0JDT:=THU"A@0IDF(3*F2+H0.FM.3D?G249)+VYQVGI4L(/MY:FH M:.LL%!,5K-$19J'-`$YDSY?GR[>_,K+P\13+)]<6Y`:J1_^,H^!=DE81:[HV M1$6]$BO2#TYI1_10V;,D2A@ZXDB)$5!?[)/THBJ\LP9KHHVL>@@>!KC!!^]0 M+^_;KH+N6L_2Q,#URR24V[9-O.9:>HZA7./YC:T]H]M.?E+<`T?]S(@(@AJ`_`EV4C MKK.L\(@:;??#V20TZ-QK>2\@F1IK(;&BIRK6^Q514(&[:SQ_Q0@ETT53YS]> M9?J(FI70T!)E:U?)/'N9K])Y:G%M3`_4;';3`E36=DF)G^18ZK,MGRS6*?!2 M-4[OO8@H,[MI-&:&:!&N:(J00NJ=(WJQV)TDVLSKSA(INN<7%1BI@TT/DW`< MGA9/PE6?_GQVCIRQ4V_W=T=N2]O&CY6NPBQ/PUTA*>*A2>-V@Z872'M;1@N! M\57QXTYY'!LF M7XOS;7KP8GYZ[CH'*^Q$T"1]#ZD7P&D#C6^L'4<.%QN?V9>CK*YS@)?I7Y=` M;$R+ID+LYFDE_4#BA!QNL-*^Z`J%Q4/7NJL7(7>MB$N!?R]V[]@^YMU:]NQ$ M\`"D2+?K) MPV9HGQM4ZW6#>+^;F@7@];U7I/P&!J4.U;GJ[_(Q&JUH[4I1>YFO]$^+:X-J MI6)36H9\5;(_AG/'HORZR,(89Q!.OPMC=AVR"MCA13"I%BND>TP';@1^/$2A M`].Q&5.+46#:\B:(48UZ@^H!6J+J*>W!A?+,PE='XLL0N%>N^QR?:VRR34B1 M1.PZYL$P^`Z?Z+5A>E<8KK-M4[C0IJ^#<]^S&E5=9L!Z-'K9D;*I^+.'1L\^ MP&OJ1F(C\@:6J8QIKC_V,KBK47L=NXN;I.A&DC#E)C!:,5\J)X1`W7VTES\`'=7(,H,"&"5O2>6(_;I7WX> M/M+(=#-%[`ES6&9OEKU$Y.(F:+SS.0IQ\!S=TY>=X!$B7P"J.$1/ M!.<^HOF\O=KE[2P\A9&7PGM(IQE&)SB&(K/H&?9T:3J=)L.BJ%"V`J?7 MO`Z.(](K'35J7^'FLA<_T>19_"X8&20X]()_D_8>N_9,EAGA'E"0@4]#>J4* MR()POR=&&F)W=CC_A#';!J#$11S@-'JBQ2B$5TX_![]XQC]0^1V\G/X-6.@W M*L/.GZ/+*$LX)/(M3E[L'9C'O\=8!)63`:#J0+^FZ+3K-#@*'WJ7I'?X3!2- MIJW!1].'H!V5-!^[\9"E26"5\4Q@ MVJKN6+V:,BRHUB,JNUPBS>A8^^J14M`"`K&Q]O0*(C9G)V-`0(E* M4E31(D'L:`O-P&=96I/?BWOI`YH\ M"0/3Y))T99J\\&=93),?R,(B2;WTB9^U$N^@XZGWM+.OK[T,"Q65-K*Z,]W# M07<74[0M3^]I:[N^\UBFZU?QNE>/5GDNM=9O,F391_%]Q&COA2EZ%*>O>8E$ M;*Y2^L4/6:U7QX;]DXR,V'9/]TTNZ58YWU91[C8,D[FJEZT'IRJ4G6_4Y3B[PT'A]UQ(;C=R MM>$F8[7:5.OCT>#&68NIKL,&Z2G*%BZVO@8XO,-Y6$7`E;F7(.-2+>&2M?T@ MJF1L-JN7?J#IF+-*M:K=[^V^MFM.,XC0J4@R92[7M7T/=^EA$4[Q4OU:]:.7 M95J2/!@,->N_67F&I3S/4,W$UXYAMOO&:5KU'A=^K>$QJGIXD?8=1&U8>(6; M2!+#8_"A..UP2K.Y,['@3G3`1*863>)ER"/6,BNB7`0N^)4($6_Z!7&VF^/H MUR0I*SF9Y&"/L;,T/M.(F1W?\VJL[-1!&3"R8[M=@XV=QO,8$\LBA+]<"[O0 M".D:V#49UH6@ES'B;,6DM*K4)5W(EO)_WQ"@Y&_R%_D'5.<@?_P_4$L#!!0` M```(`$&$ICSO<6NU>!P``!FT`0`4`!P`;FAP+3(P,3`P,S,Q7W!R92YX;6Q5 M5`D``[DGXTNY)^-+=7@+``$$)0X```0Y`0``[5U9<^0VDG[?B/T/7,W#>A]T ME/J0U&'OA$Y;,VI7A:3VS#XY*!)5Q1T66`9)'?[U"_`^`!`HD@+`WIB)<$M" M@IGY90()()'X\:^O&]]Z!BCT`OC3WNS@:,\"T`E<#ZY^VHO#?3MT/&_/"B,; MNK8?0/#3'@SV_OK?__YO/_['_OX_+^[O+#=PX@V`D>4@8$?`M5Z\:&U=!"\0 M6(_V:@60E;2[AO:3CW]X>LO^^!`LHQ<;@?S[UNSH@/SOY&A_/_O`A1WB#O&? MDAZ.#V;%7RZSCP7PBS6;'1X?X?\?G5EG7XX^?OEP;)U_+5I^Q=(LO:SII\// MN.'LR/KTY>/)E^-3:Y$U]#WXKR?\-0LK!(8_[:VC:/OE\/#EY>7@]0GY!P%: MD2]\.,P;[J4MO[R&7JWURX>\[>SPGU_O'IPUV-C['B0J=$HJT@V-;G9V=G:8 M_!4W#;TO84)_%SAVE$#4R9?%;$%^VL^;[9-?[<^.]S_,#EY#=P_KP+)^1($/ M[L'22ACX$KUM,=ZAM]GZA/'D=VL$EM@&UMM]HL:C#RGY7RYLGXCWL`8@"O`2\Z<(+-(?GC88/@L.?W;['1;L!#A&V"V*(0"VV:OEP4?GZ0(N,8[Y$H,`+F+/)W/IWP(/1K]ATXF1F+Y$>ND_9CZ#,"+>?@N_X;$0 MAMA,7#*K2K,KW%5_GO$TNO(P4N=AB!WR'+IWGOWD^9ZH)7;UT'NLP\,#2KL6 M&NJJS?M^^PH\12(?3=OU_IH78J3Q^!(#=XY].AFNA81F4?:7'V$WCKQG,5.H M->_[[J&3#1$./]JNH2U2:]Y[3P"H=!Y8!V@C/^#2J M`1#9>,F@1)S\,C&X%5[="`X47/+^\ZA/1D<<3T1OCPA/0;8C[#ULVO[QR%,( M_HBQR-?/HE%TFZ8O%]^BY?.,DN--E7&"1Z$0LQMPMX=_G"-)?`:`>@"-V>*=":^MLMZ M\B)"=#3#B^]]JUAHX']CUW+Q^(=7Z)>5P,'*>K&R;A(V,:-^X-1X\\G2.$!U M?66L1?9K`(,-]MAT*1R'AW&XO[+M;;);<`C\J/@-61"?[1_-L@7Q7[)?_UY9 MGMUX$'/DV?XB"#VBJ/.G,$+8^_*/^_83\!.6!,D.54F5Q3YL_IL-"DZKAG*. MZES;R,F[PO^L64E[.R)K<;A-UE3[SAH'N3GU$@4;&3UF3`1TW@.$#?ZGO=G1 MGA6'F*5@2ZC)`@X+LP0(`?`5P*+B>"A=4<@9!JN7 M*5D*2\;,=,Z$`X(FD(D\B:8/(5B1#SR2L<0$\\&ZE`\%)V46B3S%BD";H+"U MPL>_^+UV2#&'I5AM&+N;&X1AMS`Y@!\,`O`&JZ2Z=]>%8+N]R1"VIV-`AMKAP%SM]'Q$[#F-'.,(094N3XGO1?D^GH MR20/AAP`X?\0$W^V_>1(*+JT$7K#Z]/?;#\&%,P%Z?3<71-D/H/^XQ1'\"Q] MII(<0@^>&>WTQ)7!;(;C)&?B9L('%OCZU?%CLK?T MTX`P?H,A<&)$]L:?:#@V_FX:D`WVAXIO(_QAO7!\X*+X8#*&#Q0$3Z;HB_FB M;&&_D1495A+^#8I!-3'],D8HS2;\-8!.^@-G,2K?E6G6L;ND^='QI$,V?E1F M'MPUYO4[OAL0Q$>PV0;(1F^I0NZ!BW]!Q&-M-'81F`9UESR#K8;KZ*O;8&9? M-"`4M*WE+@K3(.\4:+!UMHX>W];3+JN_0'S#-O(:6/[?&S]^'-4I9EGHK&<>=V+;T?:2:+W()$@6P M8A%J*WT,@04JE>TIHTDFW`!RH6PWT1_'-L^3/J%V72^59F%[[BV\M+=>DH?: MWA9@M=0?4B;K&;+ZS,'4#,!*%O*O(,HO>-<`8C?3&QTVWU,^6:Y(G)S14B[P MWP4A.7*?+Q_M5_H>G5P/>IO!3B+IMX/3Y;U7WK/G`N@V=];8S?2&CF:X+6[ M:'*T?;&IFMA0VADJ4-?/,+OV(W=(C9JJ,77+_4['LC\>-DO=#%\`IUU9-.LL MKX%S+%@#)^VH;!E:/WR#-L8$__&_E)7$:8C'V1YFME1X8^<9P!CP2M^TFZAR MR0Y%E_=RF@R/4_%F@`75(_*V/H`@N@-V".[;22RL1NJN2M'M)5]"T7C5;N.8 M?C>55F(TJ\8(5PQH1(ATA4J$]S&":'67('+9$ML,&Z-)9K")SBBCH`RQCHC+ MRI`G&`Z;LSV`GQ:1%4SWUIA[R*R&.J+#XW>HW6,M?#!7`B?.T!.A.H>#[==J M`4HQ+ER_;DG4S8L&.6TU#PLYG(]S047E%<]D),D$I2Y$&BU48==I>I4[G'6. M\]LH)P/?LE>&6K4J$TG?WI!=AOS1AQ:"W-;:H\GE?IPT0@ILL[VSDX*[?'ME&"<;`6%^4-A-%^6!4'8ZPAF2^TQ97(^J0"UI0Z1 M&,@`]"@\3RN(+=,J2&FM-&<^+G@&6`0.5UA^:A(1ZNZKV(5ZUZUZ]K M'FB_JRZ*:DM3"0-_MCT8$K%!.(?7K\1E8R]1$2G6$#UCYJ'0556R^#F['C6/P369*8I+FP1(7=<:>W0A^:X[R!1 MQ3P^'YU)1+]-Z!(I$NTV'A;1PT:Z\#<+VQINIT MNP9WUX0'9P;?%4C/CHX_R"Q%#7/&\V?;\]-QJ7+K/GV>QD@-E:P=W!?!?GDTZ?33S)SLMY#>_<6 M+]9)HH[L&>P=]L8;/:BR!2&3%M_Z;D@U3HZ^)G;!7W#*68A47P;:BI1\D[H> M0%6:Z%QA"-8,WL>XDJH,QW\`;[7&X>DY'HOL%?@UWCP!-%\F\H;S.`HC&Y(S M/Q:^DO1&X"XITZ1VX)J*NO+\F*A"/!IL41@6#[;XKT:$IR3(%Q_HB]]"&T[+EN<@^&=G@D0ZS]=1$98?(I06T*/J-80#5T M^4;.JXMJ0G\+/!C]AI45H]8M'TE:C=>#DI+D_GQZ,#L>_;F^]Z@]57G9L%Z$ MK"@^]4&P^%39)%A::5]:E)^J2"CY5H$0G<(RAQE_C^00DR=`UD"#QS-EZI/6 MF6>OLM4#@'T0W.)_TF8]6B/E0-0LIJ7Q"J=::OW_JWORT6V9XT@5.GOO>&V3 MY&?,-XI41[;IBNTV#&/JRJ7^9XT1KO$YU%4'G7`B)IS*ER72I[PE:P/;,AH,U]\@UZ4#D[Y2!,^!MF3G/Q7 M#0?H3T_8!Q!LI+?'M*GI?@4<1`KS95OOZ?1%=MQ9T]QC<^=48WLK^.9+D:+@'>9Z5.:_+[L:YC%HO;?-KK/=YH,^UI?\?W MG?R<>D M>"7;&LFI$+S"6GI.ZI]F%:>`>PN+NWJ<"A%C?FSB8]&8JLO'ML\'XF?DW==I M-33J;Q`!V_?^!&ZE$%&II'/DA1B*ZE"P@S'W^`\3IV$H(^V2%)6=J0Q"<[S6)*$YK``T#/G@-23>$!(EA!C[473V`9_Y/Z MA@#CRY[OZ"M]K6O0"F99]F0EHY)B5/1F^AH"G=_B)8V)@%?H(=WJ)?8<0&+\ MYZ\>-QV&WEXYG/S,&#K3[-?SU%W$J#-Z%6SP/$B[AD%OIQP&GC455S#HO&N8 MLK1(A/X*R!T!V@Y([<_*TM]Y)E/L8-18U5#5]R#";`,W3^8_WVY1@%?&9`'! M!$"$2!4L--LIW]OJYIN]%:S#[1$F))0V.B)`8=,`I_@&[5W<@DZF(RQBG+.O MZFE2BHT]8U";Z8@$G5,-(R;&4HT)04=[';'H8)E]S*T.%,>)-W%REXJUU<,& M2)Q62[#$V6E"\,J=LM.XE2U'C1YA2."C(WZQM+B[\>)IN'>=[O?)G^-O*>?/`` M'$P4>=0+G,-UK:]9#"=C?BYPQ4KD>S;.2.1%+&WDT\E( M5O*N=X)#+"D>5&_\X*546GXO^*/LO>"07`PF_5E)A[I=#BXD%;L33&FNLM(S M86>!`G+FX%Z\?0O)T7Q1S>#8UCC[&N68P]'J$ M\S)]J19*&"E(I\HHQO2D/,P45,&4!ZR\$F\]\X46:#$:3M4^>#)K-S`,:!!E M?MZ#[8/Y$JMO2Q96U/QP7N,I&P9/[J'J3>IJ'#)/?0O3J;P4-+;!2"E!^J*8 M2)JV'L93G5[GRQL/VEC1<,6J3LAO/E5CZ99\L`*6.@XP7['D*WN%]6A#["7W MP/:O0[*U4-?)`H&-%V\H5B/;P93M2%87N65-,M#%>DWJ:N3U-6[A52;2/2!5 M6AS@/9-44]I0)$$[97N24,-(6=5ZF%)Z#/T51.L`*_`9I'HOTLOGJ%:WA9GD M*][!E(U*5A=%O=(I6Y2,'@:KF62&-$.(6ZQZNR%'W.4QST<[QHI*:3R1#;!:^LM+EF0#:@#VJ MHY\[3A#C079AO]FI,O!O4(QE].PGSZ>EEM"A$.O(+-/I(^D8K\GH843BIW"] M4A6F'7O(Z&&P:GK&V%(:W_=,?^%V8G#Z"U>N8CT]P=D+#[CY[7SR8`LB0^\5 M>`9^L"VWK&B9,6)TFF4U"/A`>;=32$#IPE7F'!E@Y3D`N$G>>'K25@K^"_#= M)>:QV#.@)T_)T!ML*G*"3OD`N^4UR?8W4<)-@&ZYUB)*:;"=B(J8+Y=F`U>, MTL1&*NZRP)[A>%O;OP?;3#MSF*@%#[=W9&T@9CR]NS38JGK+GB^KC@=^D4T3 M3(P](]'3,ZG'%+;Q^=4`8SI?YQ7?Y M5_WZ=FBF90PA^6"'D"8OL'LMK$VU'EDI!WN3Q1A+*;**^FS%<#LQ>"N&*U=N M*VH?CQTI&"9W+K'H>/V8W*($+B6ILQGQ,6@T&SD$#)X6SC*$RXQ@X*OJ"NL1 M%;%Z!_#,EN;"S11)OJZGUC63J6:-TMVB^DO#78[>(#(7>A'ID M7'F]EODF6X>,E(,]_:7?QA#1P3ETR7](J/N,@UZ2_9846FIFQU%L18[PC]7R71\G'_@.!CM/"11QZ$(3D"9TG'"\1P1XBL$U.[L.DEG7^PGA^AI\= MZH-[K$`[C%&B1U(*88X8%<]&^,:44\Y'4-?$[\IDFB>;OO3;IXRK,2)T4[8T M0144:1?T9*Z*$1BY?UX]+OH&0^'3LD9;<]?/'*'R-#Z)LW$C=DMO`H2ECI&S MQFL_DEOM`K`AM\0J98?K#VMP=MIVZ6*7^B6+$;S2)$BD+ MB.5B_4J5_TZ1M'M9G8>H>&*4*)&9B(KD0$VRQEWV;L4<+6P493]4@FDRT9V' M8;PIB[=7=]`EB%78A=S057U2152JH8HJZ+=A7BVG=0_\].@GJ_SX1G)&:,L& M$2)S#$%$FL'JTPUD`=_S2SWR*/=YN:=_GCU`HTWOCV"S#9"-WK+=D.1Q$0JN MC';FH,<0('^3K.^NI'[C:`G.Y?E:O"^>(;]*(T$Z\8:1Z#RQ@1[94O_]".H`;HSPSX!Q`TMXT!U]=Z MY<,$$0BQU+'#R&ML-C!CH*=Q_DYN_A[O7;]QZ)J=YRU/[V9.DNWR;7'^3+;T*=7'J4U4F7Q/#47-D[A]]V> M@GH/2[^P?7+IX&$-`"D]1O2U!I'G$''J=C^;S<2>=\NZM-(^K1]JO6KQL%LV MO=G^(DAW$,0>>..0J4N1(!%7=F$@#;BYLK`;:Y`(T0E+D1#!D8/GG3H$!/4S M!NP;8SC9N3] M25TR=A&8!GM;@DD7A:+(3MT"8BE*Y3Y0?Y@;FT"3/+>AR3V/HS"RH8O74X(X MURC,!+LF@O1[0L8B?N=A3;D)1.D?``Z".U%G4)F&/$.,2;\5=!EL-B3742Z, M$Z+2'WXA,2;]H$]%`P+A&[>U47`S`S>):^HFP\P,VY@M#82W$;#U+TQE!+3\ M<(W?W$"0:8':.[QK]![;F@_Q9F.CM_GRP5M!;^DY-HRR!Q:PM(O`]YS*%>1R M:_^XN;6?=60%2ZO2E57V916=]=_X%^.:?X\8[`N?GL0L2JCJ M4&$W"(N-34'IWFUG[#U\M:P4WG[KN?3,#TW/)&162F=5"/M[(8T?CL_QFRN\ M)I*S56J-YU@=[57YDP@8Y<40K@@\IU%B^+7W4$2V6[S)57F%3Q=7!"XYG9XO\>0++F*L53SQ4BMCEU[YJ>65:2=6VHN5=V,E_5A%1P.X:">W M/&^5(!X@L:[[<]TNV*,?92XH#5&>4+>CH)/*2BGO\]Y"@6KUI4]^;OIDV9/E M0:O>U_".*<@WQSNE>]#L%6K!"56&6)4+[P@F_V%IKO/J$YI6WC%-WB\E;Z>T M7^XL_>ZD[7=Y!U;:@V5#UZKV,82W\9CD.ID8X2"OY_(^)3;U[="'.I^1@:1\ M1U=:P$E-=Y0WE$O7.FUE&Y/6F5<-D6U@*;BT?`:STS)H+&%`#@MBX+;O7Q0F/FL=;U4) MK0KE(.^045CB^4$'@3K/\,)M$-K^SRB(M^$M=/R8+,GI_`JZ4.\NE?F:$*R% M]_66<^XIV?*$FK6.N"JMAYB%BIZXTY&E%8*YZ2E$C[:K[3) MK756EK:VTN9#;+,5'^?N^U%:*:X$B[D1F[WXS=5M^#$57R_;RF):X$:,(E;H[ M(7Q`BGA11(A)35+7-H)X3@Z;]Z5+CVG56LM)+$QC)436#]>+!W5UI9HR\G,/5N2E;1M& MO]H;6JD&>C-EYT`2,!1F3Y6@R^*5H'&)14.V?XN]YO7OX(T)1ZN=>7BT1&!7 MOE("2"[9(_X2[1BU]F>3U%_GG%V,2JG6%_GKFU=X&<51?Z.=B3@T1BE(" MR#EFT25LWO@VK1Y$X^\F`=!@G5.F28GFLV+A-SCNM_W_`39B>P.[J4EXL*7@ ME%!2.%G_`_C^WV'P`A^`'080N$F]&,2W,0Z8E`J=XDDWZDN72 M1(C,PTFHB-JQ+C%`+F<96-[@W]`F&V9+DR!B"I%/,93;/AK@DBZ#Q9"IM347 MFYH8!3KM4C+O>'C;JJ/8/HPZ:AW?5HC^T\K(E)V6GD$@*IS:;X\9#P_62'`/_P?U!+`P04````"`!!A*8\ID4BJ^8( M``![4```$``<`&YH<"TR,#$P,#,S,2YX0%"WJ8LENFAT!*[1H;?*B!"4LY. M>^/!J(<("WA(V>JTE\@^E@&EO9]_^OO?3O[1[_]V?GN#0AXD,6$*!8)@14+T M2-4:G?-'1M`]7JV(&"`C.,="$N'0T7@TT'_>C_K]%.X<2U"'*B-^-!AO:RY2 M:,ZF:#P>'HW@[^@8'4]';Z>3(W3V<2OY$6Q=TE3TW?`'$!R/T+OIV_?3HQ_1 M/!64P9K$&(&S3)[VUDIMIL/AX^/CX'$RX&*ETW!FYGA6P M4H(N$D5R`@GS1+(XA6K;GN_UNZ&M=*+0I=3SALB\<"*'KL(0W1^-M8'`'$(G MF#&NL((N9+[KDLV&LB5/OT*!#M54\(C<`P32'S[?7E?[KRN'=XH'7]8\"J%K M7GU-J'KN(1J>]BK*MXVX9D*RI(P:2.(!%:,QS=0D&JG(G6:`8Z")/H&Q1\Q"9*&0A]7QXO-RA06#:5_.B;A; M8T$L%Z72A@$Q+@X(!X```1D(].9J?O>O+OBY&2E92/(U`1>O'N`?FU(,MZ?; M13D798B26>42P-\0@;W-SHZZAM@?E6+OP:`,I^,AW]L7RG5S^%0?XU%I4Z^5 MNH#Z`9VI-1%G4A)WXB#*41T8&&CGLCCV?O8\DI&#I;+FD`3E/:*2O82J(VT.N M@;/2R2"%1!83.=".KCJZN%`KO"(W'#-Y2P("NTZ8J%*.=E0V$%,Z.S@<9(!0 MAM1QD7^2AZ,K"?Z1N>"P[]EGR*U;YIH5]3T;R"_O_`07Z'YWD M=TN6R*3P375:VVE/TGBCSX:V;"W(\K2G6='Y>*/)9/P[-#UXBB,GH>%K<@D- MAWEKTU8=`!9!":.47SC<;`\S0V>Y`U!4:?7+;2-(MR+_C7`$5@Z_E]_`\J%^ M%SO&*WD^]YIY'=^AGQ[J>Z%KOY+K%UDKK^-YA!>'>@XJ)'I%GV\T?J6W)T,_ MXQ2^Y3-23\!9+A1BI23=NI1AFY)\PP,#5*.BO_6=7E\7]<='_ZW6?AA9/Y^%OXWD>J6A`2:7$1D-O\, ML[Y-9+YFBL!W9:>^%(';N,%GWTY@SHK!X MOH8=AEYF(1K)0L)03;3"+X(G&R<*N[L8+*!1I-L\[2FAP6P=C'G*PWL#'"8B M/33;NH7=FYSV`D%@B[@S-,4LS#.P0^!`.:]WU^/TD[/)=Q!J*%N]BGN[_"BE M:Y4\J9%HER][WET5'3Q8K5U>-U_\%!T^1*-=ON[WB+@\%@_3:I?/.RZ-2J0V MB;7+JYJLW:)G>XFVR[OZA(?R!+2?=+M\K)Q%TNPNMKH%T=KYIB#9TF7^7E`X MLX`Y-\0<,#*GJFI:ZL0E@<-Q0.W:S<*S&*:*].&^W9S%GE]["O]5KH9D4>=I MS4MBQ5&WGVS+QIP_R<]8=HW]B50O!"695^;-'DG5@;3E3/X@>.R_95/I5UFH ME8[!+B.)$V,F1-^ED*?GHLJZO\B-AAG$L_62/M"0L%!6^.'5M=,/=]Z$,6\R M.O.,[*IMZ;0.Y@F]]EP2^_\U\S82J0LN_]4YN+]&2YV^I-*^@`ZZ\II=/05$ MRMG2O5"JYX7:',=T[G\A2CM7/__6OKC:5=>U:W6KRLHJ^E$OTRY_FL_96=+% M/7E2YQ$/ONQ_2*]4MAZ[!WU3Y6K:<_JI\?D;%-O@KS=OEH9=556[>JE^RI>22AXT2+7,I^SMM#(5%57MLMY[^[3\:*.BJEW6[WJCO[SR-,FU MRZ]/G`58KO7SLNU61V]L=+DNXU&D+7(W,,[-@]5:NE&T/>^&RWWWA`;34XE91"*?7RKE6R7;_=$WP1#'[)Y@]=2 M)OIWM-+GC-65+>V"YI>NK(V7B8[CW(":G_B1,*>DO_N6W?+.EK94Z5W?'0E` MR;ZFD5[=?#>\',5&_7]Z<57MA[GC_GYA.1RN#=WH9&AS&N#CGU!+`0(>`Q0` M```(`$&$ICQ%MV5J/9P``&72!``0`!@```````$```"D@0````!N:'`M,C`Q M,#`S,S$N>&UL550%``.Y)^-+=7@+``$$)0X```0Y`0``4$L!`AX#%`````@` M082F/$.DXXS?$```C\X``!0`&````````0```*2!AYP``&YH<"TR,#$P,#,S M,5]C86PN>&UL550%``.Y)^-+=7@+``$$)0X```0Y`0``4$L!`AX#%`````@` M082F/-%>=7\^!@``&UL550%``.Y)^-+=7@+``$$)0X```0Y`0``4$L!`AX#%`````@` M082F//MC,`-N.0``7>P"`!0`&````````0```*2!0+0``&YH<"TR,#$P,#,S M,5]L86(N>&UL550%``.Y)^-+=7@+``$$)0X```0Y`0``4$L!`AX#%`````@` M082F/.]Q:[5X'```&;0!`!0`&````````0```*2!_.T``&YH<"TR,#$P,#,S M,5]P&UL550%``.Y)^-+=7@+``$$)0X```0Y`0``4$L!`AX#%`````@` M082F/*9%(JOF"```>U```!``&````````0```*2!P@H!`&YH<"TR,#$P,#,S M,2YX`L``00E#@``!#D!``!02P4&``````8`!@`4`@`` &\A,!```` ` end XML 13 R11.xml IDEA: Medical Office Building Joint Ventures 2.0.0.10 false Medical Office Building Joint Ventures 0205 - Disclosure - Medical Office Building Joint Ventures true false false false 1 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 nhp_MedicalOfficeBuildingJointVenturesAbstract nhp false na duration string Medical Office Building Joint Ventures Abstract. false false false false false true false false false false false false 1 false false false false 0 0 false false false Medical Office Building Joint Ventures Abstract. false 3 1 nhp_MedicalOfficeBuildingJointVenturesDisclosureTextBlock nhp false na duration string This element represents certain disclosures of investment in consolidated joint ventures which own medical office buildings. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 5 - nhp:MedicalOfficeBuildingJointVenturesDisclosureTextBlock--> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>5. Medical Office Building Joint Ventures</b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>NHP/Broe, LLC and NHP/Broe II, LLC</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On August&#160;21, 2009, we acquired for $4.3&#160;million the 10% and 5% noncontrolling interests held by The Broe Companies in NHP/Broe, LLC (&#8220;Broe I&#8221;) and NHP/Broe II, LLC (&#8220;Broe II&#8221;), respectively. As a result of this acquisition, we now have direct ownership of the 36 multi-tenant medical office buildings located in nine states previously owned by Broe I and Broe II. Activity subsequent to August&#160;21, 2009 related to these facilities is included in our consolidated activity for wholly owned real estate properties (see Note 3). Prior to our acquisition of Broe&#8217;s interests, we consolidated both joint ventures in our consolidated financial statements in accordance with ASC 810. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>McShane/NHP JV, LLC</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In December&#160;2007, we entered into a joint venture with McShane called McShane/NHP JV, LLC (&#8220;McShane/NHP&#8221;) to invest in multi-tenant medical office buildings. We hold a 95% equity interest in the joint venture and McShane holds a 5% equity interest. McShane is the managing member of McShane/NHP, but we consolidate the joint venture in our consolidated financial statements. The accounting policies of the joint venture are consistent with our accounting policies. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Cash distributions from McShane/NHP are made in accordance with the members&#8217; ownership interests until specified returns are achieved. As the specified returns are achieved, McShane will receive an increasing percentage of the cash distributions from the joint venture. No cash distributions were made during the three months ended March&#160;31, 2010. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">At March&#160;31, 2010, McShane/NHP owned seven multi-tenant medical office buildings located in one state. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During the three months ended March&#160;31, 2010, McShane/NHP funded $0.1&#160;million in capital and tenant improvements at certain facilities. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">All intercompany balances with McShane/NHP have been eliminated for purposes of our consolidated financial statements. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>NHP/PMB L.P.</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In February&#160;2008, we entered into an agreement (the &#8220;Contribution Agreement&#8221;) with Pacific Medical Buildings LLC and certain of its affiliates to acquire up to 18 medical office buildings, including six in development, for $747.6&#160;million, including the assumption of approximately $282.6 million of mortgage financing. Under the Contribution Agreement, in 2008, NHP/PMB acquired interests in nine of the 18 medical office buildings, including one property which is included in our triple-net leases segment and eight properties which are multi-tenant medical office buildings (one of which consisted of a 50% interest through a joint venture which is consolidated by NHP/PMB). During 2008, we also acquired one of the 18 medical office buildings directly (not through NHP/PMB). During 2009, we elected to terminate the Contribution Agreement with respect to six properties after the conditions for us to close on such properties were not satisfied. As a result of the elimination of these six properties, under the Contribution Agreement, NHP/PMB became obligated to pay $3.0&#160;million, of which $2.7&#160;million was payable to Pacific Medical Buildings LLC. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As of February&#160;1, 2010, we entered into an amendment to the Contribution Agreement which reinstated one of the six properties that were previously eliminated from the Contribution Agreement. NHP/PMB acquired such multi-tenant medical office building for $74.0&#160;million, which was paid in a combination of cash and the issuance of 301,599 OP Units with a fair value at the date of issuance of $10.0&#160;million. As a result of such acquisition, we retired our $47.5&#160;million mortgage loan from a related party to which such acquired medical office building had served as collateral (see Note 18). Additionally, as of February&#160;1, 2010, we acquired a majority ownership interest in a joint venture which owns one multi-tenant medical office building (see <i>NHP/PMB Gilbert LLC </i>below), amended and restated our agreement with NHP/PMB, PMB LLC and PMB Real Estate Services LLC (&#8220;PMBRES&#8221;) as described below and amended our agreement with PMB Pomona LLC to provide for the future acquisition by NHP/PMB of a medical office building currently in development (see Note 18). In connection with these transactions, NHP/PMB entered into a Third Amendment to the Amended and Restated Agreement of Limited Partnership, which, among other things, authorized NHP/PMB to acquire properties affiliated with Pacific Medical Buildings LLC pursuant to agreements other than the Contribution Agreement. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As of March&#160;1, 2010, we entered into an amendment to the Contribution Agreement which reinstated another two of the six properties that were previously eliminated from the Contribution Agreement. NHP/PMB acquired a 65% interest in a joint venture which is consolidated by NHP/PMB that owns one of the two multi-tenant medical office buildings valued at $79.9&#160;million. The acquisition was paid in a combination of cash, the assumption of $48.1&#160;million of mortgage financing and the issuance of 152,238 OP Units with a fair value at the date of issuance of $5.0&#160;million. NHP/PMB acquired a 69% interest in a joint venture which is consolidated by NHP/PMB that owns the second multi-tenant medical office building valued at $69.3&#160;million. The acquisition was paid in a combination of cash, the assumption of $50.2&#160;million of mortgage financing and the issuance of 121,489 OP Units with a fair value at the date of issuance of $4.0&#160;million. Additionally, as of March&#160;1, 2010, we acquired the remaining interest in PMB SB (see Note 6). </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The amendment to the Contribution Agreement dated as of March&#160;1, 2010 also eliminated one of the two remaining properties from the Contribution Agreement, however, we concurrently entered into a joint venture with PMB Pasadena LLC (an entity affiliated with Pacific Medical Buildings LLC) to acquire this property (see <i>NHP/PMB Pasadena LLC </i>below). As a result of the elimination of this property from the Contribution Agreement, NHP/PMB became obligated to pay $2.1&#160;million (the &#8220;Premium Adjustment&#8221;), of which $1.9&#160;million was payable to Pacific Medical Buildings LLC in cash. The portion of the Premium Adjustment not payable to Pacific Medical Buildings LLC was paid in the form of $0.1&#160;million in cash and the issuance of 1,788 additional OP Units with an aggregate value of $57,000. As a result of the payment, we received an additional 4,514 Class&#160;B limited partnership units in NHP/PMB. Under the Contribution Agreement, if the agreement is terminated with respect to the remaining development property, NHP/PMB will become obligated to pay approximately $2.4&#160;million (the &#8220;Future Premium Adjustment&#8221;) which has been accrued at March&#160;31, 2010 and of which a portion would be payable to Pacific Medical Buildings LLC. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Under the terms of the Contribution Agreement, a portion of the consideration for the multi-tenant medical office buildings is to be paid in the form of OP Units. After a one-year holding period, the OP Units are exchangeable for cash or, at our option, shares of our common stock, initially on a one-for-one basis. During the three months ended March&#160;31, 2010, 401 OP Units were converted into 401 shares of our common stock. At March&#160;31, 2010, 1,626,800 of the remaining OP Units had been outstanding for one year or longer and were exchangeable for cash of $57.2 million. During the three months ended March&#160;31, 2010, cash distributions from NHP/PMB of $0.4 million were made to OP unitholders. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Additionally, we have entered into an agreement with NHP/PMB, PMB LLC and PMBRES (see Note 6) pursuant to which we or NHP/PMB currently have the right, but not the obligation, to acquire up to approximately $1.3&#160;billion of multi-tenant medical office buildings developed by PMB LLC through April&#160;2019. As of February&#160;1, 2010, this agreement was amended and restated to provide NHP/PMB with the option to acquire medical office buildings developed in the future through a joint venture between NHP and PMB LLC, obligate us to provide or arrange financing for approved developments and provide us with improved terms, including preferred returns, a reduction in PMB LLC&#8217;s promote interest and acquisition pricing determined at the time of acquisition rather that at the pre-development stage. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During the three months ended March&#160;31, 2010, NHP/PMB funded $0.1&#160;million in capital and tenant improvements at certain facilities. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">All intercompany balances with NHP/PMB have been eliminated for purposes of our consolidated financial statements. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>NHP/PMB Gilbert LLC</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As of February&#160;1, 2010, we entered into a joint venture with PMB Gilbert LLC (an entity affiliated with Pacific Medical Buildings LLC) called NHP/PMB Gilbert LLC (&#8220;Gilbert JV&#8221;) to acquire a multi-tenant medical office building. PMB Gilbert LLC contributed the multi-tenant medical office building to Gilbert JV, and we contributed $6.3&#160;million in cash. Additionally, we agreed to loan Gilbert JV up to $8.8&#160;million as project financing at an interest rate of 7.00%, including $6.8 million that was disbursed initially and remains outstanding at March&#160;31, 2010. We hold a 71.17% equity interest in the joint venture and PMB Gilbert LLC holds a 28.83% equity interest. PMB Gilbert LLC is the managing member of Gilbert JV, but we consolidate the joint venture in our consolidated financial statements. The accounting policies of the joint venture are consistent with our accounting policies. Pursuant to a contribution agreement dated as of February 1, 2010, among us, NHP/PMB, Pacific Medical Buildings LLC and PMB Gilbert LLC, NHP/PMB may in the future acquire Gilbert JV if certain conditions are met. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Net income or loss is allocated between the partners in the joint venture based on the hypothetical liquidation at book value method (the &#8220;HLBV method&#8221;). Under the HLBV method, net income or loss is allocated between the partners based on the difference between each partner&#8217;s claim on the net assets of the partnership at the end and beginning of the period, after taking into account contributions and distributions. Each partner&#8217;s share of the net assets of the partnership is calculated as the amount that the partner would receive if the partnership were to liquidate all of its assets at net book value and distribute the resulting cash to creditors and partners in accordance with their respective priorities. Under this method, in any given period, we could be recording more or less income than the joint venture has generated or more or less income than actual cash distributions received and more or less than what we may receive in the event of an actual liquidation. No cash distributions were made during the three months ended March&#160;31, 2010. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">All intercompany balances with Gilbert JV have been eliminated for purposes of our consolidated financial statements. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>NHP/PMB Pasadena LLC</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As of March&#160;1, 2010, we entered into a joint venture with PMB Pasadena LLC (an entity affiliated with Pacific Medical Buildings LLC) called NHP/PMB Pasadena LLC (&#8220;Pasadena JV&#8221;) to acquire a multi-tenant medical office building. PMB Pasadena LLC contributed the multi-tenant medical office building to Pasadena JV, and we contributed $13.5&#160;million in cash. Additionally, we provided Pasadena JV with a $56.5&#160;million mortgage loan at an initial interest rate equal to the greater of 3.50% or LIBOR plus 165 basis points (increasing to the greater of 5.125% or LIBOR plus 375 basis points as of April&#160;1, 2010), of which $49.8&#160;million has been funded, and a $3.0&#160;million mezzanine loan at an interest rate of 15.00%, both of which remain outstanding at March&#160;31, 2010. We hold a 71% equity interest in the joint venture and PMB Pasadena LLC holds a 29% equity interest. PMB Pasadena LLC is the managing member of Pasadena JV, but we consolidate the joint venture in our consolidated financial statements. The accounting policies of the joint venture are consistent with our accounting policies. Pursuant to a contribution agreement dated as of March&#160;1, 2010, among us, NHP/PMB, Pacific Medical Buildings LLC and PMB Pasadena LLC, NHP/PMB may in the future acquire Pasadena JV if certain conditions are met. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Net income or loss is allocated between the partners in the joint venture based on the HLBV method. No cash distributions were made during the three months ended March&#160;31, 2010. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">All intercompany balances with Pasadena JV have been eliminated for purposes of our consolidated financial statements. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false false This element represents certain disclosures of investment in consolidated joint ventures which own medical office buildings. No authoritative reference available. false false 1 2 false UnKnown UnKnown UnKnown false true XML 14 R10.xml IDEA: Mortgage Loans Receivable 2.0.0.10 false Mortgage Loans Receivable 0204 - Disclosure - Mortgage Loans Receivable true false false false 1 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 nhp_MortgageLoansReceivableAbstract nhp false na duration string Mortgage Loans Receivable. false false false false false true false false false false false false 1 false false false false 0 0 false false false Mortgage Loans Receivable. false 3 1 us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock us-gaap true na duration string No definition available. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 4 - us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock--> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>4. Mortgage Loans Receivable</b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">At March&#160;31, 2010, we held 15 mortgage loans receivable secured by 26 medical office buildings, 16 skilled nursing facilities, nine assisted and independent living facilities, one continuing care retirement community and one land parcel. At March&#160;31, 2010, the mortgage loans receivable had an aggregate principal balance of $216.6&#160;million and are reflected in our consolidated balance sheets net of aggregate deferred gains totaling $19.3&#160;million, with individual outstanding principal balances ranging from $0.7&#160;million to $80.1&#160;million and maturities ranging from 2010 to 2024. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During the three months ended March&#160;31, 2010, we funded one mortgage loan secured by 26 medical office buildings in the amount of $80.1&#160;million. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During the three months ended March&#160;31, 2010, we also funded $6.8&#160;million and $52.8&#160;million under loans to our consolidated joint ventures with PMB Gilbert LLC and PMB Pasadena LLC, respectively (see Note 5). As we consolidate these joint ventures, these balances have been eliminated for purposes of our consolidated financial statements. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During the three months ended March&#160;31, 2010, we sold the assisted living portion of a continuing care retirement community for which we had an existing mortgage loan secured by the skilled nursing portion of such continuing care retirement community to the tenant of the facility. For facility count purposes, this was previously accounted for in real estate properties as a continuing care retirement community (see Note 3). We provided financing of $6.5&#160;million related to the sale, including the concurrent repayment of a $0.7&#160;million unsecured loan which had previously been included in the caption &#8220;Other assets&#8221; on our consolidated balance sheets, and funded an additional $0.2&#160;million subsequent to the sale. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As of February&#160;1, 2010, we acquired the multi-tenant medical office building which served as collateral for our $47.5&#160;million mortgage loan from a related party, and as a result, the loan was retired (see Notes 5 and 18). </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In 2009, we entered into an agreement with one of our triple-net tenants, Brookdale Senior Living, Inc. (&#8220;Brookdale&#8221;), under which we became a lender with a commitment of $2.9&#160;million under their $75.0&#160;million revolving loan facility. The revolving loan facility was terminated as of February&#160;23, 2010. There was no balance outstanding at the date of termination. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false false Includes disclosure of claims held for amounts due a company. Examples include trade accounts receivables, notes receivables, loans receivables. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph k -Article 4 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3, 4 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 7 -Article 9 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Statement of Position (SOP) -Number 01-6 -Paragraph 13 -Subparagraph d false false 1 2 false UnKnown UnKnown UnKnown false true XML 15 R8.xml IDEA: Summary of Significant Accounting Policies 2.0.0.10 false Summary of Significant Accounting Policies 0202 - Disclosure - Summary of Significant Accounting Policies true false false false 1 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 nhp_SummaryOfSignificantAccountingPoliciesAbstract nhp false na duration string Summary of Significant Accounting Policies. false false false false false true false false false false false false 1 false false false false 0 0 false false false Summary of Significant Accounting Policies. false 3 1 us-gaap_SignificantAccountingPoliciesTextBlock us-gaap true na duration string No definition available. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 2 - us-gaap:SignificantAccountingPoliciesTextBlock--> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>2. Summary of Significant Accounting Policies</b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Basis of Presentation</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We have prepared the condensed consolidated financial statements included herein without audit. These financial statements include all adjustments that are, in the opinion of management, necessary for a fair presentation of the results of operations for the three months ended March&#160;31, 2010 and 2009 pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). All such adjustments are of a normal recurring nature. Certain items in prior period financial statements have been reclassified to conform to current year presentation, including those required by the provisions of Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 360, <i>Property, Plant and Equipment </i>(&#8220;ASC 360&#8221;), which require the operating results of any assets with their own identifiable cash flows that are disposed of or held for sale and in which we have no continuing interest to be removed from income from continuing operations and reported as discontinued operations. Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) have been condensed or omitted pursuant to these rules and regulations. Although we believe that the disclosures in the financial statements included herein are adequate to make the information presented not misleading, these condensed consolidated financial statements should be read in conjunction with our financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2009 filed with the SEC. The results of operations for the three months ended March&#160;31, 2010 and 2009 are not necessarily indicative of the results for a full year. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We have evaluated events subsequent to March&#160;31, 2010 for their impact on our condensed consolidated financial statements. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Principles of Consolidation</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The condensed consolidated financial statements include our accounts, the accounts of our wholly-owned subsidiaries and the accounts of our joint ventures that are controlled through voting rights or other means. We apply the provisions of ASC Topic 810, <i>Consolidation </i>(&#8220;ASC 810&#8221;), for arrangements with variable interest entities (&#8220;VIEs&#8221;) and would consolidate those VIEs where we are the primary beneficiary. All material intercompany accounts and transactions have been eliminated. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our judgment with respect to our level of influence or control of an entity and whether we are the primary beneficiary of a VIE involves the consideration of various factors including, but not limited to, the form of our ownership interest, our representation on the entity&#8217;s governing body, the size of our investment, estimates of future cash flows, our ability to participate in policy-making decisions and the rights of the other investors to participate in the decision-making process and to replace us as manager and/or liquidate the venture, if applicable. Our ability to correctly assess our influence or control over an entity or determine the primary beneficiary of a VIE affects the presentation of these entities in our consolidated financial statements. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We apply the provisions of ASC Topic 323, <i>Investments &#8212; Equity Method and Joint Ventures </i>(&#8220;ASC 323&#8221;), to investments in joint ventures. Investments in entities that we do not consolidate but for which we have the ability to exercise significant influence over operating and financial policies are reported under the equity method. Under the equity method of accounting, our share of the entity&#8217;s earnings or losses is included in our operating results. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Use of Estimates</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ materially from those estimates. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Revenue Recognition</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Rental income from operating leases is recognized in accordance with the provisions of ASC Topic 840, <i>Leases, </i>and ASC Topic 605, <i>Revenue Recognition</i>. Our leases generally contain annual rent escalators. Many of our leases contain non-contingent rent escalators for which we recognize income on a straight-line basis over the lease term. Recognizing income on a straight-line basis requires us to calculate the total non-contingent rent to be paid over the life of a lease and to recognize the revenue evenly over that life. This method results in rental income in the early years of a lease being higher than actual cash received, creating a straight-line rent receivable asset included in the caption &#8220;Other assets&#8221; on our consolidated balance sheets. At some point during the lease, depending on its terms, the cash rent payments eventually exceed the straight-line rent which results in the straight-line rent receivable asset decreasing to zero over the remainder of the lease term. Certain leases contain rent escalators contingent on revenues or other factors, including increases based on changes in the Consumer Price Index. Such revenue increases are recognized as the related contingencies are met. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We assess the collectability of straight-line rents in accordance with the applicable accounting standards and our reserve policy and defer recognition of straight-line rent if its collectability is not reasonably assured. Our assessment of the collectability of straight-line rents is based on several factors, including the financial strength of the tenant and any guarantors, the historical operations and operating trends of the facility, the historical payment pattern of the tenant and the type of facility, among others. If our evaluation of these factors indicates we may not receive the rent payments due in the future, we defer recognition of the straight-line rental income and, depending on the circumstances, we will provide a reserve against the previously recognized straight-line rent receivable asset for a portion, up to its full value, that we estimate may not be recoverable. If we change our assumptions or estimates regarding the collectability of future rent payments required by a lease, we may adjust our reserve to increase or reduce the rental revenue recognized, and/or to increase or reduce the reserve against the existing straight-line rent receivable balance. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We recorded $1.7&#160;million and $1.6&#160;million of revenues in excess of cash received during the three months ended March&#160;31, 2010 and 2009, respectively. We had straight-line rent receivables, net of reserves, recorded under the caption &#8220;Other assets&#8221; on our consolidated balance sheets of $29.3&#160;million at March&#160;31, 2010 and $27.5&#160;million at December&#160;31, 2009, net of reserves of $108.2 million and $108.3&#160;million, respectively. We evaluate the collectability of the straight-line rent receivable balances on an ongoing basis and provide reserves against receivables we believe may not be fully recoverable. The ultimate amount of straight-line rent we realize could be less than amounts currently recorded. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Gains on Sale of Facilities</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We recognize sales of facilities upon closing. Payments received from purchasers prior to closing are recorded as deposits. Gains on facilities sold are recognized using the full accrual method upon closing when the requirements of gain recognition on sale of real estate under the provisions of ASC 360 are met, including: the collectability of the sales price is reasonably assured; we have received adequate initial investment from the buyer; we are not obligated to perform significant activities after the sale to earn the gain; and other profit recognition criteria have been satisfied. Gains may be deferred in whole or in part until the sales satisfy these requirements. Gains on facilities sold to unconsolidated joint ventures in which we maintain an ownership interest are included in income from continuing operations, and the portion of the gain representing our retained ownership interest in the joint venture is deferred and included in the caption &#8220;Accounts payable and accrued liabilities&#8221; on our consolidated balance sheets. We had $15.3&#160;million of such deferred gains at March&#160;31, 2010 and December&#160;31, 2009. All other gains are included in discontinued operations. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Asset Impairment</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We review our long-lived assets individually on a quarterly basis to determine if there are indicators of impairment in accordance with the provisions of ASC 360. Indicators may include, among others, a tenant&#8217;s inability to make rent payments, operating losses or negative operating trends at the facility level, notification by a tenant that it will not renew its lease, or a decision to dispose of an asset or adverse changes in the fair value of any of our properties. For operating assets, if indicators of impairment exist, we compare the undiscounted cash flows from the expected use of the property to its net book value to determine if impairment exists. The evaluation of the undiscounted cash flows from the expected use of the property is highly subjective and is based in part on various factors and assumptions, including, but not limited to, historical operating results, available market information and known trends and market/economic conditions that may affect the property, as well as estimates of future operating income, occupancy, rental rates, leasing demand and competition. If the sum of the future estimated undiscounted cash flows is higher than the current net book value, we conclude no impairment exists. If the sum of the future estimated undiscounted cash flows is lower than its current net book value, we recognize an impairment loss for the difference between the net book value of the asset and its estimated fair value. To the extent we decide to sell an asset, we recognize an impairment loss if the current net book value of the asset exceeds its fair value less selling costs. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We evaluate our equity method investments for impairment whenever events or changes in circumstances indicate that the carrying value of our investment in an unconsolidated joint venture may exceed the fair value. If it is determined that a decline in the fair value of our investment in an unconsolidated joint venture is other-than-temporary, and if such reduced fair value is below its carrying value, an impairment is recorded. The determination of the fair value of investments in unconsolidated joint ventures involves significant judgment. Our estimates consider all available evidence including, as appropriate, the present value of the expected future cash flows discounted at market rates, general economic conditions and trends and other relevant factors. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The above analyses require us to determine whether there are indicators of impairment for individual assets or investments in unconsolidated joint ventures, to estimate the most likely stream of cash flows from operating assets and to determine the fair value of assets that are impaired or held for sale. If our assumptions, projections or estimates regarding an asset change in the future, we may have to record an impairment charge to reduce or further reduce the net book value of such individual asset or investment in unconsolidated joint venture. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">No impairment charges were recorded during the three months ended March&#160;31, 2010 or 2009. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Collectability of Receivables</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We evaluate the collectability of our rent, mortgage and other loans and other receivables on a regular basis based on factors including, among others, payment history, the financial strength of the borrower and any guarantors, the value of the underlying collateral, the operations and operating trends of the underlying collateral, if any, the asset type and current economic conditions. If our evaluation of these factors indicates we may not recover the full value of the receivable, we provide a reserve against the portion of the receivable that we estimate may not be recovered. This analysis requires us to determine whether there are factors indicating a receivable may not be fully collectible and to estimate the amount of the receivable that may not be collected. We had reserves included in the caption &#8220;Receivables, net&#8221; on our consolidated balance sheets of $14.3&#160;million at March&#160;31, 2010 and $12.7&#160;million at December&#160;31, 2009. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Accounting for Stock-Based Compensation</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We account for stock-based compensation in accordance with the provisions of ASC Topic 718, <i>Compensation-Stock Compensation, </i>which require stock-based compensation awards to be valued at the fair value on the date of grant and amortized as an expense over the vesting period and require any dividend equivalents earned to be treated as dividends for financial reporting purposes. Net income reflects stock-based compensation expense of $1.6&#160;million for each of the three months ended March 31, 2010 and 2009. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Land, Buildings and Improvements and Depreciation and Useful Lives of Assets</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We record properties at cost and use the straight-line method of depreciation for buildings and improvements over their estimated remaining useful lives of up to 40&#160;years, generally 20 to 40 years depending on factors including building type, age, quality and location. We review and adjust useful lives periodically. Depreciation expense from continuing operations was $27.8&#160;million and $25.5&#160;million for the three months ended March&#160;31, 2010 and 2009, respectively. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We allocate purchase prices of properties in accordance with the provisions of ASC Topic 805, <i>Business Combinations </i>(&#8220;ASC 805&#8221;), which require that the acquisition method of accounting be used for all business combinations and for an acquirer to be identified for each business combination. ASC 805 also establishes principles and requirements for how the acquirer recognizes and measures in its financial statements the identifiable assets acquired, the liabilities assumed and any noncontrolling interest in the acquiree. Certain transaction costs that have historically been capitalized as acquisition costs are expensed for business combinations completed on or after January&#160;1, 2009, which may have a significant impact on our future results of operations and financial position based on historical acquisition costs and activity levels. During the three months ended March&#160;31, 2010, we incurred $1.4&#160;million of acquisition costs that are included on our consolidated income statements. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The allocation of the cost between land, building and, if applicable, equipment and intangible assets and liabilities, and the determination of the useful life of a property are based on management&#8217;s estimates, which are based in part on independent appraisals or other consultants&#8217; reports. For our triple-net leased facilities, the allocation is made as if the property was vacant, and a significant portion of the cost of each property is allocated to buildings. This amount generally approximates 90% of the total property value. Historically, we have generally acquired properties and simultaneously entered into a new market rate lease for the entire property with one tenant. For our multi-tenant medical office buildings, the percentage allocated to buildings may be substantially lower as allocations are made to assets such as lease-up intangible assets, above market tenant and ground lease intangible assets and in-place lease intangible assets (collectively &#8220;intangible assets&#8221;) included on our consolidated balance sheets and/or below market tenant and ground lease intangible liabilities included in the caption &#8220;Accounts payable and accrued liabilities&#8221; on our consolidated balance sheets. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We calculate depreciation and amortization on equipment and lease costs using the straight-line method based on estimated useful lives of up to five years or the lease term, whichever is appropriate. We amortize intangible assets and liabilities over the remaining lease terms of the respective leases to real estate amortization expense or medical office building operating rent, as appropriate. We review and adjust useful lives periodically. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Cash and Cash Equivalents</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Cash and cash equivalents include short-term investments with original maturities of three months or less when purchased. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Deferred Financing Costs</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Deferred financing costs are amortized as a component of interest expense over the terms of the related borrowings using a method that approximates a level yield. Deferred financing cost amortization is included in the caption &#8220;Interest expense&#8221; on our consolidated income statements. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Derivatives</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In the normal course of business, we are exposed to financial market risks, including interest rate risk on our interest-bearing liabilities. We endeavor to limit these risks by following established risk management policies, procedures and strategies, including, on occasion, the use of derivative instruments. We do not use derivative instruments for trading or speculative purposes. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Derivative instruments are recorded on our consolidated balance sheets as assets or liabilities based on each instrument&#8217;s fair value. Changes in the fair value of derivative instruments are recognized currently in earnings, unless the derivative instrument meets the criteria for hedge accounting contained in ASC Topic 815, <i>Derivatives and Hedging </i>(&#8220;ASC 815&#8221;). If the derivative instruments meet the criteria for a cash flow hedge, the gains and losses recognized upon changes in the fair value of the derivative instrument are recorded in other comprehensive income. Gains and losses on a cash flow hedge are reclassified into earnings when the forecasted transaction affects earnings. A contract that is designated as a hedge of an anticipated transaction which is no longer likely to occur is immediately recognized in earnings. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">For investments in entities reported under the equity method of accounting, we record our pro rata share of the entity&#8217;s derivative instruments&#8217; fair value, other comprehensive income or loss and gains and losses determined in accordance with ASC 323 and ASC 815 as applicable. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Segment Reporting</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We report our consolidated financial statements in accordance with the provisions of ASC Topic 280, <i>Segment Reporting</i>. We operate in two segments based on our investment and leasing activities: triple-net leases and multi-tenant leases (see Note 16). </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Redeemable Limited Partnership Unitholders</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">NHP/PMB L.P. (&#8220;NHP/PMB&#8221;) is a limited partnership that we formed in February&#160;2008 to acquire properties from entities affiliated with Pacific Medical Buildings LLC (see Note 5). We consolidate NHP/PMB consistent with the provisions of ASC 810, as our wholly owned subsidiary is the general partner and exercises control. As of March&#160;31, 2010 and December&#160;31, 2009, third party investors owned 2,206,465 and 1,629,752 Class&#160;A limited partnership units in NHP/PMB (&#8220;OP Units&#8221;), respectively, which represented 34.7% and 53.9% of the total units outstanding at March&#160;31, 2010 and December&#160;31, 2009, respectively. During the three months ended March&#160;31, 2010, 575,326 and 1,788 OP Units were issued by NHP/PMB in connection with acquisitions and under terms of an agreement with Pacific Medical Buildings and certain of its affiliates, respectively (see Note 5). After a one year holding period, the OP Units are exchangeable for cash or, at our option, shares of our common stock, initially on a one-for-one basis. We have entered into a registration rights agreement with the holders of the OP Units which, subject to the terms and conditions set forth therein, obligates us to register the shares of common stock that we may issue in exchange for such OP Units. Since we are obligated to register the shares, the redeemable OP unitholder interests are classified outside of permanent equity on our consolidated balance sheets. During the three months ended March&#160;31, 2010, 401 OP Units were converted into 401 shares of our common stock. We applied the provisions of ASC Topic 480, <i>Distinguishing Liabilities from Equity</i>, to reflect the redeemable OP unitholder interests at the greater of cost or fair value. At March&#160;31, 2010, the fair value of the OP Units exceeded the cost basis by $1.6&#160;million, and the adjustment was recorded through capital in excess of par value. The value of the OP Units held by redeemable OP unitholder interests was $77.6&#160;million and $57.3&#160;million at March&#160;31, 2010 and December&#160;31, 2009, respectively. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Noncontrolling Interests</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We have three consolidated joint ventures in which we have equity interests, ranging from 71% to 95%, in nine multi-tenant medical office buildings (see Note 5). </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">NHP/PMB has equity interests, ranging from 50% to 69%, in three joint ventures which each own one multi-tenant medical office building (see Note 5). The joint ventures are consolidated by NHP/PMB, and we consolidate NHP/PMB in our consolidated financial statements. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We also have five partnerships in which we have equity interests, ranging from 51% to 81%, in three assisted and independent living facilities, one skilled nursing facility and one specialty hospital. We consolidate the partnerships in our consolidated financial statements. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Fair Value</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We apply the provisions of ASC Topic 820, <i>Fair Value Measurements and Disclosures </i>(&#8220;ASC 820&#8221;) to our financial assets and liabilities measured at fair value on a recurring basis and to our nonfinancial assets and liabilities that are not required or permitted to be measured at fair value on a recurring basis. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. ASC 820 also specifies a three-level hierarchy of valuation techniques based upon whether the inputs reflect assumptions other market participants would use based upon market data obtained from independent sources (observable inputs) or reflect our own assumptions of market participant valuation (unobservable inputs) and requires the use of observable inputs if such data is available without undue cost and effort. The hierarchy is as follows: </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>Level 1 &#8212; quoted prices for identical instruments in active markets.</td> </tr> </table> </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>Level 2 &#8212; observable inputs other than Level 1 inputs, including quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and other derived valuations with significant inputs or value drivers that are observable or can be corroborated by observable inputs in active markets.</td> </tr> </table> </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>Level 3 &#8212; unobservable inputs or derived valuations with significant inputs or value drivers that are unobservable.</td> </tr> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Fair value measurements at March&#160;31, 2010 are as follow: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="44%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Fair Value</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Level 1</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Level 2</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Level 3</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="14"><b>(In thousands)</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Financial assets </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">4,723</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">4,723</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Financial liabilities </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(4,723</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(4,723</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Redeemable OP unitholder interests </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">77,557</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">77,557</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">77,557</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">77,557</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">OP Units are exchangeable for cash or, at our option, shares of our common stock, initially on a one-for-one basis. As such, the fair value of OP Units outstanding at March&#160;31, 2010 is based on the closing price of our common stock on March&#160;31, 2010, which was $35.15 per share. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The provisions of ASC Topic 825, <i>Financial Instruments</i>, provide companies with an option to report selected financial assets and liabilities at fair value and establish presentation and disclosure requirements designed to facilitate comparisons between companies that choose different measurement attributes for similar types of assets and liabilities. We have not elected to apply the fair value option to any specific financial assets or liabilities. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The carrying amount of cash and cash equivalents approximates fair value because of the short maturities of these instruments. The fair value of mortgage and other loans receivable are based upon the estimates of management and on rates currently prevailing for comparable loans. The fair value of long-term debt is estimated based on discounting future cash flows utilizing current rates offered to us for debt of a similar type and remaining maturity. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The table below details the book value and fair value for mortgage and other loans receivable and the components of long-term debt at March&#160;31, 2010. These fair value estimates are not necessarily indicative of the amounts that would be realized upon disposition of these financial instruments. </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="72%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Book Value</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Fair Value</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6"><b>(In thousands)</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Mortgage loans receivable </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">216,589</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">216,349</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Other loans receivable </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">71,326</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">67,049</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Unsecured senior credit facility </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Senior notes </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">991,633</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">1,067,918</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Notes and bonds payable </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">535,950</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">532,376</td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Earnings per Share (EPS)</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Basic EPS is computed by dividing income from continuing operations available to common stockholders by the weighted average common shares outstanding. Income from continuing operations available to common stockholders is calculated by deducting amounts attributable to noncontrolling interests, amounts attributable to participating securities and dividends declared on preferred stock from income from continuing operations. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We apply the provisions of ASC Topic 260, <i>Earnings per Share</i>, which require that the two-class method of computing basic earnings per share be applied when there are unvested share-based payment awards that contain rights to nonforfeitable dividends outstanding during a reporting period. These participating securities share in undistributed earnings with common stockholders for purposes of calculating basic earnings per share. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Diluted EPS includes the effect of any potential shares outstanding, which for us is comprised of dilutive stock options, other share-settled compensation plans and, if the effect is dilutive, 7.75% Series&#160;B Cumulative Convertible Preferred Stock (&#8220;Series&#160;B Preferred Stock&#8221;), which was redeemed on January&#160;18, 2010 (see Note 10) and/or OP Units. The dilutive effect of stock options and other share-settled compensation plans that do not contain rights to nonforfeitable dividends is calculated using the treasury stock method with an offset from expected proceeds upon exercise of the stock options and unrecognized compensation expense. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Impact of New Accounting Standards Updates</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In June&#160;2009, the FASB updated ASC 810 to require ongoing analyses to determine whether an entity&#8217;s variable interest gives it a controlling financial interest in a variable interest entity (&#8220;VIE&#8221;), making it the primary beneficiary, based on whether the entity (i)&#160;has the power to direct activities of the VIE that most significantly impact its economic performance, including whether it has an implicit financial responsibility to ensure the VIE operates as designed, and (ii)&#160;has the obligation to absorb losses or the right to receive benefits of the VIE that could potentially be significant to the VIE. Enhanced disclosures regarding an entity&#8217;s involvement with VIEs are also required under the provisions of ASC 810. These requirements became effective January&#160;1, 2010. The adoption of these requirements did not have a material impact on our results of operations or financial position. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In January&#160;2010, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2010-06, <i>Improving Disclosures About Fair Value Measurements </i>(&#8220;ASU 2010-06&#8221;). ASU 2010-06 adds new requirements for disclosures of significant transfers into and out of Levels 1, 2 and 3 of the fair value hierarchy, the reasons for the transfers and the policy for determining when transfers are recognized. ASU 2010-06 also adds new requirements for disclosures about purchases, sales, issuances and settlements on a gross rather than net basis relating to the reconciliation of the beginning and ending balances of Level 3 recurring fair value measurements. It also clarifies the level of disaggregation to require disclosures by &#8220;class&#8221; rather than by &#8220;major category of assets and liabilities&#8221; and clarifies that a description of inputs and valuation techniques used to measure fair value is required for both recurring and nonrecurring fair value measurements classified as Level 2 or 3. ASU 2010-06 became effective January&#160;1, 2010 except for the requirements to provide the Level 3 activity of purchases, sales, issuances and settlements on a gross basis which are effective January&#160;1, 2011. The adoption of ASU 2010-06 has not and is not expected to have a material impact on our results of operations or financial position. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In February&#160;2010, the FASB issued ASU 2010-09, <i>Amendments to Certain Recognition and Disclosure Requirements </i>(&#8220;ASU 2010-09&#8221;). ASU 2010-09 amends ASC Topic 855, <i>Subsequent Events</i>, to require SEC registrants and conduit bond obligors to evaluate subsequent events through the date that the financial statements are issued, however, SEC registrants are exempt from disclosing the date through which subsequent events have been evaluated. All other entities are required to evaluate subsequent events through the date that the financial statements are available to be issued and must disclose the date through which subsequent events have been evaluated. ASU 2010-09 was effective upon issuance for all entities except conduit debt obligors. The adoption of ASU 2010-09 did not have an impact on our results of operations or financial position. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false false This element may be used to describe all significant accounting policies of the reporting entity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 22 -Paragraph 8 false false 1 2 false UnKnown UnKnown UnKnown false true XML 16 R22.xml IDEA: Segment Information 2.0.0.10 false Segment Information 0216 - Disclosure - Segment Information true false false false 1 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 nhp_SegmentInformationAbstract nhp false na duration string Segment Information Abstract. false false false false false true false false false false false false 1 false false false false 0 0 false false false Segment Information Abstract. false 3 1 us-gaap_SegmentReportingDisclosureTextBlock us-gaap true na duration string No definition available. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 16 - us-gaap:SegmentReportingDisclosureTextBlock--> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>16. Segment Information</b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our operations are organized into two segments &#8212; triple-net leases and multi-tenant leases. In the triple-net leases segment, we invest in healthcare related properties and lease the facilities to unaffiliated tenants under &#8220;triple-net&#8221; and generally &#8220;master&#8221; leases that transfer the obligation for all facility operating costs (including maintenance, repairs, taxes, insurance and capital expenditures) to the tenant. In the multi-tenant leases segment, we invest in healthcare related properties that have several tenants under separate leases in each building, thus requiring active management and responsibility for many of the associated operating expenses (although many of these are, or can effectively be, passed through to the tenants). During 2009 and the three months ended March&#160;31, 2010, the multi-tenant leases segment was comprised exclusively of medical office buildings. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Non-segment revenues primarily consist of interest income on mortgages and unsecured loans and other income. Interest expense, depreciation and amortization and other expenses not attributable to individual facilities are not allocated to individual segments for purposes of assessing segment performance. Non-segment assets primarily consist of corporate assets including mortgages and unsecured loans, investment in unconsolidated joint ventures, cash, deferred financing costs and other assets not attributable to individual facilities. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Certain items in prior period financial statements have been reclassified to conform to current period presentation, including those required by ASC 360 which require the operating results of any assets with their own identifiable cash flows that are disposed of or held for sale and in which we have no continuing interest to be removed from income from continuing operations and reported as discontinued operations. Summary information related to our reportable segments is as follows: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="72%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6"><b>Three months ended</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>March 31,</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2009</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6"><b>(In thousands)</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Revenue: </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Triple-net leases </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">74,214</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">74,095</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Multi-tenant leases </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">21,251</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">16,653</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Non-segment </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">6,963</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6,335</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">102,428</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">97,083</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Net operating income (1): </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Triple-net leases </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">74,214</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">74,095</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Multi-tenant leases </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">12,604</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">9,819</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">86,818</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">83,914</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="72%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2"><b>March 31,</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2"><b>December 31,</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2009</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6"><b>(In thousands)</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Assets: </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Triple-net leases </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">2,416,724</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">2,440,158</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Multi-tenant leases </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">898,910</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">572,410</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Non-segment </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">498,010</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">634,507</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">3,813,644</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">3,647,075</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left"> <div style="font-size: 3pt; margin-top: 13pt; width: 18%; border-bottom: 1px solid #000000">&#160; </div> </div> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr style="font-size: 6pt"> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="96">&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left">(1)</td> <td>&#160;</td> <td>Net operating income (&#8220;NOI&#8221;) is a non-GAAP supplemental financial measure used to evaluate the operating performance of our facilities. We define NOI for our triple-net leases segment as rent revenues. For our multi-tenant leases segment, we define NOI as revenues minus medical office building operating expenses. In some cases, revenue for medical office buildings includes expense reimbursements for common area maintenance charges. NOI excludes interest expense and amortization of deferred financing costs, depreciation and amortization expense, general and administrative expense and discontinued operations. We present NOI as it effectively presents our portfolio on a &#8220;net&#8221; rent basis and provides relevant and useful information as it measures the operating performance at the facility level on an unleveraged basis. We use NOI to make decisions about resource allocations and to assess the property level performance of our properties. Furthermore, we believe that NOI provides investors relevant and useful information because it measures the operating performance of our real estate at the property level on an unleveraged basis. We believe that net income is the GAAP measure that is most directly comparable to NOI. However, NOI should not be considered as an alternative to net income as the primary indicator of operating performance as it excludes the items described above. Additionally, NOI as presented above may not be comparable to other REITs or companies as their definitions of NOI may differ from ours.</td> </tr> </table> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">A reconciliation of net income, a GAAP measure, to NOI, a non-conforming GAAP measure, is as follows: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="72%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6"><b>Three months ended</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>March 31,</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2009</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6"><b>(In thousands)</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Net income </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">31,239</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">50,633</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Interest and other income </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(6,963</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(6,335</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Interest expense and amortization of deferred financing costs </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">23,590</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">24,071</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Depreciation and amortization expense </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">31,969</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">30,832</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">General and administrative expense </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">6,984</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">6,931</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Acquisition costs </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,443</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Income from unconsolidated joint ventures </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1,347</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1,013</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Gain on debt extinguishment </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(75</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Gains on sale of facilities, net </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(22</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(21,152</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Income from discontinued operations </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(53</td> <td nowrap="nowrap">)</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Net operating income from reportable segments </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">86,818</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">83,914</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false false This element may be used to capture the complete disclosure of reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10% or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 131 false false 1 2 false UnKnown UnKnown UnKnown false true XML 17 R18.xml IDEA: Discontinued Operations 2.0.0.10 false Discontinued Operations 0212 - Disclosure - Discontinued Operations true false false false 1 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 nhp_DiscontinuedOperationsAbstract nhp false na duration string Discontinued Operations. false false false false false true false false false false false false 1 false false false false 0 0 false false false Discontinued Operations. false 3 1 us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock us-gaap true na duration string No definition available. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 12 - us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock--> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>12. Discontinued Operations</b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">ASC 360 requires the operating results of any assets with their own identifiable cash flows that are disposed of or held for sale and in which we have no continuing interest be removed from income from continuing operations and reported as discontinued operations. The operating results for any such assets for any prior periods presented must also be reclassified as discontinued operations. If we have a continuing involvement, as in the sales to our unconsolidated joint venture, the operating results remain in continuing operations. The following table details the operating results reclassified to discontinued operations for the periods presented: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="72%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6"><b>Three months ended</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>March 31,</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2009</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6"><b>(In thousands)</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Rental income </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">325</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Interest and other income </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">19</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">344</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Expenses: </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Interest expense and amortization of deferred financing costs </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Depreciation and amortization </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">291</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">General and administrative </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Medical office building operating expenses </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">291</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Income from discontinued operations </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">53</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false false Disclosure includes the facts and circumstances leading to the completed or expected disposal, manner and timing of disposal, the gain or loss recognized in the income statement and the income statement caption that includes that gain or loss, amounts of revenues and pretax profit or loss reported in discontinued operations, the segment in which the disposal group was reported, and the classification (whether sold or classified as held for sale) and carrying value of the assets and liabilities comprising the disposal group. Includes all disposal groups, including those classified as components of the entity (discontinued operations). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 144 -Paragraph 43-48 false false 1 2 false UnKnown UnKnown UnKnown false true XML 18 R12.xml IDEA: Investment in Unconsolidated Joint Ventures 2.0.0.10 false Investment in Unconsolidated Joint Ventures 0206 - Disclosure - Investment in Unconsolidated Joint Ventures true false false false 1 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 nhp_InvestmentInUnconsolidatedJointVenturesAbstract nhp false na duration string Investment in Unconsolidated Joint Ventures Abstract. false false false false false true false false false false false false 1 false false false false 0 0 false false false Investment in Unconsolidated Joint Ventures Abstract. false 3 1 us-gaap_EquityMethodInvestmentsDisclosureTextBlock us-gaap true na duration string No definition available. false false false false false false false false false false false false 1 false false false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 6 - us-gaap:EquityMethodInvestmentsDisclosureTextBlock--> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>6. Investment in Unconsolidated Joint Ventures</b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>State Pension Fund Investor</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In January&#160;2007, we entered into a joint venture with a state pension fund investor. The purpose of the joint venture is to acquire and develop assisted living, independent living and skilled nursing facilities. We manage and own 25% of the joint venture, which will fund its investments with approximately 40% equity contributions and 60% debt. The original approved investment target was $475.0&#160;million, but we exceeded that amount in 2007, and the total potential investment amount has been increased to $975.0&#160;million. The financial statements of the joint venture are not consolidated in our financial statements as our joint venture partner has substantive participating rights, and accordingly our investment is accounted for using the equity method. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">At March&#160;31, 2010, the joint venture owned 19 assisted and independent living facilities, 14 skilled nursing facilities and one continuing care retirement community located in nine states. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During January&#160;2008, the joint venture entered into an interest rate swap contract that is designated as effectively hedging the variability of expected cash flows related to variable rate debt placed on a portion of its portfolio. The cash flow hedge has a fixed rate of 4.235%, a notional amount of $126.1&#160;million and expires on January&#160;1, 2015. The fair value of this contract at March&#160;31, 2010 and December&#160;31, 2009 was $9.9&#160;million and $8.2&#160;million, respectively, which is included in accrued liabilities on the joint venture&#8217;s balance sheet. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Cash distributions from the joint venture are made in accordance with the members&#8217; ownership interests until specified returns are achieved. As the specified returns are achieved, we will receive an increasing percentage of the cash distributions from the joint venture. During the three months ended March&#160;31, 2010, we received distributions of $0.7&#160;million from the joint venture. In addition to our share of the income, we receive a monthly management fee calculated as a percentage of the equity investment in the joint venture. This fee is included in our income from unconsolidated joint ventures and in the general and administrative expenses on the joint venture&#8217;s income statement. During the three months ended March&#160;31, 2010 and 2009, we earned management fees of $1.1&#160;million and $1.0&#160;million, respectively. During each of the three months ended March&#160;31, 2010 and 2009, our share of the net income was $0.2&#160;million. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>PMB Real Estate Services LLC</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In February&#160;2008, we entered into an agreement with Pacific Medical Buildings LLC to acquire a 50% interest in PMBRES, a full service property management company. The transaction closed on April 1, 2008. In consideration for the 50% interest, we paid $1.0&#160;million at closing, and we will make additional payments on or before March&#160;31, 2010 and 2011 equal to six times the normalized net operating profit of PMBRES for 2009 and 2010, respectively (in each case, less the amount of all prior payments). During 2009, PMBRES had a normalized net operating loss, and as such, no additional payment was made during the three months ended March&#160;31, 2010. PMBRES provides property management services for 32 multi-tenant medical office buildings that we own or in which we have an ownership interest. During the three months ended March&#160;31, 2010, our share of the net income was $28,000. During the three months ended March&#160;31, 2009, our share of the net loss was $0.2&#160;million. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>PMB SB 399-401 East Highland LLC</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In August&#160;2008, we acquired from PMB SB (an entity affiliated with Pacific Medical Buildings LLC) a 44.95% interest in an entity that owned two multi-tenant medical office buildings for $3.5 million. As of March&#160;1, 2010, we acquired the remaining 55.05% interest in PMB SB. PMB SB was valued at $17.4&#160;million at the date of acquisition, and the acquisition was paid in a combination of cash and the assumption of $11.2&#160;million of mortgage financing (of which $6.2&#160;million was previously attributable to the controlling interest in PMB SB). Prior to the acquisition, our investment in PMB SB was $3.0&#160;million which was accounted for under the equity method. In connection with the acquisition, we re-measured our previously held equity interest at the acquisition date fair value based on an independent consultant&#8217;s report and recognized a net gain on the re-measurement of $0.6&#160;million which is included in the caption &#8220;Interest and other income&#8221; on our consolidated income statements. Subsequent activity related to these facilities is included in our consolidated activity for wholly owned real estate properties (see Note 3). </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During the period from January&#160;1, 2010 to February&#160;28, 2010, we received distributions of $0.1 million from PMB SB. During the period from January&#160;1, 2010 to February&#160;28, 2010, our share of the net income was $12,000. During the three months ended March&#160;31, 2009, our share of the net income was $21,000. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false false Equity investment disclosure, or group of investments for which combined disclosure is appropriate, including: (a) the name of each investee and percentage of ownership of common stock, (b) accounting policies for investments in common stock, (c) difference between the amount at which the investment is carried and the amount of underlying equity in net assets and the accounting treatment of the difference, (d) the total fair value of each identified investment for which a market value is available, (e) summarized information as to assets, liabilities, and results of operations of the investees (for investments in unconsolidated subsidiaries, common stock of joint ventures, or other investments using the equity method), and (f) material effects of possible conversions, exercises, or contingent issuances of the investee. Other disclosures include (a) the names of any investee in which the investor owns 20 percent or more of the voting stock and investment is not accounted for using the equity method, and the reasons why not, and (b) the names of any investee in which the investor owns less than 20% of the voting stock and the investment is accounted for using the equity method, and the reasons why it is. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 18 -Paragraph 20 false false 1 2 false UnKnown UnKnown UnKnown false true XML 19 R3.xml IDEA: Condensed Consolidated Balance Sheets (Parenthetical) 2.0.0.10 false Condensed Consolidated Balance Sheets (Parenthetical) 0111 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) true false false false 1 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 false 2 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 3 1 us-gaap_StockholdersEquityAbstract us-gaap true na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false No definition available. false 4 2 us-gaap_PreferredStockParOrStatedValuePerShare us-gaap true na instant decimal No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 1 1 false false false 2 false true false false 1 1 false false false Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 129 -Paragraph 2, 3, 4, 5, 6, 7, 8 false 5 2 us-gaap_PreferredStockSharesAuthorized us-gaap true na instant shares No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 5000000 5000000 false false false 2 false true false false 5000000 5000000 false false false The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 129 -Paragraph 2, 3, 4, 5, 6, 7, 8 false 6 2 us-gaap_PreferredStockSharesIssued us-gaap true na instant shares No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 0 0 false false false 2 false true false false 513644 513644 false false false Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 false 7 2 us-gaap_PreferredStockSharesOutstanding us-gaap true na instant shares No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 0 0 false false false 2 false true false false 513644 513644 false false false Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 false 8 2 us-gaap_PreferredStockLiquidationPreference us-gaap true na instant decimal No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 100 100 false false false 2 false true false false 100 100 false false false The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph d -Article 4 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 129 -Paragraph 4, 6 false 9 2 us-gaap_CommonStockParOrStatedValuePerShare us-gaap true na instant decimal No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 0.1 0.1 false false false 2 false true false false 0.1 0.1 false false false Face amount or stated value of common stock per share; generally not indicative of the fair market value per share. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 129 -Paragraph 4 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false 10 2 us-gaap_CommonStockSharesAuthorized us-gaap true na instant shares No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 200000000 200000000 false false false 2 false true false false 200000000 200000000 false false false The maximum number of common shares permitted to be issued by an entity's charter and bylaws. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false 11 2 us-gaap_CommonStockSharesIssued us-gaap true na instant shares No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 118184009 118184009 false false false 2 false true false false 114320786 114320786 false false false Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false 12 2 us-gaap_CommonStockSharesOutstanding us-gaap true na instant shares No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 118184009 118184009 false false false 2 false true false false 114320786 114320786 false false false Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Excludes common shares repurchased by the entity and held as Treasury shares. Shares outstanding equals shares issued minus shares held in treasury. Does not include common shares that have been repurchased. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false false 2 10 false UnKnown NoRounding UnKnown false true XML 20 R14.xml IDEA: Other Assets 2.0.0.10 false Other Assets 0208 - Disclosure - Other Assets true false false false 1 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 nhp_OtherAssetsAbstract nhp false na duration string Other Assets. false false false false false true false false false false false false 1 false false false false 0 0 false false false Other Assets. false 3 1 us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock us-gaap true na duration string No definition available. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 8 - us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock--> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>8. Other Assets</b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">At March&#160;31, 2010 and December&#160;31, 2009, other assets consisted of: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="72%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2"><b>March 31,</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2"><b>December 31,</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2009</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6"><b>(In thousands)</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Other receivables, net of reserves of $4.2 million at March&#160;31, 2010 and December&#160;31, 2009 </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">67,152</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">68,535</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Straight-line rent receivables, net of reserves of $108.2&#160;million and $108.3&#160;million at March&#160;31, 2010 and December&#160;31, 2009, respectively </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">29,279</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">27,450</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Deferred financing costs </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">11,436</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">11,366</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Capitalized lease and loan origination costs </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,247</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">2,418</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Investments and restricted funds </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">13,911</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">9,545</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Prepaid ground leases </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">12,993</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">10,051</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Other </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">4,309</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">3,787</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">141,327</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">133,152</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Included in other receivables at both March&#160;31, 2010 and December&#160;31, 2009, are two unsecured loans to Emeritus Corporation in the amount of $21.4&#160;million and $30.0&#160;million due in March&#160;2012 and April&#160;2012, respectively. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Investments are recorded at fair value using quoted market prices. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false false Note disclosure of claims held for amounts due a company. Examples include trade accounts receivables, notes receivables, loans receivables, and so forth. This element may be used as a single block of text to encapsulate the entire disclosure including data and tables. No authoritative reference available. false false 1 2 false UnKnown UnKnown UnKnown false true XML 21 R15.xml IDEA: Debt 2.0.0.10 false Debt 0209 - Disclosure - Debt true false false false 1 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 nhp_DebtAbstract nhp false na duration string Debt Abstract. false false false false false true false false false false false false 1 false false false false 0 0 false false false Debt Abstract. false 3 1 us-gaap_DebtDisclosureTextBlock us-gaap true na duration string No definition available. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 9 - us-gaap:DebtDisclosureTextBlock--> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>9. Debt</b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Unsecured Senior Credit Facility</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">At March&#160;31, 2010, we had no balance outstanding on our $700.0&#160;million revolving unsecured senior credit facility. At our option, borrowings under the credit facility bear interest at the prime rate (3.25% at March&#160;31, 2010) or applicable LIBOR plus 0.70% (0.95% at March&#160;31, 2010). We pay a facility fee of 0.15% per annum on the total commitment under the agreement. The credit facility matures on December&#160;15, 2010. The maturity date may be extended by one additional year at our discretion. As of March&#160;31, 2010, we were in compliance with all covenants under the credit facility. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Senior Notes</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The aggregate principal amount of notes outstanding at March&#160;31, 2010 was $991.6&#160;million. At March&#160;31, 2010, the weighted average interest rate on the notes was 6.47% and the weighted average maturity was 4.7&#160;years. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Notes and Bonds Payable</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The aggregate principal amount of notes and bonds payable at March&#160;31, 2010 was $536.0 million. Notes and bonds payable are due through the year 2037, at interest rates ranging from 1.08% to 8.63% and are secured by real estate properties with an aggregate net book value as of March&#160;31, 2010 of $799.2&#160;million. At March&#160;31, 2010, the weighted average interest rate on the notes and bonds payable was 5.35% and the weighted average maturity was 6.7&#160;years. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During the three months ended March&#160;31, 2010, we assumed mortgages as part of certain acquisitions totaling $109.5&#160;million. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During the three months ended March&#160;31, 2010, we repaid at maturity $2.9&#160;million of fixed rate secured debt that bore interest at 8.02%. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During the three months ended March&#160;31, 2010, we exercised a 12-month extension option on a $32.4&#160;million loan that was scheduled to mature in April&#160;2010. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Debt Maturities</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The principal balances of our debt as of March&#160;31, 2010 mature as follows: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="44%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2"><b>Credit</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2"><b>Senior</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2"><b>Notes and Bonds</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2">&#160;</td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000"><b>Year</b></td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Facility</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Notes</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Payable</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Total</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="14"><b>(In thousands)</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">2010 </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">77,275</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">77,275</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">2011 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">339,040</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">71,483</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">410,523</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">2012 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">72,950</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">51,131</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">124,081</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">2013 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">269,850</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">38,997</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">308,847</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">2014 </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">22,167</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">22,167</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Thereafter (1) </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">309,793</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">274,897</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">584,690</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">991,633</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">535,950</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">1,527,583</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> </div> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr style="font-size: 6pt"> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="96">&#160;</td> </tr> <tr valign="top"> <td nowrap="nowrap" align="left">(1)</td> <td>&#160;</td> <td>There are $52.4&#160;million of senior notes due in 2037 which may be put back to us at their face amount at the option of the holder on October 1 of any of the following years: 2012, 2017 or 2027. There are $23.0&#160;million of senior notes due in 2038 which may be put back to us at their face amount at the option of the holder on July 7 of any of the following years: 2013, 2018, 2023 or 2028.</td> </tr> </table> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false false Information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19, 20, 22 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 129 -Paragraph 2, 4 false false 1 2 false UnKnown UnKnown UnKnown false true XML 22 R24.xml IDEA: Related Party Transactions 2.0.0.10 false Related Party Transactions 0218 - Disclosure - Related Party Transactions true false false false 1 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 nhp_RelatedPartyTransactionsAbstract nhp false na duration string Related Party Transactions Abstract. false false false false false true false false false false false false 1 false false false false 0 0 false false false Related Party Transactions Abstract. false 3 1 us-gaap_RelatedPartyTransactionsDisclosureTextBlock us-gaap true na duration string No definition available. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 18 - us-gaap:RelatedPartyTransactionsDisclosureTextBlock--> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>18. Related Party Transactions</b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In August&#160;2008, Dr.&#160;Jeffrey Rush became a director of NHP. In August&#160;2008, we acquired for $3.5&#160;million a 44.95% interest in PMB SB, an entity that owns two multi-tenant medical office buildings, and as of March&#160;1, 2010, we acquired the remaining interest in PMB SB (see Note 6). Dr. Rush, through an unaffiliated entity, had an ownership interest in PMB SB. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In September&#160;2008, we funded a mortgage loan secured by a multi-tenant medical office building in the amount of $47.5&#160;million. As of February&#160;1, 2010, we acquired the multi-tenant medical office building, and as a result, the loan was retired (see Notes 4 and 5). Dr.&#160;Rush has an ownership interest in another unaffiliated entity that owned the multi-tenant medical office building that was security for this loan. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In February&#160;2008, we entered into an agreement with Pacific Medical Buildings LLC to acquire a 50% interest in PMBRES, a full service property management company (see Note 6). Dr.&#160;Rush, through an unaffiliated entity, has an ownership interest in PMB Partners LLC which owns 50% of PMBRES. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We have entered into an agreement with PMB Pomona LLC to acquire a medical office building currently in development for $37.5&#160;million upon completion which was amended as of February&#160;1, 2010 to provide for the future acquisition of the medical office building by NHP/PMB. Dr.&#160;Rush, through an unaffiliated entity, has an ownership interest in PMB Pomona LLC. We have also entered into an agreement with PMB LLC, the manager of PMB Pomona LLC, to extend up to $3.0&#160;million of funding at an interest rate of 7.25%, which is secured by 100% of the membership interests in PMB Pomona LLC (see Note 17). </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As of March&#160;1, 2010, NHP/PMB became obligated to pay $2.1&#160;million under the Contribution Agreement, of which $1.9&#160;million was paid to Pacific Medical Buildings LLC in cash (see Note 5). Dr.&#160;Rush is the Chairman of and owns an interest in Pacific Medical Buildings LLC. In addition, Dr. Rush and certain of his family members own or owned interests, directly and indirectly through partnerships and trusts, in the entities that contributed the five multi-tenant medical office buildings acquired by NHP/PMB, Gilbert JV and Pasadena JV during the three months ended March&#160;31, 2010 (see Note 6) and/or own the remaining development property that may be acquired in the future under the Contribution Agreement. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false false This element may be used for the entire related party transactions disclosure as a single block of text. Disclosure may include: the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of an y tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph b -Article 3A Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph k -Article 4 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 57 -Paragraph 1-4 false false 1 2 false UnKnown UnKnown UnKnown false true XML 23 R20.xml IDEA: Comprehensive Income 2.0.0.10 false Comprehensive Income 0214 - Disclosure - Comprehensive Income true false false false 1 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 us-gaap_ComprehensiveIncomeNoteAbstract us-gaap true na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false No definition available. false 3 1 us-gaap_ComprehensiveIncomeNoteTextBlock us-gaap true na duration string No definition available. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 14 - us-gaap:ComprehensiveIncomeNoteTextBlock--> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>14. Comprehensive Income</b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During January&#160;2008, the unconsolidated joint venture we have with a state pension fund investor entered into an interest rate swap contract (see Note 6). As of March&#160;31, 2010, we had recorded our pro rata share of the unconsolidated joint venture&#8217;s accumulated other comprehensive loss related to this contract of $2.5&#160;million. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We recorded the August and September&#160;2007 Treasury lock agreements on our balance sheets at their estimated fair value of $0.1&#160;million at September&#160;30, 2007. In connection with the settlement of the August and September&#160;2007 Treasury lock agreements on October&#160;17, 2007, we recognized a gain of $1.6&#160;million. The gain was recognized through other comprehensive income and is being amortized over the life of the related $300.0&#160;million of notes which mature in 2013 as a yield reduction. During the three months ended March&#160;31, 2010 and 2009, we recorded $64,000 and $67,000 of amortization, respectively. We expect to record $0.3&#160;million of amortization during the next 12 months. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We recorded the June&#160;2006 Treasury lock agreements on our balance sheets at their estimated fair value of $1.6&#160;million at June&#160;30, 2006. In connection with the settlement of the June&#160;2006 Treasury lock agreements on July&#160;11, 2006, we recognized a gain of $1.2&#160;million. The gain was recognized through other comprehensive income and is being amortized over the life of the related $350.0&#160;million of notes which mature in 2011 as a yield reduction. During the three months ended March&#160;31, 2010 and 2009, we recorded $62,000 and $58,000 of amortization, respectively. We expect to record $0.3&#160;million of amortization during the next 12&#160;months. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The following table sets forth the computation of comprehensive income for the periods presented: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="72%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6"><b>Three months ended</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>March 31,</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2009</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 0px solid #000000"><b>(In thousands)</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Net income </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">31,239</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">50,633</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Other comprehensive income: </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Pro rata share of accumulated other comprehensive loss from unconsolidated joint venture </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(436</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(3,547</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Amortization of gains on Treasury lock agreements </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(126</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(125</td> <td nowrap="nowrap">)</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Comprehensive income </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">30,677</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">46,961</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Comprehensive loss (income)&#160;attributable to noncontrolling interests </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">190</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(27</td> <td nowrap="nowrap">)</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Comprehensive income attributable to NHP </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">30,867</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">46,934</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false false This label may include the following: 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income. Components of comprehensive income include: (1) foreign currency translation adjustments; (2) gains and losses on foreign currency transactions that are designated as, and are effective as, economic hedges of a net investment in a foreign entity; (3) gains and losses on intercompany foreign currency transactions that are of a long-term-investment nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting enterprise's financial statements; (4) change in the market value of a futures contract that qualifies as a hedge of an asset reported at fair value; (5) unrealize d holding gains and losses on available-for-sale securities and that resulting from transfers of debt securities from the held-to-maturity category to the available-for-sale category; (6) a net loss recognized as an additional pension liability not yet recognized as net periodic pension cost; and (7) the net gain or loss and net prior service cost or credit for pension plans and other postretirement benefit plans. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 130 -Paragraph 14-26 false false 1 2 false UnKnown UnKnown UnKnown false true XML 24 R4.xml IDEA: Condensed Consolidated Income Statements (Unaudited) 2.0.0.10 false Condensed Consolidated Income Statements (Unaudited) (USD $) 0120 - Statement - Condensed Consolidated Income Statements (Unaudited) true false In Thousands, except Per Share data false false 1 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 false 2 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 3 1 us-gaap_RevenuesAbstract us-gaap true na duration string No definition available. false false false false false true false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false No definition available. false 4 2 nhp_TriplenetLeaseRent nhp false credit duration monetary The total amount of revenue recognized for the period from triple-net operating leases, including minimum lease revenue,... false false false false false false false false false false false verboselabel false 1 true true false false 74214000 74214 false false false 2 true true false false 74095000 74095 false false false The total amount of revenue recognized for the period from triple-net operating leases, including minimum lease revenue, contingent revenue, percentage revenue and sublease revenue. No authoritative reference available. false 5 2 nhp_MedicalOfficeBuildingOperatingRent nhp false credit duration monetary The total amount of revenue recognized for the period from multi-tenant operating leases, including minimum lease revenue,... false false false false false false false false false false false totallabel false 1 false true false false 21251000 21251 false false false 2 false true false false 16653000 16653 false false false The total amount of revenue recognized for the period from multi-tenant operating leases, including minimum lease revenue, contingent revenue, percentage revenue and sublease revenue. No authoritative reference available. true 6 2 us-gaap_OperatingLeasesIncomeStatementLeaseRevenue us-gaap true credit duration monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 95465000 95465 false false false 2 false true false false 90748000 90748 false false false The total amount of revenue recognized for the period from operating leases, including minimum lease revenue, contingent revenue, percentage revenue and sublease revenue. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 13 -Paragraph 19 -Subparagraph b false 7 2 nhp_InterestAndOtherIncome nhp false credit duration monetary Interest earned on invested cash, including loans receivable, and various other miscellaneous revenue items. false false false false false false false false false false false totallabel false 1 false true false false 6963000 6963 false false false 2 false true false false 6335000 6335 false false false Interest earned on invested cash, including loans receivable, and various other miscellaneous revenue items. No authoritative reference available. true 8 2 us-gaap_Revenues us-gaap true credit duration monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false 102428000 102428 false false false 2 false true false false 97083000 97083 false false false Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 true 9 1 us-gaap_OperatingExpensesAbstract us-gaap true na duration string No definition available. false false false false false true false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false No definition available. false 10 2 us-gaap_InterestExpense us-gaap true debit duration monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 23590000 23590 false false false 2 false true false false 24071000 24071 false false false The cost of borrowed funds accounted for as interest that was charged against earnings during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 34 -Paragraph 21 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher OTS -Name Federal Regulation (FR) -Number Title 12 -Chapter V -Section 563c.102 -Paragraph 9 -Subsection II Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 9 -Article 9 false 11 2 us-gaap_DepreciationAndAmortization us-gaap true debit duration monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 31969000 31969 false false false 2 false true false false 30832000 30832 false false false The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 5 false 12 2 us-gaap_GeneralAndAdministrativeExpense us-gaap true debit duration monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 6984000 6984 false false false 2 false true false false 6931000 6931 false false false The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. No authoritative reference available. false 13 2 us-gaap_BusinessCombinationAcquisitionRelatedCosts us-gaap true debit duration monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 1443000 1443 false false false 2 false false false false 0 0 false false false This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141R -Paragraph 59 false 14 2 us-gaap_CostOfRealEstateRevenue us-gaap true debit duration monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false 8647000 8647 false false false 2 false true false false 6834000 6834 false false false This element represents the total of the costs related to real estate revenues, including management, leasing, and development services. No authoritative reference available. true 15 2 us-gaap_OperatingExpenses us-gaap true debit duration monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false 72633000 72633 false false false 2 false true false false 68668000 68668 false false false Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No authoritative reference available. true 16 1 us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments us-gaap true credit duration monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 29795000 29795 false false false 2 false true false false 28415000 28415 false false false Sum of operating profit and nonoperating income (expense) before income (loss) from equity method investments, income taxes, extraordinary items, cumulative effects of changes in accounting principles, and noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph h -Subparagraph 1(i) -Article 4 false 17 1 nhp_IncomeLossFromUnconsolidatedJointVentures nhp false credit duration monetary This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as... false false false false false false false false false false false verboselabel false 1 false true false false 1347000 1347 false false false 2 false true false false 1013000 1013 false false false This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. Such amount typically reflects adjustments similar to those made in preparing consolidated statements, including adjustments to eliminate intercompany gains and losses, and to amortize, if appropriate, any difference between cost and underlying equity in net assets of the investee at the date of investment. Also includes management fees received from such investees. No authoritative reference available. false 18 1 us-gaap_GainsLossesOnExtinguishmentOfDebt us-gaap true credit duration monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false 75000 75 false false false 2 false false false false 0 0 false false false Amount represents the difference between the fair value of the payments made and the carrying amount of the debt at the time of its extinguishment. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 26 -Paragraph 20, 21 true 19 1 us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest us-gaap true credit duration monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false 31217000 31217 false false false 2 false true false false 29428000 29428 false false false This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items, cumulative effects of changes in accounting principles, and noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 29 true 20 1 us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract us-gaap true na duration string No definition available. false false false false false true false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false No definition available. false 21 2 us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax us-gaap true credit duration monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 22000 22 false false false 2 false true false false 21152000 21152 false false false Gain (loss) after tax expense (benefit), not previously recognized and resulting from the sale of a business component, which is recognized at the date of sale. A gain (loss) reflects the amount by which the consideration received exceeds (is exceeded by) the net carrying amount (reflecting previous provisions for loss on disposal, if any) of the disposal group. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 144 -Paragraph 43 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 144 -Paragraph 47 -Subparagraph b false 22 2 us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax us-gaap true credit duration monetary No definition available. false false false false false false false false false false false totallabel false 1 false false false false 0 0 false false false 2 false true false false 53000 53 false false false After tax income (loss) from operations of a business component (exclusive of any gain or loss on disposal, or provision therefore) during the reporting period, until its disposal. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 144 -Paragraph 43 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 144 -Paragraph 47 -Subparagraph c true 23 2 us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax us-gaap true credit duration monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false 22000 22 false false false 2 false true false false 21205000 21205 false false false This element represents the overall income (loss) from a disposal group that is classified as a component of the entity, net of income tax, reported as a separate component of income before extraordinary items and the cumulative effect of accounting changes before deduction or consideration of the amount which may be allocable to noncontrolling interests, if any. Includes the following (net of tax): income (loss) from operations during the phase-out period, gain (loss) on disposal, provision (or any reversals of earlier provisions) for loss on disposal, and adjustments of a prior period gain (loss) on disposal. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 13 -Article 7 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 15 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 29 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 144 -Paragraph 43 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 144 -Paragraph 47 -Subparagraph c true 24 1 us-gaap_ProfitLoss us-gaap true credit duration monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 31239000 31239 false false false 2 false true false false 50633000 50633 false false false The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A1, A4, A5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 5 -Subparagraph b Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 29 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph a Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph c(1) false 25 1 us-gaap_NetIncomeLossAttributableToNoncontrollingInterest us-gaap true debit duration monetary No definition available. false false false false false false false false false false true negatedtotal false 1 false true false false 190000 190 false false false 2 false true false false -27000 -27 false false false The portion of net income (loss) attributable to the noncontrolling interest (if any) deducted in order to derive the portion attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph a Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph c(1) Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A1, A4, A5 true 26 1 us-gaap_NetIncomeLoss us-gaap true credit duration monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 31429000 31429 false false false 2 false true false false 50606000 50606 false false false The portion of consolidated profit or loss for the period, net of income taxes, which is attributable to the parent. If the entity does not present consolidated financial statements, the amount of profit or loss for the period, net of income taxes. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph d Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A7 -Appendix A Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph a Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 130 -Paragraph 10, 15 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 87-21 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28, 29, 30 false 27 1 us-gaap_PreferredStockDividends us-gaap true debit duration monetary No definition available. false false false false false false false false false false true negatedtotal false 1 false false false false 0 0 false false false 2 false true false false -1452000 -1452 false false false The amount of dividends declared or paid in the period to preferred shareholders, or the amount for which the obligation to pay them dividends arose in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 6 -Section B Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 40 -Subparagraph b true 28 1 us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic us-gaap true credit duration monetary No definition available. false false false false false false false false false false false totallabel false 1 true true false false 31429000 31429 false false false 2 true true false false 49154000 49154 false false false Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 9 true 29 1 us-gaap_EarningsPerShareBasicAbstract us-gaap true na duration string No definition available. false false false false false true false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false No definition available. false 30 2 us-gaap_IncomeLossFromContinuingOperationsPerBasicShare us-gaap true na duration decimal No definition available. false false false false false false false false false false false verboselabel true 1 true true false false 0.27 0.27 false false false 2 true true false false 0.27 0.27 false false false The amount of income (loss) from continuing operations per each share of common stock outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 21 -Article 9 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 36, 37, 38 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 20 -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 18 -Article 7 false 31 2 us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare us-gaap true na duration decimal No definition available. false false false false false false false false false false false totallabel true 1 false false false false 0 0 false false false 2 true true false false 0.21 0.21 false false false The amount of income (loss) from disposition of discontinued operations, net of related tax effect, per each share of common stock outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 8, 9, 10, 36, 37, 38 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 20 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 18 -Article 7 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 21 -Article 9 true 32 2 us-gaap_EarningsPerShareBasic us-gaap true na duration decimal No definition available. false false false false false false false false false false false totallabel true 1 true true false false 0.27 0.27 false false false 2 true true false false 0.48 0.48 false false false The amount of net income or loss for the period per each share of common stock outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 21 -Article 9 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 36, 37, 38 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 20 -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 18 -Article 7 true 33 2 us-gaap_WeightedAverageNumberOfSharesOutstandingBasic us-gaap true na duration shares No definition available. false false false false false false false false false false false totallabel false 1 false true false false 117048000 117048 false false false 2 false true false false 102355000 102355 false false false Number of [basic] shares, after adjustment for contingently issuable shares and other shares not deemed outstanding, determined by relating the portion of time within a reporting period that common shares have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 171 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 40 -Subparagraph a Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 8 true 34 1 us-gaap_EarningsPerShareDilutedAbstract us-gaap true na duration string No definition available. false false false false false true false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false No definition available. false 35 2 us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare us-gaap true na duration decimal No definition available. false false false false false false false false false false false verboselabel true 1 true true false false 0.26 0.26 false false false 2 true true false false 0.27 0.27 false false false The amount of income (loss) from continuing operations available to each share of common stock outstanding during the reporting period and each share that would have been outstanding assuming the issuance of common shares for all dilutive potential common shares outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 21 -Article 9 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 11, 12, 36, 37, 38 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 40 -Subparagraph a Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 20 -Article 5 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 18 -Article 7 false 36 2 us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare us-gaap true na duration decimal No definition available. false false false false false false false false false false false totallabel true 1 false false false false 0 0 false false false 2 true true false false 0.2 0.2 false false false The amount of income (loss) from discontinued operations, net of related tax effect, per each diluted share of common stock outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 5 -Section E -Paragraph Question 3 true 37 2 us-gaap_EarningsPerShareDiluted us-gaap true na duration decimal No definition available. false false false false false false false false false false false totallabel true 1 true true false false 0.26 0.26 false false false 2 true true false false 0.47 0.47 false false false The amount of net income or loss for the period per each share of common stock and dilutive common stock equivalents outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 11, 12, 36 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 20 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 18 -Article 7 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 21 -Article 9 true 38 2 us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding us-gaap true na duration shares No definition available. false false false false false false false false false false false totallabel false 1 false true false false 119466000 119466 false false false 2 false true false false 104408000 104408 false false false The average number of shares issued and outstanding that are used in calculating diluted EPS, determined based on the timing of issuance of shares in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 40 -Subparagraph a Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 8 true 39 2 us-gaap_CommonStockDividendsPerShareDeclared us-gaap true na duration decimal No definition available. false false false false false false false false false false false totallabel true 1 true true false false 0.44 0.44 false false false 2 true true false false 0.44 0.44 false false false Aggregate dividends declared during the period for each share of common stock outstanding. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 true false 2 37 false Thousands Thousands Hundreds false true XML 25 R16.xml IDEA: Stockholders' Equity 2.0.0.10 false Stockholders' Equity 0210 - Disclosure - Stockholders' Equity true false false false 1 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 us-gaap_StockholdersEquityNoteAbstract us-gaap true na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false No definition available. false 3 1 us-gaap_StockholdersEquityNoteDisclosureTextBlock us-gaap true na duration string No definition available. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 10 - us-gaap:StockholdersEquityNoteDisclosureTextBlock--> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>10. Stockholders&#8217; Equity</b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Preferred Stock</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On January&#160;18, 2010, we redeemed all outstanding shares of our Series&#160;B Preferred Stock at a redemption price per share of $103.875 plus an amount equal to accumulated and unpaid dividends thereon to the redemption date ($0.3875), for a total redemption price of $104.2625 per share, payable only in cash. As a result of the redemption, each share of Series&#160;B Preferred Stock was convertible until January&#160;14, 2010 into 4.5150 shares of common stock. During that time, 512,727 shares were converted into approximately 2,315,000 shares of common stock. On January&#160;18, 2010, we redeemed 917 shares that remained outstanding. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Common Stock</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We enter into sales agreements from time to time with agents to sell shares of our common stock through an at-the-market equity offering program. We entered into two new sales agreements, each dated January&#160;15, 2010, to sell up to an aggregate of 5,000,000 shares of our common stock from time to time. During the three months ended March&#160;31, 2010, we issued and sold approximately 1,269,000 shares of common stock at a weighted average price of $35.58 per share, resulting in net proceeds of approximately $44.7&#160;million after sales agent fees. At March&#160;31, 2010, approximately 4,195,000 shares of common stock were available to be sold pursuant to our at-the-market equity offering program. From April&#160;1, 2010 to May 6, 2010, we issued and sold approximately 1,592,000 shares at a weighted average price of $35.08 per share (see Note 19). </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We sponsor a dividend reinvestment plan that enables existing stockholders to purchase additional shares of common stock by automatically reinvesting all or part of the cash dividends paid on their shares of common stock at a discount ranging from 0% to 5%, determined by us from time to time in accordance with the plan. The discount at March&#160;31, 2010 was 2%. During the three months ended March&#160;31, 2010, we issued approximately 140,000 shares of common stock, at an average price of $33.09 per share, resulting in net proceeds of approximately $4.6&#160;million. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On January&#160;18, 2010, we redeemed all outstanding shares of Series&#160;B Preferred Stock, and as a result, 512,727 shares of Series&#160;B Preferred Stock were converted into approximately 2,315,000 shares of common stock during the period from January&#160;1, 2010 to January&#160;14, 2010. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During the three months ended March&#160;31, 2010, 401 OP Units issued by NHP/PMB were exchanged for 401 shares of common stock (see Note 5). </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false false Disclosures related to accounts comprising shareholders' equity, including other comprehensive income. Includes: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in ar rears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables; effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 5 -Paragraph 15 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph d -Article 4 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section C, E Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 43 -Chapter 1 -Section B -Paragraph 7, 11A Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 129 -Paragraph 2, 3, 4, 5, 6, 7, 8 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Article 4 false false 1 2 false UnKnown UnKnown UnKnown false true XML 26 R9.xml IDEA: Real Estate Properties 2.0.0.10 false Real Estate Properties 0203 - Disclosure - Real Estate Properties true false false false 1 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 nhp_RealEstatePropertiesAbstract nhp false na duration string Real Estate Properties. false false false false false true false false false false false false 1 false false false false 0 0 false false false Real Estate Properties. false 3 1 us-gaap_RealEstateDisclosureTextBlock us-gaap true na duration string No definition available. false false false false false false false false false false false false 1 false false false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 3 - us-gaap:RealEstateDisclosureTextBlock--> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>3. Real Estate Properties</b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">At March&#160;31, 2010, we had direct ownership of: </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>251 assisted and independent living facilities;</td> </tr> </table> </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>167 skilled nursing facilities;</td> </tr> </table> </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>9 continuing care retirement communities;</td> </tr> </table> </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>7 specialty hospitals;</td> </tr> </table> </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>19 triple-net medical office buildings, one of which is operated by a consolidated joint venture (see Note 5); and</td> </tr> </table> </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>67 multi-tenant medical office buildings, 20 of which are operated by consolidated joint ventures (see Note 5).</td> </tr> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We lease our owned senior housing and long-term care facilities and certain medical office buildings to single tenants under &#8220;triple-net,&#8221; and in most cases, &#8220;master&#8221; leases that are accounted for as operating leases. These leases generally have an initial term of up to 21&#160;years and generally have two or more multiple-year renewal options. As of March&#160;31, 2010, approximately 84% of these facilities were leased under master leases. In addition, the majority of these leases contain cross-collateralization and cross-default provisions tied to other leases with the same tenant, as well as grouped lease renewals and grouped purchase options. As of March&#160;31, 2010, leases covering 457 facilities were backed by security deposits consisting of irrevocable letters of credit or cash totaling $72.2&#160;million. Under the terms of the leases, the tenant is responsible for all maintenance, repairs, taxes, insurance and capital expenditures on the leased properties. As of March&#160;31, 2010, leases covering 339 facilities contained provisions for property tax impounds, and leases covering 208 facilities contained provisions for capital expenditure impounds. We generally lease medical office buildings to multiple tenants under separate non-triple-net leases, where we are responsible for many of the associated operating expenses (although many of these are, or can effectively be, passed through to the tenants). However, some of the medical office buildings are subject to triple-net leases, where the lessees are responsible for the associated operating expenses. No individual property owned by us is material to us as a whole. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During the three months ended March&#160;31, 2010, we acquired the remaining 55.05% interest in PMB SB 399-401 East Highland LLC (&#8220;PMB SB&#8221;), an entity affiliated with Pacific Medical Buildings LLC that owns two multi-tenant medical office buildings. PMB SB was valued at $17.4&#160;million at the date of acquisition, and the acquisition was paid in a combination of cash and the assumption of $11.2 million of mortgage financing (of which $6.2&#160;million was previously attributable to the controlling interest in PMB SB) (see Note 6). </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During the three months ended March&#160;31, 2010, we funded $3.7&#160;million in expansions, construction and capital improvements at certain facilities in our triple-net leases segment in accordance with existing lease provisions. Such expansions, construction and capital improvements generally result in an increase in the minimum rents earned by us on these facilities either at the time of funding or upon completion of the project. At March&#160;31, 2010, we had committed to fund additional expansions, construction and capital improvements of $108.8&#160;million. During the three months ended March&#160;31, 2010, we also funded $0.2&#160;million in capital and tenant improvements at certain multi-tenant medical office buildings. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During the three months ended March&#160;31, 2010, we sold the assisted living portion of a continuing care retirement community for which we had an existing mortgage loan secured by the skilled nursing portion of such continuing care retirement community (see Note 4) to the tenant of the facility. We provided financing of $6.5&#160;million related to the sale, including the concurrent repayment of a $0.7&#160;million unsecured loan which had previously been included in the caption &#8220;Other assets&#8221; on our consolidated balance sheets (see Note 4). As we have a continuing interest in the facility, operating results from the facility are included in income from continuing operations on our consolidated income statements. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">No impairment charges were recorded on our real estate properties during the three months ended March&#160;31, 2010 or 2009. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false false This element represents certain disclosures of real estate investment financial statements, real estate investment trust operating support agreements, real estate owned, retail land sales, time share transactions, as well as other real estate related disclosures. This element may be used as a single block of text to encapsulate the entire real estate disclosure including data and tables. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 6 -Subparagraph a -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Interpretation (FIN) -Number 46R -Paragraph 23, 24 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 11 -Article 9 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Statement of Position (SOP) -Number 04-2 -Paragraph 41, 63, 64 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 43 -Chapter 3 -Section A -Paragraph 9 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 67 -Paragraph 4, 5, 6, 7 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Statement of Position (SOP) -Number 01-6 -Paragraph 13 -Subparagraph f Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph c -Subparagraph Schedule III -Article 5 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Statement of Position (SOP) -Number 75-2 -Paragraph 47, 51, 52 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 34 -Paragraph 9, 11, 12, 13, 14, 15, 21 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher OTS -Name Federal Regulation (FR) -Number Title 12 -Chapter V -Section 563c.102 -Paragraph 11 -Subsection I Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 15 -Paragraph 28 Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 10 -Subparagraph 4 -Article 9 Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Audit and Accounting Guide (AAG) -Number AAG-DEP -Chapter 11 -Paragraph 2, 6, 9-11, 18, 20 -IssueDate 2006-05-01 Reference 15: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 66 -Paragraph 4, 5, 37, 50, 59, 65, 95, 97 Reference 16: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 154 -Paragraph 22 Reference 17: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 28 -Article 12 Reference 18: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 57 -Paragraph 2 Reference 19: http://www.xbrl.org/2003/role/presentationRef -Publisher OTS -Name Federal Regulation (FR) -Number Title 12 -Chapter V -Section 563c.102 -Paragraph 10 -Subparagraph a, b -Subsection I Reference 20: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 144 -Paragraph 7, 34 false false 1 2 false UnKnown UnKnown UnKnown false true XML 27 R6.xml IDEA: Condensed Consolidated Statements of Cash Flows (Unaudited) 2.0.0.10 false Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $) 0140 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) true false In Thousands false false 1 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 false 2 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 3 1 us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract us-gaap true na duration string No definition available. false false false false false true false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities include all transactions and events that are not defined as investing or financing activities. Operating activities generally involve producing and delivering goods and providing services. Cash flows from operating activities are generally the cash effects of transactions and other events that enter into the determination of net income. false 4 2 us-gaap_ProfitLoss us-gaap true credit duration monetary No definition available. false false false false false false false false false false false verboselabel false 1 true true false false 31239000 31239 false false false 2 true true false false 50633000 50633 false false false The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A1, A4, A5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 5 -Subparagraph b Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 29 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph a Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph c(1) false 5 2 us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract us-gaap true na duration string No definition available. false false false false false true false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false No definition available. false 6 3 nhp_DepreciationAndAmortizationAdjustment nhp false debit duration monetary The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not... false false false false false false false false false false false verboselabel false 1 false true false false 31969000 31969 false false false 2 false true false false 31123000 31123 false false false The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. Includes amounts related to discontinued operations. No authoritative reference available. false 7 3 us-gaap_ShareBasedCompensation us-gaap true debit duration monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 1594000 1594 false false false 2 false true false false 1573000 1573 false false false The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock options, amortization of restricted stock, and adjustment for officers compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 false 8 3 us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGainOrLoss us-gaap true credit duration monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false -620000 -620 false false false 2 false false false false 0 0 false false false In a business combination achieved in stages, this element represents the amount of gain or loss recognized by the entity as a result of re measuring to fair value the equity interest in the acquiree it held before the business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141R -Paragraph 48 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141R -Paragraph 68 -Subparagraph q(2) false 9 3 us-gaap_GainLossOnSaleOfProperties us-gaap true credit duration monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false -22000 -22 false false false 2 false true false false -21152000 -21152 false false false The difference between the carrying value and the sale price of real estate or properties that were intended to be sold or held for capital appreciation or rental income. This element refers to the gain (loss) included in earnings and not to the cash proceeds of the sale. This element is a noncash adjustment to net income when calculating net cash generated by operating activities using the indirect method. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 false 10 3 us-gaap_GainsLossesOnExtinguishmentOfDebt us-gaap true credit duration monetary No definition available. false false false false false false false false false false true negated false 1 false true false false -75000 -75 false false false 2 false false false false 0 0 false false false Amount represents the difference between the fair value of the payments made and the carrying amount of the debt at the time of its extinguishment. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 26 -Paragraph 20, 21 false 11 3 us-gaap_AmortizationOfFinancingCosts us-gaap true debit duration monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 719000 719 false false false 2 false true false false 703000 703 false false false The component of interest expense comprised of the periodic charge against earnings over the life of the financing arrangement to which such costs relate. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 8 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 8 -Article 9 false 12 3 us-gaap_MortgageLoansOnRealEstateAmortizationOfPremium us-gaap true credit duration monetary No definition available. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false true false false 19000 19 false false false The amount of premium on mortgage loans on real estate amortized during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph c -Subparagraph Schedule IV -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 29 -Article 12 false 13 3 us-gaap_IncreaseDecreaseInDeferredRentReceivables us-gaap true credit duration monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false -1733000 -1733 false false false 2 false true false false -1621000 -1621 false false false The net change during the reporting period in the amount due that is the result of the cumulative difference between actual rent due and rental income recognized on a straight-line basis. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 false 14 3 us-gaap_IncomeLossFromEquityMethodInvestments us-gaap true credit duration monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false -286000 -286 false false false 2 false true false false 5000 5 false false false This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. Such amount typically reflects adjustments similar to those made in preparing consolidated statements, including adjustments to eliminate intercompany gains and losses, and to amortize, if appropriate, any difference between cost and underlying equity in net assets of the investee at the date of investment. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 18 -Paragraph 19 -Subparagraph c Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 11 -Article 7 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 9 -Article 5 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 18 -Paragraph 6 -Subparagraph b false 15 3 us-gaap_EquityMethodInvestmentDividendsOrDistributions us-gaap true debit duration monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 258000 258 false false false 2 false true false false 201000 201 false false false This item represents disclosure of the amount of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporation; these investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 13 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 18 -Paragraph 19 false 16 3 us-gaap_IncreaseDecreaseInOperatingCapitalAbstract us-gaap true na duration string No definition available. false false false false false true false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false No definition available. false 17 4 us-gaap_IncreaseDecreaseInReceivables us-gaap true credit duration monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false -1706000 -1706 false false false 2 false true false false -525000 -525 false false false The net change during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 false 18 4 nhp_IncreaseDecreaseInIntangibleAndOtherAssets nhp false credit duration monetary The net change during the reporting period in intangible and other assets not otherwise defined in the taxonomy. false false false false false false false false false false false verboselabel false 1 false true false false -210000 -210 false false false 2 false true false false -987000 -987 false false false The net change during the reporting period in intangible and other assets not otherwise defined in the taxonomy. No authoritative reference available. false 19 4 us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities us-gaap true debit duration monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false -17394000 -17394 false false false 2 false true false false -16063000 -16063 false false false The net change during the reporting period in the aggregate amount of obligations and expenses incurred but not paid. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 true 20 3 us-gaap_NetCashProvidedByUsedInOperatingActivities us-gaap true na duration monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false 43733000 43733 false false false 2 false true false false 43909000 43909 false false false The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 26 true 21 1 us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract us-gaap true na duration string No definition available. false false false false false true false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false No definition available. false 22 2 us-gaap_PaymentsToAcquireAndDevelopRealEstate us-gaap true credit duration monetary No definition available. false false false false false false false false false false true negated false 1 false true false false -65056000 -65056 false false false 2 false true false false -8583000 -8583 false false false The cash outflow from the acquisition of a piece of land, anything permanently fixed to it, including buildings, structures on it and so forth for development; includes real estate intended to generate income; excludes real estate acquired for use by the owner. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 17 false 23 2 us-gaap_ProceedsFromSaleOfRealEstateHeldforinvestment us-gaap true debit duration monetary No definition available. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false true false false 36284000 36284 false false false Cash received from the sale of real estate that is held for investment, that is, it is part of an investing activity during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 16 false 24 2 us-gaap_PaymentsToAcquireLoansHeldForInvestment us-gaap true credit duration monetary No definition available. false false false false false false false false false false true negated false 1 false true false false -140437000 -140437 false false false 2 false true false false -13179000 -13179 false false false The cash outflow associated with purchasing loans held for investment purposes during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 102 -Paragraph 9 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 17 -Subparagraph a false 25 2 us-gaap_ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment us-gaap true debit duration monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 1270000 1270 false false false 2 false true false false 5445000 5445 false false false The cash inflow from repayments of the balance excluding interest (principal) on loans receivable and leases held for investment purposes. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 102 -Paragraph 9 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 13 -Subparagraph b false 26 2 us-gaap_PaymentsToAcquireInterestInJointVenture us-gaap true credit duration monetary No definition available. false false false false false false false false false false true negated false 1 false false false false 0 0 false false false 2 false true false false -110000 -110 false false false The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 17 -Subparagraph b false 27 2 nhp_DistributionsInExcessOfEarningsFromUnconsolidatedJointVentures nhp false debit duration monetary The cash inflow from unconsolidated joint ventures in which the entity does not have sufficient US GAAP earnings (accumulated... false false false false false false false false false false false totallabel false 1 false true false false 751000 751 false false false 2 false true false false 559000 559 false false false The cash inflow from unconsolidated joint ventures in which the entity does not have sufficient US GAAP earnings (accumulated or in the current period) to distribute funds to partners, thereby constituting a return of investment. No authoritative reference available. true 28 2 us-gaap_NetCashProvidedByUsedInInvestingActivities us-gaap true debit duration monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false -203472000 -203472 false false false 2 false true false false 20416000 20416 false false false The net cash inflow (outflow) from investing activity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 26 true 29 1 us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract us-gaap true na duration string No definition available. false false false false false true false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false No definition available. false 30 2 us-gaap_RepaymentsOfUnsecuredDebt us-gaap true credit duration monetary No definition available. false false false false false false false false false false true negated false 1 false false false false 0 0 false false false 2 false true false false -27000000 -27000 false false false The cash outflow from the payment of uncollateralized debt obligation (where debt is not backed by the pledge of collateral). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 18 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 20 -Subparagraph b false 31 2 us-gaap_ProceedsFromIssuanceOfSecuredDebt us-gaap true debit duration monetary No definition available. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false true false false 6862000 6862 false false false The cash inflow from the issuance of collateralized debt obligation (backed by pledge, mortgage or other lien in the entity's assets). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 18 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 19 -Subparagraph b false 32 2 us-gaap_RepaymentsOfSecuredDebt us-gaap true credit duration monetary No definition available. false false false false false false false false false false true negated false 1 false true false false -5020000 -5020 false false false 2 false true false false -1652000 -1652 false false false The cash outflow from the payment of collateralized debt obligation (backed by pledge, mortgage or other lien in the entity's assets). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 18 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 20 -Subparagraph b false 33 2 us-gaap_ProceedsFromIssuanceOrSaleOfEquity us-gaap true debit duration monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 45875000 45875 false false false 2 false true false false 3309000 3309 false false false The cash inflow from the issuance of common, preferred, and treasury stocks, stock options, and such forth. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 18 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 19 -Subparagraph a false 34 2 us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock us-gaap true credit duration monetary No definition available. false false false false false false false false false false true negated false 1 false true false false -92000 -92 false false false 2 false false false false 0 0 false false false The cash outflow to reacquire callable preferred stock which is identified as being convertible to another type of financial security. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 18 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 20 -Subparagraph a false 35 2 us-gaap_PaymentsToMinorityShareholders us-gaap true credit duration monetary No definition available. false false false false false false false false false false true negated false 1 false true false false -283000 -283 false false false 2 false true false false -364000 -364 false false false The cash outflow to return capital to noncontrolled interest, which generally occurs when noncontrolling shareholders reduce their ownership stake (in a subsidiary of the entity). This element does not include dividends paid to noncontrolling shareholders. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 18 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 20 -Subparagraph a false 36 2 us-gaap_PaymentsOfCapitalDistribution us-gaap true credit duration monetary No definition available. false false false false false false false false false false true negated false 1 false true false false -370000 -370 false false false 2 false true false false -682000 -682 false false false The cash outflow from any dividend or other distribution in cash with respect to any shares of, or other ownership interest in, an entity, except a dividend consisting of distribution of earnings or stock dividend or pro rata stock split. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 18 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 20 -Subparagraph a false 37 2 us-gaap_PaymentsOfDividends us-gaap true credit duration monetary No definition available. false false false false false false false false false false true negated false 1 false true false false -51979000 -51979 false false false 2 false true false false -46681000 -46681 false false false The cash outflow from the entity's earnings to the shareholders. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 18 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 20 -Subparagraph a false 38 2 us-gaap_PaymentsOfFinancingCosts us-gaap true credit duration monetary No definition available. false false false false false false false false false false true negatedtotal false 1 false true false false -80000 -80 false false false 2 false true false false -82000 -82 false false false The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 18, 19, 20 true 39 2 us-gaap_NetCashProvidedByUsedInFinancingActivities us-gaap true debit duration monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false -11949000 -11949 false false false 2 false true false false -66290000 -66290 false false false The net cash inflow (outflow) from financing activity for the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 26 true 40 1 us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease us-gaap true na duration monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false -171688000 -171688 false false false 2 false true false false -1965000 -1965 false false false The net change between the beginning and ending balance of cash and cash equivalents. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 26 false 41 1 us-gaap_CashAndCashEquivalentsAtCarryingValue us-gaap true debit instant monetary No definition available. false false false false false false false false true false false periodstartlabel false 1 false true false false 382278000 382278 false false false 2 false true false false 82250000 82250 false false false Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased th ree years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits should not be reported as cash and cash equivalents. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7, 26 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 8, 9 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7 -Footnote 1 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 false 42 1 us-gaap_CashAndCashEquivalentsAtCarryingValue us-gaap true debit instant monetary No definition available. false false false false false false false false false true false periodendlabel false 1 false true false false 210590000 210590 false false false 2 false true false false 80285000 80285 false false false Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased th ree years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits should not be reported as cash and cash equivalents. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7, 26 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 8, 9 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7 -Footnote 1 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 false 44 2 nhp_NonCashInvestingActivitiesAbstract nhp false na duration string Non-cash investing activities. false false false false false true false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false Non-cash investing activities. false 45 3 us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed us-gaap true credit instant monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false 109514000 109514 false false false 2 false false false false 0 0 false false false The amount of debt that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 32 true 46 3 us-gaap_NotesReduction us-gaap true debit duration monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false 47500000 47500 false false false 2 false false false false 0 0 false false false The value of notes retired (or transferred to another entity) in noncash investing or financing transactions. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 32 true 47 3 nhp_NoncashContributionsFromNoncontrollingInterests nhp false credit duration monetary Value of property contributed by noncontrolling interests in noncash (or part noncash) investing and financing activities. false false false false false false false false false false false terselabel false 1 false true false false 25289000 25289 false false false 2 false false false false 0 0 false false false Value of property contributed by noncontrolling interests in noncash (or part noncash) investing and financing activities. No authoritative reference available. false 48 3 nhp_TemporaryEquityIssued nhp false credit duration monetary The fair value of temporary equity issued in noncash (or part noncash) investing and financing activities. false false false false false false false false false false false totallabel false 1 false true false false 18986000 18986 false false false 2 false false false false 0 0 false false false The fair value of temporary equity issued in noncash (or part noncash) investing and financing activities. No authoritative reference available. true 49 3 us-gaap_MortgageLoanRelatedToPropertySales us-gaap true debit duration monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false 6258000 6258 false false false 2 false false false false 0 0 false false false Mortgage loan related to property sales in noncash investing and financing activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 32 true 50 2 nhp_NonCashFinancingActivitiesAbstract nhp false na duration string Non-cash financing activities. false false false false false true false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false Non-cash financing activities. false 51 3 us-gaap_ConversionOfStockAmountConverted us-gaap true debit instant monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false 51272000 51272 false false false 2 false false false false 0 0 false false false The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 32 true 52 3 nhp_AdjustRedeemableOPUnitholderInterestsToCurrentRedemptionValue nhp false credit duration monetary Adjustment to additional paid in capital to reflect the carrying amount of temporary equity at the greater of cost or fair... false false false false false false false false false false true negatedtotal false 1 true true false false 1562000 1562 false false false 2 false false false false 0 0 false false false Adjustment to additional paid in capital to reflect the carrying amount of temporary equity at the greater of cost or fair value. No authoritative reference available. true false 2 49 false Thousands UnKnown UnKnown false true XML 28 R5.xml IDEA: Condensed Consolidated Statement of Equity (Unaudited) 2.0.0.10 true Condensed Consolidated Statement of Equity (Unaudited) (USD $) 0130 - Statement - Condensed Consolidated Statement of Equity (Unaudited) true false In Thousands false false 1 usd $ true false false false us-gaap_PreferredStockMember us-gaap_StatementEquityComponentsAxis xbrldi http://xbrl.org/2006/xbrldi us-gaap_PreferredStockMember us-gaap_StatementEquityComponentsAxis explicitMember Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 false 2 usd $ true false false false us-gaap_CommonStockMember us-gaap_StatementEquityComponentsAxis xbrldi http://xbrl.org/2006/xbrldi us-gaap_CommonStockMember us-gaap_StatementEquityComponentsAxis explicitMember Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 false 3 usd $ true false false false us-gaap_AdditionalPaidInCapitalMember us-gaap_StatementEquityComponentsAxis xbrldi http://xbrl.org/2006/xbrldi us-gaap_AdditionalPaidInCapitalMember us-gaap_StatementEquityComponentsAxis explicitMember USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 false 4 usd $ true false false false us-gaap_RetainedEarningsUnappropriatedMember us-gaap_StatementEquityComponentsAxis xbrldi http://xbrl.org/2006/xbrldi us-gaap_RetainedEarningsUnappropriatedMember us-gaap_StatementEquityComponentsAxis explicitMember USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 false 5 usd $ true false false false us-gaap_AccumulatedOtherComprehensiveIncomeMember us-gaap_StatementEquityComponentsAxis xbrldi http://xbrl.org/2006/xbrldi us-gaap_AccumulatedOtherComprehensiveIncomeMember us-gaap_StatementEquityComponentsAxis explicitMember USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 false 6 usd $ true false false false us-gaap_RetainedEarningsAppropriatedMember us-gaap_StatementEquityComponentsAxis xbrldi http://xbrl.org/2006/xbrldi us-gaap_RetainedEarningsAppropriatedMember us-gaap_StatementEquityComponentsAxis explicitMember USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 false 7 usd $ true false false false us-gaap_NoncontrollingInterestMember us-gaap_StatementEquityComponentsAxis xbrldi http://xbrl.org/2006/xbrldi us-gaap_NoncontrollingInterestMember us-gaap_StatementEquityComponentsAxis explicitMember USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 false 8 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 6 3 us-gaap_SharesIssued us-gaap true na instant shares No definition available. false false false true false false false false true false false periodstartlabel false 1 false true false false 514000 514 true false false 2 false true false false 114321000 114321 true false false 3 false false false false 0 0 true false false 4 false false false false 0 0 true false false 5 false false false false 0 0 true false false 6 false false false false 0 0 true false false 7 false false false false 0 0 true false false 8 false false false false 0 0 false false false Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. No authoritative reference available. false 5 3 us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest us-gaap true credit instant monetary No definition available. false false false true false false false false true false false periodstartlabel false 1 true true false false 51364000 51364 true false false 2 true true false false 11432000 11432 true false false 3 true true false false 2128843000 2128843 true false false 4 true true false false -1862996000 -1862996 true false false 5 true true false false -823000 -823 true false false 6 true true false false 1705279000 1705279 true false false 7 true true false false 637000 637 true false false 8 true true false false 2033736000 2033736 false false false Total of Stockholders' Equity (deficit) items, net of receivables from officers, directors owners, and affiliates of the entity including portions attributable to both the parent and noncontrolling interests (previously referred to as minority interest), if any. The entity including portions attributable to the parent and noncontrolling interests is sometimes referred to as the economic entity. This excludes temporary equity and is sometimes called permanent equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 25 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 26 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A3 -Appendix A false 7 3 us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract us-gaap true na duration string No definition available. false false false false false true false false false false false verboselabel false 1 false false false false 0 0 true false false 2 false false false false 0 0 true false false 3 false false false false 0 0 true false false 4 false false false false 0 0 true false false 5 false false false false 0 0 true false false 6 false false false false 0 0 true false false 7 false false false false 0 0 true false false 8 false false false false 0 0 false false false No definition available. false 8 4 us-gaap_ProfitLoss us-gaap true credit duration monetary No definition available. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 true false false 2 false false false false 0 0 true false false 3 false false false false 0 0 true false false 4 false false false false 0 0 true false false 5 false false false false 0 0 true false false 6 false true false false 31429000 31429 true false false 7 false true false false -190000 -190 true false false 8 false true false false 31239000 31239 false false false The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A1, A4, A5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 5 -Subparagraph b Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 29 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph a Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph c(1) false 9 4 us-gaap_OtherComprehensiveIncomeReclassificationAdjustmentOnDerivativesIncludedInNetIncomeNetOfTax us-gaap true debit duration monetary No definition available. false false false false false false false false false false true negated false 1 false false false false 0 0 true false false 2 false false false false 0 0 true false false 3 false false false false 0 0 true false false 4 false false false false 0 0 true false false 5 false true false false -126000 -126 true false false 6 false false false false 0 0 true false false 7 false false false false 0 0 true false false 8 false true false false -126000 -126 false false false Net of tax effect of the reclassification adjustment for accumulated gains and losses from derivative instrument designated and qualifying as the effective portion of cash flow hedges included in accumulated comprehensive income that was realized in net income during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 130 -Paragraph 18, 19 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph c(3) Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 130 -Paragraph 24 -Subparagraph b Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 133 -Paragraph 31, 46 false 10 4 us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax us-gaap true credit duration monetary No definition available. false false false false false false false false false false false totallabel false 1 false false false false 0 0 true false false 2 false false false false 0 0 true false false 3 false false false false 0 0 true false false 4 false false false false 0 0 true false false 5 false true false false -436000 -436 true false false 6 false false false false 0 0 true false false 7 false false false false 0 0 true false false 8 false true false false -436000 -436 false false false Change in accumulated gains and losses from derivative instrument designated and qualifying as the effective portion of cash flow hedges, net of tax effect. The after tax effect change includes an entity's share of an equity investee's increase (decrease) in deferred hedging gains or losses. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 130 -Paragraph 17, 20 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 130 -Paragraph 121 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph c(3) Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 130 -Paragraph 24 -Subparagraph b Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 133 -Paragraph 46 true 11 4 us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest us-gaap true credit duration monetary No definition available. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 true false false 2 false false false false 0 0 true false false 3 false false false false 0 0 true false false 4 false false false false 0 0 true false false 5 false false false false 0 0 true false false 6 false false false false 0 0 true false false 7 false false false false 0 0 true false false 8 false true false false 30677000 30677 false false false The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the economic entity, including both controlling (parent) and noncontrolling interests. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, including any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A5 -Appendix A Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 29 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph a false 12 3 nhp_StockIssuedDuringPeriodValueConversionRedemptionOfConvertibleSecurities nhp false credit duration monetary Value of stock issued during the period upon the conversion and/or redemption of convertible securities. false false false false false false false false false false false verboselabel false 1 false true false false -51364000 -51364 true false false 2 false true false false 231000 231 true false false 3 false true false false 51041000 51041 true false false 4 false false false false 0 0 true false false 5 false false false false 0 0 true false false 6 false false false false 0 0 true false false 7 false false false false 0 0 true false false 8 false true false false -92000 -92 false false false Value of stock issued during the period upon the conversion and/or redemption of convertible securities. No authoritative reference available. false 13 3 nhp_StockIssuedDuringPeriodSharesConversionRedemptionOfConvertibleSecurities nhp false na duration shares Number of shares issued during the period as a result of the conversion and/or redemption of convertible securities. false false false false false false false false false false false verboselabel false 1 false true false false -514000 -514 true false false 2 false true false false 2315000 2315 true false false 3 false false false false 0 0 true false false 4 false false false false 0 0 true false false 5 false false false false 0 0 true false false 6 false false false false 0 0 true false false 7 false false false false 0 0 true false false 8 false false false false 0 0 false false false Number of shares issued during the period as a result of the conversion and/or redemption of convertible securities. No authoritative reference available. false 14 3 us-gaap_StockIssuedDuringPeriodValueNewIssues us-gaap true credit duration monetary No definition available. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 true false false 2 false true false false 155000 155 true false false 3 false true false false 45821000 45821 true false false 4 false false false false 0 0 true false false 5 false false false false 0 0 true false false 6 false false false false 0 0 true false false 7 false false false false 0 0 true false false 8 false true false false 45976000 45976 false false false Value of new stock issued during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false 15 3 us-gaap_StockIssuedDuringPeriodSharesNewIssues us-gaap true na duration shares No definition available. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 true false false 2 false true false false 1548000 1548 true false false 3 false false false false 0 0 true false false 4 false false false false 0 0 true false false 5 false false false false 0 0 true false false 6 false false false false 0 0 true false false 7 false false false false 0 0 true false false 8 false false false false 0 0 false false false Number of new stock issued during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 false 16 3 us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue us-gaap true credit duration monetary No definition available. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 true false false 2 false false false false 0 0 true false false 3 false true false false 1594000 1594 true false false 4 false false false false 0 0 true false false 5 false false false false 0 0 true false false 6 false false false false 0 0 true false false 7 false false false false 0 0 true false false 8 false true false false 1594000 1594 false false false This element represents the amount of recognized share-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph 39 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph 64 -Subparagraph b Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph A91 false 17 3 us-gaap_DividendsCommonStock us-gaap true debit duration monetary No definition available. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 true false false 2 false false false false 0 0 true false false 3 false false false false 0 0 true false false 4 false true false false -52075000 -52075 true false false 5 false false false false 0 0 true false false 6 false false false false 0 0 true false false 7 false false false false 0 0 true false false 8 false true false false -52075000 -52075 false false false Aggregate cash, stock, and paid-in-kind dividends declared for common shareholders during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 false 18 3 nhp_AdjustRedeemableOPUnitholderInterestsToCurrentRedemptionValue nhp false credit duration monetary Adjustment to additional paid in capital to reflect the carrying amount of temporary equity at the greater of cost or fair... false false false false false false false false false false false verboselabel false 1 false false false false 0 0 true false false 2 false false false false 0 0 true false false 3 false true false false -1562000 -1562 true false false 4 false false false false 0 0 true false false 5 false false false false 0 0 true false false 6 false false false false 0 0 true false false 7 false false false false 0 0 true false false 8 false true false false -1562000 -1562 false false false Adjustment to additional paid in capital to reflect the carrying amount of temporary equity at the greater of cost or fair value. No authoritative reference available. false 19 3 nhp_NoncashContributionsFromNoncontrollingInterests nhp false credit duration monetary Value of property contributed by noncontrolling interests in noncash (or part noncash) investing and financing activities. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 true false false 2 false false false false 0 0 true false false 3 false false false false 0 0 true false false 4 false false false false 0 0 true false false 5 false false false false 0 0 true false false 6 false false false false 0 0 true false false 7 false true false false 25289000 25289 true false false 8 false true false false 25289000 25289 false false false Value of property contributed by noncontrolling interests in noncash (or part noncash) investing and financing activities. No authoritative reference available. false 20 3 us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders us-gaap true debit duration monetary No definition available. false false false false false false false false false false false totallabel false 1 false false false false 0 0 true false false 2 false false false false 0 0 true false false 3 false false false false 0 0 true false false 4 false false false false 0 0 true false false 5 false false false false 0 0 true false false 6 false false false false 0 0 true false false 7 false true false false -283000 -283 true false false 8 false true false false -283000 -283 false false false Decrease in noncontrolling interest balance from payment of dividends or other distributions to noncontrolling interest holders. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph c(2) true 21 3 us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest us-gaap true credit instant monetary No definition available. false false false true false false false false false true false periodendlabel false 1 true true false false 0 0 true false false 2 true true false false 11818000 11818 true false false 3 true true false false 2225737000 2225737 true false false 4 true true false false -1915071000 -1915071 true false false 5 true true false false -1385000 -1385 true false false 6 true true false false 1736708000 1736708 true false false 7 true true false false 25453000 25453 true false false 8 true true false false 2083260000 2083260 false false false Total of Stockholders' Equity (deficit) items, net of receivables from officers, directors owners, and affiliates of the entity including portions attributable to both the parent and noncontrolling interests (previously referred to as minority interest), if any. The entity including portions attributable to the parent and noncontrolling interests is sometimes referred to as the economic entity. This excludes temporary equity and is sometimes called permanent equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 25 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 26 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A3 -Appendix A false 22 3 us-gaap_SharesIssued us-gaap true na instant shares No definition available. false false false true false false false false false true false periodendlabel false 1 false true false false 0 0 true false false 2 false true false false 118184000 118184 true false false 3 false false false false 0 0 true false false 4 false false false false 0 0 true false false 5 false false false false 0 0 true false false 6 false false false false 0 0 true false false 7 false false false false 0 0 true false false 8 false false false false 0 0 false false false Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. No authoritative reference available. false false 8 18 false Thousands Thousands UnKnown false true XML 29 R23.xml IDEA: Commitments and Contingencies 2.0.0.10 false Commitments and Contingencies 0217 - Disclosure - Commitments and Contingencies true false false false 1 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 nhp_CommitmentsAndContingenciesAbstract nhp false na duration string Commitments and Contingencies. false false false false false true false false false false false false 1 false false false false 0 0 false false false Commitments and Contingencies. false 3 1 us-gaap_CommitmentsAndContingenciesDisclosureTextBlock us-gaap true na duration string No definition available. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 17 - us-gaap:CommitmentsAndContingenciesDisclosureTextBlock--> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>17. Commitments and Contingencies</b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Litigation</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">From time to time, we are a party to various legal proceedings, lawsuits and other claims (as to some of which we may not be insured) that arise in the normal course of our business. Regardless of their merits, these matters may require us to expend significant financial resources. Except as described herein, we are not aware of any other legal proceedings or claims that we believe may have, individually or taken together, a material adverse effect on our business, results of operations or financial position. However, we are unable to predict the ultimate outcome of pending litigation and claims, and if our assessment of our liability with respect to these actions and claims is incorrect, such actions and claims could have a material adverse effect on our business, results of operations or financial position. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In late 2004 and early 2005, we were served with several lawsuits in connection with a fire at the Greenwood Healthcare Center in Hartford, Connecticut, that occurred on February&#160;26, 2003. At the time of the fire, the Greenwood Healthcare Center was owned by us and leased to and operated by Lexington Healthcare Group. There were a total of 13 lawsuits arising from the fire. Those suits have been filed by representatives of patients who were either killed or injured in the fire. The lawsuits seek unspecified monetary damages. The complaints allege that the fire was set by a resident who had previously been diagnosed with depression. The complaints allege theories of negligent operation and premises liability against Lexington Healthcare, as operator, and us as owner. Lexington Healthcare has filed for bankruptcy. The matters have been consolidated into one action in the Connecticut Superior Court Complex Litigation Docket at the Judicial District at Hartford and are in various stages of discovery and motion practice. We have filed a motion for summary judgment with regard to certain pending claims and will be filing additional summary judgment motions for any remaining claims. Mediation was commenced with respect to most of the claims, and a settlement has been reached in 10 of the 13 pending claims within the limits of our commercial general liability insurance. We obtained a judgment of nonsuit in one case whereby it is now dismissed, and the two remaining claims will be subject to summary judgment motions and ongoing efforts at resolution. Summary judgment rulings are not expected until the middle of 2011, if not later. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Lexington Insurance, which potentially owes insurance coverage for these claims to us, has filed a lawsuit against us which seeks no monetary damages, but which does seek a court order limiting its insurance coverage obligations to us. We have filed a counterclaim against Lexington Insurance demanding additional insurance coverage from Lexington in amounts up to $10.0&#160;million. The parties to that case, which is pending on the Complex Litigation Docket for the Judicial District of Hartford, filed cross-motions for summary judgment. Those motions have been decided, resulting in an outcome that is largely favorable for us. The court&#8217;s ruling indicates $10.0 million in aggregate coverage is available from Lexington Insurance for both the various plaintiffs&#8217; claims and our claims under the Professional Liability part of the Lexington Insurance policy. The court then found that there were 13 separate medical incidents for each of the 13 plaintiffs&#8217; claims. However, the court limited the coverage to $500,000 per claim with a $250,000 self insured retention per claim, which retention will not be paid due to the bankruptcy of Lexington Healthcare. Further, the court has ruled that both the various plaintiffs&#8217; claims and our claims are subject to the same policy limits. The court declined to find coverage for our claims under the comprehensive general liability portions of the Lexington Insurance policy. Lexington Insurance has filed a motion seeking an articulation of the rulings and is pursuing an appeal of the rulings. We anticipate that we will be defending the appeal by Lexington Insurance and pursuing our own issues on appeal. We do not expect the appeal to be resolved before the middle of 2011, if not later. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We are being defended in the matter by our commercial general liability carrier. We believe that we have substantial defenses to the claims and that we have adequate insurance to cover the risks, should liability nonetheless be imposed. However, because the remaining claims are still in the process of discovery and motion practice, it is not possible to predict the ultimate outcome of these claims. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Revolving Loan Facility</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In 2009, we entered into an agreement with one of our triple-net tenants, Brookdale under which we became a lender with a commitment of $2.9&#160;million under their $75.0&#160;million revolving loan facility. The revolving loan facility was terminated as of February&#160;23, 2010. There was no balance outstanding at the date of termination. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Lines of Credit</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Under the terms of an agreement with PMB LLC, we agreed to extend to PMB LLC a $10.0&#160;million line of credit at an interest rate equal to LIBOR plus 175 basis points to fund certain costs of PMB LLC with respect to the proposed development of multi-tenant medical office buildings. During the three months ended March&#160;31, 2010, we funded $0.1&#160;million under the line of credit. At March 31, 2010, $3.3&#160;million was outstanding and is included in the caption &#8220;Other assets&#8221; on our consolidated balance sheet. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We have entered into an agreement with PMB LLC, the manager of PMB Pomona LLC, to extend up to $3.0&#160;million of funding at an interest rate of 7.25%, which is secured by 100% of the membership interests in PMB Pomona LLC (see Note 18). During the three months ended March&#160;31, 2010, we funded $0.3&#160;million. At March&#160;31, 2010, $1.9&#160;million was outstanding and is included in the caption &#8220;Other assets&#8221; on our consolidated balance sheet. On April&#160;1, 2010, the total $1.9&#160;million outstanding was repaid (see Note 19). </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As of February&#160;1, 2010, in connection with the formation of Gilbert JV, a consolidated joint venture, we agreed to loan Gilbert JV up to $8.8&#160;million as project financing at an interest rate of 7.00%, including $6.8&#160;million that was disbursed initially and remains outstanding at March&#160;31, 2010 (see Note 5). </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As of March&#160;1, 2010, in connection with the formation of Pasadena JV, a consolidated joint venture, we agreed to loan Pasadena JV up to $56.5&#160;million as project financing at an initial interest rate equal to the greater of 3.50% or LIBOR plus 165 basis points (increasing to the greater of 5.125% or LIBOR plus 375 basis points as of April&#160;1, 2010), including $49.8&#160;million that was disbursed initially and remains outstanding at March&#160;31, 2010 (see Note 5). </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Indemnities</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We have entered into indemnification agreements with those partners who contributed appreciated property into NHP/PMB. Under these indemnification agreements, if any of the appreciated real estate contributed by the partners is sold by NHP/PMB in a taxable transaction within a specified number of years after the property was contributed, we will reimburse the affected partners for the federal and state income taxes associated with the pre-contribution gain that is specially allocated to the affected partner under the Code. We have no current plans to sell any of these properties. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false false Includes disclosure of commitments and contingencies. This element may be used as a single block of text to encapsulate the entire disclosure including data and tables. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Interpretation (FIN) -Number 14 -Paragraph 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 5 -Paragraph 9, 10, 11, 12 false false 1 2 false UnKnown UnKnown UnKnown false true XML 30 defnref.xml IDEA: XBRL DOCUMENT No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The total amount of revenue recognized for the period from triple-net operating leases, including minimum lease revenue, contingent revenue, percentage revenue and sublease revenue. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. Such amount typically reflects adjustments similar to those made in preparing consolidated statements, including adjustments to eliminate intercompany gains and losses, and to amortize, if appropriate, any difference between cost and underlying equity in net assets of the investee at the date of investment. Also includes management fees received from such investees. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Value of property contributed by noncontrolling interests in noncash (or part noncash) investing and financing activities. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Adjustment to additional paid in capital to reflect the carrying amount of temporary equity at the greater of cost or fair value. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. This element represents certain disclosures of investment in consolidated joint ventures which own medical office buildings. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. This block of text may be used to disclose all or part of the information related to intangible assets and liabilities. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The total amount of revenue recognized for the period from multi-tenant operating leases, including minimum lease revenue, contingent revenue, percentage revenue and sublease revenue. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. Includes amounts related to discontinued operations. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Value of stock issued during the period upon the conversion and/or redemption of convertible securities. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The cash inflow from unconsolidated joint ventures in which the entity does not have sufficient US GAAP earnings (accumulated or in the current period) to distribute funds to partners, thereby constituting a return of investment. No authoritative reference available. No authoritative reference available. No authoritative reference available. The balance represents the amount of loans that are secured by real estate mortgages due from related parties. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The amount as of the balance sheet date of cumulative dividends to shareholders. No authoritative reference available. Number of shares issued during the period as a result of the conversion and/or redemption of convertible securities. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The amount as of the balance sheet date of cumulative net income. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The balance represents the amount of loans that are secured by real estate mortgages, net of unearned income, allowance for loan losses and unamortized purchased premiums or discounts, if any. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The net change during the reporting period in intangible and other assets not otherwise defined in the taxonomy. No authoritative reference available. Interest earned on invested cash, including loans receivable, and various other miscellaneous revenue items. No authoritative reference available. No authoritative reference available. No authoritative reference available. The fair value of temporary equity issued in noncash (or part noncash) investing and financing activities. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. XML 31 R21.xml IDEA: Income Taxes 2.0.0.10 false Income Taxes 0215 - Disclosure - Income Taxes true false false false 1 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 nhp_IncomeTaxesAbstract nhp false na duration string Income Taxes Abstract. false false false false false true false false false false false false 1 false false false false 0 0 false false false Income Taxes Abstract. false 3 1 us-gaap_IncomeTaxDisclosureTextBlock us-gaap true na duration string No definition available. false false false false false false false false false false false false 1 false false false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 15 - us-gaap:IncomeTaxDisclosureTextBlock--> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>15. Income Taxes</b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The provisions of ASC Topic 740, <i>Income Taxes</i>, which clarify the accounting for uncertainty in income taxes recognized in financial statements and prescribe a recognition threshold and measurement attribute of tax positions taken or expected to be taken on a tax return became effective January&#160;1, 2007. No amounts have been recorded for unrecognized tax benefits or related interest expense and penalties. The taxable periods ending December&#160;31, 2005 through December&#160;31, 2009 remain open to examination by the Internal Revenue Service and the tax authorities of the significant jurisdictions in which we do business. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><i>Hearthstone Acquisition</i> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On June&#160;1, 2006, we acquired the stock of Hearthstone Assisted Living, Inc. (&#8220;HAL&#8221;), causing HAL to become a qualified REIT subsidiary. As a result of the acquisition, we succeeded to HAL&#8217;s tax attributes, including HAL&#8217;s tax basis in its net assets. Prior to the acquisition, HAL was a corporation subject to federal and state income taxes. In connection with the acquisition of HAL, NHP acquired approximately $82.5&#160;million of federal net operating losses (&#8220;NOLs&#8221;) which we can carry forward to future periods and the use of which is subject to annual limitations imposed by IRC Section&#160;382. While we believe that these NOLs are accurate, any adjustments to HAL&#8217;s tax returns for periods prior to June&#160;1, 2006 by the Internal Revenue Service could change the amount of the NOLs that we can utilize. We have used a portion of this amount in 2007 and 2008 and anticipate using additional amounts in future years. These NOLs are set to expire between 2017 and 2025. NOLs related to various states were also acquired and are set to expire based on the various laws of the specific states. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In addition, we may be subject to a corporate-level tax on any taxable disposition of HAL&#8217;s pre-acquisition assets that occurs within ten years after the June&#160;1, 2006 acquisition. The corporate-level tax would be assessed only to the extent of the built-in gain that existed on the date of acquisition, based on the fair market value of the asset on June&#160;1, 2006. We do not expect to dispose of any asset included in the HAL acquisition if such a disposition would result in the imposition of a material tax liability, and no such sales have taken place through March&#160;31, 2010. Accordingly, we have not recorded a deferred tax liability associated with this corporate-level tax. Gains from asset dispositions occurring more than 10&#160;years after the acquisition will not be subject to this corporate-level tax. However, we may dispose of HAL assets before the 10-year period if we are able to complete a tax-deferred exchange. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false false Description containing the entire income tax disclosure. Examples include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information. This element may be used as a single block of text to encapsulate the entire disclosure including data and tables. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph h -Article 4 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Paragraph 136, 172 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Paragraph 43, 44, 45, 46, 47, 48, 49 false false 1 2 false UnKnown UnKnown UnKnown false true XML 32 R13.xml IDEA: Intangible Assets and Liabilities 2.0.0.10 false Intangible Assets and Liabilities 0207 - Disclosure - Intangible Assets and Liabilities true false false false 1 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 nhp_IntangibleAssetsAndLiabilitiesAbstract nhp false na duration string Intangible Assets and Liabilities. false false false false false true false false false false false false 1 false false false false 0 0 false false false Intangible Assets and Liabilities. false 3 1 nhp_IntangibleAssetsAndLiabilitiesDisclosureTextBlock nhp false na duration string This block of text may be used to disclose all or part of the information related to intangible assets and liabilities. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 7 - nhp:IntangibleAssetsAndLiabilitiesDisclosureTextBlock--> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>7. Intangible Assets and Liabilities</b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Intangible assets include items such as lease-up intangible assets, above market tenant and ground lease intangible assets and in-place lease intangible assets. At March&#160;31, 2010 and December 31, 2009, the gross balance of intangible lease assets was $187.8&#160;million and $130.0&#160;million, respectively. At March&#160;31, 2010 and December&#160;31, 2009, the accumulated amortization of intangible lease assets was $37.7&#160;million and $36.3&#160;million, respectively. Intangible liabilities include below market tenant and ground lease intangible liabilities. At March&#160;31, 2010 and December&#160;31, 2009, we had $18.9&#160;million and $18.3&#160;million, respectively, of gross intangible liabilities recorded under the caption &#8220;Accounts payable and accrued liabilities&#8221; on our consolidated balance sheets. At March&#160;31, 2010 and December&#160;31, 2009, the accumulated amortization of intangible liabilities was $4.0&#160;million and $3.9&#160;million, respectively. </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">For the three months ended March&#160;31, 2010 and 2009, medical office building operating rent included $0.1&#160;million and $0.2&#160;million, respectively, from the amortization of above/below market lease intangibles. For the three months ended March&#160;31, 2010 and 2009, expenses included $4.0 million and $5.1&#160;million, respectively, from the amortization of other intangible lease assets and liabilities. </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false false This block of text may be used to disclose all or part of the information related to intangible assets and liabilities. No authoritative reference available. false false 1 2 false UnKnown UnKnown UnKnown false true XML 33 R1.xml IDEA: Document and Entity Information 2.0.0.10 false Document and Entity Information (USD $) 00 - Document - Document and Entity Information true false false false 1 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 false 2 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 false 3 usd $ false false USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 2 0 nhp_DocumentAndEntityInformationAbstract nhp false na duration string Document And Entity Information. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false Document And Entity Information. false 3 1 dei_EntityRegistrantName dei false na duration normalizedstring No definition available. false false false false false false false false false false false false 1 false false false false 0 0 NATIONWIDE HEALTH PROPERTIES INC NATIONWIDE HEALTH PROPERTIES INC false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12b -Subsection 1 false 4 1 dei_EntityCentralIndexKey dei false na duration na No definition available. false false false false false false false false false false false false 1 false false false false 0 0 0000780053 0000780053 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12b -Subsection 1 false 5 1 dei_DocumentType dei false na duration na No definition available. false false false false false false false false false false false false 1 false false false false 0 0 10-Q 10-Q false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type should be limited to the same value as the supporting SEC submission type. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, NCSR, N-Q, and Other. No authoritative reference available. false 6 1 dei_DocumentPeriodEndDate dei false na duration date No definition available. false false false false false false false false false false false false 1 false false false false 0 0 2010-03-31 2010-03-31 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements this will be the filing date. The format of the date is CCYY-MM-DD. No authoritative reference available. false 7 1 dei_AmendmentFlag dei false na duration na No definition available. false false false false false false false false false false false false 1 false false false false 0 0 false false false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false If the value is true, then the document as an amendment to previously-filed/accepted document. No authoritative reference available. false 8 1 dei_DocumentFiscalYearFocus dei false na duration positiveinteger No definition available. false false false false false false false false false false false false 1 false true false false 2010 2010 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. No authoritative reference available. false 9 1 dei_DocumentFiscalPeriodFocus dei false na duration na No definition available. false false false false false false false false false false false false 1 false false false false 0 0 Q1 Q1 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY. No authoritative reference available. false 10 1 dei_CurrentFiscalYearEndDate dei false na duration monthday No definition available. false false false false false false false false false false false false 1 false false false false 0 0 --12-31 --12-31 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false End date of current fiscal year in the format --MM-DD. No authoritative reference available. false 11 1 dei_EntityWellKnownSeasonedIssuer dei false na duration na No definition available. false false false false false false false false false false false false 1 false false false false 0 0 Yes Yes false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A. No authoritative reference available. false 12 1 dei_EntityVoluntaryFilers dei false na duration na No definition available. false false false false false false false false false false false false 1 false false false false 0 0 No No false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. No authoritative reference available. false 13 1 dei_EntityCurrentReportingStatus dei false na duration na No definition available. false false false false false false false false false false false false 1 false false false false 0 0 Yes Yes false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. No authoritative reference available. false 14 1 dei_EntityFilerCategory dei false na duration na No definition available. false false false false false false false false false false false false 1 false false false false 0 0 Large Accelerated Filer Large Accelerated Filer false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. No authoritative reference available. false 15 1 dei_EntityPublicFloat dei false credit instant monetary No definition available. false false false false false false false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false 3 true true false false 2662290000 2662290000 false false false State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K. No authoritative reference available. false 16 1 dei_EntityCommonStockSharesOutstanding dei false na instant shares No definition available. false false false false false false false false false false false false 1 false false false false 0 0 false false false 2 false true false false 119797061 119797061 false false false 3 false false false false 0 0 false false false Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument No authoritative reference available. false false 3 15 false NoRounding NoRounding UnKnown false true XML 34 R2.xml IDEA: Condensed Consolidated Balance Sheets 2.0.0.10 false Condensed Consolidated Balance Sheets (USD $) 0110 - Statement - Condensed Consolidated Balance Sheets true false In Thousands false false 1 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 false 2 usd $ false false 4 2 us-gaap_RealEstateInvestmentPropertyNetAbstract us-gaap true na duration string No definition available. false false false false false true false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false No definition available. false 5 3 us-gaap_Land us-gaap true debit instant monetary No definition available. false false false false false false false false false false false verboselabel false 1 true true false false 317531000 317531 false false false 2 true true false false 318457000 318457 false false false Carrying amount as of the balance sheet date of real estate held for productive use. This excludes land held for sale. No authoritative reference available. false 6 3 us-gaap_InvestmentBuildingAndBuildingImprovements us-gaap true debit instant monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false 3346489000 3346489 false false false 2 false true false false 3088183000 3088183 false false false Aggregate of the carrying amounts as of the balance sheet date of investments in building and building improvements. No authoritative reference available. true 7 3 us-gaap_RealEstateInvestmentPropertyAtCost us-gaap true debit instant monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 3664020000 3664020 false false false 2 false true false false 3406640000 3406640 false false false Represents a total which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments. No authoritative reference available. false 8 3 us-gaap_RealEstateInvestmentPropertyAccumulatedDepreciation us-gaap true credit instant monetary No definition available. false false false false false false false false false false true negatedtotal false 1 false true false false -606231000 -606231 false false false 2 false true false false -585294000 -585294 false false false The cumulative amount of depreciation for real estate property held for investment purposes. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 7 true 9 3 us-gaap_RealEstateInvestmentPropertyNet us-gaap true debit instant monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 3057789000 3057789 false false false 2 false true false false 2821346000 2821346 false false false The net book value of real estate property held for investment purposes. No authoritative reference available. false 10 3 nhp_MortgageLoansOnRealEstateNet nhp false debit instant monetary The balance represents the amount of loans that are secured by real estate mortgages, net of unearned income, allowance for... false false false false false false false false false false false verboselabel false 1 false true false false 197271000 197271 false false false 2 false true false false 110613000 110613 false false false The balance represents the amount of loans that are secured by real estate mortgages, net of unearned income, allowance for loan losses and unamortized purchased premiums or discounts, if any. No authoritative reference available. false 11 3 nhp_MortgageLoansFromRelatedParty nhp false debit instant monetary The balance represents the amount of loans that are secured by real estate mortgages due from related parties. false false false false false false false false false false false verboselabel false 1 false true false false 0 0 false false false 2 false true false false 47500000 47500 false false false The balance represents the amount of loans that are secured by real estate mortgages due from related parties. No authoritative reference available. false 12 3 us-gaap_EquityMethodInvestments us-gaap true debit instant monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false 47797000 47797 false false false 2 false true false false 51924000 51924 false false false This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment losses recognized. No authoritative reference available. true 13 3 us-gaap_RealEstateInvestments us-gaap true debit instant monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 3302857000 3302857 false false false 2 false true false false 3031383000 3031383 false false false Investments in real estate held solely for investment purposes (income production and capital appreciation). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Subparagraph d -Article 7 false 14 2 us-gaap_CashAndCashEquivalentsAtCarryingValue us-gaap true debit instant monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 210590000 210590 false false false 2 false true false false 382278000 382278 false false false Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased th ree years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits should not be reported as cash and cash equivalents. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7, 26 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 8, 9 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7 -Footnote 1 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 false 15 2 us-gaap_AccountsReceivableNet us-gaap true debit instant monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 8750000 8750 false false false 2 false true false false 6605000 6605 false false false For an unclassified balance sheet, the amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business, reduced to their estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3 -Article 5 false 16 2 us-gaap_IntangibleAssetsNetExcludingGoodwill us-gaap true debit instant monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 150120000 150120 false false false 2 false true false false 93657000 93657 false false false Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 142 -Paragraph 42, 45 false 17 2 us-gaap_OtherAssets us-gaap true debit instant monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false 141327000 141327 false false false 2 false true false false 133152000 133152 false false false Carrying amount as of the balance sheet date of assets not otherwise specified in the taxonomy. Also serves as the sum of assets not individually reported in the financial statements, or not separately disclosed in notes. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 17 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 10 -Article 7 true 18 2 us-gaap_Assets us-gaap true debit instant monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false 3813644000 3813644 false false false 2 false true false false 3647075000 3647075 false false false Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Concepts (CON) -Number 6 -Paragraph 25 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 18 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 12 -Article 7 true 19 1 us-gaap_LiabilitiesAndStockholdersEquityAbstract us-gaap true na duration string No definition available. false false false false false true false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false No definition available. false 20 2 us-gaap_LineOfCredit us-gaap true credit instant monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 0 0 false false false 2 false true false false 0 0 false false false The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the a greement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19, 20, 22 -Article 5 false 21 2 us-gaap_UnsecuredDebt us-gaap true credit instant monetary No definition available. false false false false false false false false false false false terselabel false 1 false true false false 991633000 991633 false false false 2 false true false false 991633000 991633 false false false Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 16 -Article 9 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Article 5 -Subsection 19, 20, 22 false 22 2 us-gaap_SecuredDebt us-gaap true credit instant monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 535950000 535950 false false false 2 false true false false 431456000 431456 false false false Carrying value as of the balance sheet date , including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19, 20, 22 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 16 -Article 9 false 23 2 us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent us-gaap true credit instant monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false 125244000 125244 false false false 2 false true false false 132915000 132915 false false false Carrying value as of the balance sheet date of obligations incurred and payable. pertaining to goods and services received from vendors; and for costs that are statutory in nature, are incurred in connection with contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent, salaries and benefits, and utilities. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 15 -Article 7 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 15 -Subparagraph 1, 5 -Article 9 true 24 2 us-gaap_Liabilities us-gaap true credit instant monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 1652827000 1652827 false false false 2 false true false false 1556004000 1556004 false false false Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. No authoritative reference available. false 25 2 us-gaap_TemporaryEquityRedemptionValue us-gaap true credit instant monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 77557000 77557 false false false 2 false true false false 57335000 57335 false false false The aggregate amount to be paid by the entity upon redemption of the security that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 28 -Subparagraph b -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 00-19 -Paragraph 12 false 26 2 us-gaap_CommitmentsAndContingencies2009 us-gaap true na duration string No definition available. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 &nbsp; &nbsp; false false false 2 false false false false 0 0 &nbsp; &nbsp; false false false Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. This caption alerts the reader that one or more notes to the financial statements disclose pertinent information about the entity's commitments and contingencies. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 7 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 5 -Paragraph 8, 9 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 25 -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 17 -Article 9 false 28 3 us-gaap_StockholdersEquityAbstract us-gaap true na duration string No definition available. false false false false false true false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false No definition available. false 29 4 us-gaap_PreferredStockValue us-gaap true credit instant monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 0 0 false false false 2 false true false false 51364000 51364 false false false Dollar value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) whether issued at par value, no par or stated value. This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 129 -Paragraph 2, 3, 4, 5, 6, 7, 8 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 false 30 4 us-gaap_CommonStockValue us-gaap true credit instant monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 11818000 11818 false false false 2 false true false false 11432000 11432 false false false Dollar value of issued common stock whether issued at par value, no par or stated value. This item includes treasury stock repurchased by the entity. Note: elements for number of common shares, par value and other disclosure concepts are in another section within stockholders' equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false 31 4 us-gaap_AdditionalPaidInCapital us-gaap true credit instant monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 2225737000 2225737 false false false 2 false true false false 2128843000 2128843 false false false Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of APIC associated with common AND preferred stock. For APIC associated with only common stock, use the element Additional Paid In Capital, Common Stock. For APIC associated with only preferred stock, use the element Additional Paid In Capital, Preferred Stock. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 false 32 4 nhp_AccumulatedNetIncome nhp false credit instant monetary The amount as of the balance sheet date of cumulative net income. false false false false false false false false false false false verboselabel false 1 false true false false 1736708000 1736708 false false false 2 false true false false 1705279000 1705279 false false false The amount as of the balance sheet date of cumulative net income. No authoritative reference available. false 33 4 us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax us-gaap true credit instant monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false -1385000 -1385 false false false 2 false true false false -823000 -823 false false false Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at fiscal year-end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, and unrealized gains and losses on certain investments in debt and equity securities as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 130 -Paragraph 14, 17, 26 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 false 34 4 nhp_AccumulatedDividends nhp false credit instant monetary The amount as of the balance sheet date of cumulative dividends to shareholders. false false false false false false false false false false false totallabel false 1 false true false false -1915071000 -1915071 false false false 2 false true false false -1862996000 -1862996 false false false The amount as of the balance sheet date of cumulative dividends to shareholders. No authoritative reference available. true 35 4 us-gaap_StockholdersEquity us-gaap true credit instant monetary No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 2057807000 2057807 false false false 2 false true false false 2033099000 2033099 false false false Total of all Stockholders' Equity (deficit) items, net of receivables from officers, directors owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A3 -Appendix A Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false 36 3 us-gaap_MinorityInterest us-gaap true credit instant monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false 25453000 25453 false false false 2 false true false false 637000 637 false false false Total of all Stockholders' Equity (deficit) items, net of receivables from officers, directors owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 27 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 20 -Article 7 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 26 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A3 -Appendix A true 37 3 us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest us-gaap true credit instant monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false 2083260000 2083260 false false false 2 false true false false 2033736000 2033736 false false false Total of Stockholders' Equity (deficit) items, net of receivables from officers, directors owners, and affiliates of the entity including portions attributable to both the parent and noncontrolling interests (previously referred to as minority interest), if any. The entity including portions attributable to the parent and noncontrolling interests is sometimes referred to as the economic entity. This excludes temporary equity and is sometimes called permanent equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 25 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 26 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A3 -Appendix A true 38 3 us-gaap_LiabilitiesAndStockholdersEquity us-gaap true credit instant monetary No definition available. false false false false false false false false false false false totallabel false 1 true true false false 3813644000 3813644 false false false 2 true true false false 3647075000 3647075 false false false Total of all Liabilities and Stockholders' Equity items. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 32 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 25 -Article 7 true false 2 34 false Thousands UnKnown UnKnown false true XML 35 FilingSummary.xml IDEA: XBRL DOCUMENT 2.0.0.10 true Sheet 00 - Document - Document and Entity Information Document and Entity Information http://nhp-reit.com/role/DocumentAndEntityInformation false R1.xml false Sheet 0110 - Statement - Condensed Consolidated Balance Sheets Condensed Consolidated Balance Sheets http://nhp-reit.com/role/BalanceSheets false R2.xml false Sheet 0111 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Condensed Consolidated Balance Sheets (Parenthetical) http://nhp-reit.com/role/BalanceSheetsParenthetical false R3.xml false Sheet 0120 - Statement - Condensed Consolidated Income Statements (Unaudited) Condensed Consolidated Income Statements (Unaudited) http://nhp-reit.com/role/IncomeStatements false R4.xml false Sheet 0130 - Statement - Condensed Consolidated Statement of Equity (Unaudited) Condensed Consolidated Statement of Equity (Unaudited) http://nhp-reit.com/role/StatementOfEquity false R5.xml false Sheet 0140 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Condensed Consolidated Statements of Cash Flows (Unaudited) http://nhp-reit.com/role/StatementsOfCashFlows false R6.xml false Sheet 0201 - Disclosure - Organization Organization http://nhp-reit.com/role/Organization false R7.xml false Sheet 0202 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies http://nhp-reit.com/role/SummaryOfSignificantAccountingPolicies false R8.xml false Sheet 0203 - Disclosure - Real Estate Properties Real Estate Properties http://nhp-reit.com/role/RealEstateProperties false R9.xml false Sheet 0204 - Disclosure - Mortgage Loans Receivable Mortgage Loans Receivable http://nhp-reit.com/role/MortgageLoansReceivable false R10.xml false Sheet 0205 - Disclosure - Medical Office Building Joint Ventures Medical Office Building Joint Ventures http://nhp-reit.com/role/MedicalOfficeBuildingJointVentures false R11.xml false Sheet 0206 - Disclosure - Investment in Unconsolidated Joint Ventures Investment in Unconsolidated Joint Ventures http://nhp-reit.com/role/InvestmentInUnconsolidatedJointVentures false R12.xml false Sheet 0207 - Disclosure - Intangible Assets and Liabilities Intangible Assets and Liabilities http://nhp-reit.com/role/IntangibleAssetsAndLiabilities false R13.xml false Sheet 0208 - Disclosure - Other Assets Other Assets http://nhp-reit.com/role/OtherAssets false R14.xml false Sheet 0209 - Disclosure - Debt Debt http://nhp-reit.com/role/Debt false R15.xml false Sheet 0210 - Disclosure - Stockholders' Equity Stockholders' Equity http://nhp-reit.com/role/StockholdersEquity false R16.xml false Sheet 0211 - Disclosure - Earnings Per Share (EPS) Earnings Per Share (EPS) http://nhp-reit.com/role/EarningsPerShare false R17.xml false Sheet 0212 - Disclosure - Discontinued Operations Discontinued Operations http://nhp-reit.com/role/DiscontinuedOperations false R18.xml false Sheet 0213 - Disclosure - Derivatives Derivatives http://nhp-reit.com/role/Derivatives false R19.xml false Sheet 0214 - Disclosure - Comprehensive Income Comprehensive Income http://nhp-reit.com/role/ComprehensiveIncome false R20.xml false Sheet 0215 - Disclosure - Income Taxes Income Taxes http://nhp-reit.com/role/IncomeTaxes false R21.xml false Sheet 0216 - Disclosure - Segment Information Segment Information http://nhp-reit.com/role/SegmentInformation false R22.xml false Sheet 0217 - Disclosure - Commitments and Contingencies Commitments and Contingencies http://nhp-reit.com/role/CommitmentsAndContingencies false R23.xml false Sheet 0218 - Disclosure - Related Party Transactions Related Party Transactions http://nhp-reit.com/role/RelatedPartyTransactions false R24.xml false Sheet 0219 - Disclosure - Subsequent Events Subsequent Events http://nhp-reit.com/role/SubsequentEvents false R25.xml false Book All Reports All Reports false 1 30 7 0 3 154 false false ThreeMonthsEnded_31Mar2010_Retained_Earnings_Unappropriated_Member 1 BalanceAsOf_31Mar2010_Noncontrolling_Interest_Member 1 BalanceAsOf_31Dec2009_Retained_Earnings_Appropriated_Member 1 BalanceAsOf_30Jun2009 1 BalanceAsOf_06May2010 1 BalanceAsOf_31Dec2009_Retained_Earnings_Unappropriated_Member 1 ThreeMonthsEnded_31Mar2010_Additional_Paid_In_Capital_Member 4 BalanceAsOf_31Dec2009_Common_Stock_Member 2 ThreeMonthsEnded_31Mar2010_Accumulated_Other_Comprehensive_Income_Member 2 TwelveMonthsEnded_31Dec2009 1 BalanceAsOf_31Dec2009 39 ThreeMonthsEnded_31Mar2010_Retained_Earnings_Appropriated_Member 1 ThreeMonthsEnded_31Mar2010_Preferred_Stock_Member 2 BalanceAsOf_31Mar2010_Retained_Earnings_Unappropriated_Member 1 BalanceAsOf_31Mar2010_Accumulated_Other_Comprehensive_Income_Member 1 BalanceAsOf_31Dec2008 1 BalanceAsOf_31Mar2010_Preferred_Stock_Member 2 BalanceAsOf_31Mar2010 41 ThreeMonthsEnded_31Mar2010_Noncontrolling_Interest_Member 3 BalanceAsOf_31Dec2009_Accumulated_Other_Comprehensive_Income_Member 1 ThreeMonthsEnded_31Mar2009 59 BalanceAsOf_31Dec2009_Additional_Paid_In_Capital_Member 1 BalanceAsOf_31Mar2010_Retained_Earnings_Appropriated_Member 1 ThreeMonthsEnded_31Mar2010_Common_Stock_Member 4 BalanceAsOf_31Mar2009 1 BalanceAsOf_31Dec2009_Noncontrolling_Interest_Member 1 BalanceAsOf_31Mar2010_Additional_Paid_In_Capital_Member 1 BalanceAsOf_31Mar2010_Common_Stock_Member 2 BalanceAsOf_31Dec2009_Preferred_Stock_Member 2 January-01-2010_March-31-2010 99 true true EXCEL 36 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls MT,\1X*&Q&N$`````````````````````/@`#`/[_"0`&```````````````# M`````0``````````$```#@$```$```#^____```````````"`````P```/__ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M_______________________]_____O____W____]____!0````8````'```` M"`````D````*````"P````P````-````#@````\````0````$0```!(````3 M````%````!4````6````%P```!@````9````&@```!L````<````'0```!X` M```?````(````"$````B````(P```"0````E````)@```"<````H````*0`` M`"H````K````+````"T````N````+P```#`````Q````,@```#,````T```` M-0```#8````W````.````#D````Z````.P```#P````]````/@```#\```!` M````00```$(```!#````1````$4```!&````1P```$@```!)````2@```$L` M``!,````30```$X```!/````4````%$```!2````4P```%0```!5````5@`` M`%<```!8````60```%H```!;````7````%T```!>````7P```&````!A```` M8@```&,```!D````90```&8```!G````:````&D```!J````:P```&P```!M M````;@```&\```!P````<0```'(```!S````=````'4```!V````=P```'@` M``!Y````>@```'L```!\````?0```'X```!_````@````%(`;P!O`'0`(`!% M`&X`=`!R`'D````````````````````````````````````````````````` M```````````6``4`__________\"```````````````````````````````` M`````````,"H-;5;[````GP```*````"A M````H@```*,```"D````I0```*8```"G````J````*D```"J````JP```*P` M``"M````K@```*\```"P````L0```+(```"S````M````+4```"V````MP`` M`+@```"Y````N@```+L```"\````O0```+X```"_````P````,$```#"```` MPP```,0```#%````Q@```,<```#(````R0```,H```#+````S````,T```#. M````SP```-````#1````T@```-,```#4````U0```-8```#7````V````-D` M``#:````VP```-P```#=````W@```-\```#@````X0```.(```#C````Y``` M`.4```#F````YP```.@```#I````Z@```.L```#L````[0```.X```#O```` M\````/$```#R````\P```/0```#U````]@```/<```#X````^0```/H```#[ M````_````/T```#^````_P`````!```!`0```@$```,!```$`0``!0$```8! M```'`0``"`$```D!```*`0``"P$```P!```-`0``_O____[____^________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M_____________________________________________________PD($``` M!@4`1AC-!\&````&`@``X0`"`+`$P0`"````X@```%P`<``'``!S!#<`!0`9``$B`"0`(@`C`"P`(P`C`#``7P`I`#L`7``H`"`` M(@`D`"(`(P`L`",`(P`P`%P`(``I`!X$00`&`!X``2(`)``B`",`+``C`",` M,`!?`"D`.P!;`%(`90!D`%T`7``H`"``(@`D`"(`(P`L`",`(P`P`%P`(``I M`!X$0P`'`!\``2(`)``B`",`+``C`",`,``N`#``,`!?`"D`.P!<`"@`(``B M`"0`(@`C`"P`(P`C`#``+@`P`#``7``@`"D`'@1-``@`)``!(@`D`"(`(P`L M`",`(P`P`"X`,``P`%\`*0`[`%L`4@!E`&0`70!<`"@`(``B`"0`(@`C`"P` M(P`C`#``+@`P`#``7``@`"D`'@1Q`"H`-@`!7P`H`"(`)``B`"H`(``C`"P` M(P`C`#``7P`I`#L`7P`H`"(`)``B`"H`(`!<`"@`(``C`"P`(P`C`#``7``@ M`"D`.P!?`"@`(@`D`"(`*@`@`"(`+0`B`%\`*0`[`%\`*``@`$``7P`@`"D` M'@1?`"D`+0`!7P`H`"H`(``C`"P`(P`C`#``7P`I`#L`7P`H`"H`(`!<`"@` M(``C`"P`(P`C`#``7``@`"D`.P!?`"@`*@`@`"(`+0`B`%\`*0`[`%\`*``@ M`$``7P`@`"D`'@2!`"P`/@`!7P`H`"(`)``B`"H`(``C`"P`(P`C`#``+@`P M`#``7P`I`#L`7P`H`"(`)``B`"H`(`!<`"@`(``C`"P`(P`C`#``+@`P`#`` M7``@`"D`.P!?`"@`(@`D`"(`*@`@`"(`+0`B`#\`/P!?`"D`.P!?`"@`(`!` M`%\`(``I`!X$;P`K`#4``5\`*``J`"``(P`L`",`(P`P`"X`,``P`%\`*0`[ M`%\`*``J`"``7``H`"``(P`L`",`(P`P`"X`,``P`%P`(``I`#L`7P`H`"H` M(``B`"T`(@`_`#\`7P`I`#L`7P`H`"``0`!?`"``*0`>!!\`I``-``$C`"P` M(P`C`#``.P`H`",`+``C`",`,``I`!X$(P"E``\``20`(P`L`",`(P`P`#L` M*``D`",`+``C`",`,``I`!X$*P"F`!,``2,`+``C`",`,``N`",`(P`[`"@` M(P`L`",`(P`P`"X`(P`C`"D`'@0O`*<`%0`!)``C`"P`(P`C`#``+@`C`",` M.P`H`"0`(P`L`",`(P`P`"X`(P`C`"D`X``4``````#U_R`````````````` M`,`@X``4``$```#U_R```/0``````````$$@X``4``$```#U_R```/0````` M`````$$@X``4``(```#U_R```/0``````````$$@X``4``(```#U_R```/0` M`````````$$@X``4``````#U_R```/0``````````$$@X``4``````#U_R`` M`/0``````````$$@X``4``````#U_R```/0``````````$$@X``4``````#U M_R```/0``````````$$@X``4``````#U_R```/0``````````$$@X``4```` M``#U_R```/0``````````$$@X``4``````#U_R```/0``````````$$@X``4 M``````#U_R```/0``````````$$@X``4``````#U_R```/0``````````$$@ MX``4``````#U_R```/0``````````$$@X``4```````!`"`````````````` M`,`@X``4``$`*P#U_R```/@``````````$$@X``4``$`*0#U_R```/@````` M`````$$@X``4``$`+`#U_R```/@``````````$$@X``4``$`*@#U_R```/@` M`````````$$@X``4``$`"0#U_R```/@``````````$$@X``4``4````!`"`` M``@``````````,`@X``4``4````!`"@``!@``````````,`@X``4``4````! M`"H``!@``````````,`@X``4```````!`"@``!```````````,`@X``4```` M```)`"```````````````,`@X``4```````)`"@``!```````````,`@X``4 M```````)``@``!```````````,`@X``4````I``!`"````0``````````,`@ MX``4````I0`!`"````0``````````,`@X``4``8`I``!`"````P````````` M`,`@X``4``8`I0`!`"````P``````````,`@X``4````I@`!`"````0````` M`````,`@X``4````IP`!`"````0``````````,`@X``4``8````!`"````@` M`````````,`@X``4``8`IP`!`"````P``````````,`@DP($``"``/^3`@0` M$(`#_Y,"!``1@`;_DP($`!*`!/^3`@0`$X`'_Y,"!``4@`7_8`$"````A0!& M`.J_`0```!\!1`!O`&,`=0!M`&4`;@!T`"``80!N`&0`(`!%`&X`=`!I`'0` M>0`@`$D`;@!F`&\`<@!M`&$`=`!I`&\`;@"%`$8`A\0!````'P%#`&\`;@!D M`&4`;@!S`&4`9``@`$,`;P!N`',`;P!L`&D`9`!A`'0`90!D`"``0@!A`&P` M80!N`&,`90`@`(4`1@#.S0$````?`3$`7P!#`&\`;@!D`&4`;@!S`&4`9``@ M`$,`;P!N`',`;P!L`&D`9`!A`'0`90!D`"``0@!A`&P`80!N`&,`A0!&`*?1 M`0```!\!0P!O`&X`9`!E`&X`@!A`'0`:0!O`&X`A0!&`!7P`0```!\!4P!U`&T` M;0!A`'(`>0`@`&\`9@`@`%,`:0!G`&X`:0!F`&D`8P!A`&X`=``@`$$`8P!C M`&\`=0!N`'0`:0"%`#0`"/(!````%@%2`&4`80!L`"``10!S`'0`80!T`&4` M(`!0`'(`;P!P`&4`<@!T`&D`90!S`(4`.@#[\P$````9`4T`;P!R`'0`9P!A M`&<`90`@`$P`;P!A`&X`0<"````%`%#`&\`;0!P`'(`90!H`&4`;@!S M`&D`=@!E`"``20!N`&,`;P!M`&4`A0`@`&P)`@````P!20!N`&,`;P!M`&4` M(`!4`&$`>`!E`',`A0`N`%\+`@```!,!4P!E`&<`;0!E`&X`=``@`$D`;@!F M`&\`<@!M`&$`=`!I`&\`;@"%`$(`4@T"````'0%#`&\`;0!M`&D`=`!M`&4` M;@!T`',`(`!A`&X`9``@`$,`;P!N`'0`:0!N`&<`90!N`&,`:0!E`',`A0`\ M`$4/`@```!H!4@!E`&P`80!T`&4`9``@`%``80!R`'0`>0`@`%0`<@!A`&X` M0`@`$D`;@!F`&\`<@!M M`&$`=`!I`&\`;@`@`%L`00!B`',`=`!R`&$`8P!T`%T`%@`!10!N`'0`:0!T M`'D`(`!2`&4`9P!I`',`=`!R`&$`;@!T`"``3@!A`&T`90`@``%.`$$`5`!) M`$\`3@!7`$D`1`!%`"``2`!%`$$`3`!4`$@`(`!0`%(`3P!0`$4`4@!4`$D` M10!3`"``20!.`$,`&``!10!N`'0`:0!T`'D`(`!#`&4`;@!T`'(`80!L`"`` M20!N`&0`90!X`"``2P!E`'D`"@`!,``P`#``,``W`#@`,``P`#4`,P`-``%$ M`&\`8P!U`&T`90!N`'0`(`!4`'D`<`!E``0``3$`,``M`%$`&``!1`!O`&,` M=0!M`&4`;@!T`"``4`!E`'(`:0!O`&0`(`!%`&X`9``@`$0`80!T`&4`"@`! M,@`P`#$`,``M`#``,P`M`#,`,0`.``%!`&T`90!N`&0`;0!E`&X`=``@`$8` M;`!A`&<`!0`!9@!A`&P`0`@`$8`:0!L`&4`<@!S``(``4X`;P`?``%%`&X`=`!I M`'0`>0`@`$,`=0!R`'(`90!N`'0`(`!2`&4`<`!O`'(`=`!I`&X`9P`@`%,` M=`!A`'0`=0!S`!4``44`;@!T`&D`=`!Y`"``1@!I`&P`90!R`"``0P!A`'0` M90!G`&\`<@!Y`!<``4P`80!R`&<`90`@`$$`8P!C`&4`;`!E`'(`80!T`&4` M9``@`$8`:0!L`&4`<@`3``%%`&X`=`!I`'0`>0`@`%``=0!B`&P`:0!C`"`` M1@!L`&\`80!T`"<``44`;@!T`&D`=`!Y`"``0P!O`&T`;0!O`&X`(`!3`'0` M;P!C`&L`+``@`%,`:`!A`'(`90!S`"``3P!U`'0`0`L``%) M`&X`=@!E`',`=`!M`&4`;@!T`',`(`!I`&X`(`!U`&X`8P!O`&X`0`,``%3`&4`;@!I`&\`<@`@`&X`;P!T`&4``!C`&4`0`:``%0`'(`90!F`&4`<@!R M`&4`9``@`',`=`!O`&,`:P`L`"``<`!A`'(`(`!V`&$`;`!U`&4`(@`!4`!R M`&4`9@!E`'(`<@!E`&0`(`!S`'0`;P!C`&L`+``@`',`:`!A`'(`90!S`"`` M80!U`'0`:`!O`'(`:0!Z`&4`9``J``$W`"X`-P`U`#``)0`@`%,`90!R`&D` M90!S`"``0@`@`$,`;P!N`'8`90!R`'0`:0!B`&P`90`L`"``@!E`&0`&P`!0P!O M`&T`;0!O`&X`(`!S`'0`;P!C`&L`+``@`',`:`!A`'(`90!S`"``:0!S`',` M=0!E`&0`(``!0P!O`&T`;0!O`&X`(`!S`'0`;P!C`&L`+``@`',`:`!A`'(` M90!S`"``;P!U`'0``!P`&4`;@!S`&4``!P`&4`;@!S`&4`'0`!1`!E`'``<@!E`&,`:0!A`'0`:0!O`&X` M(`!A`&X`9``@`&$`;0!O`'(`=`!I`'H`80!T`&D`;P!N`!H``4<`90!N`&4` M<@!A`&P`(`!A`&X`9``@`&$`9`!M`&D`;@!I`',`=`!R`&$`=`!I`'8`90`1 M``%!`&,`<0!U`&D``!T`&D`;@!G`'4`:0!S`&@`;0!E`&X`=``A``%)`&X` M8P!O`&T`90`@`&8`<@!O`&T`(`!C`&\`;@!T`&D`;@!U`&D`;@!G`"``;P!P M`&4`<@!A`'0`:0!O`&X```%.`&4`=``@`&D` M;@!C`&\`;0!E`"``80!T`'0`<@!I`&(`=0!T`&$`8@!L`&4`(`!T`&\`(`!. M`$@`4``9``%0`'(`90!F`&4`<@!R`&4`9``@`',`=`!O`&,`:P`@`&0`:0!V M`&D`9`!E`&X`9`!S`#(``4X`90!T`"``:0!N`&,`;P!M`&4`(`!A`'0`=`!R M`&D`8@!U`'0`80!B`&P`90`@`'0`;P`@`$X`2`!0`"``8P!O`&T`;0!O`&X` M(`!S`'0`;P!C`&L`:`!O`&P`9`!E`'(`@!A`'0`:0!O`&X`(`!O`&8`(`!S`'0`;P!C`&L`+0!B M`&$`@!A`'0`:0!O`&X` M(`!O`&8`(`!D`&4`9@!E`'(`<@!E`&0`(`!F`&D`;@!A`&X`8P!I`&X`9P`@ M`&,`;P!S`'0`@!A`'0`:0!O`&X`$@`!4P!T`'(`80!I`&<`:`!T`"T`;`!I`&X`90`@`'(` M90!N`'0`-0`!10!Q`'4`:0!T`'D`(`!I`&X`(`!E`&$`<@!N`&D`;@!G`',` M(`!F`'(`;P!M`"``=0!N`&,`;P!N`',`;P!L`&D`9`!A`'0`90!D`"``:@!O M`&D`;@!T`"``=@!E`&X`=`!U`'(`90!S`#H``40`:0!S`'0`<@!I`&(`=0!T M`&D`;P!N`',`(`!O`&8`(`!I`&X`8P!O`&T`90`@`&8`<@!O`&T`(`!U`&X` M8P!O`&X`@!A`'0`:0!O`&X`%P`!3P!R`&<`80!N M`&D`>@!A`'0`:0!O`&X`(`!;`$$`8@!S`'0`<@!A`&,`=`!=`(`,`2``(``@ M``T`#0`-``T`,0`N`"``3P!R`&<`80!N`&D`>@!A`'0`:0!O`&X`(``@``T` M#0!.`&$`=`!I`&\`;@!W`&D`9`!E`"``2`!E`&$`;`!T`&@`(`!0`'(`;P!P M`&4`<@!T`&D`90!S`"P`(`!)`&X`8P`N`"P`(`!A`"``30!A`'(`>0!L`&$` M;@!D`"``8P!O`'(`<`!O`'(`80!T`&D`;P!N`"P`(`!I`',`(`!A`"``<@!E M`&$`;``@`&4`0`@`&@`80!V`&4`(`!S M`&4`=@!E`'(`80!L`"``=`!E`&X`80!N`'0``!P`&4`;@!S`&4`0`@`&\`9@`@`'0`:`!E`',`90`@`&$`<@!E M`"P`(`!O`'(`(`!C`&$`;@`@`&4`9@!F`&4`8P!T`&D`=@!E`&P`>0`@`&(` M90`L`"``<`!A`',``!T`&4`;@!T`"``8@!E`&,`80!U`',`90`@`'<`90`@ M`'8`:0!E`'<`(`!T`&@`90`@`'(`:0!S`&L`0`@`&$`0`@`&8`;P!R`"``=`!A M`'@`80!T`&D`;P!N`"``80!S`"``80`@`%(`10!)`%0`+``@`&$`;@!D`"`` M=P!E`"``9`!I`',`=`!R`&D`8@!U`'0`90`@`#$`,``P`"4`(`!O`&8`(`!O M`'4`<@`@`'0`80!X`&$`8@!L`&4`(`!I`&X`8P!O`&T`90`@`'0`;P`@`&\` M=0!R`"``0`@`&X`;P!T`"``8@!E`"```!E`',`(`!O`&X`(`!O`'4`<@`@`&D`;@!C`&\` M;0!E`"``=`!H`&$`=``@`&D`0`@`&$`(`!C`&\`;@!S`&\`;`!I`&0`80!T`&4`9``@`&H` M;P!I`&X`=``@`'8`90!N`'0`=0!R`&4`(``H`',`90!E`"``3@!O`'0`90`@ M`#4`*0`[`"``80!N`&0`(``@`"``(``-``T`#0`)`"``"0`)`#8`-P`@`&T` M=0!L`'0`:0`M`'0`90!N`&$`;@!T`"``;0!E`&0`:0!C`&$`;``@`&\`9@!F M`&D`8P!E`"``8@!U`&D`;`!D`&D`;@!G`',`+``@`#(`,``@`&\`9@`@`'<` M:`!I`&,`:``@`&$`<@!E`"``;P!P`&4`<@!A`'0`90!D`"``8@!Y`"``8P!O M`&X`0`@`&\`9@`@`%,`:0!G`&X`:0!F`&D`8P!A`&X`=``@ M`$$`8P!C`&\`=0!N`'0`:0!N`&<`(`!0`&\`;`!I`&,`:0!E`',`(``@``T` M#0!"`&$``!C`&@`80!N`&<`90`@`$,`;P!M`&T`:0!S`',`:0!O`&X` M(``H`%,`10!#`"D`+@`@`$$`;`!L`"``0!E`&$`<@`@`'``<@!E`',`90!N`'0`80!T`&D`;P!N`"P`(`!I`&X` M8P!L`'4`9`!I`&X`9P`@`'0`:`!O`',`90`@`'(`90!Q`'4`:0!R`&4`9``@ M`&(`>0`@`'0`:`!E`"``<`!R`&\`=@!I`',`:0!O`&X`0`@`&D`;@!D`&D`8P!A`'0`:0!V`&4`(`!O`&8`(`!T`&@`90`@`'(`90!S M`'4`;`!T`',`(`!F`&\`<@`@`&$`(`!F`'4`;`!L`"``>0!E`&$`<@`N`"`` M(``-``T`5P!E`"``:`!A`'8`90`@`&4`=@!A`&P`=0!A`'0`90!D`"``90!V M`&4`;@!T`',`(`!S`'4`8@!S`&4`<0!U`&4`;@!T`"``=`!O`"``30!A`'(` M8P!H`#,`,0`L`"``,@`P`#$`,``@`&8`;P!R`"``=`!H`&4`:0!R`"``:0!M M`'``80!C`'0`(`!O`&X`(`!O`'4`<@`@`&,`;P!N`&0`90!N`',`90!D`"`` M8P!O`&X`0`@`'0`;P`@`'``80!R`'0`:0!C`&D`<`!A`'0`90`@`&D`;@`@`'``;P!L M`&D`8P!Y`"T`;0!A`&L`:0!N`&<`(`!D`&4`8P!I`',`:0!O`&X`0`@`&$`0`@`&(`90!N`&4`9@!I`&,`:0!A`'(`>0`@`&\`9@`@`&$` M(`!6`$D`10`@`&$`9@!F`&4`8P!T`',`(`!T`&@`90`@`'``<@!E`',`90`6 M``%2`&4`80!L`"``10!S`'0`80!T`&4`(`!0`'(`;P!P`&4`<@!T`&D`90!S M`"$``5(`90!A`&P`(`!%`',`=`!A`'0`90`@`%``<@!O`'``90!R`'0`:0!E M`',`(`!;`$$`8@!S`'0`<@!A`&,`=`!=`(`,`2``(``-``T`#0`S`"X`(`!2 M`&4`80!L`"``10!S`'0`80!T`&4`(`!0`'(`;P!P`&4`<@!T`&D`90!S`"`` M(``-``T`00!T`"``30!A`'(`8P!H`#,`,0`L`"``,@`P`#$`,``L`"``=P!E M`"``:`!A`&0`(`!D`&D`<@!E`&,`=``@`&\`=P!N`&4`<@!S`&@`:0!P`"`` M;P!F`#H`(``@``T`#0`-``D`(``)``D`,@`U`#$`(`!A`',`0`@`&@`;P!S`'`` M:0!T`&$`;`!S`#L`(``@`"``(``-``T`#0`)`"``"0`)`#$`.0`@`'0`<@!I M`'``;`!E`"T`;@!E`'0`(`!M`&4`9`!I`&,`80!L`"``;P!F`&8`:0!C`&4` M(`!B`'4`:0!L`&0`:0!N`&<`0`@`&,`;P!N`',`;P!L`&D`9`!A`'0`90!D`"`` M:@!O`&D`;@!T`"``=@!E`&X`=`!U`'(`90!S`"``*`!S`&4`90`@`$X`;P!T M`&4`(``U`"D`+@`@`"``(``@``T`#0!7`&4`(`!L`&4`80!S`&4`(`!O`'4` M<@`@`&\`=P!N`&4`9``@`',`90!N`&D`;P!R`"``:`!O`'4`0!E`&$`<@!S`"``80!N`&0`(`!G`&4` M;@!E`'(`80!L`&P`>0`@`&@`80!V`&4`(`!T`'<`;P`@`&\`<@`@`&T`;P!R M`&4`(`!M`'4`;`!T`&D`<`!L`&4`+0!Y`&4`80!R`"``<@!E`&X`90!W`&$` M;``@`&\`<`!T`&D`;P!N`',`+@`@`$$`0`@`',`90!C M`'4`<@!I`'0`>0`@`&0`90!P`&\`0`@`&$` M9@!F`&D`;`!I`&$`=`!E`&0`(`!W`&D`=`!H`"``4`!A`&,`:0!F`&D`8P`@ M`$T`90!D`&D`8P!A`&P`(`!"`'4`:0!L`&0`:0!N`&<``!I`',`=`!I`&X` M9P`@`&P`90!A`',`90`@`'``<@!O`'8`:0!S`&D`;P!N`',`+@`@`%,`=0!C M`&@`(`!E`'@`<`!A`&X`0`@`"@``!I`',`=`!I`&X`9P`@`&T`;P!R`'0`9P!A`&<`90`@`&P` M;P!A`&X`(`!S`&4`8P!U`'(`90!D`"``8@!Y`"``=`!H`&4`(`!S`&L`:0!L M`&P`90!D`"``;@!U`'(`0!M`&4`;@!T`"``;P!F`"`` M80`@`"0`,``N`#<`;0!I`&P`;`!I`&\`;@`@`'4`;@!S`&4`8P!U`'(`90!D M`"``;`!O`&$`;@`@`'<`:`!I`&,`:``@`&@`80!D`"``<`!R`&4`=@!I`&\` M=0!S`&P`>0`@`&(`90!E`&X`(`!I`&X`8P!L`'4`9`!E`&0`(`!I`&X`(`!T M`&@`90`@`&,`80!P`'0`:0!O`&X`(`!/`'0`:`!E`'(`(`!A`',`0`@`'<` M80!S`"``=`!E`'(`;0!I`&X`80!T`&4`9``@`&$`0`R`#,`+``@`#(`,``Q`#``+@`@`%0`:`!E`'(`90`@`'<` M80!S`"``;@!O`"``8@!A`&P`80!N`&,`90`@`&\`=0!T`',`=`!A`&X`9`!I M`&X`9P`@`&$`=``@`'0`:`!E`"``9`!A`'0`90`@`&\`9@`@`'0`90!R`&T` M:0!N`&$`=`!I`&\`;@`N`"``(``@`"``(``@``T`#0`@`"``(``@`"``)@`! M30!E`&0`:0!C`&$`;``@`$\`9@!F`&D`8P!E`"``0@!U`&D`;`!D`&D`;@!G M`"``2@!O`&D`;@!T`"``5@!E`&X`=`!U`'(`90!S`#$``4T`90!D`&D`8P!A M`&P`(`!/`&8`9@!I`&,`90`@`$(`=0!I`&P`9`!I`&X`9P`@`$H`;P!I`&X` M=``@`%8`90!N`'0`=0!R`&4`0`@`&8`;P!R`"``=P!H`&\`;`!L M`'D`(`!O`'<`;@!E`&0`(`!R`&4`80!L`"``90!S`'0`80!T`&4`(`!P`'(` M;P!P`&4`<@!T`&D`90!S`"``*`!S`&4`90`@`$X`;P!T`&4`(``S`"D`+@`@ M`%``<@!I`&\`<@`@`'0`;P`@`&\`=0!R`"``80!C`'$`=0!I`',`:0!T`&D` M;P!N`"``;P!F`"``0@!R`&\`90!S`"``:0!N`'0`90!R`&4`0`R`#``,``X`"P`(`!W`&4`(`!E`&X` M=`!E`'(`90!D`"``:0!N`'0`;P`@`&$`;@`@`&$`9P!R`&4`90!M`&4`;@!T M`"``*`!T`&@`90`@`$,`;P!N`'0`<@!I`&(`=0!T`&D`;P!N`"``00!G`'(` M90!E`&T`90!N`'0`*0`@`'<`:0!T`&@`(`!0`&$`8P!I`&8`:0!C`"``30!E M`&0`:0!C`&$`;``@`$(`=0!I`&P`9`!I`&X`9P!S`"``3`!,`$,`(`!A`&X` M9``@`&,`90!R`'0`80!I`&X`(`!O`&8`(`!I`'0``!I M`&T`80!T`&4`;`!Y`"``)``R`#@`,@`N`#8`(`!M`&D`;`!L`&D`;P!N`"`` M;P!F`"``;0!O`'(`=`!G`&$`9P!E`"``9@!I`&X`80!N`&,`:0!N`&<`+@`@ M`%4`;@!D`&4`<@`@`'0`:`!E`"``0P!O`&X`=`!R`&D`8@!U`'0`:0!O`&X` M(`!!`&<`<@!E`&4`;0!E`&X`=``L`"``:0!N`"``,@`P`#``.``L`"``3@!( M`%``+P!0`$T`0@`@`&$`8P!Q`'4`:0!R`&4`9``@`&D`;@!T`&4`<@!E`',` M=`!S`"``:0!N`"``;@!I`&X`90`@`&\`9@`@`'0`:`!E`"``,0`X`"``;0!E M`&0`:0!C`&$`;``@`&\`9@!F`&D`8P!E`"``8@!U`&D`;`!D`&D`;@!G`',` M+``@`&D`;@!C`&P`=0!D`&D`;@!G`"``;P!N`&4`(`!P`'(`;P!P`&4`<@!T M`'D`(`!W`&@`:0!C`&@`(`!I`',`(`!I`&X`8P!L`'4`9`!E`&0`(`!I`&X` M(`!O`'4`<@`@`'0`<@!I`'``;`!E`"T`;@!E`'0`(`!L`&4`80!S`&4`0`@`$X`2`!0`"\`4`!-`$(`*0`N`"``1`!U M`'(`:0!N`&<`(``R`#``,``X`"P`(`!W`&4`(`!A`&P```@`'``<@!O`'``90!R`'0`:0!E`',`(`!A`&8`=`!E`'(`(`!T`&@` M90`@`&,`;P!N`&0`:0!T`&D`;P!N`',`(`!F`&\`<@`@`'4`0`R`#``,``W`"P`(`!W`&4`(`!E`&X`=`!E`'(`90!D`"``:0!N`'0` M;P`@`&$`(`!J`&\`:0!N`'0`(`!V`&4`;@!T`'4`<@!E`"``=P!I`'0`:``@ M`&$`(`!S`'0`80!T`&4`(`!P`&4`;@!S`&D`;P!N`"``9@!U`&X`9``@`&D` M;@!V`&4``!I`&T` M80!T`&4`;`!Y`"``-``P`"4`(`!E`'$`=0!I`'0`>0`@`&,`;P!N`'0`<@!I M`&(`=0!T`&D`;P!N`',`(`!A`&X`9``@`#8`,``E`"``9`!E`&(`=``N`"`` M5`!H`&4`(`!O`'(`:0!G`&D`;@!A`&P`(`!A`'``<`!R`&\`=@!E`&0`(`!I M`&X`=@!E`',`=`!M`&4`;@!T`"``=`!A`'(`9P!E`'0`(`!W`&$`0`@`&\`=0!R`"``:0!N`'8` M90!S`'0`;0!E`&X`=``@`&D`0`Q`"P`(``R`#``,0`U`"X`(`!4`&@`90`@`&8`80!I`'(`(`!V`&$`;`!U M`&4`(`!O`&8`(`!T`&@`:0!S`"``8P!O`&X`=`!R`&$`8P!T`"``80!T`"`` M30!A`'(`8P!H`#,`,0`L`"``,@`P`#$`,``@`&$`;@!D`"``1`!E`&,`90!M M`&(`90!R`#,`,0`L`"``,@`P`#``.0`@`'<`80!S`"``)``Y`"X`.0!M`&D` M;`!L`&D`;P!N`"``80!N`&0`(``D`#@`+@`R`&T`:0!L`&P`:0!O`&X`+``@ M`'(`90!S`'``90!C`'0`:0!V`&4`;`!Y`"P`(`!W`&@`:0!C`&@`(`!I`',` M(`!I`&X`8P!L`'4`9`!E`&0`(`!I`&X`(`!A`&,`8P!R`'4`90!D`"``;`!I M`&$`8@!I`&P`:0!T`&D`90!S`"``;P!N`"``=`!H`&4`(`!J`&\`:0!N`'0` M(`!V`&4`;@!T`'4`<@!E`',`(`!B`&$`;`!A`&X`8P!E`"``0`N`"`` M5`!H`&4`(`!T`'(`80!N`',`80!C`'0`:0!O`&X`(`!C`&P`;P!S`&4`9``@ M`&\`;@`@`$$`<`!R`&D`;``@`#$`+``@`#(`,``P`#@`+@`@`$D`;@`@`&,` M;P!N`',`:0!D`&4`<@!A`'0`:0!O`&X`(`!F`&\`<@`@`'0`:`!E`"``-0`P M`"4`(`!I`&X`=`!E`'(`90!S`'0`+``@`'<`90`@`'``80!I`&0`(``D`#$` M+@`P`&T`:0!L`&P`:0!O`&X`(`!A`'0`(`!C`&P`;P!S`&D`;@!G`"P`(`!A M`&X`9``@`'<`90`@`'<`:0!L`&P`(`!M`&$`:P!E`"``80!D`&0`:0!T`&D` M;P!N`&$`;``@`'``80!Y`&T`90!N`'0`0!M`&4`;@!T M`"``=P!A`',`(`!M`&$`9`!E`"``9`!U`'(`:0!N`&<`(`!T`&@`90`@`'0` M:`!R`&4`90`@`&T`;P!N`'0`:`!S`"``90!N`&0`90!D`"``30!A`'(`8P!H M`#,`,0`L`"``,@`P`#$`,``N`"``4`!-`$(`4@!%`%,`(`!P`'(`;P!V`&D` M9`!E`',`(``A``%)`&X`=`!A`&X`9P!I`&(`;`!E`"``00!S`',`90!T`',` M(`!A`&X`9``@`$P`:0!A`&(`:0!L`&D`=`!I`&4`0`N`"`` M00!T`"``30!A`'(`8P!H`#,`,0`L`"``,@`P`#$`,``@`&$`;@!D`"``1`!E M`&,`90!M`&(`90!R`#,`,0`L`"``,@`P`#``.0`L`"``=`!H`&4`(`!A`&,` M8P!U`&T`=0!L`&$`=`!E`&0`(`!A`&T`;P!R`'0`:0!Z`&$`=`!I`&\`;@`@ M`&\`9@`@`&D`;@!T`&$`;@!G`&D`8@!L`&4`(`!L`&4`80!S`&4`(`!A`',` M0`N`"``20!N`'0`80!N`&<`:0!B`&P`90`@`&P`:0!A M`&(`:0!L`&D`=`!I`&4`0`L`"``;P!F`"``9P!R`&\``!P`&4`;@!S`&4`0`@`"``"0`) M`"``"0`R`#D`+``R`#<`.0`@``D`"0`@``D`"0`R`#<`+``T`#4`,``@``D` M#0`-``T`1`!E`&8`90!R`'(`90!D`"``9@!I`&X`80!N`&,`:0!N`&<`(`!C M`&\`0`N`"``(``-``T`20!N`'8` M90!S`'0`;0!E`&X`=`!S`"``80!R`&4`(`!R`&4`8P!O`'(`9`!E`&0`(`!A M`'0`(`!F`&$`:0!R`"``=@!A`&P`=0!E`"``=0!S`&D`;@!G`"``<0!U`&\` M=`!E`&0`(`!M`&$`<@!K`&4`=``@`'``<@!I`&,`90!S`"X`(``@`"``!``! M1`!E`&(`=``/``%$`&4`8@!T`"``6P!!`&(`0`@`"``#0`-`$$`=``@`$T`80!R`&,`:``S`#$`+``@`#(`,``Q`#`` M+``@`'<`90`@`&@`80!D`"``;@!O`"``8@!A`&P`80!N`&,`90`@`&\`=0!T M`',`=`!A`&X`9`!I`&X`9P`@`&\`;@`@`&\`=0!R`"``)``W`#``,``N`#`` M;0!I`&P`;`!I`&\`;@`@`'(`90!V`&\`;`!V`&D`;@!G`"``=0!N`',`90!C M`'4`<@!E`&0`(`!S`&4`;@!I`&\`<@`@`&,`<@!E`&0`:0!T`"``9@!A`&,` M:0!L`&D`=`!Y`"X`(`!!`'0`(`!O`'4`<@`@`&\`<`!T`&D`;P!N`"P`(`!B M`&\`<@!R`&\`=P!I`&X`9P!S`"``=0!N`&0`90!R`"``=`!H`&4`(`!C`'(` M90!D`&D`=``@`&8`80!C`&D`;`!I`'0`>0`@`&(`90!A`'(`(`!I`&X`=`!E M`'(`90!S`'0`(`!A`'0`(`!T`&@`90`@`'``<@!I`&T`90`@`'(`80!T`&4` M(``H`#,`+@`R`#4`)0`@`&$`=``@`$T`80!R`&,`:``S`#$`+``@`#(`,``Q M`#``*0`@`&\`<@`@`&$`<`!P`&P`:0!C`&$`8@!L`&4`(`!,`$D`0@!/`%(` M(`!P`&P`=0!S`"``,``N`#<`,``E`"``*``P`"X`.0`U`"4`(`!A`'0`(`!- M`&$`<@!C`&@`,P`Q`"P`(``R`#``,0`P`"D`+@`@`%<`90`@`'``80!Y`"`` M80`@`&8`80!C`&D`;`!I`'0`>0`@`&8`90!E`"``;P!F`"``,``N`#$`-0`E M`"``<`!E`'(`(`!A`&X`;@!U`&T`(`!O`&X`(`!T`&@`90`@`'0`;P!T`&$` M;``@`&,`;P!M`&T`:0!T`&T`90!N`'0`(`!U`&X`9`!E`'(`(`!T`&@`90`@ M`&$`9P!R`&4`90!M`&4`;@!T`"X`(`!4`&@`90`@`&,`<@!E`&0`:0!T`"`` M9@!A`&,`:0!L`&D`=`!Y`"``;0!A`'0`=0!R`&4`0!E`&$`<@`@`&$`=``@`&\`=0!R`"``9`!I`',`8P!R`&4`=`!I`&\`;@`N M`"``00!S`"``;P!F`"``30!A`'(`8P!H`#,`,0`L`"``,@`P`#$`,``L`"`` M=P!E`"``=P!E`'(`90`@`&D`;@`@`&,`;P!M`'``;`!I`&$`;@!C`&4`(`!W M`&D`=`!H`"``80!L`&P`(`!C`&\`=@!E`&X`80!N`'0`0!A`&(`;`!E`"``(``-``T`5`!H`&4`(`!A`&<` M9P!R`&4`9P!A`'0`90`@`'``<@!I`&X`8P!I`'``80!L`"``80!M`&\`=0!N M`'0`(`!O`&8`(`!N`&\`=`!E`',`(`!A`&X`9``@`&(`;P!N`&0`0`@`'(`90!A`&P`(`!E`',`=`!A`'0`90`@`'``<@!O`'`` M90!R`'0`:0!E`',`(`!W`&D`=`!H`"``80!N`"``80!G`&<`<@!E`&<`80!T M`&4`(`!N`&4`=``@`&(`;P!O`&L`(`!V`&$`;`!U`&4`(`!A`',`(`!O`&8` M(`!-`&$`<@!C`&@`,P`Q`"P`(``R`#``,0`P`"``;P!F`"``)``W`#D`.0`N M`#(`;0!I`&P`;`!I`&\`;@`N`"``00!T`"``30!A`'(`8P!H`#,`,0`L`"`` M,@`P`#$`,``L`"``=`!H`&4`(`!W`&4`:0!G`&@`=`!E`&0`(`!A`'8`90!R M`&$`9P!E`"``:0!N`'0`90!R`&4`0!A M`&(`;`!E`"``=P!A`',`(``U`"X`,P`U`"4`(`!A`&X`9``@`'0`:`!E`"`` M=P!E`&D`9P!H`'0`90!D`"``80!V`&4`<@!A`&<`90`@`&T`80!T`'4`<@!I M`'0`>0`@`'<`80!S`"``-@`N`#<`>0!E`&$`<@!S`"X`(``@``T`#0!$`'4` M<@!I`&X`9P`@`'0`:`!E`"``=`!H`'(`90!E`"``;0!O`&X`=`!H`',`(`!E M`&X`9`!E`&0`(`!-`&$`<@!C`&@`,P`Q`"P`(``R`#``,0`P`"P`(`!W`&4` M(`!A`',``!E`&0`(`!R`&$`=`!E`"``0`?``%3`'0`;P!C`&L`:`!O M`&P`9`!E`'(``!I`&T` M80!T`&4`;`!Y`"``,@`L`#,`,0`U`"P`,``P`#``(`!S`&@`80!R`&4`0`@`&\`9@!F`&4`<@!I`&X`9P`@`'``<@!O`&<` M<@!A`&T`+@`@`%<`90`@`&4`;@!T`&4`<@!E`&0`(`!I`&X`=`!O`"``=`!W M`&\`(`!N`&4`=P`@`',`80!L`&4`0`@`#$`+``R`#8`.0`L`#``,``P M`"``0`@`#8`+``@`#(`,``Q`#``+``@`'<`90`@`&D` M0`@`#$`+``U`#D`,@`L`#``,``P`"``0`@`&$`=0!T`&\`;0!A`'0`:0!C`&$`;`!L M`'D`(`!R`&4`:0!N`'8`90!S`'0`:0!N`&<`(`!A`&P`;``@`&\`<@`@`'`` M80!R`'0`(`!O`&8`(`!T`&@`90`@`&,`80!S`&@`(`!D`&D`=@!I`&0`90!N M`&0``!I`&T`/``; M(`%A`'0`90!L`'D`(``D`#0`+@`V`&T`:0!L`&P`:0!O`&X`+@`@`"``(``@ M`"``(``-``T`#0`-`$\`;@`@`$H`80!N`'4`80!R`'D`,0`X`"P`(``R`#`` M,0`P`"P`(`!W`&4`(`!R`&4`9`!E`&4`;0!E`&0`(`!A`&P`;``@`&\`=0!T M`',`=`!A`&X`9`!I`&X`9P`@`',`:`!A`'(`90!S`"``;P!F`"``4P!E`'(` M:0!E`',`0@`@`%``<@!E`&8`90!R`'(`90!D`"``4P!T`&\`8P!K`"P`(`!A M`&X`9``@`&$`0`Q`"P` M(``R`#``,0`P`"``=`!O`"``2@!A`&X`=0!A`'(`>0`Q`#0`+``@`#(`,``Q M`#``+@`@`"``#0`-`$0`=0!R`&D`;@!G`"``=`!H`&4`(`!T`&@`<@!E`&4` M(`!M`&\`;@!T`&@``!C M`&@`80!N`&<`90!D`"``9@!O`'(`(``T`#``,0`@`',`:`!A`'(`90!S`"`` M;P!F`"``8P!O`&T`;0!O`&X`(`!S`'0`;P!C`&L`(``H`',`90!E`"``3@!O M`'0`90`@`#4`*0`N`"``(``@`!@``44`80!R`&X`:0!N`&<`0`@`'``;P!T`&4`;@!T M`&D`80!L`"``0`N`"``5`!H`&4` M(`!C`&$`;`!C`'4`;`!A`'0`:0!O`&X`(`!B`&4`;`!O`'<`(`!E`'@`8P!L M`'4`9`!E`',`(``R`#<`+``P`#``,``@`'(`90!S`'0`<@!I`&,`=`!E`&0` M(`!S`'0`;P!C`&L`(`!U`&X`:0!T`',`+``@`#@`+``W`#``,``@`'(`90!S M`'0`<@!I`&,`=`!E`&0`(`!S`'0`;P!C`&L`(`!S`&@`80!R`&4``!C`&4`<`!T`"`` M<`!E`'(`(``)``T`#0`)`"``"0!S`&@`80!R`&4`(`!A`&T`;P!U`&X`=`!S M`"D`(``)``T`#0`-`$X`=0!M`&4`<@!A`'0`;P!R`#H`(``@``D`"0`@``D` M"0`@``D`"0`@``D`"0`-``T`#0!)`&X`8P!O`&T`90`@`&8`<@!O`&T`(`!C M`&\`;@!T`&D`;@!U`&D`;@!G`"``;P!P`&4`<@!A`'0`:0!O`&X`0`@`&$`0`@`',`=0!C M`&@`(`!A`',``!P`&4`;@!S`&4`(`!A`&X`9``@`&$`;0!O`'(`=`!I`'H` M80!T`&D`;P!N`"``;P!F`"``9`!E`&8`90!R`'(`90!D`"``9@!I`&X`80!N M`&,`:0!N`&<`(`!C`&\`@!A`'0`:0!O`&X`(``@``D`"0`@``D`"0`@``D`"0`@``D` M,@`Y`#$`(``)``T`#0`-`$<`90!N`&4`<@!A`&P`(`!A`&X`9``@`&$`9`!M M`&D`;@!I`',`=`!R`&$`=`!I`'8`90`@`"``"0`)`"``"0`)`"``"0`)`"`` M"0`)``T`#0`-`$T`90!D`&D`8P!A`&P`(`!O`&8`9@!I`&,`90`@`&(`=0!I M`&P`9`!I`&X`9P`@`&\`<`!E`'(`80!T`&D`;@!G`"``90!X`'``90!N`',` M90!S`"``(``)``D`(``)``D`(``)``D`(``)``D`#0`-``T`"0`@``D`"0`@ M``D`"0`-``T`#0`)`"``"0`)`"``"0`)`"``"0`R`#D`,0`@``D`#0`-``T` M"0`@``D`"0`@``D`"0`-``T`#0!)`&X`8P!O`&T`90`@`&8`<@!O`&T`(`!D M`&D```M`&T`;P!N`'0`:``@`%0`<@!E`&$`0`@`&P`;P!C`&L` M(`!A`&<`<@!E`&4`;0!E`&X`=`!S`"``=`!O`'0`80!L`&D`;@!G`"``)``R M`#4`,``N`#``;0!I`&P`;`!I`&\`;@`@`&$`=``@`&$`(`!W`&4`:0!G`&@` M=`!E`&0`(`!A`'8`90!R`&$`9P!E`"``<@!A`'0`90`@`&\`9@`@`#0`+@`R M`#$`,@`E`"X`(`!7`&4`(`!E`&X`=`!E`'(`90!D`"``:0!N`'0`;P`@`'0` M:`!E`',`90`@`%0`<@!E`&$`0`@`&P`;P!C`&L`(`!A`&<`<@!E M`&4`;0!E`&X`=`!S`"``:0!N`"``;P!R`&0`90!R`"``=`!O`"``:`!E`&0` M9P!E`"``=`!H`&4`(`!E`'@`<`!E`&,`=`!E`&0`(`!I`&X`=`!E`'(`90!S M`'0`(`!P`&$`>0!M`&4`;@!T`',`(`!A`',`0`@`'(` M80!T`&4`(`!L`&4``!C`&4`90!D`&4`9``@ M`'0`:`!E`"``<@!A`'0`90!S`"``:0!N`"``=`!H`&4`(`!4`'(`90!A`',` M=0!R`'D`(`!L`&\`8P!K`"``80!G`'(`90!E`&T`90!N`'0`0!M`&4`;@!T`',` M(`!T`&\`(`!U`',`(`!O`&8`(``D`#$`+@`V`&T`:0!L`&P`:0!O`&X`+``@ M`'<`:`!I`&,`:``@`'<`80!S`"``<@!E`&,`;P!R`&0`90!D`"``80!S`"`` M;P!T`&@`90!R`"``8P!O`&T`<`!R`&4`:`!E`&X`0!I`&4`;`!D`"``<@!E`&0`=0!C M`'0`:0!O`&X`+@`@`$0`=0!R`&D`;@!G`"``=`!H`&4`(`!T`&@`<@!E`&4` M(`!M`&\`;@!T`&@``!P`&4`8P!T`"``=`!O M`"``<@!E`&,`;P!R`&0`(``D`#``+@`S`&T`:0!L`&P`:0!O`&X`(`!O`&8` M(`!A`&T`;P!R`'0`:0!Z`&$`=`!I`&\`;@`@`&0`=0!R`&D`;@!G`"``=`!H M`&4`(`!N`&4`>`!T`"``,0`R`&T`;P!N`'0`:`!S`"X`(``@``T`#0!)`&X` M(`!*`'4`;@!E`#(`,``P`#8`+``@`'<`90`@`&4`;@!T`&4`<@!E`&0`(`!I M`&X`=`!O`"``=`!W`&\`(``D`#$`,@`U`"X`,`!M`&D`;`!L`&D`;P!N`"P` M(`!T`'<`;P`M`&T`;P!N`'0`:``@`%0`<@!E`&$`0`@`&P`;P!C M`&L`(`!A`&<`<@!E`&4`;0!E`&X`=`!S`"``:0!N`"``;P!R`&0`90!R`"`` M=`!O`"``:`!E`&0`9P!E`"``=`!H`&4`(`!E`'@`<`!E`&,`=`!E`&0`(`!I M`&X`=`!E`'(`90!S`'0`(`!P`&$`>0!M`&4`;@!T`',`(`!A`',`0`@`'<`90!R`&4`(`!H`&D`9P!H`&P`>0`@`&4`9@!F`&4` M8P!T`&D`=@!E`"``8P!A`',`:``@`&8`;`!O`'<`(`!H`&4`9`!G`&4`0`@`'(`80!T`&4`(`!E`'@`8P!E`&4`9`!E`&0` M(`!T`&@`90`@`'(`80!T`&4`0!M`&4`;@!T`',`(`!T M`&\`(`!U`',`(`!O`&8`(``D`#$`+@`R`&T`:0!L`&P`:0!O`&X`+``@`'<` M:`!I`&,`:``@`'<`80!S`"``<@!E`&,`;P!R`&0`90!D`"``80!S`"``;P!T M`&@`90!R`"``8P!O`&T`<`!R`&4`:`!E`&X`0!I`&4`;`!D`"``<@!E`&0`=0!C`'0` M:0!O`&X`+@`@`$0`=0!R`&D`;@!G`"``=`!H`&4`(`!T`&@`<@!E`&4`(`!M M`&\`;@!T`&@``!P`&4`8P!T`"``=`!O`"`` M<@!E`&,`;P!R`&0`(``D`#``+@`S`&T`:0!L`&P`:0!O`&X`(`!O`&8`(`!A M`&T`;P!R`'0`:0!Z`&$`=`!I`&\`;@`@`&0`=0!R`&D`;@!G`"``=`!H`&4` M(`!N`&4`>`!T`"``,0`R`&T`;P!N`'0`:`!S`"X`(``@`"``%``!0P!O`&T` M<`!R`&4`:`!E`&X`0!I`&4`;`!D`"``<@!E`&0`=0!C`'0`:0!O`&X`+@`@ M`$0`=0!R`&D`;@!G`"``=`!H`&4`(`!T`&@`<@!E`&4`(`!M`&\`;@!T`&@` M`!P`&4`8P!T`"``=`!O`"``<@!E`&,`;P!R M`&0`(``D`#``+@`S`&T`:0!L`&P`:0!O`&X`(`!O`&8`(`!A`&T`;P!R`'0` M:0!Z`&$`=`!I`&\`;@`@`&0`=0!R`&D`;@!G`"``=`!H`&4`(`!N`&4`>`!T M`"``,0`R`"``;0!O`&X`=`!H`',`+@`@`"``#0`-`%<`90`@`'(`90!C`&\` M<@!D`&4`9``@`'0`:`!E`"``2@!U`&X`90`R`#``,``V`"``5`!R`&4`80!S M`'4`<@!Y`"``;`!O`&,`:P`@`&$`9P!R`&4`90!M`&4`;@!T`',`(`!O`&X` M(`!O`'4`<@`@`&(`80!L`&$`;@!C`&4`(`!S`&@`90!E`'0`@!E`&0`(`!T`&@`<@!O`'4`9P!H`"``;P!T`&@`90!R M`"``8P!O`&T`<`!R`&4`:`!E`&X`@!A`'0`:0!O`&X`+``@`'(`90!S`'`` M90!C`'0`:0!V`&4`;`!Y`"X`(`!7`&4`(`!E`'@`<`!E`&,`=``@`'0`;P`@ M`'(`90!C`&\`<@!D`"``)``P`"X`,P!M`&D`;`!L`&D`;P!N`"``;P!F`"`` M80!M`&\`<@!T`&D`>@!A`'0`:0!O`&X`(`!D`'4`<@!I`&X`9P`@`'0`:`!E M`"``;@!E`'@`=``@`#$`,@!M`&\`;@!T`&@`@H!(``@``T`#0`-`#$`-0`N`"``20!N`&,`;P!M`&4`(`!4`&$`>`!E`',` M(``@``T`#0!4`&@`90`@`'``<@!O`'8`:0!S`&D`;P!N`',`(`!O`&8`(`!! M`%,`0P`@`%0`;P!P`&D`8P`@`#<`-``P`"P`(`!)`&X`8P!O`&T`90`@`%0` M80!X`&4`0`@`'0`:`!E M`"``80!C`&,`;P!U`&X`=`!I`&X`9P`@`&8`;P!R`"``=0!N`&,`90!R`'0` M80!I`&X`=`!Y`"``:0!N`"``:0!N`&,`;P!M`&4`(`!T`&$`>`!E`',`(`!R M`&4`8P!O`&<`;@!I`'H`90!D`"``:0!N`"``9@!I`&X`80!N`&,`:0!A`&P` M(`!S`'0`80!T`&4`;0!E`&X`=`!S`"``80!N`&0`(`!P`'(`90!S`&,`<@!I M`&(`90`@`&$`(`!R`&4`8P!O`&<`;@!I`'0`:0!O`&X`(`!T`&@`<@!E`',` M:`!O`&P`9``@`&$`;@!D`"``;0!E`&$```@`'``;P!S`&D`=`!I`&\` M;@!S`"``=`!A`&L`90!N`"``;P!R`"``90!X`'``90!C`'0`90!D`"``=`!O M`"``8@!E`"``=`!A`&L`90!N`"``;P!N`"``80`@`'0`80!X`"``<@!E`'0` M=0!R`&X`(`!B`&4`8P!A`&T`90`@`&4`9@!F`&4`8P!T`&D`=@!E`"``2@!A M`&X`=0!A`'(`>0`Q`"P`(``R`#``,``W`"X`(`!.`&\`(`!A`&T`;P!U`&X` M=`!S`"``:`!A`'8`90`@`&(`90!E`&X`(`!R`&4`8P!O`'(`9`!E`&0`(`!F M`&\`<@`@`'4`;@!R`&4`8P!O`&<`;@!I`'H`90!D`"``=`!A`'@`(`!B`&4` M;@!E`&8`:0!T`',`(`!O`'(`(`!R`&4`;`!A`'0`90!D`"``:0!N`'0`90!R M`&4``!A`&T`:0!N`&$`=`!I`&\`;@`@`&(`>0`@`'0`:`!E`"``20!N`'0`90!R M`&X`80!L`"``4@!E`'8`90!N`'4`90`@`%,`90!R`'8`:0!C`&4`(`!A`&X` M9``@`'0`:`!E`"``=`!A`'@`(`!A`'4`=`!H`&\`<@!I`'0`:0!E`',`(`!O M`&8`(`!T`&@`90`@`',`:0!G`&X`:0!F`&D`8P!A`&X`=``@`&H`=0!R`&D` M0`N`"``00!S`"``80`@ M`'(`90!S`'4`;`!T`"``;P!F`"``=`!H`&4`(`!A`&,`<0!U`&D`0`@`&$`9`!J`'4```@`'(`90!T`'4`<@!N`',`(`!F`&\`<@`@`'``90!R`&D`;P!D M`',`(`!P`'(`:0!O`'(`(`!T`&\`(`!*`'4`;@!E`#$`+``@`#(`,``P`#8` M(`!B`'D`(`!T`&@`90`@`$D`;@!T`&4`<@!N`&$`;``@`%(`90!V`&4`;@!U M`&4`(`!3`&4`<@!V`&D`8P!E`"``8P!O`'4`;`!D`"``8P!H`&$`;@!G`&4` M(`!T`&@`90`@`&$`;0!O`'4`;@!T`"``;P!F`"``=`!H`&4`(`!.`$\`3`!S M`"``=`!H`&$`=``@`'<`90`@`&,`80!N`"``=0!T`&D`;`!I`'H`90`N`"`` M5P!E`"``:`!A`'8`90`@`'4`0!E`&$`<@!S`"X`(`!4 M`&@`90!S`&4`(`!.`$\`3`!S`"``80!R`&4`(`!S`&4`=``@`'0`;P`@`&4` M>`!P`&D`<@!E`"``8@!E`'0`=P!E`&4`;@`@`#(`,``Q`#<`(`!A`&X`9``@ M`#(`,``R`#4`+@`@`$X`3P!,`',`(`!R`&4`;`!A`'0`90!D`"``=`!O`"`` M=@!A`'(`:0!O`'4``!A`&(`;`!E`"`` M9`!I`',`<`!O`',`:0!T`&D`;P!N`"``;P!F`"``2`!!`$P`0!E M`&$`<@!S`"``80!F`'0`90!R`"``=`!H`&4`(`!*`'4`;@!E`#$`+``@`#(` M,``P`#8`(`!A`&,`<0!U`&D```@`'<`;P!U`&P` M9``@`&(`90`@`&$``!T`&4`;@!T`"``;P!F`"``=`!H`&4`(`!B`'4`:0!L`'0` M+0!I`&X`(`!G`&$`:0!N`"``=`!H`&$`=``@`&4`>`!I`',`=`!E`&0`(`!O M`&X`(`!T`&@`90`@`&0`80!T`&4`(`!O`&8`(`!A`&,`<0!U`&D`0`@`&$`0!E`&$`<@!S`"``80!F`'0`90!R`"``=`!H`&4`(`!A M`&,`<0!U`&D`0!E`&$`<@`@`'``90!R`&D`;P!D`"``:0!F`"``=P!E`"``80!R`&4`(`!A M`&(`;`!E`"``=`!O`"``8P!O`&T`<`!L`&4`=`!E`"``80`@`'0`80!X`"T` M9`!E`&8`90!R`'(`90!D`"``90!X`&,`:`!A`&X`9P!E`"X`(``@`"``(``@ M`"``#0`-`"``(``@`"``(``3``%3`&4`9P!M`&4`;@!T`"``20!N`&8`;P!R M`&T`80!T`&D`;P!N`!X``5,`90!G`&T`90!N`'0`(`!)`&X`9@!O`'(`;0!A M`'0`:0!O`&X`(`!;`$$`8@!S`'0`<@!A`&,`=`!=`(`,`2``(``-``T`#0`Q M`#8`+@`@`%,`90!G`&T`90!N`'0`(`!)`&X`9@!O`'(`;0!A`'0`:0!O`&X` M(``@``T`#0!/`'4`<@`@`&\`<`!E`'(`80!T`&D`;P!N`',`(`!A`'(`90`@ M`&\`<@!G`&$`;@!I`'H`90!D`"``:0!N`'0`;P`@`'0`=P!O`"```!E`',`+``@`&D`;@!S`'4`<@!A`&X`8P!E`"``80!N`&0`(`!C M`&$`<`!I`'0`80!L`"``90!X`'``90!N`&0`:0!T`'4`<@!E`',`*0`@`'0` M;P`@`'0`:`!E`"``=`!E`&X`80!N`'0`+@`@`$D`;@`@`'0`:`!E`"``;0!U M`&P`=`!I`"T`=`!E`&X`80!N`'0`(`!L`&4`80!S`&4``!P`&4`;@!S`&4`0`@`&\`9@`@`'0`:`!E`',`90`@`&$`<@!E`"P`(`!O`'(`(`!C`&$`;@`@ M`&4`9@!F`&4`8P!T`&D`=@!E`&P`>0`@`&(`90`L`"``<`!A`',`0`@`&D`;@!F`&\`<@!M`&$`=`!I M`&\`;@`@`'(`90!L`&$`=`!E`&0`(`!T`&\`(`!O`'4`<@`@`'(`90!P`&\` M<@!T`&$`8@!L`&4`(`!S`&4`9P!M`&4`;@!T`',`(`!I`',`(`!A`',`(`!F M`&\`;`!L`&\`=P!S`#H`(``@``T`#0`-``D`(``)``D`(``)``D`(``)``D` M(``)``T`#0`)`"``"0!4`&@`<@!E`&4`(`!M`&\`;@!T`&@``!P`&4`;@!S`&4`(`!R`&4`:0!M M`&(`=0!R`',`90!M`&4`;@!T`',`(`!F`&\`<@`@`&,`;P!M`&T`;P!N`"`` M80!R`&4`80`@`&T`80!I`&X`=`!E`&X`80!N`&,`90`@`&,`:`!A`'(`9P`= M``%#`&\`;0!M`&D`=`!M`&4`;@!T`',`(`!A`&X`9``@`$,`;P!N`'0`:0!N M`&<`90!N`&,`:0!E`',`*``!0P!O`&T`;0!I`'0`;0!E`&X`=`!S`"``80!N M`&0`(`!#`&\`;@!T`&D`;@!G`&4`;@!C`&D`90!S`"``6P!!`&(``!C`&4`<`!T`"``80!S`"``9`!E`',` M8P!R`&D`8@!E`&0`(`!H`&4`<@!E`&D`;@`L`"``=P!E`"``80!R`&4`(`!N M`&\`=``@`&$`=P!A`'(`90`@`&\`9@`@`&$`;@!Y`"``;P!T`&@`90!R`"`` M;`!E`&<`80!L`"``<`!R`&\`8P!E`&4`9`!I`&X`9P!S`"``;P!R`"``8P!L M`&$`:0!M`',`(`!T`&@`80!T`"``=P!E`"``8@!E`&P`:0!E`'8`90`@`&T` M80!Y`"``:`!A`'8`90`L`"``:0!N`&0`:0!V`&D`9`!U`&$`;`!L`'D`(`!O M`'(`(`!T`&$`:P!E`&X`(`!T`&\`9P!E`'0`:`!E`'(`+``@`&$`(`!M`&$` M=`!E`'(`:0!A`&P`(`!A`&0`=@!E`'(`0`@`'<`:0!T`&@`(`!R`&4`0`@`#(`,``P`#4`+``@`'<`90`@`'<`90!R M`&4`(`!S`&4`<@!V`&4`9``@`'<`:0!T`&@`(`!S`&4`=@!E`'(`80!L`"`` M;`!A`'<`0`R`#8`+``@`#(`,``P`#,`+@`@`$$`=``@`'0` M:`!E`"``=`!I`&T`90`@`&\`9@`@`'0`:`!E`"``9@!I`'(`90`L`"``=`!H M`&4`(`!'`'(`90!E`&X`=P!O`&\`9``@`$@`90!A`&P`=`!H`&,`80!R`&4` M(`!#`&4`;@!T`&4`<@`@`'<`80!S`"``;P!W`&X`90!D`"``8@!Y`"``=0!S M`"``80!N`&0`(`!L`&4`80!S`&4`9``@`'0`;P`@`&$`;@!D`"``;P!P`&4` M<@!A`'0`90!D`"``8@!Y`"``3`!E`'@`:0!N`&<`=`!O`&X`(`!(`&4`80!L M`'0`:`!C`&$`<@!E`"``1P!R`&\`=0!P`"X`(`!4`&@`90!R`&4`(`!W`&4` M<@!E`"``80`@`'0`;P!T`&$`;``@`&\`9@`@`#$`,P`@`&P`80!W`',`=0!I M`'0`0`@`'(`90!P`'(`90!S`&4`;@!T`&$` M=`!I`'8`90!S`"``;P!F`"``<`!A`'0`:0!E`&X`=`!S`"``=P!H`&\`(`!W M`&4`<@!E`"``90!I`'0`:`!E`'(`(`!K`&D`;`!L`&4`9``@`&\`<@`@`&D` M;@!J`'4`<@!E`&0`(`!I`&X`(`!T`&@`90`@`&8`:0!R`&4`+@`@`%0`:`!E M`"``;`!A`'<`0`@`&0`80!M`&$`9P!E`',`+@`@ M`%0`:`!E`"``8P!O`&T`<`!L`&$`:0!N`'0`0`@`&$`9P!A`&D`;@!S`'0`(`!,`&4`>`!I`&X`9P!T`&\` M;@`@`$@`90!A`&P`=`!H`&,`80!R`&4`+``@`&$`0`@`&$`;@!D`"``;0!O`'0`:0!O`&X`(`!P`'(`80!C M`'0`:0!C`&4`+@`@`%<`90`@`&@`80!V`&4`(`!F`&D`;`!E`&0`(`!A`"`` M;0!O`'0`:0!O`&X`(`!F`&\`<@`@`',`=0!M`&T`80!R`'D`(`!J`'4`9`!G M`&T`90!N`'0`(`!W`&D`=`!H`"``<@!E`&<`80!R`&0`(`!T`&\`(`!C`&4` M<@!T`&$`:0!N`"``<`!E`&X`9`!I`&X`9P`@`&,`;`!A`&D`;0!S`"``80!N M`&0`(`!W`&D`;`!L`"``8@!E`"``9@!I`&P`:0!N`&<`(`!A`&0`9`!I`'0` M:0!O`&X`80!L`"``0`@`&H`=0!D`&<`;0!E`&X`=``@ M`&T`;P!T`&D`;P!N`',`(`!F`&\`<@`@`&$`;@!Y`"``<@!E`&T`80!I`&X` M:0!N`&<`(`!C`&P`80!I`&T`0`@`&D`;@!S`'4`<@!A`&X`8P!E`"X`(`!7 M`&4`(`!O`&(`=`!A`&D`;@!E`&0`(`!A`"``:@!U`&0`9P!M`&4`;@!T`"`` M;P!F`"``;@!O`&X`0`@`&\`=P!E M`',`(`!I`&X``!I`&X`9P!T`&\`;@`@`&D`;@`@`&$`;0!O`'4`;@!T M`',`(`!U`'``(`!T`&\`(``D`#$`,``N`#``;0!I`&P`;`!I`&\`;@`N`"`` M5`!H`&4`(`!P`&$`<@!T`&D`90!S`"``=`!O`"``=`!H`&$`=``@`&,`80!S M`&4`+``@`'<`:`!I`&,`:``@`&D`0`@`&8`80!V`&\`<@!A`&(`;`!E`"``9@!O`'(`(`!U`',`+@`@ M`%0`:`!E`"``8P!O`'4`<@!T`',`(`!R`'4`;`!I`&X`9P`@`&D`;@!D`&D` M8P!A`'0`90!S`"``)``Q`#``+@`P`"``;0`:``%2`&4`;`!A`'0`90!D`"`` M4`!A`'(`=`!Y`"``5`!R`&$`;@!S`&$`8P!T`&D`;P!N`',`)0`!4@!E`&P` M80!T`&4`9``@`%``80!R`'0`>0`@`%0`<@!A`&X`0`@`'0`:`!A`'0`(`!O`'<`;@!S`"``=`!W M`&\`(`!M`'4`;`!T`&D`+0!T`&4`;@!A`&X`=``@`&T`90!D`&D`8P!A`&P` M(`!O`&8`9@!I`&,`90`@`&(`=0!I`&P`9`!I`&X`9P!S`"P`(`!A`&X`9``@ M`&$`0`L`"``:`!A`&0`(`!A`&X`(`!O`'<`;@!E`'(`0`@`&$`(`!M`'4`;`!T`&D`+0!T M`&4`;@!A`&X`=``@`&T`90!D`&D`8P!A`&P`(`!O`&8`9@!I`&,`90`@`&(` M=0!I`&P`9`!I`&X`9P`@`&D`;@`@`'0`:`!E`"``80!M`&\`=0!N`'0`(`!O M`&8`(``D`#0`-P`N`#4`;0!I`&P`;`!I`&\`;@`N`"``00!S`"``;P!F`"`` M1@!E`&(`<@!U`&$`<@!Y`#$`+``@`#(`,``Q`#``+``@`'<`90`@`&$`8P!Q M`'4`:0!R`&4`9``@`'0`:`!E`"``;0!U`&P`=`!I`"T`=`!E`&X`80!N`'0` M(`!M`&4`9`!I`&,`80!L`"``;P!F`&8`:0!C`&4`(`!B`'4`:0!L`&0`:0!N M`&<`+``@`&$`;@!D`"``80!S`"``80`@`'(`90!S`'4`;`!T`"P`(`!T`&@` M90`@`&P`;P!A`&X`(`!W`&$`0`@`&T`80!N M`&$`9P!E`&T`90!N`'0`(`!C`&\`;0!P`&$`;@!Y`"``*`!S`&4`90`@`$X` M;P!T`&4`(``V`"D`+@`@`$0`<@`N`%(`=0!S`&@`+``@`'0`:`!R`&\`=0!G M`&@`(`!A`&X`(`!U`&X`80!F`&8`:0!L`&D`80!T`&4`9``@`&4`;@!T`&D` M=`!Y`"P`(`!H`&$`0`@`$X`2`!0`"\`4`!-`$(`+@`@`$0`<@`N`%(`=0!S`&@`+``@ M`'0`:`!R`&\`=0!G`&@`(`!A`&X`(`!U`&X`80!F`&8`:0!L`&D`80!T`&4` M9``@`&4`;@!T`&D`=`!Y`"P`(`!H`&$`0`@`$X`2`!0`"\`4`!-`$(`+``@`$<`:0!L`&(`90!R`'0`(`!*`%8` M(`!A`&X`9``@`%``80!S`&$`9`!E`&X`80`@`$H`5@`@`&0`=0!R`&D`;@!G M`"``=`!H`&4`(`!T`&@`<@!E`&4`(`!M`&\`;@!T`&@``!I`&T`80!T`&4` M;`!Y`"``)``U`#@`;0!I`&P`;`!I`&\`;@`@`&\`9@`@`&D`;@!V`&4`0`@`#8`+``@`#(`,``Q`#``+``@`'<` M90`@`&D`0`@`#$`+``U`#D`,@`L`#``,``P`"``Q`$` M#0`"``$`#``"`&0`#P`"``$`$0`"````$``(`/RI\=)-8E`_7P`"``$`*@`" M````*P`"````@@`"``$`@``(````````````)0($````_P"!``(`P004```` M%0```(,``@```(0``@```*$`(@`)`&0``0`!``$`1@!8`E@"````````X#\` M``````#@/P$`50`"``@`?0`,``````"V/`\````$`'T`#``!``,`MA@/```` M!`!]``P`!`#_`"0)#P````0```(.```````1```````$````"`(0```````` M`/\````````!#P`(`A```0````,`_P````````$/``@"$``"``````#_```` M`````0\`"`(0``,````!`/\````````!#P`(`A``!`````$`_P````````$/ M``@"$``%`````0#_`````````0\`"`(0``8````!`/\````````!#P`(`A`` M!P````$`_P````````$/``@"$``(`````0#_`````````0\`"`(0``D````! M`/\````````!#P`(`A``"@````$`_P````````$/``@"$``+`````0#_```` M`````0\`"`(0``P````!`/\````````!#P`(`A``#0````$`_P````````$/ M``@"$``.`````0#_`````````0\`"`(0``\````#`/\````````!#P`(`A`` M$`````(`_P````````$/`/T`"@``````%P```````0(&``$````7`/T`"@`! M``$`%P`!````_0`*``$``@`7``(```#]``H``0`#`!<``P```/T`"@`"```` M%@`$````_0`*``,````8``4```#]``H``P`!`!L`!@```/T`"@`$````&``' M````_0`*``0``0`;``@```#]``H`!0```!@`"0```/T`"@`%``$`&P`*```` M_0`*``8````8``L```#]``H`!@`!`!L`#````/T`"@`'````&``-````_0`* M``<``0`;``X```#]``H`"````!@`#P```'X""@`(``$`'```:)]`_0`*``D` M```8`!````#]``H`"0`!`!L`$0```/T`"@`*````&``2````_0`*``H``0`; M`!,```#]``H`"P```!@`%````/T`"@`+``$`&P`5````_0`*``P````8`!8` M``#]``H`#``!`!L`%P```/T`"@`-````&``8````_0`*``T``0`;`!4```#] M``H`#@```!@`&0```/T`"@`.``$`&P`:````_0`*``\````8`!L````#`@X` M#P`#`!T`````2NK5XT']``H`$````!@`'````'X""@`0``(`'``6U8\?+P``@#]``H`!0```!@`(P```+T`$@`%``$` M'`!2HM\`'`"8_4E!`@#]``H`!@```!@`)`````,"#@`&``$`'@``````+H`B MP7X""@`&``(`'@"$`!01X``$$`00(`_0`*`!`````8`"X```"]`!(`$``! M`!X`,L3H`!X`CIG>``(`_0`*`!$````6`"\```#]``H`$@```!@`,````+T` M$@`2``$`'```````'````````@#]``H`$P```!@`,0```+T`$@`3``$`'`!& MACP`'`!&ACP``@#]``H`%````!@`,@```+T`$@`4``$`'``<6R!!'`"`51I! M`@#]``H`%0```!@`,P```+T`$@`5``$`'@#`D_Y`'@"8.0!!`@#]``H`%@`` M`!@`-````+T`$@`6``$`'`!NX60`'``DOC=!`@#]``H`%P```!@`-0```+T` M$@`7``$`'`!0[_)`'`#@_NM``@#]``H`&````!@`-@```/T`"@`8``$`&P`W M````_0`*`!@``@`;`#<```#]``H`&0```!8`.````/T`"@`:````&``Y```` MO0`2`!H``0`<```````<`(`4Z4`"`/T`"@`;````&``Z````O0`2`!L``0`< M```5QT`<``!4QD`"`/T`"@`<````&``[````O0`2`!P``0`<`";9AP`<`"[O M@0`"`/T`"@`=````&``\````O0`2`!T``0`<``2`.D$<`/X4:``"`/T`"@`> M````&``]````O0`2`!X``0`<``"DE<`<``"XB<`"`/T`"@`?````&``^```` M`P(.`!\``0`>``````"_.#W!?@(*`!\``@`>`%1M/,'7`$0`R`8``&P"#@`J M``X`)``D`"0`+@`D`"0`)``D`"0`)``D`"0`)``D``X`)``D`"0`)``D`"0` M*@`.`"0`)``D`"0`)``(`A``(`````(`_P````````$/``@"$``A`````@#_ M`````````0\`"`(0`"(````"`/\````````!#P`(`A``(P````(`_P`````` M``$/`/T`"@`@````&``_````O0`2`"```0`<`#Z9?0`<`"X7?``"`/T`"@`A M````&`!`````O0`2`"$``0`>`$#;V$`>``#H@T`"`/T`"@`B````&`!!```` MO0`2`"(``0`>`+S)/T$>`$@(/T$"`/T`"@`C````&`!"````O0`2`",``0`? M`#+$Z``?`(Z9W@`"`-<`#`#@````/``D`"0`)``^`A(`M@``````0``````` M````````H``$`&0`9``=``\``P````````$`````````[P`&````-P````H` M```)"!````80`$88S0?!@```!@(```L"%`````````````P`````````2-$! M``T``@`!``P``@!D``\``@`!`!$``@```!``"`#\J?'236)0/U\``@`!`"H` M`@```"L``@```((``@`!`(``"````````````"4"!````/\`@0`"`,$$%``` M`!4```"#``(```"$``(```"A`"(`"0!D``$``0`!`$8`6`)8`@```````.`_ M````````X#\!`%4``@`(`'T`#```````MCP/````!`!]``P``0`"`+88#P`` M``0`?0`,``,`_P`D"0\````$```"#@``````#````````P````@"$``````` M``#_`````````0\`"`(0``$````"`/\````````!#P`(`A```@``````_P`` M``````$/``@"$``#`````@#_`````````0\`"`(0``0````"`/\````````! M#P`(`A``!0````(`_P````````$/``@"$``&`````@#_`````````0\`"`(0 M``<````"`/\````````!#P`(`A``"`````(`_P````````$/``@"$``)```` M`@#_`````````0\`"`(0``H````"`/\````````!#P`(`A``"P````(`_P`` M``````$/`/T`"@``````%P!#`````0(&``$````7`/T`"@`!``$`%P!$```` M_0`*``$``@`7`$4```#]``H``@```!8`1@```/T`"@`#````&`!'````O0`2 M``,``0`<````\#\<````\#\"`/T`"@`$````&`!(````O0`2``0``0`<`-`2 M4T$<`-`24T$"`/T`"@`%````&`!)````O0`2``4``0`<```````<`+!9'T$" M`/T`"@`&````&`!*````O0`2``8``0`<```````<`+!9'T$"`/T`"@`'```` M&`!+````O0`2``<``0`<````64`<````64`"`/T`"@`(````&`!,````O0`2 M``@``0`@``$`)$`@``$`)$`"`/T`"@`)````&`!-````O0`2``D``0`<`(37 MIT$<`(37IT$"`/T`"@`*````&`!.````O0`2``H``0`<`"9A+1P<`$J601L" M`/T`"@`+````&`!/````O0`2``L``0`<`"9A+1P<`$J601L"`-<`'`!V`@`` MW``.`"8`#@`D`"0`)``D`"0`)``D`"0`/@(2`+8``````$`````````````` M`*``!`!D`&0`'0`/``,````````!`````````.\`!@```#<````*````"0@0 M```&$`!&&,T'P8````8"```+`A@````````````G`````````$?9`0`#VP$` M#0`"``$`#``"`&0`#P`"``$`$0`"````$``(`/RI\=)-8E`_7P`"``$`*@`" M````*P`"````@@`"``$`@``(````````````)0($````_P"!``(`P004```` M%0```(,``@```(0``@```*$`(@`)`&0``0`!``$`1@!8`E@"````````X#\` M``````#@/P$`50`"``@`?0`,``````"V/`\````$`'T`#``!``(`MA@/```` M!`!]``P``P#_`"0)#P````0```(.```````G```````#````"`(0```````` M`/\````````!#P`(`A```0````(`_P````````$/``@"$``"``````#_```` M`````0\`"`(0``,````"`/\````````!#P`(`A``!`````(`_P````````$/ M``@"$``%`````@#_`````````0\`"`(0``8````"`/\````````!#P`(`A`` M!P````(`_P````````$/``@"$``(``````#_`````````0\`"`(0``D````" M`/\````````!#P`(`A``"@````(`_P````````$/``@"$``+`````@#_```` M`````0\`"`(0``P````!`/\````````!#P`(`A``#0````(`_P````````$/ M``@"$``.`````@#_`````````0\`"`(0``\````"`/\````````!#P`(`A`` M$`````(`_P````````$/``@"$``1`````@#_`````````0\`"`(0`!(````" M`/\````````!#P`(`A``$P``````_P````````$/``@"$``4`````@#_```` M`````0\`"`(0`!4````"`/\````````!#P`(`A``%@````(`_P````````$/ M``@"$``7`````@#_`````````0\`"`(0`!@````"`/\````````!#P`(`A`` M&0````(`_P````````$/``@"$``:`````@#_`````````0\`"`(0`!L````" M`/\````````!#P`(`A``'```````_P````````$/``@"$``=`````@#_```` M`````0\`"`(0`!X````"`/\````````!#P`(`A``'P````(`_P````````$/ M`/T`"@``````%P!0````_0`*``$````7`%$```#]``H``0`!`!<``0```/T` M"@`!``(`%P!2````_0`*``(````6`%,```#]``H``P```!@`5````+T`$@`# M``$`'0!@'O)`'0#P%O)``@#]``H`!````!@`50```+T`$@`$``$`'@#`P-1` M'@!`0]!``@#]``H`!0```!@`5@```+T`$@`%``$`'`"03O=`'`#`)_9``@#] M``H`!@```!@`5P```+T`$@`&``$`'@``,[M`'@``O[A``@#]``H`!P```!@` M6````+T`$@`'``$`'@#``?E`'@"PL_=``@#]``H`"````!8`60```/T`"@`) M````&`!:````O0`2``D``0`<`(`)UT`<`,"!UT`"`/T`"@`*````&`!;```` MO0`2``H``0`<`$`XWT`<````$!\WD`>``"]W$`"`/T`"@`3````%@!D M````_0`*`!0````8`&4```"]`!(`%``!`!P````V0!P``*C40`(`_0`*`!4` M```8`&8````!`@8`%0`!`"(`?@(*`!4``@`>``"`2D#]``H`%@```!@`9P`` M`+T`$@`6``$`'@```#9`'@!`M=1``@#]``H`%P```!@`:````+T`$@`7``$` M'`#`@=Y`'``@N>A``@#]``H`&````!@`:0```+T`$@`8``$`'@``P&=`'@`` M`#O``@#]``H`&0```!@`:@```+T`$@`9``$`'`!`L=Y`'`#`M>A``@#]``H` M&@```!@`:P````$"!@`:``$`(@!^`@H`&@`"`!X``+"6P/T`"@`;````&`!L M````O0`2`!L``0`?`$"QWD`?`$``Z$`"`/T`"@`<````%@!M````_0`*`!T` M```8`&X```"]`!(`'0`!`"$``0`[0"$``0`[0`(`_0`*`!X````8`&\````! M`@8`'@`!`"(`?@(*`!X``@`C``$`-4#]``H`'P```!@`;````+T`$@`?``$` M(P`!`#M`(P`!`$A``@#7`$0`F`8``&P"#@`J``X`)``D`"0`)``D``X`)``D M`"0`'``D`"0`)``D`"8`)``.`"0`)@`D`"0`)``D`"8`)``.`"0`)@`(`A`` M(`````(`_P````````$/``@"$``A``````#_`````````0\`"`(0`"(````" M`/\````````!#P`(`A``(P````(`_P````````$/``@"$``D`````@#_```` M`````0\`"`(0`"4````"`/\````````!#P`(`A``)@````(`_P````````$/ M`/T`"@`@````&`!P````O0`2`"```0`>`("3_$`>`##]^$`"`/T`"@`A```` M%@!Q````_0`*`"(````8`&X```"]`!(`(@`!`"$``0`Z0"$``0`[0`(`_0`* M`",````8`&\````!`@8`(P`!`"(`?@(*`",``@`C``$`-$#]``H`)````!@` M;````+T`$@`D``$`(P`!`#I`(P`!@$=``@#]``H`)0```!@`<@```+T`$@`E M``$`'@"@*OU`'@"`??E``@#]``H`)@```!@`@```/T`"@`!``<`%P![````_0`*``$`"``7`'P```#]``H``@`` M`!@`?0```+T`$@`"``$`'```$(!`'``0Z?M``@#]``H``P```!@`?@```+T` M-@`#``$`'0"`%.E`'0``5,9`'0`N[X$`'0!4;3S!'0``N(G`'0#^%&@`'0`` MZ(-`'0!("#]!"`#]``H`!````!8`?P```/T`"@`%````&`!H````O0`8``4` M!@`<`$"QWD`<``#`9\`<`,"!WD`(`/T`"@`&````&`"`````?@(*``8`!0`< M``"`7\!^`@H`!@`(`!P``(!?P/T`"@`'````&`"!````O@`.``<``0`B`"(` M(@`B``0`?@(*``<`!0`>``!`>\"^``H`!P`&`"(`(@`'`'X""@`'``@`'@`` M0'O`_0`*``@````8`((```!^`@H`"``(`!P`0/7=0/T`"@`)````&`"#```` MO0`8``D``0`<`(`4Z<`<``#@;$`<`"#LZ$`#`'X""@`)``@`'````%?`_0`* M``H````8`(0```"]`!(`"@`!`!P``!"`P!P``!:B0`(`_0`*``L````8`(4` M``"]`!(`"P`"`!P``&!C0!P`H%_F0`,`?@(*``L`"``<``!SYD#]``H`#``` M`!@`A@```'X""@`,``(`'```,)A`_0`*``T````8`(<```!^`@H`#0`#`!P` M`.B80'X""@`-``@`'```Z)A`_0`*``X````8`(@```!^`@H`#@`$`!P`8&WI MP'X""@`.``@`'`!@;>G`_0`*``\````8`(D```!^`@H`#P`#`!P``&B8P'X" M"@`/``@`'```:)C`_0`*`!`````8`(H```"]`!(`$``'`!P`0++80!P`0++8 M0`@`_0`*`!$````8`(L```"^`!(`$0`!`"(`(@`B`"(`(@`B``8`O0`2`!$` M!P`>``"P<<`>``"P<<`(`/T`"@`2````&`",````O0`8`!(``0`=```````= M```5QT`=`";9AP`#``,"#@`2``0`'0``````OS@]P;T`'@`2``4`'0``I)7` M'0`$@#I!'0!`V]A`'0"\R3]!"`#]``H`$P```!@`C0```+T`$@`3``$`'``` M````'`"`VOQ``@#7`"P`6`4``'P!#@!^`"0`2``.`"H`*@!*`!P`.``D`#(` M'``J`"H`*@`D`#H`7@`^`A(`M@``````0```````````````H``$`&0`9``= M``\``P````````$`````````[P`&````-P````H````)"!````80`$88S0?! M@```!@(```L"&````````````#,`````````=>D!`+7M`0`-``(``0`,``(` M9``/``(``0`1``(````0``@`_*GQTDUB4#]?``(``0`J``(````K``(```"" M``(``0"```@````````````E`@0```#_`($``@#!!!0````5````@P`"```` MA``"````H0`B``D`9``!``$``0!&`%@"6`(```````#@/P```````.`_`0!5 M``(`"`!]``P``````+8\#P````0`?0`,``$``@"V&`\````$`'T`#``#`/\` M)`D/````!````@X``````#,```````,````(`A``````````_P````````$/ M``@"$``!`````@#_`````````0\`"`(0``(``````/\````````!#P`(`A`` M`P````(`_P````````$/``@"$``$``````#_`````````0\`"`(0``4````" M`/\````````!#P`(`A``!@````(`_P````````$/``@"$``'`````0#_```` M`````0\`"`(0``@````"`/\````````!#P`(`A``"0````$`_P````````$/ M``@"$``*`````@#_`````````0\`"`(0``L````"`/\````````!#P`(`A`` M#`````(`_P````````$/``@"$``-`````@#_`````````0\`"`(0``X````" M`/\````````!#P`(`A``#P``````_P````````$/``@"$``0`````@#_```` M`````0\`"`(0`!$````"`/\````````!#P`(`A``$@````(`_P````````$/ M``@"$``3`````@#_`````````0\`"`(0`!0``````/\````````!#P`(`A`` M%0````(`_P````````$/``@"$``6`````@#_`````````0\`"`(0`!<````" M`/\````````!#P`(`A``&`````(`_P````````$/``@"$``9`````@#_```` M`````0\`"`(0`!H````"`/\````````!#P`(`A``&P````(`_P````````$/ M``@"$``<``````#_`````````0\`"`(0`!T````"`/\````````!#P`(`A`` M'@````(`_P````````$/``@"$``?`````@#_`````````0\`_0`*```````7 M`(X```#]``H``0```!<`'@```/T`"@`!``$`%P`!````_0`*``$``@`7`%(` M``#]``H``@```!8`CP```/T`"@`#````&`!H````O0`2``,``0`=`,"!WD`= M`""YZ$`"`/T`"@`$````%@"0````_0`*``4````8`%L```"]`!(`!0`!`!P` M0#C?0!P`P&3>0`(`_0`*``8````8`)$```"]`!(`!@`!`!P``.B80!P``)28 M0`(`_0`*``<````8`)(```!^`@H`!P`!`!P``&"#P/T`"@`(````&`!E```` MO0`2``@``0`<````-L`<``"HU,`"`/T`"@`)````&`!B````?@(*``D``0`< M``#`4L#]``H`"@```!@`DP```+T`$@`*``$`'```>(9`'```^(5``@#]``H` M"P```!@`E````'X""@`+``(`'````#-`_0`*``P````8`)4```"]`!(`#``! M`!P``!2;P!P``%29P`(`_0`*``T````8`)8```"]`!(`#0`!`!P``.!QP!P` M```40`(`_0`*``X````8`)<```"]`!(`#@`!`!P``"!P0!P``"!I0`(`_0`* M``\````6`)@```#]``H`$````!@`F0```+T`$@`0``$`'```J)K`'```:(#` M`@#]``H`$0```!@`F@```+T`$@`1``$`'```0&K`'```V([``@#]``H`$@`` M`!@`,P```+T`$@`2``$`'@"`_-#`'@"`7\_``@#]``H`$P```!@`FP```+T` M$@`3``$`'@"@6N5`'@"@<.5``@#]``H`%````!8`G````/T`"@`5````&`"= M````O0`2`!4``0`<``#$[\`<`(##P,`"`/T`"@`6````&`">````?@(*`!8` M`@`<`("WX4#]``H`%P```!@`GP```+T`$@`7``$`'`"H)`'!'`"`O````5,`>``"`5,`" M`/T`"@`F````&`"L````O0`2`"8``0`>`(!6Q\`>`"`O\,`"`/T`"@`G```` M&`"M````O0`2`"<``0`<`$#U!,$<``"TGL`"`/T`"@`H````&`"N````O0`2 M`"@``0`<`!A5%T$<`*`4]$`"`/T`"@`I````&`"O````O0`2`"D``0`<`/"T M"4$<`-"9\T`"`/T`"@`J````%@"P````_0`*`"L````8`+$```!^`@H`*P`! M`!X`H+SZ0`$"!@`K``(`(@#]``H`+````!@`L@```'X""@`L``$`'@"`,>=` M`0(&`"P``@`B`/T`"@`M````&`"S````?@(*`"T``0`<`$"RV$#]``H`+@`` M`!@`M````'X""@`N``$`'@"`BM)``0(&`"X``@`B`/T`"@`O````&`"U```` M?@(*`"\``0`>``!RN$`!`@8`+P`"`"(`_0`*`#`````6`+8```#]``H`,0`` M`!@`MP```'X""@`Q``$`'@``">E``0(&`#$``@`B`/T`"@`R````&`")```` M?@(*`#(``0`?``!HF$`!`@8`,@`"`"(`UP`J`/@#``!H`20`'``D`"0`)``D M`"0`)``D`"0`#@`F`"8`'``F`"8`#@`F`#X"$@"V``````!````````````` M``"@``0`9`!D`!T`#P`#`````````0````````#O``8````W````"@````D( M$```!A``1AC-!\&````&`@``"P(4````````````!`````````#&[P$`#0`" M``$`#``"`&0`#P`"``$`$0`"````$``(`/RI\=)-8E`_7P`"``$`*@`"```` M*P`"````@@`"``$`@``(````````````)0($````_P"!``(`P004````%0`` M`(,``@```(0``@```*$`(@`)`&0``0`!``$`1@!8`E@"````````X#\````` M``#@/P$`50`"``@`?0`,``````"V/`\````$`'T`#``!``$`MA@/````!`!] M``P``@#_`"0)#P````0```(.```````$```````"````"`(0`````````/\` M```````!#P`(`A```0````$`_P````````$/``@"$``"``````#_```````` M`0\`"`(0``,````!`/\````````!#P#]``H``````!<`N`````$"!@`!```` M%P#]``H``0`!`!<``0```/T`"@`"````%@"Y````_0`*``,````8`+@```#] M``H``P`!`!L`N@```-<`#`"@````/``.`!@`#@`^`A(`M@``````0``````` M````````H``$`&0`9``=``\``P````````$`````````[P`&````-P````H` M```)"!````80`$88S0?!@```!@(```L"%`````````````0`````````N?$! M``T``@`!``P``@!D``\``@`!`!$``@```!``"`#\J?'236)0/U\``@`!`"H` M`@```"L``@```((``@`!`(``"````````````"4"!````/\`@0`"`,$$%``` M`!4```"#``(```"$``(```"A`"(`"0!D``$``0`!`$8`6`)8`@```````.`_ M````````X#\!`%4``@`(`'T`#```````MCP/````!`!]``P``0`!`+88#P`` M``0`?0`,``(`_P`D"0\````$```"#@``````!````````@````@"$``````` M``#_`````````0\`"`(0``$````!`/\````````!#P`(`A```@``````_P`` M``````$/``@"$``#`````0#_`````````0\`_0`*```````7`+L````!`@8` M`0```!<`_0`*``$``0`7``$```#]``H``@```!8`O````/T`"@`#````&`"[ M````_0`*``,``0`;`+T```#7``P`H````#P`#@`8``X`/@(2`+8``````$`` M`````````````*``!`!D`&0`'0`/``,````````!`````````.\`!@```#<` M```*````"0@0```&$`!&&,T'P8````8"```+`A0````````````$```````` M`*SS`0`-``(``0`,``(`9``/``(``0`1``(````0``@`_*GQTDUB4#]?``(` M`0`J``(````K``(```""``(``0"```@````````````E`@0```#_`($``@#! M!!0````5````@P`"````A``"````H0`B``D`9``!``$``0!&`%@"6`(````` M``#@/P```````.`_`0!5``(`"`!]``P``````+8\#P````0`?0`,``$``0"V M&`\````$`'T`#``"`/\`)`D/````!````@X```````0```````(````(`A`` M````````_P````````$/``@"$``!`````0#_`````````0\`"`(0``(````` M`/\````````!#P`(`A```P````$`_P````````$/`/T`"@``````%P"^```` M`0(&``$````7`/T`"@`!``$`%P`!````_0`*``(````6`+\```#]``H``P`` M`!@`O@```/T`"@`#``$`&P#`````UP`,`*`````\``X`&``.`#X"$@"V```` M``!```````````````"@``0`9`!D`!T`#P`#`````````0````````#O``8` M```W````"@````D($```!A``1AC-!\&````&`@``"P(4````````````!``` M``````"?]0$`#0`"``$`#``"`&0`#P`"``$`$0`"````$``(`/RI\=)-8E`_ M7P`"``$`*@`"````*P`"````@@`"``$`@``(````````````)0($````_P"! M``(`P004````%0```(,``@```(0``@```*$`(@`)`&0``0`!``$`1@!8`E@" M````````X#\```````#@/P$`50`"``@`?0`,``````"V/`\````$`'T`#``! M``$`MA@/````!`!]``P``@#_`"0)#P````0```(.```````$```````"```` M"`(0`````````/\````````!#P`(`A```0````$`_P````````$/``@"$``" M``````#_`````````0\`"`(0``,````!`/\````````!#P#]``H``````!<` MP0````$"!@`!````%P#]``H``0`!`!<``0```/T`"@`"````%@#"````_0`* M``,````8`,$```#]``H``P`!`!L`PP```-<`#`"@````/``.`!@`#@`^`A(` MM@``````0```````````````H``$`&0`9``=``\``P````````$````````` M[P`&````-P````H````)"!````80`$88S0?!@```!@(```L"%``````````` M``0`````````DO XML 37 R25.xml IDEA: Subsequent Events 2.0.0.10 false Subsequent Events 0219 - Disclosure - Subsequent Events true false false false 1 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 nhp_SubsequentEventsAbstract nhp false na duration string Subsequent Events Abstract. false false false false false true false false false false false false 1 false false false false 0 0 false false false Subsequent Events Abstract. false 3 1 us-gaap_ScheduleOfSubsequentEventsTextBlock us-gaap true na duration string No definition available. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 19 - us-gaap:ScheduleOfSubsequentEventsTextBlock--> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>19. Subsequent Events</b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On April&#160;1, 2010, the total $1.9&#160;million outstanding under our agreement with PMB LLC, the manager of PMB Pomona LLC, was repaid (see Note 17). </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">From April&#160;1, 2010 to May&#160;6, 2010, we completed approximately $58&#160;million of investments in eight medical office buildings and one skilled nursing facility. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">From April&#160;1, 2010 to May 6, 2010, we issued and sold approximately 1,592,000 shares at a weighted average price of $35.08 per share through our at-the-market equity offering program (see Note 10). </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false false Describes disclosed significant events or transactions that occurred after the balance sheet date, but before the issuance of the financial statements. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, losses resulting from fire or flood, losses on receivables, significant realized and unrealized gains and losses that result from changes in quoted market prices of securities, declines in market prices of inventory, changes in authorized or issued debt (SEC), significant foreign exchange rate changes, substantial loans to insiders or affiliates, significant long-term investments, and substantial dividends not in the ordinary course of business. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 5 -Paragraph 11 false false 1 2 false UnKnown UnKnown UnKnown false true XML 38 R7.xml IDEA: Organization 2.0.0.10 false Organization 0201 - Disclosure - Organization true false false false 1 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 nhp_OrganizationAbstract nhp false na duration string Organization. false false false false false true false false false false false false 1 false false false false 0 0 false false false Organization. false 3 1 us-gaap_NatureOfOperations us-gaap true na duration string No definition available. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 1 - us-gaap:NatureOfOperations--> <!-- xbrl,ns --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"><b></b> </div> <div align="left"> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"><b></b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"><b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>1. Organization</b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Nationwide Health Properties, Inc., a Maryland corporation, is a real estate investment trust (&#8220;REIT&#8221;) that invests in healthcare related real estate, primarily senior housing, long-term care properties and medical office buildings. Whenever we refer herein to &#8220;NHP&#8221; or to &#8220;us&#8221; or use the terms &#8220;we&#8221; or &#8220;our,&#8221; we are referring to Nationwide Health Properties, Inc. and its subsidiaries, unless the context otherwise requires. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We primarily make our investments by acquiring an ownership interest in senior housing and long-term care facilities and leasing them to unaffiliated tenants under &#8220;triple-net&#8221; &#8220;master&#8221; leases that transfer the obligation for all facility operating costs (including maintenance, repairs, taxes, insurance and capital expenditures) to the tenant. We also invest in medical office buildings which are not generally subject to &#8220;triple-net&#8221; leases and generally have several tenants under separate leases in each building, thus requiring active management and responsibility for many of the associated operating expenses (although many of these are, or can effectively be, passed through to the tenants). Some of the medical office buildings are subject to &#8220;triple-net&#8221; leases. In addition, but to a much lesser extent because we view the risks of this activity to be greater due to less favorable bankruptcy treatment and other factors, from time to time, we extend mortgage loans and other financing to operators. For the three months ended March&#160;31, 2010, approximately 93% of our revenues were derived from leases, with the remaining 7% from mortgage loans, other financing activities and other miscellaneous income. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We believe we have operated in such a manner as to qualify as a REIT under Sections&#160;856 through 860 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;). We intend to continue to qualify as such and therefore distribute at least 90% of our REIT taxable income (computed without regard to the dividends paid deduction and excluding capital gain) to our stockholders. If we qualify for taxation as a REIT, and we distribute 100% of our taxable income to our stockholders, we will generally not be subject to U.S. federal income taxes on our income that is distributed to stockholders. Accordingly, no provision has been made for federal income taxes. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As of March&#160;31, 2010, we had investments in 606 healthcare facilities and one land parcel located in 43 states, consisting of: </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Consolidated facilities: </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>251 assisted and independent living facilities;</td> </tr> </table> </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>167 skilled nursing facilities;</td> </tr> </table> </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>9 continuing care retirement communities;</td> </tr> </table> </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>7 specialty hospitals;</td> </tr> </table> </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>19 triple-net medical office buildings, one of which is operated by a consolidated joint venture (see Note 5); and</td> </tr> </table> </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>67 multi-tenant medical office buildings, 20 of which are operated by consolidated joint ventures (see Note 5).</td> </tr> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Unconsolidated facilities: </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>19 assisted and independent living facilities;</td> </tr> </table> </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>14 skilled nursing facilities; and</td> </tr> </table> </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>1 continuing care retirement community.</td> </tr> </table> </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Mortgage loans secured by: </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>26 medical office buildings;</td> </tr> </table> </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>16 skilled nursing facilities;</td> </tr> </table> </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>9 assisted and independent living facilities;</td> </tr> </table> </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>1 continuing care retirement community; and</td> </tr> </table> </div> <div style="margin-top: 10pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="4%" style="background: transparent">&#160;</td> <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td> <td width="1%">&#160;</td> <td>1 land parcel.</td> </tr> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As of March&#160;31, 2010, our directly owned facilities, other than our multi-tenant medical office buildings, were operated by 84 different healthcare providers, including the following publicly traded companies: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="86%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2"><b>Number of</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2"><b>Facilities</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Operated</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b><b>&#8226;</b> </b>Assisted Living Concepts, Inc. </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">4</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px"><b><b>&#8226;</b> </b>Brookdale Senior Living, Inc. </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">96</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b><b>&#8226;</b> </b>Emeritus Corporation </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">6</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px"><b><b>&#8226;</b> </b>Extendicare, Inc. </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b><b>&#8226;</b> </b>HealthSouth Corporation </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">2</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px"><b><b>&#8226;</b> </b>Kindred Healthcare, Inc. </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b><b>&#8226;</b> </b>Sun Healthcare Group, Inc. </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">4</td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Two of our triple-net lease tenants each accounted for more than 10% of our revenues at March 31, 2010 as follows: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="86%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b><b>&#8226;</b> </b>Brookdale Senior Living, Inc. </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">14.3</td> <td nowrap="nowrap">%</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px"><b><b>&#8226;</b> </b>Hearthstone Senior Services, L.P. </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">10.1</td> <td nowrap="nowrap">%</td> </tr> <!-- End Table Body --> </table> </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false false Describes the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings). Disclosures about the nature of operations need not be quantified; relative importance could be conveyed by use of terms such as "predominately", "about equally", or "major and other". This element is also referred to as "Business Description". Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Statement of Position (SOP) -Number 94-6 -Paragraph 10 false false 1 2 false UnKnown UnKnown UnKnown false true XML 39 R17.xml IDEA: Earnings Per Share (EPS) 2.0.0.10 false Earnings Per Share (EPS) 0211 - Disclosure - Earnings Per Share (EPS) true false false false 1 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 us-gaap_EarningsPerShareAbstract us-gaap true na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false No definition available. false 3 1 us-gaap_EarningsPerShareTextBlock us-gaap true na duration string No definition available. false false false false false false false false false false false false 1 false false false false 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 11 - us-gaap:EarningsPerShareTextBlock--> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>11. Earnings Per Share (EPS)</b> </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Certain of our share-based payment awards are considered participating securities which requires the use of the two-class method for the computation of basic and diluted EPS. </div> <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Diluted EPS also includes the effect of any potential shares outstanding, which for us is comprised of dilutive stock options, other share-settled compensation plans and, if the effect is dilutive, Series&#160;B Preferred Stock, which was redeemed on January&#160;18, 2010 (see Note 10) and/or OP Units. There were 270,100 and 243,000 stock options that would not be dilutive for the three months ended March&#160;31, 2010 and 2009, respectively. The calculation below excludes 27,000 restricted stock units, 8,700 restricted stock shares and 6,900 stock appreciation rights that would not be dilutive for the three months ended March&#160;31, 2010 and 1,200 performance shares and 538,000 stock appreciation rights that would not be dilutive for the three months ended March&#160;31, 2009. The Series&#160;B Preferred Stock is not dilutive for any period presented. The table below details the components of the basic and diluted EPS calculations: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"> <!-- Begin Table Head --> <tr valign="bottom"> <td width="72%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> <td width="3%">&#160;</td> <td width="1%">&#160;</td> <td width="9%">&#160;</td> <td width="1%">&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6"><b>Three months ended</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>March 31,</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2009</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6"><b>(In thousands, except per</b></td> <td>&#160;</td> </tr> <tr style="font-size: 10pt" valign="bottom"> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="center" colspan="6"><b>share amounts)</b></td> <td>&#160;</td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Numerator:</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Income from continuing operations </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">31,217</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">29,428</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Net (income)&#160;loss attributable to noncontrolling interests </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">190</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(27</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Net income attributable to participating securities </div></td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(326</td> <td nowrap="nowrap">)</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(206</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Undistributed earnings attributable to participating securities </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(13</td> <td nowrap="nowrap">)</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Series&#160;B preferred stock dividends </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" align="left">&#160;</td> <td align="right">(1,452</td> <td nowrap="nowrap">)</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Numerator for Basic and Diluted EPS from continuing operations </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">31,081</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">27,730</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"><!-- Blank Space --> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Income from discontinued operations </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">22</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">21,205</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Numerator for Basic and Diluted EPS from discontinued operations </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">22</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">21,205</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"><!-- Blank Space --> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Denominator:</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Basic weighted average shares outstanding </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">117,048</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">102,355</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Effect of dilutive securities: </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:45px; text-indent:-15px">Stock options </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">70</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">58</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:45px; text-indent:-15px">Other share-settled compensation plans </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">426</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">165</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:45px; text-indent:-15px">OP Units </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,922</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">1,830</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Diluted weighted average shares outstanding </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">119,466</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">104,408</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"><!-- Blank Space --> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Basic earnings per share amounts:</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Income from continuing operations attributable to NHP common stockholders </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">0.27</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">0.27</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Discontinued operations attributable to NHP common stockholders </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">0.21</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Net income attributable to NHP common stockholders </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">0.27</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">0.48</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"><!-- Blank Space --> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px"><b>Diluted earnings per share amounts:</b> </div></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Income from continuing operations attributable to NHP common stockholders </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">0.26</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">0.27</td> <td>&#160;</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:30px; text-indent:-15px">Discontinued operations attributable to NHP common stockholders </div></td> <td>&#160;</td> <td>&#160;</td> <td align="right">&#8212;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td align="right">0.20</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td> <td>&#160;</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:30px; text-indent:-15px">Net income attributable to NHP common stockholders </div></td> <td>&#160;</td> <td align="left">$</td> <td align="right">0.26</td> <td>&#160;</td> <td>&#160;</td> <td align="left">$</td> <td align="right">0.47</td> <td>&#160;</td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">&#160; </div></td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> </div> <!-- Folio --> <!-- /Folio --> </div> <!-- PAGEBREAK --> <div style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in"> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note false false false This element may be used to capture the complete disclosure pertaining to an entity's earnings per share. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 40 false false 1 2 false UnKnown UnKnown UnKnown false true -----END PRIVACY-ENHANCED MESSAGE-----